

ESC CONGRESS 2024

Scientific Programme as of 26 July 2024

New ESC
Guidelines

Friday, 30 August 2024

08:15 - 09:45

London - Main Auditorium

2024 ESC Guidelines overview

Session Number: 1000

Chairpersons: E Prescott (Copenhagen, DK) (F) - JJV McMurray (Glasgow, GB) (M)

- 08:15** **2024 ESC Guidelines for the Management of Elevated Blood Pressure and Hypertension**
J Mcevoy (Galway, IE, M)

R Touyz (Montreal, GB, F)
- 08:37** **2024 ESC Guidelines for the Management of Chronic Coronary Syndromes**
F Andreotti (Rome, IT, F)

CJM Vrints (Edegem, BE, M)
- 09:00** **2024 ESC Guidelines for the Management of Atrial Fibrillation**
IC Van Gelder (Groningen, NL, F)

D Kotecha (Birmingham, GB, M)
- 09:22** **2024 ESC Guidelines for the Management of Peripheral Arterial and Aortic Diseases**
L Mazzolai (Lausanne, CH, F)

J Rodriguez Palomares (Barcelona, ES, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Online Live, Young Community Track

New modalities and strategies in catheter ablation of atrial fibrillation

Session Number: 823

Chairpersons: M Hocini (Pessac, FR) (F) - N Marrouche (New Orleans, US) (M)

- 08:15 State-of-the art lecture on new modalities and strategies for catheter ablation for atrial fibrillation**
V Reddy (New York, US, M)
- 08:33 The impact of body mass index for atrial fibrillation ablation; real-world data on outcomes and quality of life**
J Vermeer (Eindhoven, NL, M)
- 08:51 Impact of GLP1-agonists on the outcomes of catheter ablation for atrial fibrillation in obese patients**
- 09:09 Discordance between left atrial volume and scar burden in patients with atrial fibrillation and its impact on atrial fibrillation recurrence after catheter ablation**
K Lee (Seoul, KR, F)
- 09:27 Outcomes and clinical characteristics of atrial fibrillation ablation in heart failure patients with reduced and preserved left ventricular ejection fraction**
C Nebuwa (- , NG, F)

Learning Objectives:

Categories: Online Live

Impact of lipid and adipose tissue changes in acute coronary syndromes

Session Number: 831

Chairpersons: L Badimon (Barcelona, ES) (F) - AK Gitt (Ludwigshafen, DE) (M)

- 08:15 State-of-the-art lecture on impact of lipid and adipose tissue changes in acute coronary syndromes**
M Sabatine (Boston, US, M)
- 08:33 Causal association between visceral fat and coronary artery disease: a large-scale mendelian randomization analysis**
T Porcheddu (Sassari, IT, M)
- 08:52 Triple-hormone receptor agonist retatrutide significantly improves lipoprotein and apolipoprotein profiles in participants with obesity or overweight**
S Nicholls (Clayton, AU, M)
- 09:11 Clinical outcomes according to residual cholesterol and inflammatory risk in patients undergoing PCI**
B Bay (Hamburg, DE, M)

Learning Objectives:

Categories:

Device-based hypertension therapies: third pillar in hypertension management?

Session Number: 836

Chairpersons: AS Mihailidou (Sydney, AU) (F) - MJ Heradien (Kuils River, ZA) (M)

- 08:15 State-of-the-art lecture on device-based hypertension management**
I Sudano (Zurich, CH, F)
- 08:33 Blood pressure and renal function changes in patients with severe chronic kidney disease undergoing radiofrequency renal denervation: 12 months outcomes from the Global SYMPPLICITY Registry DEFINE**
M Schlaich (Perth, AU, M)
- 08:51 Efficacy comparison of transcatheter aorticorenal ganglion ablation and renal denervation in a hypertensive canine model**
YX Long (Chongqing, CN, M)
- 09:09 Nighttime blood pressure reductions after radiofrequency renal denervation through 24 months in patients with uncontrolled hypertension: pooled analysis from the SPYRAL HTN trials**
- 09:27 The relationship between lung MIBG uptake and clinical response to renal denervation**
H Dalpiaz (Pisa, IT, M)

Learning Objectives:

Categories:

Adjunct pharmacology in PCI: beyond antiplatelet therapy, the next chapter**Session Number: 283**Chairpersons: J Siller-Matula (Vienna, AT) (F) - M Morice (Massy, FR) (F)

08:15 Uncoupling ischaemic and bleeding complications: are new factor XI inhibitors too good to be true?
C Gibson (Boston, US, M)

08:33 Tackling obesity in PCI patients: biological and technical considerations
M Roffi (Geneva, CH, M)

08:51 How low can you go? LDL-lowering therapy in PCI patients
KK Ray (London, GB, M)

09:09 Extinguishing the fire: tackling inflammation in PCI patients
D Capodanno (Catania, IT, M)

09:27 Adjunct pharmacology in PCI: beyond antiplatelet therapy, the next chapter - discussion
R Schnabel (Hamburg, DE, F)

Learning Objectives:

Categories: Obesity Track, Online Live

**Great Debates: management of cardiac arrest and cardiogenic shock
- how? where? and when?****Session Number: 200**Chairpersons: M Alasnag (Jeddah, SA) (F) - A Combes (Paris, FR) (M)

- 08:15 All cardiac arrest patients should be transferred to a cardiac arrest centre: pro**
C Malta Hansen (Copenhagen, DK, F)
- 08:30 All cardiac arrest patients should be transferred to a cardiac arrest centre: con**
T Patterson (London, GB, F)
- 08:45 All cardiac arrest patients should be transferred to a cardiac arrest centre - discussion**
J Belohlavek (Praha, CZ, M)
- 09:00 Patients with cardiac arrest should be excluded from cardiogenic shock trials: pro**
A Chieffo (Milan, IT, F)
- 09:15 Patients with cardiac arrest should be excluded from cardiogenic shock trials: con**
H Thiele (Leipzig, DE, M)
- 09:30 Patients with cardiac arrest should be excluded from cardiogenic shock trials - discussion**
P Vranckx (Hasselt, BE, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Online Live, Young Community Track

Clinical trial updates on the GLP-1 receptor agonist, semaglutide

Session Number: 1030

Chairpersons: B Bozkurt (Houston, US) (F) - M Senni (Bergamo, IT) (M)

- 08:15 Atrial fibrillation and efficacy of semaglutide 2.4 mg in obesity-related HFpEF: A Patient Level Pooled analysis of STEP-HFpEF and STEP-HFpEF DM trials**
S Verma (Toronto, CA, M)
- 08:26 Effects of semaglutide on clinical events in heart failure with preserved ejection fraction: a pooled, participant-level analysis of SELECT, FLOW, STEP-HFpEF and STEP-HFpEF DM trials**
M Kosiborod (Kansas City, US, M)
- 08:37 STEP-HFpEF Program Echocardiography Substudy**
S Solomon (Boston, US, M)
- 08:48 Inflammation in obesity-related HFpEF: the STEP-HFpEF programme**
S Verma (Toronto, CA, M)
- 09:00 Effects of the GLP-1 receptor agonist, semaglutide, on heart failure outcomes: a pre-specified analysis of the FLOW trial in participants with type 2 diabetes and chronic kidney disease**
R Pratley (Orlando, US, M)
- 09:11 The effect of semaglutide on mortality and COVID-19-related deaths - a pre-specified analysis from the SELECT trial**
B Scirica (Boston, US, M)
- 09:22 Semaglutide and cardiovascular outcomes by baseline chronic kidney disease status and albuminuria in type 2 diabetes and chronic kidney disease: results from the FLOW trial**
KW Mahaffey (Stanford, US, M)
- 09:33 Semaglutide and cardiovascular outcomes in females with overweight and obesity: A prespecified analysis of the SELECT trial**
S Verma (Toronto, CA, M)

Learning Objectives:

Categories:

Biomarkers to guide the treatment of heart failure: where are we going?

Session Number: 826

Chairpersons: S Piper (London, GB) (F) - A Bayes Genis (Badalona, ES) (M)

- 08:15 State-of-the-art lecture on biomarkers to guide the treatment of heart failure: where are we going?**
J Januzzi (Boston, US, M)
- 08:33 Outcomes and effects of sacubitril/valsartan according to NT-proBNP level in patients with heart failure: a patient-level pooled analysis of the PARADIGM-HF and PARAGON-HF trials**
T Kondo (Glasgow, GB, M)
- 08:51 Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial**
YL Yu (Leuven, BE, F)
- 09:09 Heart failure and renal outcomes in patient treated with GLP1 agonists.**
N del-Cuerpo-Salinas (San Juan De Alicante, ES, M)
- 09:27 Liver function tests in patients receiving high-intensity care after hospital admission for acute heart failure: the STRONG-HF trial**
P Myhre (Oslo, NO, M)

Learning Objectives:

Categories:

Pre-diabetes: a risk factor for cardiovascular disease?**Session Number: 130**Chairpersons: A Ceriello (Milan, IT) (M) - A Rakisheva (Almaty, KZ) (F)**08:15 How is pre-diabetes defined?**

L Mellbin (Bromma, SE, F)

08:37 Pre-diabetes should be included in cardiovascular risk assessment

F Cosentino (Stockholm, SE, M)

09:00 Pre-diabetes should not be included in cardiovascular risk assessment

N Marx (Aachen, DE, M)

09:22 Pre-diabetes: a risk factor for cardiovascular disease? - discussion

M Lettino (Milano, IT, F)

Learning Objectives:

Categories:

Pulmonary hypertension: from diagnosis to personalised care**Session Number: 323**Chairpersons: S Gibbs (London, GB) (M) - I Simkova (Bratislava, SK) (F)**08:15 What's hot in pulmonary hypertension?**

N Frey (Kiel, DE, M)

08:33 Not all pulmonary arterial hypertension (PAH) patients are young women

C Hjalmarsson (Gothenburg, SE, F)

08:51 Obesity and pulmonary hypertension

A Boucly (Le Kremlin Bicetre, FR, F)

09:09 Personalising treatment of chronic thromboembolic pulmonary hypertension (CTEPH): right treatment for the right patient

A Andersen (Aarhus N, DK, M)

09:27 Pulmonary hypertension: from diagnosis to personalised care - discussion

M Aleksic (Belgrade, RS, F)

Learning Objectives:

Categories: Spotlight of the Congress

Myocardial infarction with non-obstructive coronary arteries (MINOCA): state-of-the-art imaging evaluation**Session Number: 267**Chairpersons: W Chan (Hong Kong, HK) (F) - T Pezel (Paris, FR) (M)**08:15 MINOCA: definitions and clinical importance**

C Bucciarelli-Ducci (London, GB, F)

08:33 How I use non-invasive imaging to evaluate my patient with MINOCA

J Schulz-Menger (Berlin, DE, F)

08:51 Novel imaging techniques to phenotype patients with MINOCA

MG Friedrich (Montreal, CA, M)

09:09 Invasive evaluation provides crucial information in MINOCA

P O'Boyle (Dublin, IE, M)

09:27 Myocardial infarction with non-obstructive coronary arteries (MINOCA): state-of-the-art imaging evaluation - discussion

R Dalmau (Madrid, ES, F)

Learning Objectives:

Categories: Online Live

Smaller trials, trial updates, and other studies on inflammation and immunity in cardiovascular disease

Session Number: 1031

Chairpersons: N Arnold (Hamburg, DE) (F) - P Libby (Boston, US) (M)

- 08:15 Low-dose interleukin-2 for the reduction of vascular inflammation in acute coronary syndromes (IVORY) / IVORY - Clinical Outcomes And Follow-up (IVORY FINALE) Study**
R Sriranjani (Cambridge, GB, F)
- 08:26 Anakinra versus placebo double blind Randomized controlled trial for the treatment of Acute Myocarditis**
M Kerneis (Paris, FR, M)
- 08:37 Colchicine for secondary prevention of stroke and other cardiovascular events: a meta-analysis of randomised trials**
A Fiolet (- , NL, M)
- 08:48 Cardiovascular benefit of colchicine in relation to baseline risk**
N Mohammadnia (Nijmegen, NL, M)
- 09:00 Effect of pre-hospital pulse-dose glucocorticoid on infarct size in st-segment elevation myocardial infarction: a randomized, blinded, placebo-controlled clinical trial**
J Madsen (Copenhagen, DK, F)
- 09:11 Randomized double-blind trial to study the benefit of Colchicine in Patients with Acutely Decompensated Heart Failure**
D Pascual Figal (Murcia, ES, M)
- 09:22 Intravenous immunoglobulin therapy improves long-term outcome in dilated cardiomyopathy by modulating cardiac immune cell function. An update of a randomized placebo-controlled study.**
S Heymans (Maastricht, NL, M)
- 09:33 Effect of short-term prednisone therapy on C-reactive protein change in emergency department patients with acute heart failure and elevated inflammatory markers**
G cotter (Paris, FR, M)

Learning Objectives:

Categories:

Session Number:	410	Innovations and future frontiers in aortic, mitral, and tricuspid valve therapies Joint session with the Journal of the American College of Cardiology (JACC)
<u>Chairpersons:</u>	H Krumholz (New Haven, US) (M)	

- | | |
|-------|---|
| 08:15 | Introduction |
| 08:17 | Considerations for lifetime management of aortic stenosis
A Gupta (Los Angeles, US, F) |
| 08:27 | The future of aortic valve intervention: asymptomatic aortic stenosis, moderate aortic stenosis, bicuspid aortic stenosis, aortic insufficiency
H Eltchaninoff (Rouen Cedex, FR, F) |
| 08:37 | Role of surgery for aortic valve treatment in the era of TAVR
S Bleiziffer (Bad Oeynhausen, DE, F) |
| 08:47 | Innovations and future frontiers in aortic, mitral, and tricuspid valve therapies - panel discussion 1 |
| 08:53 | Transcatheter mitral valve therapies: overcoming hurdles, seizing opportunities
R Makkar (Los Angeles, US, M) |
| 09:03 | Mitral valve surgery in 2024: evolution, techniques, and patient outcomes
M Borger (Leipzig, DE, M) |
| 09:13 | Innovations and future frontiers in aortic, mitral, and tricuspid valve therapies - panel discussion 2 |
| 09:19 | Revolutionising tricuspid valve therapies: from forgotten to the forefront
S Windecker (Bern, CH, M) |
| 09:29 | Paving the path: key lessons from my experience with transcatheter valvular interventions
M Leon (New York, US, M) |
| 09:39 | Innovations and future frontiers in aortic, mitral, and tricuspid valve therapies - panel discussion 3 |

Learning Objectives:

Categories:

How will digital technologies improve the personalised management of atrial fibrillation

Session Number: 166

Chairpersons: G Hindricks (Berlin, DE) (M) - A Russo (Moorestown, US) (F)

- 08:15 Personalising care in atrial fibrillation: state of the art**
D Duncker (Hannover, DE, M)
- 08:33 Machine learning to personalise care in atrial fibrillation**
T Baykaner (Stanford, US, F)
- 08:51 Modern mobile health technologies to screen for atrial fibrillation**
E Svennberg (Stockholm, SE, F)
- 09:09 Using digital health technologies to integrate the care of atrial fibrillation**
M Proietti (Milan, IT, M)
- 09:27 How will digital technologies improve the personalised management of atrial fibrillation - discussion**
S Boveda (Toulouse, FR, M)

Learning Objectives:

Categories: Clinical Implementation Track, Digital Health, Online Live, Spotlight of the Congress

Mechanisms of ageing in cardiovascular disease**Session Number: 342**Chairpersons: D Carnevale (Pozzilli, IT) (F) - S Bibli (, DE) (F)

- 08:15 Ageing, metabolism, and epigenetics in heart failure**
G Condorelli (Milan, IT, M)
- 08:33 Ageing of the vasculature**
V Andres Garcia (Madrid, ES, M)
- 08:51 Immune ageing in cardiovascular diseases**
P Alcaide (Boston, US, F)
- 09:09 Targeting autophagy in cardiac ageing**
M Abdellatif (Paris, FR, M)
- 09:27 Mechanisms of ageing in cardiovascular disease - discussion**
G Camici (Schlieren, CH, M)

Learning Objectives:

Categories:

Comprehensive diagnosis and treatment of coronary microvascular dysfunction in patients with chronic coronary syndromes
Joint session with the Japanese Circulation Society (JCS) international young community

Session Number: 205

Chairpersons: H Kiriya (Tokyo, JP) (M) - Y Appelman (Amsterdam, NL) (F)

08:15 Prevalence of microvascular dysfunction in patients with chronic coronary syndromes

S Banerjee (Reigate, GB, F)

08:30 Cath lab evaluation of microvascular function in patients with chronic coronary syndromes

T Warisawa (Tokyo, JP, M)

08:45 Treatment of microvascular dysfunction in patients with chronic coronary syndromes

K Nishimiya (Nijmegen, NL, M)

09:00 Outcomes of microvascular dysfunction in patients with chronic coronary syndromes

M Gulati (Los Angeles, US, F)

Learning Objectives: This session will discuss coronary microvascular dysfunction in patients with chronic coronary syndromes.

This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Online Live, Young Community Track

Risk stratification models after acute coronary syndrome

Session Number: 3042

Chairpersons: M Kelm (Duesseldorf, DE) (M) - A Lansky (New Haven, US) (F)

- 08:15 Early risk stratification of patients with acute myocardial infarction complicated by severe cardiogenic shock - The ECLS-SHOCK Risk Score**
T Thevathasan (Berlin, DE, M)
- 08:25 An ensemble machine learning approach for predicting heart failure risk in acute coronary syndrome patients: heartguardai**
G Petretto (Sassari, IT, M)
- 08:35 Baseline heart rate as a key prognostic indicator in AMI patients with cardiogenic shock undergoing successful primary PCI**
T Abe (Saitama, JP, M)
- 08:45 Prognostic value of IL-22 levels and the TH17 pathway in patients with acute myocardial infarction**
Y Wang (Zurich, CH, M)
- 08:55 Differences in risk profiles and clinical outcomes according to age in patients with high-risk myocardial infarction: insights from the PARADISE-MI trial**
K Jering (Boston, US, F)
- 09:05 Risk score guided dual antiplatelet therapy duration in patients with acute coronary syndrome: insights from the FORCE-ACS registry**
D Chan Pin Yin (Amstelveen, NL, M)

Learning Objectives:

Categories:

Leadless vs. transvenous devices: efficacy and safety**Session Number: 3015**Chairpersons: E Jedrzejczyk-Patej (Zabrze, PL) (F) - C Leclercq (Rennes Cedex, FR) (M)

- 08:15 Real-world evidence of implanting leadless pacemakers after transcatheter aortic valve implantation procedures**
S Zweibel (Hartford, US, M)
- 08:27 Comparative safety outcomes of leadless versus transvenous cardiac pacemaker: a systematic review and meta-analysis**
MH Ohn (London, MM, F)
- 08:39 Eight year Follow-Up Data on a Leadless Pacing System Real life experience in comparison to data of the prospective trial**
S Winter (Cologne, DE, M)
- 08:51 Infection management in the extravascular implantable cardioverter defibrillator: experience from the EV ICD Pivotal study**
N Clementy (Montpellier, FR, M)
- 09:03 Periprocedural complications during transvenous lead extraction. Lessons learned from the GermAn Laser Lead Extraction Registry (GALLERY)**
D Chung (Hamburg, DE, M)

Learning Objectives:

Categories:

Cardiac amyloidosis: my heart is filled with so much...**Session Number: 3063**Chairpersons: M Fontana (London, GB) (F) - M Maurer (New York, US) (M)

- 08:15 Patient characteristics and incidence of cardiac amyloidosis: an observational study in the UK clinical setting using electronic health records**
L Anderson (London, GB, F)
- 08:25 Usefulness of scintigraphy with [99mTc]Tc-DPD for the detection of transthyretin cardiac amyloidosis. Reference centre experience in an endemic area.**
N Orta (Palma De Mallorca, ES, F)
- 08:35 Cardiac magnetic resonance T1 imaging for the diagnosis of cardiac amyloidosis among patients with symptomatic heart failure**
R Gessner (Leipzig, DE, F)
- 08:45 Prevalence and prognostic significance of restriction versus systolic dysfunction in patients with transthyretin and light chain cardiac amyloidosis**
M Zampieri (Verona, IT, M)
- 08:55 Efficacy of tafamidis on mortality and echocardiographic parameters in transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis.**
M Ahmed (Karachi, PK, M)
- 09:05 Evaluation of the 2021 ESC recommendations for family screening in hereditary transthyretin cardiac amyloidosis**
SA Muller (Utrecht, NL, M)

Learning Objectives:

Categories:

New findings across the spectrum of cardiovascular disease

Session Number: 3089

Chairpersons: N Kraenkel (Berlin, DE) (F) - D Grobbee (Utrecht, NL) (M)

- 08:15 Enhancing primary prevention: the incremental predictive value of high-sensitivity cardiac troponin T beyond ASCVD risk assessment**
S Andraz (Faro, PT, F)
- 08:25 Catheter-directed treatment in acute pulmonary embolism**
K Keller (Mainz, DE, M)
- 08:35 Relationship between obesity and hypertrophic or dilated cardiomyopathy: the role of sex**
A Antonopoulos (Athens, GR, M)
- 08:45 Serum metabolomics improve risk stratification for incident heart failure**
RR Oexner (London, GB, M)
- 08:55 Cardiovascular health and risks of atrial fibrillation and its prognosis**
Z Lu (Beijing, CN, M)
- 09:05 Plasma trimethylamine-n-oxide associates with reduced hippocampal volume and cognitive impairment in atrial fibrillation**
T Ziswiler (Menzingen, CH, F)

Learning Objectives:

Categories:

**Revolutionising cardiac diagnosis: exploring deep learning in
electrocardiography and beyond****Session Number: 3113**Chairpersons: D Adedinsewo (Jacksonville, US) (F) - R Carter (Jacksonville, US) (M)

- 08:15** **Unsupervised electrocardiogram feature extraction using deep learning empowers discovery of genetic and phenotypic determinants of cardiac electrophysiology**
E Sieliwonczyk (Edegem, BE, F)
- 08:25** **Artificial intelligence applied to electrocardiographic images for scalable screening of cardiac amyloidosis**
V Sangha (New Haven, US, M)
- 08:35** **Interethnic validation of an artificial intelligence algorithm for prediction of atrial fibrillation using sinus rhythm electrocardiogram**
JH Lee (Seongnam, KR, M)
- 08:45** **Long-term time-to-ventricular arrhythmic event prediction using a deep learning based model on the electrocardiogram signal**
J Ramirez (Zaragoza, ES, F)
- 08:55** **A novel 12-lead standard ECG derived scoring system for risk stratification in the emergency department**
F Theurl (Innsbruck, AT, M)
- 09:05** **121 year after Einthoven: show me the normal ECG?**
P M Van Dam (Arnhem, NL, M)

Learning Objectives:

Categories:

Acute coronary syndromes (1)**Session Number: 3300**Chairpersons: C Bonanad Lozano (Valencia, ES) (F) - R Twerenbold (Hamburg, DE) (M)**08:15 Acute coronary syndromes - get ready for the session**

R Twerenbold (Hamburg, DE, M)

08:20 Giant coronary artery pseudoaneurysm and mycobacterium abscessus infected stent

J Iliff (Sydney, AU, M)

08:33 Smooth lesions mandating a smooth approach: acute coronary syndrome in a risk-factor-free 35-year-old woman

I Anastasiou (Heraklion, GR, M)

08:56 Left ventricular free wall rupture after myocardial infarction: transcatheter closure as a valuable option, about two cases.

C Belafia (Montpellier, FR, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals

Categories: Mobile App - Vote, Young Community Track

Cases of medication-adverse effects

Session Number: 3339

Chairpersons: M Gawalko (Warszawa, PL) (F) - J Plasek (Ostrava, CZ) (M)

08:15 Repetitive Torsades de Pointes secondary to acute arsenic intoxication from herbal medicinal ointment

L Tran (Ho Chi Minh City, VN, F)

08:30 Taming the storm: a case report of flecainide toxicity managed with ECMO

A Zimmerman (Detroit, US, F)

08:45 Amiodarone: hero or villain? About a case.

G Navas Moreira (Guayaquil, EC, M)

09:00 5-FU associated acute pericarditis with left ventricular dysfunction

I Nardi Agmon (Petah Tikva, IL, F)

Learning Objectives:

Categories:

ECG and further diagnostics and therapy**Session Number: 3359**Chairpersons:

R Wijesurendra (Oxford, GB) (M) - J Cranley (Cambridge, GB) (M)

- 08:15 Severe LV dysfunction caused by complex and uncontrollable polymorphic premature ventricular complexes: CRT as a viable solution**
N Cabanelas (Coimbra, PT, M)
- 08:27 Reviving rhythms: a triumph over functional atrial-ventricular block in a youth through cardio-neural ablation**
M Johari (Kuala Lumpur, MY, M)
- 08:39 Native-valve infective endocarditis presenting with ST-segment elevation myocardial infarction due to septic emboli**
H Yousaf (Buffalo, US, M)
- 08:51 Two types of T wave alternans in an old patient with intermittent palpitation**
C Liu (Tianjin, CN, M)
- 09:03 Reversible heart failure in a young female: Importance of looking at the ECG carefully**
A Aggarwal (Delhi, IN, M)

Learning Objectives:

Categories:

Session Number:	5102	Personalised care in heart failure patients: insights from Belgium and Croatia Organised in collaboration with the Belgian Society of Cardiology and the Croatian Cardiac Society
<u>Chairpersons:</u>	BLM Gerber (Woluwe-St. Lambert, BE) (M) - D Milicic (Zagreb, HR) (M)	

09:30 Approaches to personalised revalidation of heart failure patients: the Belgian perspective
E Van Craenenbroeck (Edegem, BE, F)

09:42 Personalised approach to a patient with advanced heart failure: the Croatian perspective
I Planinc (Zagreb, HR, M)

09:54 Personalised care in heart failure patients: insights from Belgium and Croatia - discussion
A Pouleur (Brussels, BE, F)

M Cikes (Zagreb, HR, F)

Learning Objectives: To understand the importance of personalised care in managing heart failure patients; to identify key patient characteristics and clinical factors that influence treatment decisions; to explore the role of advanced diagnostic techniques in tailoring treatment approaches; to review the integration of multidisciplinary teams; and to identify challenges and opportunities for implementing personalised care in clinical practice.

Categories: Online Live, Spotlight of the Congress

Get out your crystal ball: predicting heart failure events using models

Session Number: 3035

Chairpersons: JM Ter Maaten (Groningen, NL) (F) - M Vaduganathan (, US) (M)

09:30 Development and validation of a predicting model for risk of rehospitalization within 30 days in heart failure patients with preserved ejection fraction

Y Zhu (Xiangtan, CN, M)

09:40 Machine learning to improve the performance of natriuretic peptides across age groups for the diagnosis of acute heart failure

D Perez Vicencio (Edinburgh, GB, M)

09:50 Enhancing the selection of heart failure patients for invasive procedures: how machine learning can predict the diagnostic yield of endomyocardial biopsy

C Basile (Naples, IT, M)

10:00 High prevalence of cardiotropic viruses in endomyocardial biopsies from patients with inflammatory cardiomyopathy demonstrated by a novel targeted NGS approach

C Baumeier (Berlin, DE, M)

10:10 Predicting heart failure in cancer survivors: use of polygenic risk vs clinical score

C Soh (Melbourne, AU, M)

10:20 The influence of testicular cancer on outcomes of heart failure: insights from national inpatient sample

R Sekandlapuram (New York City, US, M)

Learning Objectives:

Categories:

Hot topics in percutaneous mitral and tricuspid valve interventions

Session Number: 3075

Chairpersons: N Karam (Paris, FR) (F) - J Granada (Orangeburg, US) (M)

- 09:30** **The prognostic impact of intra-procedural mitral valve gradient following transcatheter edge-to-edge repair for primary mitral regurgitation**
S Ludwig (Hamburg, DE, M)
- 09:40** **Trans catheter edge to edge repair for mitral regurgitation and left ventricular outflow obstruction in hypertrophic cardiomyopathy**
S Carasso (Modiin, IL, M)
- 09:50** **Leveraging mixed reality in mitralclip implantation: A preliminary case series toward a pilot study**
J Hecko (Trinec, CZ, M)
- 10:00** **One-year outcomes of transcatheter mitral valve replacement in patients with severe mitral regurgitation**
S Wang (Beijing, CN, M)
- 10:10** **Intra, short and long-term results of mitral VIV for the degenerated surgical mitral prosthesis from italian VIV registry (MIVIV registry)**
E Zancanaro (Milano, IT, M)
- 10:20** **Association of TRI-SCORE with clinical outcomes after percutaneous tricuspid annuloplasty**
A Piris Sanchez (- , ES, M)

Learning Objectives:

Categories:

Novel targets against myocardial damage

Session Number: 3123

Chairpersons: R Madonna (Pisa, IT) (F) - S Lebek (Regensburg, DE) (M)

- 09:30 Renal Semaphorin 3C mediates cardiac adaptive response**
Y Otaki (Yamagata, JP, M)
- 09:40 Vaccination targeting senescence-associated transmembrane protein alleviated cardiovascular pathology in the mice**
CL Hsiao (Tokyo, JP, F)
- 09:50 Nap1L1 Ubiquitination Degradation-dependent Protective Effects of Wnt2 on Cardiac Ischemia/Reperfusion Injury**
Y Wang (Shanghai, CN, F)
- 10:00 The development of small-molecule ERBB4 agonists as a treatment for heart failure**
J Cools (Antwerp, BE, F)
- 10:10 The protective role of Baz2b ablation in aging-related heart failure**
T Zang (Shanghai, CN, F)
- 10:20 SGLT2 inhibitor empagliflozin prevents anthracycline-induced cardiotoxicity in a large-animal model**
D Medina-Hernandez (Madrid, ES, F)

Learning Objectives:

Categories:

Elderly with cardiovascular disease: diagnostics and outcome

Session Number: 3105

Chairpersons: C Bonanad Lozano (Valencia, ES) (F) - H Rittger (Fuerth, DE) (M)

- 09:30 Increased risk of cardiovascular events in the weeks following hospitalised COPD exacerbations: the EXACOS-CV French nationwide case-crossover study**
V Aboyans (Limoges, FR, M)
- 09:40 A two-point strategy to clarify prognosis in >80 year olds experiencing out of hospital cardiac arrest**
E Paratz (Melbourne, AU, F)
- 09:50 Association between cardiac consultation and outcomes in patients with perioperative myocardial infarction/injury**
NC Glarner (Basel, CH, F)
- 10:00 Survival in very elderly patients with severe aortic stenosis submitted to TAVI compared to the general population**
M Sobral Domingues (Lisboa, PT, M)
- 10:10 SMART-2D: a novel scoring system to predict non diagnostic exercise stress echocardiography in renal transplant candidates.**
T Abrahams (Toorak, AU, M)
- 10:20 Sex differences in clinical data and long-term outcomes of elderly patients with acute myocardial infarction presenting with cardiogenic shock undergoing percutaneous coronary intervention**
J Choe (Busan, KR, M)

Learning Objectives:

Categories:

Long-term impact of COVID-19: direct and indirect consequences

Session Number: 3118

Chairpersons: J Camaradou (Plymouth, GB) (F) - J Redfern (Sydney, AU) (F)

- 09:30 Substantial morbidity and mortality due to cardiovascular diseases in hospitalized vaccinated and un-vaccinated patients with COVID-19 from 16 countries: the WHF COVID-19 Long-term study**
K Singh (New Delhi, IN, F)
- 09:40 Vaccination status and long COVID symptoms among patients hospitalized with COVID-19: the WHF COVID-19 Long-term Study**
D Prabhakaran (Gurugram, IN, M)
- 09:50 Effect of COVID-19 pandemic on the management of hypertension and the prevalence of lifestyle disease**
T Isogaki (Hamamatsu, JP, M)
- 10:00 Effects of deferment of clinic visit on cardiovascular outcomes during COVID-19 outbreak: a prospective cohort study**
G Tan (Hong Kong, HK, M)
- 10:10 The effect of 2 years COVID-19 pandemic on myocardial infarction and stroke admissions: nationwide registry study, sex differences and mortality**
P Sedova (Brno, CZ, F)
- 10:20 Treatment of Post-COVID-19 POTS by inhibiting FcRn: a phase 2 randomized, placebo controlled, double-blind, proof of concept study with efgartigimod**
J van Middendorp (Gent, NL, M)

Learning Objectives:

Categories:

Arterial hypertension**Session Number: 3307**Chairpersons: C Stefanescu Schmidt (Boston, US) (F) - B Akinci (Istanbul, TR) (F)**09:30 Arterial hypertension - get ready for the session**

C Stefanescu Schmidt (Boston, US, F)

09:35 Left adrenal adenoma diagnosed without confirmation test but via adrenal vein sampling and treated with super-selective adrenal arterial embolization: facing the complexity of real world

Y Li (Beijing, CN, M)

09:48 Renal sympathetic denervation in a patient with renal artery fibromuscular dysplasia

R Ingaramo (Trelew, AR, M)

10:01 Diagnostic dilemma: pheochromocytoma presenting as NSTEMI

J Valdez (Santo Domingo, DO, M)

10:14 Management of orthostatic hypotension in the elderly hypertensive patient

G Bingol (Istanbul, TR, F)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals

Categories: Mobile App - Vote, Young Community Track

Challenges in heart surgery**Session Number: 3345**Chairpersons: D Franco (Napoli, IT) (M) - C Margineanu (Bucharest, RO) (F)

- 09:30 Severe reversible heart graft dysfunction associated with poor glycemic control in a type II diabetic patient**
S Kersten (Buenos Aires, AR, F)
- 09:42 Hemolytic anemia of mechanical origin with mitral valve prosthesis: atypical revealing of prosthetic valve dehiscence**
Y Lahmouz (Rabat, MA, M)
- 09:54 Successful management of chylothorax after coronary artery bypass surgery using video-assisted thoracic surgery (VATS) and octreotide.**
M Delos Santos (Manila, PH, M)
- 10:06 Acute ST-segment elevation myocardial infarction during peri-aortic dissection surgery**
S Hattakitpanitchakul (Bangkok, TH, M)
- 10:18 Cardiac surgery in a patient with end-stage renal disease due to rheumatological comorbidities a severe impairment of heart function in a non-cardiac specialized center**
U Salas Rodriguez (Mexico City, MX, M)

Learning Objectives:

Categories:

Inherited conditions with arrhythmic presentations**Session Number: 3382**Chairpersons:

I Jonauskiene (Kaunas, LT) (F) - S Sohaib (London, GB) (M)

09:30 Brugada like-pattern in patient with ACS and aritmic storm: incidental finding or Brugada syndrome?

A Guareschi (Milano, IT, M)

09:42 What exactly runs in this family of marathons runners with arrhythmias?

M Casian (Bucharest, RO, M)

09:54 Anxiety, asthenia and altered equilibrium: a case of arrhythmogenic cardiomyopathy complicated with biventricular thrombosis.

F Di Lenarda (Milan, IT, F)

10:06 What a coincidence: double threat of sudden cardiac death

E Papiol Morales (Lleida, ES, F)

10:18 Multi-disciplinary approach in fatal ventricular arrhythmias and refractory shock stabilized with axillary mechanical support as a bridge to heart transplant in ARVC.

R Goswami (Jacksonville, US, M)

Learning Objectives:

Categories:

Session Number:	5112	Navigating complexities in valvular heart disease: perspectives from Portugal and Tunisia Organised in collaboration with the Portuguese Society of Cardiology and the Tunisian Society of Cardiology and Cardio-Vascular Surgery
<u>Chairpersons:</u>	H Gamra (Monastir, TN) (M) - M Cabral (Porto, PT) (F)	

- | | |
|-------|---|
| 10:30 | Case 1 - aortic stenosis management in a limited resource country: the Tunisian TAVI/AVR national program
S Abdessalem (Tunis, TN, M) |
| 10:40 | Aortic stenosis management in a limited resource country: the Tunisian TAVI/AVR national program - discussion of guideline implementation
L Abid (Sfax, TN, F) |
| 10:52 | Case 2 - pursuing optimal patient care in secondary mitral regurgitation: insights from the Portuguese context
C Sousa (Porto, PT, F) |
| 11:02 | Pursuing optimal patient care in secondary mitral regurgitation: insights from the Portuguese context - discussion of guideline implementation
C Jorge (Arruda Dos Vinhos, PT, F) |

Learning Objectives:	To provide practical insights and strategies for effectively navigating the complexities of managing valvular heart disease with a focus on translating ESC Guidelines into the daily clinical practices of Portugal and Tunisia.
Categories:	Online Live

Experimental studies in coronary atherosclerosis disease

Session Number: 3051

Chairpersons: O Manfrini (Bologna, IT) (F) - PH Kolh (Liege, BE) (M)

- 10:45 MsrB1 protects microvascular ischemia-reperfusion injury by alleviating endothelial ferroptosis via macrophage anti-inflammatory polarization**
M Liu (Shanghai, CN, F)
- 10:55 Coronary artery disease ameliorates extracellular vesicle lncRNA PUNISHER regulates angiogenic response and endothelial cells function via NFkB-dependent mechanism**
Dr Hosen (Bonn, DE, M)
- 11:05 Role of Galectin-3 in resident macrophages and effects on atherosclerosis**
Y Li (Munich, DE, F)
- 11:15 Cardiac fibroblasts enhance macrophages inflammatory response in myocardial infarction through the C3a-C3aR axis**
X Bo (Nanjing, CN, F)
- 11:25 Early CSWT relieves myocardial fibrosis by inhibiting TGF-Smad2/3-MMP-9**
Y Wang (Kunming, CN, F)
- 11:35 Association of ethanolamine desaturase TMEM189-plasmalogen axis with the stability of atherosclerotic plaque and cardiovascular events after acute coronary syndrome**
H Yu (Beijing, CN, F)

Learning Objectives:

Categories:

New insights from the ECG: screening and prediction

Session Number: 3013

Chairpersons: T Baykaner (Stanford, US) (F) - A Baranchuk (Kingston, CA) (M)

- 10:45 The impact of QRS complex fragmentation status before and after cardiac resynchronization therapy with defibrillator implantation: Is it a predictor of arrhythmic events?**
L De Miguel (Madrid, ES, F)
- 10:55 Predicting atrial fibrillation from ECG characteristics**
C Binding (Copenhagen, DK, M)
- 11:05 Utilizing unsupervised machine learning to uncover novel phenogroups within the broad QRS complex**
M Gurnani (London, GB, F)
- 11:15 ECG as a screening tool for detection of significant functional mitral regurgitation in patients with left bundle branch block**
O Andrei (Bucharest, RO, F)
- 11:25 Predicting 1-year atrial fibrillation risk from a patch-based ambulatory ECG monitoring without atrial fibrillation**
E Hytopoulos (- , US, M)
- 11:35 Clinical validation of the 2021 European Society of Cardiology guidelines on pre-existing right bundle branch block patients undergoing transcatheter aortic valve replacement**
M Salis (Basel, CH, M)

Learning Objectives:

Categories:

Advancing knowledge in aortic stenosis

Session Number: 3061

Chairpersons: G Camici (Schlieren, CH) (M) - MA Clavel (Quebec, CA) (F)

- 10:45 Progression of aortic stenosis in patients with diabetes mellitus type 2 compared with matched controls**
S Kontogeorgos (Gotheborg, SE, F)
- 10:55 Reduced Sox7 contributes to abnormal valve development resulting in congenital aortic stenosis**
Y Wu (- , CN, F)
- 11:05 Aortic valve calcium score to mean gradient ratio: a new frontier in aortic stenosis prognostication**
C Tsai (Danbury, US, F)
- 11:15 Measures of insulin resistance and aortic valve calcification in the general population**
A Wang Gottlieb (Stockholm, SE, F)
- 11:25 Aortic valve replacement and mortality with left ventricular hypertrophy in setting of normal LVEF**
J Wasfy (Boston, US, M)
- 11:35 Invasive hemodynamic response to exercise in hemodynamically significant aortic stenosis with preserved left ventricular ejection fraction**
M Ali (Odense C, DK, M)

Learning Objectives:

Categories:

Lifestyle, obesity, and dyslipidaemia

Session Number: 3087

Chairpersons: P MORRIS (Mount Pleasant, US) (F) - V Aboyans (Limoges, FR) (M)

- 10:45 The impact of pre-myocardial infarction exercise frequency on prognosis in acute myocardial infarction patients**
T Gu (Tianjin, CN, M)
- 10:57 Revisiting the obesity paradox: lean body mass, fat mass, and mortality in patients with atrial fibrillation**
Y Lu (Shanghai, CN, F)
- 11:09 High discontinuation rate of statins among PCSK9i users: a nationwide study from 2015-2023**
I Engebretsen (Oslo, NO, F)
- 11:21 Association between achieved cholesterol levels and the risk of major adverse cardiovascular events after acute coronary syndromes**
C Follonier (Geneva, CH, M)
- 11:33 Comparing PCSK9 inhibitor prescription rates within high-risk populations: diabetes mellitus, multi-territory vascular disease, multivessel and recurrent coronary artery disease**
WB He (Melbourne, AU, M)

Learning Objectives:

Categories:

The many faces of stress echocardiography

Session Number: 3000

Chairpersons: YB Bououdina (Algiers, DZ) (F) - R Fontes Carvalho (Porto, PT) (M)

10:45 Noninvasive identification of ANOCA endotypes by stepwise, multi-stress, multi-marker stress echocardiography
S Dedic (Belgrade, RS, M)

10:55 The application of supine bicycle exercise stress echocardiograph for identification of susceptibility to acute mountain sickness
Y WANG (Chengdu, CN, F)

11:05 Pulmonary valve acceleration fraction as a novel echo parameter to evaluate systolic pulmonary artery pressure during exercise echocardiography
K Vakalis (London, GB, M)

11:15 Functional correlates of ischemic electrocardiographic changes during stress echocardiography. data form stress echo 2030 survey
S Kobal (Lehavim, IL, M)

11:25 Comparative analysis of the 2016 diastolic guidelines and left atrial stiffness in predicting exercise tolerance and cardiac events
SA Noh (Seongnam, KR, F)

11:35 Predictive ability and prognostic correlation of global longitudinal strain in patients with negative dipyridamole stress echocardiography by wall motion criteria.
DA Mei (Modena, IT, M)

Learning Objectives:

Categories:

Chronic heart failure**Session Number: 3308**Chairpersons: A Esteban Fernandez (Madrid, ES) (M) - H Arfsten (Vienna, AT) (F)

- 10:45 Chronic heart failure - get ready for the session**
A Esteban Fernandez (Madrid, ES, M)
- 10:50 Sudden death and ventricular tachycardia in a family with pathogenic mutation of the LMNA gene (C.568C>T). Evidence of the progressive nature of hereditary arrhythmogenic cardiomyopathy.**
- 11:03 Tailoring heart failure therapy using novel non-invasive remote monitoring of cardiac filling pressures**
A Bohm (Bratislava, SK, M)
- 11:16 Falling off the edge: a case report of advanced heart failure in a young patient with left ventricular non-compaction cardiomyopathy**
A Piermartiri (Bologna, IT, M)
- 11:29 Rapid up-titration of the guideline directed medical therapy after a heart failure hospitalization in the daily clinical practice: a case series**
B Muk (Budapest, HU, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals

Categories: Mobile App - Vote, Young Community Track

Chronic coronary syndromes**Session Number: 3353**Chairpersons:

B Vitola (Riga, LV) (F) - A Greco (Catania, IT) (M)

- 10:45** **A single-patient atlas of microcirculation: navigating the complexity of refractory angina**
O Velollari (Mainz, DE, F)
- 10:57** **Case series - Two cases of cardiac allograft vasculopathy (CAV) in young adults followed for approximately 10 years after heart transplantation**
M Han (- , KR, F)
- 11:09** **Coronary Disease indicating Autoimmune Vasculopathy in a Patient Treated with Multiple coronary artery bypass graft (CABG) and Coronary angioplasty (PTCA) procedures**
A Puzzovivo (Bari, IT, F)
- 11:21** **Patient with reduced ejection fraction and ischemic cardiomyopathy - is there a place for revascularization?**
L Lutsenko (Kyiv, UA, F)
- 11:33** **Angina in patient with single coronary artery abnormality: a very rare case**
A Tonang (Tangerang, ID, M)

Learning Objectives:

Categories:

Valvular vegetations beyond infections**Session Number: 3369**Chairpersons: M Von Roeder (Leipzig, DE) (M) - V Reskovic Luksic (Zagreb, HR) (F)**10:45 NBTE in oligodendroglioma patients: a rare and challenging myocardial infarction presentation.**

Y Miura (Osaka, JP, M)

10:57 Multimodal imaging diagnosis of atypical papillary fibroelastoma

MA Ma (Kunming, CN, F)

11:09 The thrombotic puzzle: unmasking a cancer of unknown primary origin

JJ Quintal (Setubal, PT, F)

11:21 Thrombus or tumour?

S Roghani (Dudley, GB, M)

11:33 Challenging diagnosis and treatment in a case of prosthetic valve thrombosis

I Fragkoulis (Athens, GR, M)

Learning Objectives:

Categories:

HOT LINE 1

Session Number: 1010

Chairpersons: E Gonzalez Lopez (Madrid, ES) (F) - TF Luscher (London, GB) (M) - S James (Uppsala, SE) (M)

- 11:00 HELIOS-B - Primary results from phase 3 study of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy**
M Fontana (London, GB, F)
- 11:12 Discussant review - HELIOS-B**
S Cuddy (Boston, US, F)
- 11:17 Panel discussion - HELIOS-B**
- 11:22 Beta blocker interruption in patients with prior myocardial infarction: results of the ABYSS trial and effect on blood pressure and heart rate control**
J Silvain (Paris, FR, M)
- 11:37 Discussant review - ABYSS**
J Armitage (Oxford, GB, F)
- 11:42 Panel discussion - ABYSS**
- 11:47 STOP-or-NOT - Impact of renin-angiotensin system inhibitors continuation versus discontinuation on postoperative complications: a multicenter randomised, controlled trial**
M Legrand (San Francisco, US, M)
- 11:59 Discussant review - STOP-or-NOT**
P Devereaux (Hamilton, CA, M)
- 12:04 Panel discussion - STOP-or-NOT**

Learning Objectives:

Categories: Online Live

Guidelines in Practice: risk stratification for sudden cardiac death in non-dilated left ventricular cardiomyopathy

Session Number: 161

Chairpersons: J Schulz-Menger (Berlin, DE) (F) - P Seferovic (Belgrade, RS) (M)

- 11:00 Non-sustained ventricular tachycardia in non-dilated left ventricular cardiomyopathy with left ventricular late enhancement: case presentation**
H Vago (Budapest, HU, F)
- 11:15 Non-sustained ventricular tachycardia in non-dilated left ventricular cardiomyopathy with left ventricular late enhancement: what do the guidelines say?**
E Arbelo (Barcelona, ES, F)
- 11:30 Non-sustained ventricular tachycardia in non-dilated left ventricular cardiomyopathy with left ventricular late enhancement: how to implement the guidelines and take-home messages**
G Sinagra (Trieste, IT, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Clinical Implementation Track, Young Community Track

How to diagnose and manage uncommon causes of myocardial infarction

Session Number: 202

Chairpersons: A Maas (Nijmegen, NL) (F) - BE Stahli (Zurich, CH) (F)

11:00 How to diagnose and manage coronary artery embolism
J Tamis-Holland (Cleveland, US, F)

11:20 How to diagnose and manage coronary artery dissection
S Zaman (Sydney, AU, F)

11:40 How to diagnose and manage epicardial and/or microvessel coronary spasm
P Ong (Stuttgart, DE, M)

Learning Objectives:

Categories: Clinical Implementation Track, Online Live

Emerging cardiovascular drugs: watch this space

Session Number: 239

**Joint session with the International Society of Cardiovascular
Pharmacotherapy (ISCP)**

Chairpersons: J Tamargo (Madrid, ES) (M) - A Scridon (Santana De Mures, RO) (F)

11:00 Myotropic drugs

D Tan (Singapore, SG, F)

11:15 New targeted antiarrhythmic drugs

GA Dan (Bucharest, RO, M)

11:30 RNA-based diagnostic and therapeutic strategies for cardiovascular disease

T Thum (Hannover, DE, M)

11:45 Biologics in dyslipidaemia

AJ Berberich (London, CA, F)

Learning Objectives: This session aims to make the public aware of new emerging drugs and personalisation of therapy in the near future.

Categories:

STEMI: state of the art

Session Number: 835

Chairpersons: D Itchhaporia (Newport Beach, US) (F) - E Barbato (Roma, IT) (M)

11:00 State-of-the-art lecture STEMI and shock: what works and what doesn't?
H Thiele (Leipzig, DE, M)

11:20 Cardioprotection with transcoronary saline infusion during primary angioplasty for ST-elevation myocardial infarction: design and rationale of the STEMI-Cool pilot study
E Carulli (- , IT, M)

11:40 Prognostic impact of intravascular imaging in percutaneous coronary intervention according to atherothrombotic risk
J Ha (Seoul, KR, M)

Learning Objectives:

Categories:

Great Debate: atrial fibrillation and heart failure - 'to ablate or not to ablate, that is the question'**Session Number: 100**Chairpersons: M Metra (Brescia, IT) (M) - S Ernst (London, GB) (F)

11:00 Atrial fibrillation ablation should be more widely used in heart failure: pro
C Linde (Stockholm, SE, F)

11:15 Atrial fibrillation ablation should be more widely used in heart failure: con
M Packer (Dallas, US, M)

11:30 Atrial fibrillation ablation should be more widely used in heart failure - discussion
J Bauersachs (Hannover, DE, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Online Live, Young Community Track

Environmental health concerns for cardiologists

Session Number: 453 **Joint session with the World Heart Federation (WHF)**

Chairpersons: DJ Pineiro (Buenos Aires, AR) (M) - F Weidinger (Vienna, AT) (M)

- 11:00 The cardiovascular consequences of noise**
T Munzel (Mainz, DE, M)
- 11:15 The cardiovascular consequences of climate change**
D Prabhakaran (Gurugram, IN, M)
- 11:30 Air pollution and cardiovascular disease**
- 11:45 Policies to tackle air pollution and to mitigate the impact on cardiovascular health**

Learning Objectives:
Categories: Online Live

Obesity in heart failure: observations, outcomes, and options

Session Number: 105

Chairpersons: T McDonagh (London, GB) (F) - A Voors (Groningen, NL) (M)

- 11:00 Obesity as a risk factor for heart failure and impact on outcomes**
C Lam (Singapore, SG, F)
- 11:15 Treating obesity to prevent heart failure**
M Kosiborod (Kansas City, US, M)
- 11:30 Treating obesity in established heart failure**
M Petrie (Glasgow, GB, M)
- 11:45 Obesity in heart failure: observations, outcomes, and options - discussion**
S Zieroth (Winnipeg, CA, F)

Learning Objectives:

Categories: Obesity Track, Online Live

How to protect the kidney in patients with diabetes and heart disease**Session Number: 133**Chairpersons: F Cosentino (Stockholm, SE) (M) - A Abreu (Lisboa, PT) (F)

- 11:00** **Prevalence and shared mechanisms of cardiovascular-kidney-metabolic syndrome**
N Sattar (Glasgow, GB, M)
- 11:15** **Evidence for cardio-renal protection through weight reduction**
S Verma (Toronto, CA, M)
- 11:30** **GLP1 receptor agonists, SGLT2 inhibitors, or both for cardio-renal protection?**
A Van Craenenbroeck (Leuven, BE, F)
- 11:45** **How to protect the kidney in patients with diabetes and heart disease - discussion**
K Marx-Schuett (Aachen, DE, F)

Learning Objectives:

Categories:

Personalised care for atrial septal defect

Session Number: 331

Joint session with the International Society for Adult Congenital Heart Disease (ISACHD)

Chairpersons: GK Kandavello (Kuala Lumpur, MY) (F) - H Sievert (Frankfurt, DE) (M)

11:00 Atrial septal defect with pulmonary hypertension: to close or not to close?

C Stefanescu Schmidt (Boston, US, F)

11:15 Atrial septal defect closure in the elderly: is age just a number?

EL Heng (London, GB, F)

11:30 Superior sinus venosus defect: surgery or stenting?

E Rosenthal (St Albans, GB, M)

11:45 New devices and technology for atrial septal defect closure

S Hascoet (Le Plessis-Robinson, FR, M)

Learning Objectives: This session will highlight some of the challenges and controversies in managing atrial septal defects in adults, a common lesion seen by both general and congenital cardiologists; and will update emerging innovative techniques and devices for closure of atrial septal and sinus venosus defects.

Categories: Online Live, Spotlight of the Congress

**Guidelines in Practice: personalised imaging a heart failure patient
undergoing cancer therapy**

Session Number: 253

Chairpersons: S Dent (Hillsborough, US) (F) - A Lyon (London, GB) (M)

**11:00 Personalised imaging a heart failure patient undergoing cancer therapy: case
presentation**

ZY Vasquez-Ortiz (Distrito Federal, MX, F)

**11:15 Personalised imaging a heart failure patient undergoing cancer therapy: what do
the guidelines say?**

T Lopez Fernandez (Madrid, ES, F)

**11:30 Personalised imaging a heart failure patient undergoing cancer therapy: how to
implement the guidelines and take-home messages**

T Suter (Bern, CH, M)

Learning Objectives:

Categories: Clinical Implementation Track, Spotlight of the Congress

The floor is yours: bring your questions on the risks of other tobacco products (i.e. vaping, snus)

Session Number: 152

Chairpersons: EA Bakker (Nijmegen, NL) (F) - CJF Camm (Oxford, GB) (M)

11:00 The floor is yours: bring your questions on the risks of other tobacco products (i.e. vaping, snus) - get ready for the session
CJF Camm (Oxford, GB, M)

11:05 The floor is yours: bring your questions on the risks of other tobacco products (i.e. vaping, snus) - expert panel
S Gielen (Detmold, DE, M)

G Biondi-Zoccai (Latina, IT, M)

ML Lochen (Tromsø, NO, F)

C Chrysoschoou (Athens, GR, F)

D Richter (Athens, GR, M)

O Ozden Kayhan (Istanbul, TR, F)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Mobile App - Ask a Question, Young Community Track

The floor is yours: bring your questions on minimising the risk of stroke during cardiovascular interventions

Session Number: 294

Chairpersons: S Nardai (Budapest, HU) (M) - A Halliday (Oxford, GB) (F) - A Gonzalez Garcia (Madrid, ES) (F)

11:00 The floor is yours: bring your questions on minimising the risk of stroke during cardiovascular interventions - get ready for the session
A Gonzalez Garcia (Madrid, ES, F)

11:05 The floor is yours: bring your questions on minimising the risk of stroke during cardiovascular interventions - expert panel
P Papakonstantinou (Athens, GR, M)

J Kovac (Leicester, GB, M)

P Widimsky (Prague, CZ, M)

J Saw (Vancouver, CA, F)

L Abrahao Hajjar (Sao Paulo, BR, F)

BA Mulder (Groningen, NL, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Mobile App - Ask a Question, Young Community Track

Using artificial intelligence to bridge gaps in cardiovascular care

Session Number: 371

Chairpersons: V Delgado (Barcelona, ES) (F) - A Meyer (Berlin, DE) (M)

- 11:00** Can artificial intelligence improve cardiovascular disease screening in women?
C Bucciarelli-Ducci (London, GB, F)
- 11:15** Utilisation of artificial intelligence to prevent disease across ethnicities
M van Assen (Atlanta, US, F)
- 11:30** Does artificial intelligence increase the socioeconomic gap?
D Adedinsewo (Jacksonville, US, F)
- 11:45** Using artificial intelligence to bridge gaps in cardiovascular care - discussion
FW Asselbergs (Amsterdam, NL, M)

Learning Objectives:

Categories: Digital Health

Preventing breast cancer cardiotoxicity with CARDIOCARE**Session Number: 442**Chairpersons: J Toste Batista Joaquinito (Lisboa, PT) (F) - M Anker (Berlin, DE) (M)**11:00 Breast cancer and cardiotoxicity: an update**

K Keramida (Athens, GR, F)

11:15 How the technology can decrease cardiotoxicity in breast cancer

I Marco Clement (Madrid, ES, F)

11:30 CARDIOCARE: an interdisciplinary approach for the management of the elderly multimorbid patient with breast cancer therapy-induced cardiac toxicity

D Fotiadis (Ioannina, GR, M)

Learning Objectives:

Categories:

Novel approaches in cardiac regeneration

Session Number: 842

Chairpersons: P Cattaneo (Milan, IT) (F) - C Kupatt (Munich, DE) (M)

- 11:00 State-of-the-art lecture on novel approaches in cardiac regeneration**
M Giacca (London, GB, M)
- 11:20 Cardiomyocyte proliferation is promoted by intracellular Gas6-mediated Yap activity during neonatal heart regeneration**
Y Liu (Nanjing, CN, F)
- 11:40 MiRNA-519e promotes cardiomyocyte cell division accompanied by pro-angiogenic and anti-apoptotic effects**
Y Gong (Zurich, CH, M)

Learning Objectives:

Categories:

Daily Highlights by the Asian Pacific Society of Cardiology

Session Number: 5135

This session is brought to you by the Asian Pacific Society of Cardiology and is not part of the official ESC programme

Chairpersons:

Learning Objectives:

Categories: Online Live

**Young Investigator Award Session in Arrhythmias, Pacing and
Electrophysiology****Session Number: 801**Chairpersons: IC Van Gelder (Groningen, NL) (F) - S Boveda (Toulouse, FR) (M)Judges: J Heijman (Graz, AT) - A Sarkozy (Brussels, BE) - AM Gomez (Orsay, FR)**12:00 PPGAF-score: a photoplethysmographic risk prediction tool for developing atrial
fibrillation**

L Freyer (Muenchen, DE, F)

**12:15 Efficacy of percutaneous stellate ganglion block according to ventricular
arrhythmia cycle length: a post-hoc sub-analysis of the STAR study**

E Baldi (Pavia, IT, M)

**12:30 Generative adversarial networks (GANs) to produce synthetic 12-lead
electrocardiogram signals for specific and rare diseases: a novel, powerful tool
towards clinical advancements**

P Pantelidis (Athens, GR, M)

**12:45 Risk factors for fatal ventricular arrhythmias in heart failure with preserved
ejection fraction: a report from the CHART-2 Study**

T Ito (Sendai, JP, M)

Learning Objectives:

Categories:

Young Investigator Award Session in Interventional Cardiology

Session Number: 806

Chairpersons: A Chieffo (Milan, IT) (F) - O De Backer (Copenhagen, DK) (M)Judges: H Nef (Giessen, DE) - S Bleiziffer (Bad Oeynhausen, DE) - M Alasnag (Jeddah, SA)

- 12:15** **SGLT2-'eyes' on the reno-protection prize: reduction of post-PCI contrast-associated AKI in diabetic patients using SGLT2 inhibitors**
SN Hyder (Ann Arbor, US, M)
- 12:30** **Prognostic significance of type 4a myocardial infarction and periprocedural myocardial injury in NSTEMI patients**
F Bodega (- , IT, F)
- 12:45** **Trends in major cardiac events after ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention from 2003 to 2017: the western Denmark heart registry**
P Thrane (Aarhus, DK, F)

Learning Objectives:

Categories:

**Young Investigator Award Session in Basic and Translational
Sciences****Session Number: 803**Chairpersons: CA Remme (Amsterdam Z0, NL) (F) - A Maguy (Bern, CH) (M)Judges: I Andreadou (Athens, GR) - J Wojta (Vienna, AT) - S Kaab (Munich, DE)

- 12:00** **Complement factor D deficiency ameliorates adverse cardiac remodelling by inhibiting C5a-C5aR mediated ISGs+ neutrophil activation post myocardial infarction**
NX Wang (Harbin, CN, F)
- 12:15** **Quantitative molecular imaging of cardiac fibrosis and response to treatment using a novel collagen III-specific MR imaging probe**
N Chaheer (London, GB, F)
- 12:30** **Loss of Y-chromosomal genes in macrophages induces paracrine phenotypic alterations in cardiac cells**
L Zanders (Frankfurt Am Main, DE, M)
- 12:45** **The interplay between coronary microvascular resistance, arterial reservoir function and coronary flow reserve: unravelling the significance of high microvascular resistance**
A Tas (Istanbul, TR, M)

Learning Objectives:

Categories:

Young Investigator Award Session in Cardiovascular Imaging

Session Number: 804

Chairpersons: M Garbi (Cambridge, GB) (F) - D Muraru (Milan, IT) (F)

Judges: LD Gillam (Morristown, US) - NAB Ntusi (Cape Town, ZA) - BA Popescu (Bucharest, RO)

- 12:00** **Valvular and myocardial fibroblast activation in aortic stenosis: a prospective positron emission tomography study**
N Craig (Edinburgh, GB, M)
- 12:15** **The prognostic impact of inducible ischemia in severe ischaemic cardiomyopathy: a randomised comparison of medical therapy and revascularisation**
H Morgan (London, GB, F)
- 12:30** **Prognostic value of additional midwall late gadolinium enhancement in patients with ischemic cardiomyopathy**
A Unger (Bruxelles, BE, M)
- 12:45** **Left atrial reservoir strain measured by three-dimensional echocardiography is associated with major adverse cardiovascular events in the general population**
M Yafasov (Copenhagen, DK, M)

Learning Objectives:

Categories:

Antiplatelet therapy: novel approaches for acute coronary syndrome and percutaneous coronary intervention**Session Number: 3109**Chairpersons: T Nguyen (Sydney, AU) (F) - J ten Berg (Nieuwegein, NL) (M)

- 12:00 P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: a systematic review and meta-analysis**
M Galli (Rome, IT, M)
- 12:10 Clopidogrel versus aspirin monotherapy for secondary prevention after percutaneous coronary intervention - a nationwide population-based study**
JH Cho (Seoul, KR, M)
- 12:20 Implementation of prasugrel and prognostic outcomes after percutaneous coronary intervention for myocardial infarction: a nationwide observational study**
MR Jacobsen (Copenhagen, DK, F)
- 12:30 Impact of different P2Y12 inhibitors in acute coronary syndrome patients with severe chronic kidney disease: insights from the CORALYS registry**
F Giacobbe (Cirie, IT, M)
- 12:40 Pretreatment with dual antiplatelet therapy in acute myocardial infarction**
Z Motovska (Prague, CZ, F)
- 12:50 Cangrelor versus no cangrelor during percutaneous coronary intervention in hemodynamically unstable patients: a cohort study on benefits and risks**
OL Emilsson (Lund, SE, M)

Learning Objectives:

Categories:

Dyslipidaemias**Session Number: 3322**Chairpersons: SL Mosteoru (Timisoara, RO) (F) - RV Shamoyan (Yerevan, AM) (M)**12:00 Dyslipidaemias - get ready for the session****12:05 Always expect the unexpected – familial hypercholesterolemia hiding beneath severe hypertriglyceridemia**

P Gorzelak-Pabis (Lodz, PL, F)

12:18 Understanding familial hypercholesterolemia: emphasizing diagnosis, management strategies and the importance of early detection

N Muhammad (Detroit, US, F)

12:31 Multiple co-existing endotypes in a patient with ischaemia and non-obstructive coronary artery disease – approach to diagnosis and stratified therapy.

H RAJABALI (London, GB, M)

12:44 The Hidden Culprit: When a Stroke Unveils the Presence of Arteria Lusoria

O Soussi (Rabat, MA, F)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals**Categories:** Mobile App - Vote, Young Community Track

Challenges with cardiovascular comorbidities**Session Number: 3349**Chairpersons:

T Stegmann (Leipzig, DE) (F) - A Ramasamy (London, GB) (M)

- 12:00 Angiotensin receptor-neprilysin inhibition in patients with end-stage kidney disease and refractory hypertension**
C Huang (Taipei, TW, M)
- 12:12 At the intersection of ischemic and bleeding risk – What type-2 myocardial infarction unveils in young patient with HIV infection and uterine fibroma**
M Iurascu-Botezatu (Bucharest, RO, F)
- 12:24 Thrombotic odyssey: navigating the challenges in a complex medical case**
AP Stoica (Bucharest, RO, F)
- 12:36 Peritoneal dialysis: is it time to move to DOACs?**
S Burja Piko (Maribor, SI, F)
- 12:48 Systemic sclerosis/ polymyositis (SSC/ PM) overlap syndrome induced cardiomyopathy in the context of renal crisis- a diagnostic dilemma**
A Karthik (Preston, GB, M)

Learning Objectives:

Categories:

Dazzling presentations of endocarditis**Session Number: 3366**Chairpersons:

F Ilardi (Naples, IT) (F) - YB Bououdina (Algiers, DZ) (F)

- 12:00 Double valve infective endocarditis in a patient with first diagnosis of acquired immunodeficiency syndrome**
S Angelopoulou (Trikala, GR, F)
- 12:12 Infective endocarditis with septic pulmonary embolies in ventricular septal defect - small but lethal.**
A Jaspattananon (Phuket, TH, M)
- 12:24 Neglected twice but finally recognized: a devastating presentation of infective endocarditis**
A Sanchez Arjona (Madrid, ES, M)
- 12:36 Endocarditis on a native mitral valve in a young patient**
L Suhov (Timisoara, RO, F)
- 12:48 The long and winding road of a patient with native aortic valve endocarditis and multiple systemic emboli**
I Isfan (Bucharest, RO, F)

Learning Objectives:

Categories:

**Making progress in cardiovascular care for oncology patients in
Latvia and Azerbaijan****Organised in collaboration with the Latvian Society of Cardiology and
the Azerbaijan Society of Cardiology****Session Number: 5103**Chairpersons: K Trusinskis (Riga, LV) (M) - U Mirzoyev (Baku, AZ) (M)**12:30 The Latvian perspective in management of complex cardiovascular disease in
cancer patients**

A Erglis (Riga, LV, M)

**12:42 Call to action: how to improve quality of care and outcomes for patients with
chronic cardiovascular diseases and co-morbid conditions and cancer in
Azerbaijan**

T Sadigova (Baku, AZ, F)

**12:54 Making progress in cardiovascular care for oncology patients in Latvia and
Azerbaijan - discussion**

I Mintale (Riga, LV, F)

R Gabulova (Baku, AZ, F)

Learning Objectives: To explore interactions between cardiovascular disease and cancer as well as their management
with an eye to improving quality, safety, and outcomes.

Categories: Online Live, Spotlight of the Congress

Advanced heart failure: new challenges, new opportunities

Session Number: 3039

Chairpersons: A Vest (Boston, US) (F) - E Joyce (Dublin 7, IE) (F)

- 13:15 Outcomes of intra-aortic balloon pump in patients with advanced heart failure and cardiogenic shock undergoing heart transplantation**
V Bellini (Sao Paulo, BR, F)
- 13:25 Reversibility of precapillary pulmonary hypertension and outcomes after heart transplantation bridged with left ventricular assist devices: insight from the UNOS**
H Alnsasra (Beer Sheva, IL, M)
- 13:35 The hemodynamic classification system for hemodynamic-related adverse events in left ventricular assist device patients**
G Gallone (Torino, IT, M)
- 13:45 Outflow graft stenosis after left ventricular assist device implantation: the rotterdam experience**
P Jahangiri (Rotterdam, NL, M)
- 13:55 Impact of HF etiology on the sustainability of favorable response after LVAD weaning: A VAD Wean Registry analysis**
S Drakos (Salt Lake, US, M)
- 14:05 Donor-derived cell-free DNA versus left ventricular global longitudinal strain in noninvasive detection of heart allograft injury**
T Teszak (Budapest, HU, F)

Learning Objectives:

Categories:

Challenges in the management of atrial fibrillation**Session Number: 3021**Chairpersons: A Russo (Moorestown, US) (F) - M Proietti (Milan, IT) (M)

- 13:15 Rhythm control for atrial fibrillation in patients with end-stage or chronic kidney disease**
D Kim (Seoul, KR, M)
- 13:27 Risks of incident genitourinary malignancies in anticoagulated atrial fibrillation patients experiencing hematuria**
T Chao (Taipei, TW, M)
- 13:39 Polygenic risk score and risk of cardiovascular event in atrial fibrillation patients with low to intermediate stroke risk**
J Kim (Cheonan-Si, KR, F)
- 13:51 Rising trends and disparities in cardiac arrest-related mortality among patients with atrial fibrillation: a 22-year comprehensive analysis**
H Pham (Tucson, US, M)
- 14:03 The association between heart rate and deformational echocardiographic parameters in patients with atrial fibrillation and their impact on clinical outcomes**
J Liao (Taipei City, TW, F)

Learning Objectives:

Categories:

Molecular tools to understand the complexity of adult congenital heart disease**Session Number: 3067**Chairpersons: K Dimopoulos (London, GB) (M) - A Egorova (Leiden, NL) (F)

- 13:15 Mitral valve phenotypes in SMAD3-related thoracic aortic disease: insights from the Montalcino Aortic Consortium**
K Asokan (Houston, US, M)
- 13:25 Histological assessment of the shared vascular wall in anomalous aortic origin of coronary arteries with an interarterial course.**
DBH Verheijen (Leiden, NL, M)
- 13:35 Unraveling Marfan hearts: ultrastructural evidence for myocardial remodeling and cardiomyopathy**
V Deleeuw (Ghent, BE, F)
- 13:45 Multi-omics integration analysis identifies pathogenic candidate genes of congenital heart defects with vascular malformation**
X Ding (Shanghai, CN, F)
- 13:55 Different microRNA expression in the right ventricular outflow tract myocardium of tetralogy of Fallot**
H Suzuki (Okayama, JP, M)
- 14:05 E-selectin and asymmetric dimethylarginine plasma levels in adult cyanotic congenital heart disease patients: relation to biochemical parameters, vascular function, and clinical status.**
S Nartowicz (Poznan, PL, F)

Learning Objectives:

Categories:

Cardio-oncology in practice

Session Number: 3099

Chairpersons: J Bergler-Klein (Vienna, AT) (F) - A La Gerche (Fitzroy, AU) (M)

- 13:15** **Comparison between non-vitamin K antagonist oral anticoagulants and low-molecular-weight heparin in Asian individuals with cancer-associated venous thromboembolism**
- 13:27** **Cardiovascular events in CML patients treated with nilotinib: validation of the HFA-ICOS baseline risk score**
M Andres (London, GB, F)
- 13:39** **The safety of standardized management of suspected cardiovascular immune-related events in patients treated by immunecheckpoints inhibitors**
F Cribari (Rome, IT, M)
- 13:51** **Cardiovascular mortality among patients with diffuse large B-cell lymphoma: a population-based study**
D Hong (Shantou, CN, F)
- 14:03** **Unraveling immune checkpoint inhibitors effects on atherosclerosis: mechanisms and preventive approaches**
I Nardi Agmon (Petah Tikva, IL, F)

Learning Objectives:

Categories:

Innovations in digital care and patient engagement

Session Number: 3116

Chairpersons: L Neubeck (Edinburgh, GB) (F) - A Verstrael (Antwerpen, BE) (M)

- 13:15** **KardioNet Digital - a structured care model involving digital tools for intersectoral communication and a patient-focused strategy for treatment of heart failure**
F Goss (Munich, DE, M)
- 13:25** **Effect of a cardiovascular post discharge sms support program on healthcare utilisation - the hearthealth program**
B Sheahen (Westmead, AU, M)
- 13:35** **Introducing online narrated video animations to facilitate patients' understanding of cardiac procedures in a high-volume tertiary centre**
J Almutawa (Liverpool, GB, F)
- 13:45** **Do physicians and patients speak different languages: quantitative evidence from linguistic analysis**
P Whittaker (Oxford, GB, M)
- 13:55** **Delivering shared decision-making before transcatheter aortic valve implantation using digital and remote techniques to enhance patient engagement and convenience**
E Carulli (- , IT, M)
- 14:05** **Self-management app usage and expectations by patients with heart failure: results of a qualitative study**
T Helms (Hamburg, DE, M)

Learning Objectives:

Categories:

Mitral valve interventions**Session Number: 3317**Chairpersons: GE Mandoli (Siena, IT) (F) - T Kister (Leipzig, DE) (M)**13:15 Mitral valve interventions - get ready for the session**

T Kister (Leipzig, DE, M)

13:20 Double percutaneous mitral and tricuspid valve replacement

C Chong-Nguyen (Bern, CH, F)

13:38 Successful MitraClip case for degenerative severe mitral regurgitation with double orifice mitral valve

M Yoshizawa (Morioka, JP, F)

13:56 A successful case of surgical mitral valve replacement with ultra-low aortic clamping in a patient with severe mitral regurgitation and high surgical risk due to porcelain aorta

C Porras Bueno (Floridablanca, CO, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals

Categories: Mobile App - Vote, Young Community Track

Pulmonary hypertension (1)**Session Number: 3336**Chairpersons: H Atef (Newcastle Under Lyme, GB) (M) - M Hemmat Gaber (Alexandria, EG) (F)

- 13:15 How many shunts are too many- a case of complex adult congenital heart disease**
D Perpelea (Bucharest, RO, M)
- 13:27 Unraveling complexity: truncus arteriosus, heart failure, and pulmonary hypertension.**
NY Sari (Indonesia, ID, F)
- 13:39 Pulmonary artery aneurysm associated with in situ thrombosis and severe tracheal compression**
R Zebadua (Mexico City, MX, M)
- 13:51 Congenital isolated unilateral agenesis of pulmonary arteries with 3-year follow-up after initiation of treatment**
M Nakata (Urasoe, JP, M)
- 14:03 High-output heart failure in pulmonary hypertension: unraveling complexities through exercise hemodynamics**
T Donisan (Rochester, US, F)

Learning Objectives:

Categories:

Challenging cardiac masses**Session Number: 3375**Chairpersons: I Kotlar (Skopje, MK) (F) - E Androulakis (London, GB) (M)

- 13:15 Spontaneous left atrial haematoma presented as left atrial mass.**
A Magdy (Cairo, EG, M)
- 13:30 An interesting rare case of Primary Cardiac Lymphoma in an immunocompetent patient.**
A T Elsaid (Medina, GB, M)
- 13:45 Navigating the uncharted waters: a rare odyssey through diagnosis and surgical endeavors in cardiac paraganglioma**
E Boxhammer (Salzburg, AT, F)
- 14:00 Cardiac myxofibrosarcoma: a diagnostic and therapeutic challenge**
MJ Santa Ana-Bayona (Mexico City, MX, F)

Learning Objectives:

Categories:

Daily Highlights by the Netherlands Society of Cardiology

Session Number: 5120

This session is brought to you by the Netherlands Society of Cardiology and is not part of the official ESC programme

Chairpersons:

Learning Objectives:

Categories: Online Live

2024 ESC Guidelines for the Management of Elevated Blood Pressure and Hypertension

Session Number: 1001

Chairpersons: J Mcevoy (Galway, IE) (M) - R Touyz (Montreal, GB) (F)

Management of electrical storm**Session Number: 173**Chairpersons: P Vergara (Milano, IT) (M) - S Al-Khatib (Durham, US) (F)**13:45 Antiarrhythmic drugs and device re-programming in electrical storm**

M M Saba (New Malden, GB, M)

14:00 Neuromodulation in electrical storm

E Baldi (Pavia, IT, M)

14:15 Mechanical circulatory support in electrical storm

P Peichl (Prague, CZ, M)

14:30 Catheter ablation in electrical storm

M Hocini (Pessac, FR, F)

14:45 Management of electrical storm - discussion

A Sarkozy (Brussels, BE, F)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Online Live, Young Community Track

Identification and risk stratification of relevant coronary artery disease in clinical practice

Session Number: 830

Chairpersons: F Andreotti (Rome, IT) (F) - F Pinto (Lisbon, PT) (M)

- 13:45 State-of-the-art lecture on identification and risk stratification of relevant coronary artery disease in clinical practice**
P Steg (Paris, FR, M)
- 14:03 Investigating the influence of possible liver fibrosis on mortality in patients with coronary artery disease - a post-hoc ISCHEMIA trial analysis**
T Caldonazo (Jena, DE, M)
- 14:22 Icosapent ethyl by baseline small dense low-density lipoprotein cholesterol: an analysis of REDUCE-IT**
R Aggarwal (Boston, US, M)
- 14:41 Electrocardiogram-based artificial intelligence to identify prevalent coronary artery disease**
S Kany (Hamburg, DE, M)

Learning Objectives:

Categories:

Novel antithrombotic therapies in cardiovascular disease: what's on the horizon?**Session Number: 235**Chairpersons: B Gigante (Stockholm, SE) (F) - S Halvorsen (Oslo, NO) (F)**13:45 Subcutaneous P2Y12 inhibition**

RF Storey (Sheffield, GB, M)

14:00 Subcutaneous GP IIb/IIIa inhibition

J ten Berg (Nieuwegein, NL, M)

14:15 Glycoprotein VI inhibition

C Christersson (Uppsala, SE, F)

14:30 FXIa inhibition

D Gorog (London, GB, F)

14:45 Novel antithrombotic therapies in cardiovascular disease: what's on the horizon? - discussion

B Rocca (Rome, IT, F)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Young Community Track

Delivering optimal care for patients with obesity during cardiac procedures

Session Number: 286

Chairpersons: V Falk (Berlin, DE) (M) - S Rao (Indore, IN) (F)

13:45 Preparation, access, and radiation considerations in PCI for patients with obesity
A Chieffo (Milan, IT, F)

14:00 Alternative access, harvesting, and special equipment in surgical patients with obesity
Gry Dahle (Oslo, NO, F)

14:15 Post-procedural care for PCI and surgery in patients with obesity
J Siller-Matula (Vienna, AT, F)

14:30 Weight management before and after cardiac procedures in patients with obesity
P Taub (Rancho Santa Fe, US, F)

14:45 Delivering optimal care for patients with obesity during cardiac procedures - discussion
J Rymer (Durham, US, F)

Learning Objectives:

Categories: Obesity Track

Great Debate: modern medical treatment is better than myomectomy for obstructive hypertrophic cardiomyopathy**Session Number: 230**Chairpersons:

M Michels (Rotterdam, NL) (F) - F De Robertis (Harefield, GB) (M)

13:45 Modern medical treatment is better than myomectomy for obstructive hypertrophic cardiomyopathy: pro

I Olivotto (Firenze, IT, M)

14:05 Modern medical treatment is better than myomectomy for obstructive hypertrophic cardiomyopathy: con

JR Gimeno Blanes (Murcia, ES, M)

14:25 Modern medical treatment is better than myomectomy for obstructive hypertrophic cardiomyopathy - discussion

K Haugaa (Oslo, NO, F)

Learning Objectives:

Categories: Online Live

Registries, observational, and other studies on TAVI

Session Number: 1032

Chairpersons: C Agatiello (Buenos Aires, AR) (F)

- 13:45 Long-term structural valve deterioration after TAVI: insights from the European Valve Durability TAVI registry**
C Giannini (Pisa, IT, F)
- 13:57 Long-term benefit of isolated surgical tricuspid valve repair and replacement in patients with severe functional tricuspid regurgitation: Impact of the TRI-SCORE**
J Dreyfus (Saint-Denis, FR, M)
- 14:10 SAVR and TAVI comparison across the Globe based on current regional registry evidence - a meta-analysis of reconstructed time-to-event data**
T Doenst (Jena, DE, M)
- 14:22 Aortic valve calcific volume by computed tomography angiography in patients with aortic stenosis**
J Geers (Brussels, BE, F)
- 14:35 Serial volumetric assessment of ascending aort dilatation in severe aortic stenosis patients who receive Transcatheter aortic valve replacement: Comparison of bicuspid and tricuspid aortic stenosis**
HS Kim (Seoul, KR, M)
- 14:47 Sex related differences in frequency, management and outcome of severe native valvular heart disease. Results from the ESC-EORP Valvular Heart Disease II survey**
J Mascherbauer (Vienna, AT, F)

Learning Objectives:

Categories:

Showcasing successes in advanced heart failure**Session Number: 109**Chairpersons: M Senni (Bergamo, IT) (M) - R Hamdan (Dubai, LB) (F)

13:45 Temporary mechanical circulatory support as a bridge to transplant: what have we learned from the ASIS-TC registry?

E Barge Caballero (A Coruna, ES, M)

14:00 Reducing residual risk in left ventricular assist device carriers: lessons from ARIES-HM3 trial

M Mehra (Boston, US, M)

14:15 Real-world data on patients with left ventricular assist devices: the ELEVATE Registry

F Gustafsson (Copenhagen, DK, M)

14:30 Update on heart transplantation

S Mirabet Perez (Barcelona, ES, F)

14:45 Showcasing successes in advanced heart failure - discussion

A Kydd (Cambridge, GB, F)

Learning Objectives:

Categories: Online Live

Caring for kidney disease patients in a cardiology setting: what is important?

Session Number: 838

Chairpersons: E Prescott (Copenhagen, DK) (F) - W Herrington (Oxford, GB) (M)

- 13:45 State-of-the-art lecture on caring for kidney disease patients in a cardiology setting: what is important?**
C Wanner (Wuerzburg, DE, M)
- 14:03 Relative effectiveness of high-dose vs. standard-dose quadrivalent influenza vaccine in chronic kidney disease: a secondary analysis of the DANFLU-1 trial**
KV Bartholdy (Kongens Lyngby, DK, F)
- 14:22 Prognostic value of C-reactive protein / albumin ratio for amputation and/or mortality after lower extremity revascularization in haemodialysis patients with peripheral artery disease**
H Takahashi (Toyoake, JP, M)
- 14:41 Association of a history of acute kidney injury with major adverse cardiovascular events in chronic kidney disease patients**
B Tyl (La Garenne Colombes Cedex, FR, M)

Learning Objectives:

Categories:

A roadmap to eradicate rheumatic heart disease**Session Number: 325**Chairpersons: E Marijon (Paris, FR) (M) - A Saxena (New Delhi, IN) (F)

- 13:45 The global burden of rheumatic heart disease: trends and challenges**
G Roth (Seattle, US, M)
- 14:00 Group A streptococcal vaccine development: challenges and opportunities**
M Mirabel (Paris, FR, F)
- 14:15 Active surveillance for rheumatic heart disease: challenges and risks**
T Pilgrim (Bern, CH, M)
- 14:30 Antibiotic prophylaxis for latent rheumatic heart disease**
C Bouleti (Paris, FR, F)
- 14:45 A roadmap to eradicate rheumatic heart disease - discussion**
L Abid (Sfax, TN, F)

Learning Objectives:

Categories: Online Live

**Clinical applications of artificial intelligence in cardiovascular
imaging**

Session Number: 820

Chairpersons: A Scatteia (Naples, IT) (F) - E Alexanderson Rosas (Mexico, MX) (M)

- 13:45 Clinical applications of artificial intelligence in cardiovascular imaging: state-of-the-art lecture**
J Strom (Boston, US, M)
- 14:03 DELINEATE-Regurgitation: deep learning for automated assessment of aortic, mitral, and tricuspid regurgitation from echocardiography**
A Long (State College, US, M)
- 14:22 Artificial intelligence-based automated plaque quantification from CCTA to predict acute coronary syndrome on top of obstructive or ischemic coronary artery disease**
S Bar (Turku, FI, F)
- 14:41 Machine learning model using cardiovascular magnetic resonance to predict cardiovascular events in asymptomatic patients with known CAD**
J Amar (Neuilly Sur Seine, FR, M)

Learning Objectives:

Categories: Digital Health

Registries, observational, and other studies on artificial intelligence

Session Number: 1033

Chairpersons:

- 13:45** **Artificial intelligence-based prediction of mortality, bleeding, and ischaemic events in cancer patients with acute coronary syndrome: A modelling study in the UK and Switzerland**
FA Wenzl (Schlieren, CH, M)
- 13:57** **Artificial intelligence for analysis of ambulatory electrocardiography**
LS Johnson (Malmö, SE, F)
- 14:10** **Heart Failure detection using Artificial Intelligence for diagnostic decision support applied to echocardiography - HFDetect-AI**
G Strange (Woronora, AU, M)
- 14:22** **MitrAI score: machine learning models to predict mortality at 12, 24, 36 and 48 months in patients with primary and secondary mitral regurgitation treated by transcatheter edge-to-edge repair.**
L Biasco (Lugano, CH, M)
- 14:35** **Machine-learning based scoring system to predict cardiogenic shock in acute coronary syndrome**
A Bohm (Bratislava, SK, M)
- 14:47** **Machine learning algorithm using point-of-care high-sensitivity cardiac troponin I for rapid rule-out of myocardial infarction**
B Toprak (Hamburg, DE, F)

Learning Objectives:

Categories: Digital Health

Practice-changing studies from NEJM 2024

Session Number: 411

Joint session with the New England Journal of Medicine (NEJM)

Chairpersons: JAL Leopold (Boston, US) (F) - JJV McMurray (Glasgow, GB) (M)

13:45 Targeting lipids: lessons learned with novel therapeutics and horizons ahead
J Kastelein (Amsterdam, NL, M)

14:03 Coronary stents and transcatheter therapies for structural heart disease: what have we learned in 2024?
BE Stahli (Zurich, CH, F)

14:22 Getting to the heart of the matter: GLP1 receptor agonists and cardiovascular disease
D McGuire (Dallas, US, M)

14:41 Moving beyond diuretics: advances in treatment of cardiomyopathies and heart failure
T McDonagh (London, GB, F)

Learning Objectives: To review practice-changing studies published in NEJM in 2024 with a focus on novel therapeutics, including:

- siRNAs for lipid management;
- how GLP-1 receptor agonists are used to treat cardiovascular diseases such as heart failure with preserved ejection fraction or to reduce the risk of adverse cardiovascular events;
- advances in coronary interventions and structural heart disease; and
- new therapies for cardiomyopathies, including amyloid heart disease and hypertrophic cardiomyopathy.

Categories:

Telehealth interventions in heart failure management: state of the art

Session Number: 840

Chairpersons: JJ Brugts (Rotterdam, NL) (M) - TM Norekval (Bergen, NO) (F)

13:45 State-of-the-art lecture on telehealth interventions for heart failure management

A Bhatt (Boston, US, F)

14:03 Telehealth-aided outpatient management of acute heart failure in a specialist virtual ward compared to standard care

D Rasoul (Liverpool, GB, M)

14:22 Digital literacy of patients with chronic heart failure using telemedicine in france: a national observational cohort study

N Girerd (Nancy, FR, M)

14:41 Automatic telephonic follow up in heart failure by a natural language processing artificial intelligence: pilot program

A Olivella (Barcelona, ES, M)

Learning Objectives:

Categories: Digital Health, Online Live

Ask the Trialist - HELIOS-B

Session Number: 1070

Chairpersons: S Cuddy (Boston, US) (F)

13:45 Ask the Trialist - HELIOS-B
M Fontana (London, GB, F)

Learning Objectives:
Categories:

Heart-brain and brain-heart interactions in cardiovascular health and disease**Session Number: 351**Chairpersons: J Balligand (Brussels, BE) (M) - A D'souza (Manchester, GB) (F)

- 13:45 Heart-brain crosstalk in Takotsubo cardiomyopathy: does sex matter?**
C Gebhard (Zurich, CH, F)
- 14:00 Autonomic control of cardiac function in health and disease: impact on arrhythmogenesis**
K Scherschel (Duesseldorf, DE, F)
- 14:15 Neurovascular crosstalk in atherosclerosis**
C Weber (Muenchen, DE, M)
- 14:30 Neurocardiac crosstalk in the ageing and diseased heart**
J Wagner (Frankfurt Am Main, DE, M)
- 14:45 Heart-brain and brain-heart interactions in cardiovascular health and disease - discussion**
D Carnevale (Pozzilli, IT, F)

Learning Objectives:

Categories:

Ask the Trialists	Friday, 30 August 2024	14:10 - 14:25	Helsinki - Lecture room
-------------------	------------------------	---------------	-------------------------

Ask the Trialist - STOP-or-NOT

Session Number: 1072

Chairpersons: P Devereaux (Hamilton, CA) (M)

14:10 Ask the Trialist - STOP-or-NOT
M Legrand (San Francisco, US, M)

Learning Objectives:
Categories:

Factors influencing the decision to revascularise in chronic coronary syndromes

Session Number: 206

Joint session with the Brazilian Society of Cardiology (BSC)

Chairpersons:

P Caramori (Porto Alegre, BR) (M) - L Shaw (New York, US) (F)

**14:30 Factors influencing the decision to revascularise in chronic coronary syndromes:
extent of ischaemia**

J Tamis-Holland (Cleveland, US, F)

**14:45 Factors influencing the decision to revascularise in chronic coronary syndromes:
extent of coronary artery disease**

AK Gitt (Ludwigshafen, DE, M)

**15:00 Factors influencing the decision to revascularise in chronic coronary syndromes:
left ventricular function**

LZM Zytynski Moura (Curitiba, BR, F)

**15:15 Factors influencing the decision to revascularise in chronic coronary syndromes:
angina burden**

RP Pavanello (Sao Paulo, BR, M)

Learning Objectives: This session will review the current evidence and discuss potential indications of invasive procedures on top of guideline-based OMT in patients with chronic coronary syndromes, including how symptoms, ischaemic burden (both invasive and non-invasive), and left ventricular dysfunction affect that decision in clinical practice.

Categories: Online Live

The pandemic of ageing in heart failure: age, frailty, and cognition**Session Number: 3034**Chairpersons: AS Mihailidou (Sydney, AU) (F) - W Doehner (Berlin, DE) (M)

- 14:30 Patient characteristics and mortality trends among octogenarians with heart failure over two decades - a Danish nationwide study**
CH Garred (Gentofte, DK, F)
- 14:40 Obesity paradox exists in super elderly patients with heart failure**
T Tachibana (Tokyo, JP, M)
- 14:50 Age-based comparison of patients with heart failure treated with sacubitril-valsartan in France: a real-world evaluation**
O Hanon (Paris, FR, M)
- 15:00 Elderly patients with decompensated heart failure: prospective analysis from the LECRA-HF registry.**
A Siniarski (Krakow, PL, M)
- 15:10 Multiple comorbidities are associated with poor prognosis in patients with ADHF-HFpEF and non-frailty or mild frailty but not moderate-severe frailty -PURSUIT-HFpEF Registry-**
T Kondo (Sumiyoshi-Ku, JP, M)
- 15:20 Temporal trends in mortality and hospitalisation risk in patients with heart failure according to frailty status**
N Abassi (Gentofte, DK, F)

Learning Objectives:

Categories:

**Beyond angiography: coronary applications of intravascular
ultrasound and optical coherence tomography****Session Number: 3080**Chairpersons: DW Park (Seoul, KR) (M) - A Maehara (New York, US) (F)

- 14:30 Long-term clinical outcomes of acute myocardial infarction based on a center's experience with IVUS in the contemporary drug-eluting stent era**
N Kim (Daegu, KR, M)
- 14:40 Intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention for acute myocardial infarction with cardiogenic shock**
Y Kim (Yongin, KR, M)
- 14:50 Association between stent implantation results and target vessel failure after IVUS-Guided PCI: A FLAVOUR substudy**
S Tu (Shanghai, CN, M)
- 15:00 Coronary stent edge segments as determinant of clinical outcomes: An OCTOBER Trial Substudy**
S Bulow Rasmussen (Aarhus, DK, M)
- 15:10 Characterization of plaque hemorrhage with optical coherence tomography imaging in statin-treated patients with coronary artery disease: comparison with noncontrast T1-weighted MRI**
J Nakata (Sapporo, JP, M)
- 15:20 Serial optical coherence tomography assessment of coronary atherosclerosis and long-term clinical outcomes**
K Yamaji (Kyoto, JP, M)

Learning Objectives:

Categories:

Lipids and adipose tissue interaction in cardiovascular disease

Session Number: 3126

Chairpersons: S Steffens (Munich, DE) (F) - C Binder (Vienna, AT) (M)

- 14:30 Lipoprotein(a) induces spontaneous aortic dissection via increasing monocyte mediated vascular smooth muscle cell phenotype transformation in human Lp(a) transgenic mice**
C Han (Shanghai, CN, M)
- 14:40 Lipoprotein(a) regulates vascular redox state and inflammatory response in patients with coronary artery disease**
I Badi (Oxford, GB, F)
- 14:50 Targeting an altered sphingolipid profile with consecutive lipotoxicity as therapeutic approach to calcific aortic valve disease**
T Rusack (Luebeck, DE, M)
- 15:00 Stress memory of heart failure in hematopoietic niche promotes recurrence via adipocytic skewing of mesenchymal stromal cells**
K Goto (Tokyo, JP, M)
- 15:10 Human epicardial adipose tissue secretome alters metabolomic profile and induces endothelial-to-mesenchymal transition in human lymphatic endothelial cells**
I Abe (Oita, JP, M)
- 15:20 Metabolomic reprogramming of subcutaneous adipose tissue aggravates atherosclerosis via impaired adipocyte-macrophage crosstalk**
B Lou (Xi'an, CN, M)

Learning Objectives:

Categories:

Pharmacological management of hypertension

Session Number: 3081

Chairpersons: M Dorobantu (Bucharest, RO) (F) - M Camafort (Barcelona, ES) (M)

- 14:30 Subgroup results from KARDIA-2: impact of demographic and baseline disease characteristics on zilebesiran response in patients with hypertension uncontrolled by a standard oral antihypertensive**
M Saxena (London, GB, M)
- 14:40 Safety, tolerability and blood pressure lowering of the innovative guanylyl cyclase a-receptor activator MANP in an ethnically diverse resistant hypertension population: a phase 1B clinical trial**
H Chen (Rochester, US, M)
- 14:50 Antihypertensive treatment of masked hypertension guided by ambulatory blood pressure monitoring: a double-blind, placebo-controlled trial**
DY Zhang (Shanghai, CN, F)
- 15:00 Angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers vs. calcium channel blockers for 12,478 young hypertensive patients under 40 in 10-year follow-up**
SH Jo (Anyangsi Gyeonggi-do, KR, M)
- 15:10 Blood pressure lowering efficacy of antihypertensive drugs and their combinations: a systematic review and meta-analysis of 500 randomised, double-blind placebo-controlled trials**
N Wang (Sydney, AU, M)
- 15:20 Antihypertensive treatment during pregnancy and maternal and fetal outcomes**
J Vaclavik (Olomouc, CZ, M)

Learning Objectives:

Categories:

Hereditary thoracic aortic disease in the spotlight

Session Number: 3070

Chairpersons: J Dumfarth (Innsbruck, AT) (F) - G Jondeau (Paris, FR) (M)

- 14:30 Sex differences in aortic prognosis in Marfan patients, a retrospective longitudinal study from the REPAG registry**
G Teixido Tura (Barcelona, ES, F)
- 14:40 Marfan syndrome in children: large, single centre experience on management and outcome**
A Freixa-Benavente (London, GB, F)
- 14:50 Genome wide association studies on three-dimensional aortic geometric indices measured with magnetic resonance imaging**
C Beeche (Philadelphia, US, M)
- 15:00 Association of lifelong exercise characteristics with aortic pathology in patients with Marfan syndrome**
R van Kimmenade (Weert, NL, M)
- 15:10 Double arch technique - a novel surgical procedure for the hypoplastic aortic arch syndrome**
C Zhou (Beijing, CN, M)
- 15:20 Estimated aortic pulse wave velocity predicts adverse events in females with thoracic aortic aneurysms**
T Coutinho (Rochester, US, F)

Learning Objectives:

Categories:

Multimodality imaging**Session Number: 3310**Chairpersons: L Murphy (Dublin 7, IE) (F) - P Zwetsloot (Utrecht, NL) (M)**14:30 Multimodality imaging - get ready for the session****14:35 A rare case of malignant anomalous and hyperdominant RCA with absent LCX : multimodality imaging approach to diagnosis and management**
LK Wang (Singapore, SG, M)**14:48 A case of eosinophilic granulomatosis with polyangiitis with Loeffler-endomyocarditis and travel history: complexity in need of multimodality imaging and interdisciplinary communication**
J-H Steul (Dresden, DE, M)**15:01 Multimodality imaging assessment of rapidly developing, sepsis-related myocardial calcification with biventricular dysfunction: an unusual case.**
T Obafemi (Aberdeen, GB, M)**15:14 Clinical suspicion and multimodal imaging in a subtle cardiac sarcoidosis case report**
E Bal (Istanbul, TR, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals

Categories: Mobile App - Vote, Young Community Track

Non-coronary cardiac interventions**Session Number: 3335**Chairpersons: A Beneduce (Milan, IT) (M) - BCQ Caneiro-Queija (Vigo, ES) (F)

- 14:30 Intervention of resistant hypertension due to renal artery stenosis with solitary kidney guided by intravascular ultrasound and fractional flow reserve with very little contrast agent**
X Liu (Beijing, CN, M)
- 14:42 Making of the robo-heart, interventional closure of an atrial septal defect - better late than ever?**
P Craciun (Bucharest, RO, M)
- 14:54 A rare case of refractory hypoxaemia in a patient with large ostial right coronary artery thrombus and large atrial septal defect**
M Fares (Oxford, GB, M)
- 15:06 Aneurysmal pipe to Congested pump**
S Chiramel (Bengaluru, IN, M)
- 15:18 Staged treatment of a post-infarction ventricular septal defect – first percutaneous, then surgical**
C Kenn (Trier, DE, F)

Learning Objectives:

Categories:

Adult congenital heart disease cases (1)**Session Number: 3376**Chairpersons: D Dorobantu (Exeter, GB) (M)

- 14:30** **Decision crossroads in the management of a patient with Tetralogy of Fallot**
MD Drakopoulou (Athens, GR, F)
- 14:42** **A case of an 18 year old female diagnosed with pentalogy of fallot who underwent surgical repair and embolization of major aortopulmonary collaterals**
B Songco (City Of San Fernando, PH, F)
- 14:54** **Anomalous Aortic Origin of the Left Coronary Artery in a Patient with Inferior ST-Segment Elevation Myocardial Infarction (STEMI)**
F Gandolfo (Buenos Aires, AR, M)
- 15:06** **Pregnancy management in a patient with uncorrected truncus arteriosus: a challenging case report**
GC Yilmaz (Ankara, TR, F)
- 15:18** **A symphony of shadows: a case of unique congenital heart disease**
MD Drakopoulou (Athens, GR, F)

Learning Objectives:

Categories:

Ask the Trialist - ABYSS

Session Number: 1071

Chairpersons: J Armitage (Oxford, GB) (F)

14:35 Ask the Trialist - ABYSS
J Silvain (Paris, FR, M)

Learning Objectives:

Categories:

Daily Highlights by the British Cardiovascular Society

Session Number: 5121

This session is brought to you by the British Cardiovascular Society and is not part of the official ESC programme

Chairpersons:

Learning Objectives:

Categories: Online Live

Diagnosis and treatment of microvascular and epicardial coronary artery disease**Session Number: 3052**Chairpersons: A Maas (Nijmegen, NL) (F) - P Ong (Stuttgart, DE) (M)

- 15:45 Simplification of coronary continuous thermodilution**
T Mahendiran (Lausanne, CH, M)
- 15:55 Dysregulation of sympathoadrenal system activity in patients with microvascular angina**
N Nasirdinov (Andijan, UZ, M)
- 16:05 Prevalence of coronary microvascular disease in myocardial infarction with non-obstructive coronary artery disease**
J Carrington (Rochester, US, M)
- 16:15 Sex-differences in ANOCA patients undergoing invasive coronary function testing: preliminary results from the Dutch national NL-CFT registry**
J Woudstra (Amsterdam, NL, F)
- 16:25 Ticagrelor or prasugrel versus clopidogrel in patients with coronary heart disease**
L Costa (Sao Paulo, BR, M)
- 16:35 Health-related quality of life and long-term incidence of major adverse events in patients with acute coronary syndromes**
C Follonier (Geneva, CH, M)

Learning Objectives:

Categories:

Pulsed field ablation for atrial fibrillation ablation: latest findings**Session Number: 3019**Chairpersons: C Sticherling (Basel, CH) (M) - J Vogler (Luebeck, DE) (F)

- 15:45 Incidence of acute pericarditis after pulsed-field ablation for the treatment of atrial fibrillation**
C Isenegger (Basel, CH, F)
- 15:55 Long-term patient clinical benefits and healthcare utilization after pulsed field ablation in paroxysmal atrial fibrillation: sub-analyses from the multicenter insPLRE trial**
T De Potter (Aalst, BE, M)
- 16:05 Characterization of sedation strategies in real-world use of pulsed field ablation: sub-analysis of the EU-PORIA registry**
- 16:15 Pulsed-field ablation for atrial fibrillation with a novel simplified protocol: the Swiss PFA dose multicenter study**
P Badertscher (Basel, CH, M)
- 16:25 Risk and management of acute kidney injury resulting from hemoglobinuria following pulsed-field ablation in atrial fibrillation**
S Mohanty (Austin, US, F)
- 16:35 Influence of a three-dimensional mapping system on acute safety and efficacy of pulsed-field ablation for atrial fibrillation**
R Rordorf (Milano, IT, M)

Learning Objectives:

Categories:

Pulmonary hypertension: advanced diagnostics**Session Number: 3056**Chairpersons: P Thistlethwaite (La Jolla, US) (F) - A Vonk Noordegraaf (Amsterdam, NL) (M)

- 15:45 Multiscan-PH: a multimodal deep learning approach for enhanced screening of pulmonary hypertension**
Z Huang (Beijing, CN, M)
- 15:55 Circulating Angiopoietin-2 (Angpt2) levels predict diagnosis of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)**
L Hobohm (Mainz, DE, M)
- 16:05 TAPSE/sPAP by echocardiography to detect elevated pulmonary vascular resistance > 4 WU in postcapillary pulmonary hypertension patients: insights from the French PH HF registry**
F Bauer (Rouen Cedex, FR, M)
- 16:15 Advancing pulmonary hypertension early detection through deep-learning enhanced chest radiographic analysis**
Z Huang (Beijing, CN, M)
- 16:25 Assessment of sub clinical right ventricular ischemia using oxygen sensitive cardiac magnetic resonance imaging in patients with systemic sclerosis: mechanistic insights from advanced cardiac imaging**
B Egberts (Adelaide, AU, F)
- 16:35 The pregnant patient with pulmonary arterial hypertension and her offspring in the current era. Time to take into account the vasoreactive profile**
T SEGURA DE LA CAL (Madrid, ES, F)

Learning Objectives:

Categories:

Dyslipidaemia: novel diagnostics and therapy options**Session Number: 3092**Chairpersons: L Tokgozoglu (Ankara, TR) (F) - U Laufs (Leipzig, DE) (M)

- 15:45 Comparative efficacy of colchicine and intensive LDL-C lowering in patients with ASCVD receiving statins: a network meta-analysis of randomised controlled trials**
Z Ou (Chongqing, CN, M)
- 15:55 Deciphering lipoprotein(a) atherogenicity with use of high-throughput proteomics**
J Morze (Olsztyn, PL, M)
- 16:05 The upfront lipid-lowering combination therapy of statins and ezetimibe vs statin monotherapy in the reduction of cardiovascular outcomes. A meta-analysis.**
M Banach (Lodz, PL, M)
- 16:15 Contemporary LDL-cholesterol management in male and female patients at high-cardiovascular risk: results from the European observational SANTORINI study**
D Nanchen (Lausanne, CH, M)
- 16:25 The change of paradigm: high HDL-c levels could not mean a long lifespan**
F Sousa (Lisbon, PT, M)
- 16:35 Interleukin-6 signalling, lipoprotein (a) lowering and cardiovascular disease: a mendelian randomisation study**
S Brennan (Dublin, IE, M)

Learning Objectives:

Categories:

Cutting-edge advancements in cardiac magnetic resonance

Session Number: 3010

Chairpersons: E Perez-David (Majadahonda, ES) (F) - M Malahfji (Houston, US) (M)

- 15:45** **Functional status is associated with mean right atrial pressure derived from cardiac MRI**
T Newman (Sheffield, GB, M)
- 15:55** **Challenging endomyocardial biopsies' gold standard status in rejection screening: a prospective blinded study on cardiovascular magnetic resonance in heart transplant patients**
M Taipale (Hyvinkaa, FI, M)
- 16:05** **Novel cardiovascular magnetic resonance imaging heterogeneity biomarkers to diagnose and predict cardiovascular disease: a UK Biobank CMR strain study**
K Hesse (Yarm, GB, M)
- 16:15** **Iron chelation therapy failed to improve cardiac dysfunction caused by mitochondrial injury in rats with iron overload cardiomyopathy a 7T Cardiac MR research in vivo**
X Fan (Kunming, CN, F)
- 16:25** **Image quality of the non-contrast BOOST cardiac magnetic resonance sequence to visualize the pulmonary veins in patients with atrial fibrillation**
Z Dohy (Budapest, HU, F)
- 16:35** **Redefining genotype-phenotype correlation among patients with arrhythmogenic cardiomyopathy: a CMR cohort study**
G La Vecchia (Rome, IT, F)

Learning Objectives:

Categories:

Ventricular tachycardia (1)**Session Number: 3306**Chairpersons: M Ebert (Dresden, DE) (F) - BA Mulder (Groningen, NL) (M)

- 15:45 Ventricular tachycardia - get ready for the session**
M Ebert (Dresden, DE, F)
- 15:50 Arrhythmic Nightmare - Polymorphic ventricular tachycardia-related arrhythmic storm following de novo heart failure with reduced ejection fraction admission and severe multivessel coronary disease**
A Fonseca Vazao (Leiria, PT, F)
- 16:03 When to go beyond guidelines for VT management ? – A STAR is born**
A Mircea (Bucharest, RO, M)
- 16:16 Ventricular tachycardia substrate in a patient with ischemic cardiomyopathy: deciphering the structure of a complex circuit**
S Alexiou (Thessaloniki, GR, F)
- 16:29 A case of ventricular tachycardia secondary to prosthetic dehiscence in a patient with repaired Tetralogy of Fallot**
M Gonzalez Arribas (Bilbao, ES, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals

Categories: Mobile App - Vote, Young Community Track

Cardio-oncology (1)

Session Number: 3338

Chairpersons: M Hemmat Gaber (Alexandria, EG) (F) - M Falter (Hasselt, BE) (M)

- 15:45** **Cardiac tamponade secondary to ruxolitinib discontinuation syndrome**
J Wong (Melbourne, AU, M)
- 16:00** **Successful surgical treatment of pulmonary artery intimal sarcoma mimicking pulmonary thromboembolism**
T Sasaki (Morioka, JP, M)
- 16:15** **Pazopanib cardiotoxicity presenting as biventricular cystic masses**
K Korkmaz (Ankara, TR, F)
- 16:30** **Ghosts from the past: a story of hodgkin lymphoma, severe aortic stenosis, and calcified multivessel coronary disease**
JA Borovac (Split, HR, M)

Learning Objectives:

Categories:

Complex aortic disease cases**Session Number: 3364**Chairpersons: H Schaubroeck (Aalter, BE) (F) - O Ozden Kayhan (Istanbul, TR) (F)

- 15:45 Giant thoracic aorta aneurysm as a rare cause of acute pulmonary oedema**
C Theodosopoulou (Athens, GR, F)
- 15:57 Sometimes It Is Better to Do Nothing: Aortic Aneurysm in a Patient with Complex Congenital Heart Disease**
JC Campos Barba (Ciudad De Mexico, MX, M)
- 16:09 The Unwanted Path: a case of a 71 year-old male with fusiform aneurysm of the ascending aorta who developed dissection of the aortic arch up to the bilateral ilio-femoral arteries intraoperatively.**
M Correa (Metro Manila, PH, F)
- 16:21 Utility of transesophageal echocardiography in suspected aortic dissection**
S Moussa (Stony Brook, US, M)
- 16:33 Carotid glomus paraganglioma: rare disease or reflection of complex diseases?**
D Mercea (Baia Mare, RO, F)

Learning Objectives:

Categories:

Atrial fibrillation and heart failure with preserved ejection fraction (HFpEF): managing a common combination

Session Number: 174

Chairpersons: A Sarkozy (Brussels, BE) (F) - L Mont (Barcelona, ES) (M)

- 16:15 Atrial fibrillation and HFpEF: diagnosis and prognosis**
C Lam (Singapore, SG, F)
- 16:27 Atrial fibrillation and HFpEF: what role does catheter ablation play?**
N Marrouche (New Orleans, US, M)
- 16:39 Atrial fibrillation and HFpEF: the potential for atrioventricular node ablation and conduction system pacing**
D Rodriguez Munoz (Madrid, ES, M)
- 16:51 Atrial fibrillation and HFpEF: personalised accelerated pacing**
M Infeld (Boston, US, F)
- 17:03 Atrial fibrillation and heart failure with preserved ejection fraction (HFpEF): managing a common combination - discussion**
P Kistler (Melbourne, AU, M)

Learning Objectives:

Categories: Online Live

Inflammation and coronary artery disease: from diagnosis to management

Session Number: 193

Chairpersons: A Saraste (Turku, FI) (M) - L Badimon (Barcelona, ES) (F)

16:15 Non-invasive detection of coronary artery inflammation

S Achenbach (Erlangen, DE, M)

16:35 Invasive detection of coronary artery inflammation

L Raber (Bern, CH, M)

16:55 Treatment of coronary inflammation: ready for prime time?

M O'Donoghue (Boston, US, F)

Learning Objectives:

Categories: Clinical Implementation Track, Online Live

Clash of the titans: when cardiovascular and kidney diseases overlap

Session Number: 238

Joint session with the European Renal Association (ERA)

Chairpersons: JM Ter Maaten (Groningen, NL) (F) - R Torra (Barcelona, ES) (F)

16:15 Towards the cure of CKD in T2DM: are we ready to implement four foundational therapies? - pro

B Fernandez Fernandez (Madrid, ES, F)

16:30 Towards the cure of CKD in T2DM: are we ready to implement four foundational therapies? - con

J Floege (Aachen, DE, M)

16:45 What to do with key cardiovascular drugs when kidney function worsens

J Spaak (Stockholm, SE, M)

17:00 How to manage heart failure when kidney function worsens

W Mullens (Genk, BE, M)

Learning Objectives: This session will discuss the FLOW study results to be presented in May/June 2024 as well as the four foundational therapies available for the treatment of DKD and the controversial strategies to apply to patients in order to do no harm (eGFR decline).

Categories: Clinical Implementation Track

Personalised stroke management

Session Number: 298

Joint session with the European Stroke Organisation (ESO)

Chairpersons: Z Gdovinova (Kosice, SK) (F) - J Kovac (Leicester, GB) (M)

16:15 Information and communications technology and artificial intelligence to improve pre-hospital stroke networks

M Olive Gadea (Barcelona, ES, F)

16:30 The Dundee experience: really personalised acute stroke treatment!

I Grunwald (- , GB, F)

16:45 The ABC of integrating stroke care

P Papakonstantinou (Athens, GR, M)

17:00 Personalised secondary prevention after stroke

M Katan (Basel, CH, F)

Learning Objectives: This session aims to update the knowledge about individualised stroke management from the hyperacute stroke phase to secondary prevention.

Categories: Spotlight of the Congress

2024 ESC Guidelines for the Management of Elevated Blood Pressure and Hypertension: Ask the Guidelines Task Force

Session Number: 1101

Smaller trials, trial updates, and other studies on heart failure (1)

Session Number: 1034

Chairpersons: A Rakisheva (Almaty, KZ) (F)

- 16:15 The effect of dapagliflozin on accelerometer-based measures of physical activity in heart failure: an exploratory analysis of the DETERMINE trials**
K F Docherty (Glasgow, GB, M)
- 16:27 Synchronized left ventricular pacing improves cardiac resynchronization therapy outcomes: insights from AdaptResponse**
D Birnie (Ottawa, CA, M)
- 16:39 Catheter ablation in end-stage heart failure with atrial fibrillation: two-year follow-up of the CASTLE-HTx trial**
C Sohns (Bad Oeynhausen, DE, M)
- 16:51 A randomised, double-blind, placebo-controlled study to investigate the safety and tolerability of XXB750 in heart failure patients with reduced or mildly reduced ejection fraction**
T Hauser (Cambridge, US, M)
- 17:03 Rapid detection of incident heart failure by artificial intelligence: lessons from the NIL-CHF trial**
S Stewart (Blackwood, AU, M)

Learning Objectives:

Categories:

The right ventricle in heart failure: forget me not**Session Number: 111**Chairpersons: M Schou (Herlev, DK) (M) - S Zieroth (Winnipeg, CA) (F)

16:15 Right heart failure and tricuspid regurgitation in heart failure: more common than you imagine?

J Bauersachs (Hannover, DE, M)

16:30 Evaluating the right ventricle and tricuspid valve in heart failure

J Celutkiene (Vilnius, LT, F)

16:45 Repairing the tricuspid valve in heart failure: is it beneficial?

R Hahn (New York, US, F)

17:00 The right ventricle in heart failure: forget me not - discussion

F Gustafsson (Copenhagen, DK, M)

Learning Objectives:

Categories:

Great Debate: should all menopausal women be prescribed hormone replacement therapy to reduce risk?**Session Number: 150**Chairpersons: E Yang (Mercer Island, US) (M) - M Tiberi (Pesaro, IT) (F)**16:15 Should all menopausal women be prescribed hormone replacement therapy to reduce risk? - pro**

C Gebhard (Zurich, CH, F)

16:30 Should all menopausal women be prescribed hormone replacement therapy to reduce risk? - con

M Gulati (Los Angeles, US, F)

16:45 Should all menopausal women be prescribed hormone replacement therapy to reduce risk? - discussion

V Vassiliou (Cambridge, GB, M)

A Abreu (Lisboa, PT, F)

Learning Objectives:

Categories: Online Live

Guidelines in Practice: a challenging case of endocarditis

Session Number: 318

Chairpersons: M Brida (Zagreb, HR) (F) - S Sengupta (Nagpur, IN) (M)

16:15 Endocarditis in a patient with congenital heart disease: case presentation

M Ladouceur (Geneva, CH, F)

16:30 Endocarditis in a patient with congenital heart disease: what do the guidelines say?

P Erba (Bergamo, IT, F)

16:45 Endocarditis in a patient with congenital heart disease: how to implement the guidelines and take-home messages

G Habib (Marseille, FR, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Clinical Implementation Track, Online Live, Young Community Track

Guidelines in Practice: a patient with syncope and a hypertrophic heart - key role of multimodality imaging

Session Number: 254

Chairpersons: L Sierra-Galan (Mexico City, MX) (F)

16:15 Left ventricular hypertrophy and syncope: case presentation
S Mushtaq (Milan, IT, F)

16:30 Left ventricular hypertrophy and syncope: what do the guidelines say?
R Jurcut (Bucharest, RO, F)

16:45 Left ventricular hypertrophy and syncope: how to implement the guidelines and take-home messages
A Maceira Gonzalez (Valencia, ES, F)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Clinical Implementation Track, Young Community Track

The floor is yours: bring your questions on current management of acute intermediate high-risk pulmonary embolism

Session Number: 320

Chairpersons: S Konstantinides (Mainz, DE) (M) - S Papa (Roma, IT) (F) - S Ersozlu (Zurich, CH) (F)

16:15 The floor is yours: bring your questions on current management of acute intermediate high-risk pulmonary embolism - get ready for the session
S Ersozlu (Zurich, CH, F)

16:20 The floor is yours: bring your questions on current management of acute intermediate high-risk pulmonary embolism - expert panel
C Gerdes (Vienna, AT, M)

E Klok (Leiden, NL, M)

A Sharp (Cardiff, GB, M)

C Becattini (Perugia, IT, F)

L Meijboom (Amsterdam, NL, F)

T Tichelbaecker (Cologne, DE, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Mobile App - Ask a Question, Young Community Track

ESC cardiovascular statistics, the Atlas project: leveraging evidence-based care

Session Number: 456

Chairpersons: A Timmis (London, GB) (M) - N Kraenkel (Berlin, DE) (F)

16:15 Trends in ESC cardiovascular statistics

V Aboyans (Limoges, FR, M)

16:30 Challenges and champions: addressing disparities in cardiovascular care

N P Townsend (Bristol, GB, M)

16:45 Efficiency and sustainability: investigating the economic impact of cardiovascular diseases in ESC countries

A Torbica (Milan, IT, F)

17:00 The future of cardiac care: predictions and preparation driven by data

P Vardas (Athens, GR, M)

Learning Objectives:

Categories:

**Digital health: value of data from wearable devices before and after
acute cardiac presentations****Session Number: 197**Chairpersons: E Svennberg (Stockholm, SE) (F) - S Clarke (Cambridge, GB) (F)

- 16:15 Can cardiovascular data from consumer-based wearable devices be used for clinical decision-making?**
T Chico (Sheffield, GB, M)
- 16:30 Potential use of wearable devices to facilitate safe discharge from the cardiac care unit**
M Marketou (Heraklion, GR, F)
- 16:45 Wearable devices - patient perspective**
I Drossart (Brussels, BE, F)
- 17:00 Digital health: value of data from wearable devices before and after acute cardiac presentations - discussion**
H Bueno (Madrid, ES, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Digital Health, Includes a patient perspective, Young Community Track

Breaking barriers in international cardiovascular research: the Global Cardiovascular Research Funders Forum (GCRFF)

Session Number: 454

Chairpersons: R Schouten (The Hague, NL) (F) - G Jennings (Docklands, AU) (M)

- 16:15 Overview of Global Cardiovascular Research Funders Forum and its mission**
C Griffiths (London, GB, F)
- 16:25 The GCRFF grant database and the GCRFF data challenge**
J Hall (Dallas, US, F)
- 16:33 Introduction to the GCRFF Women's Cardiovascular Health Research Initiative**
C Faubert (Toronto Ontario, CA, F)
- 16:43 What can the research community expect of the GCRFF moving forward?**
D Tancredi (Boston, US, M)
- 16:51 Breaking barriers in international cardiovascular research: the Global Cardiovascular Research Funders Forum (GCRFF) - questions and answers**

Learning Objectives:

Categories:

Emerging risk factors for cardiovascular diseases**Session Number: 350**Chairpersons: AM Zeiher (Frankfurt, DE) (M) - S Sattler (, GB) (F)**16:15 Clonal haematopoiesis and cardiovascular diseases**

J Fuster (Madrid, ES, M)

16:30 Loss of the Y chromosome and cardiovascular diseases

K Walsh (Charlottesville, US, M)

16:45 Air pollution and cardiovascular diseases

D Newby (Edinburgh, GB, M)

17:00 Emerging risk factors for cardiovascular diseases - discussion

W Abplanalp (Frankfurt Am Main, DE, M)

Learning Objectives:

Categories:

Coronary thrombus management in patients with acute coronary syndromes: insights from Turkish and Italian Cardiac Society perspectives**Organised in collaboration with the Italian Federation of Cardiology and the Turkish Society of Cardiology****Session Number: 5106**Chairpersons: C Indolfi (Catanzaro, IT) (M) - M Degertekin (Istanbul, TR) (M)

- 16:45 Case 1 - ST-Elevation Myocardial Infarction (STEMI) in patients with high thrombus burden: Turkey high volume centre perspective**
O Yildirimturk (Istanbul, TR, F)
- 16:55 ST-Elevation Myocardial Infarction (STEMI) in patients with high thrombus burden: Turkey high volume centre perspective - discussion of guideline implementation**
A Kilicgedik (Istanbul, TR, F)
- 17:07 Case 2 - Non-ST-Elevation Myocardial Infarction (NSTEMI): vision from Italy**
L De Luca (Roma, IT, M)
- 17:17 Non-ST-Elevation Myocardial Infarction (NSTEMI): vision from Italy - discussion of guideline implementation**
S Nodari (Brescia, IT, F)

Learning Objectives: To be aware that patients with acute coronary syndromes and high thrombus burdens present complicated clinical scenarios requiring patient specific treatments.

Categories: Online Live

Special Event	Friday, 30 August 2024	17:30 - 18:30	London - Main Auditorium
---------------	------------------------	---------------	--------------------------

Inaugural session

Session Number: 5000

Chairpersons:

00:00 Inaugural session

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Online Live, Young Community Track

Daily Highlights by the Cardiac Society of Australia and New Zealand

This session is brought to you by the Cardiac Society of Australia and New Zealand and is not part of the official ESC programme

Session Number: 5127

Chairpersons:

Learning Objectives:

Categories: Online Live

HOT LINE 2

Session Number: 1011

Chairpersons: R Touyz (Montreal, GB) (F) - N Poulter (London, GB) (M) - F Mahfoud (Homburg, DE) (M)

- 08:15 The BedMed and BedMed-Frail randomised controlled trials - Effect of antihypertensive timing on mortality and morbidity**
SR Garrison (Edmonton, CA, M)
- 08:30 Meta-analysis of trials of antihypertensive medication bedtime dosing including individual-patient data from BedMed and BedMed-Frail**
R Turgeon (Vancouver, CA, M)
- 08:42 Discussant review - BedMed, BedMed-Frail and Meta-analysis**
IS Mackenzie (Dundee, GB, F)
- 08:49 Panel discussion - BedMed, BedMed-Frail and Meta-analysis**
- 08:54 GMRx2 - Efficacy and safety of a novel triple single pill combination**
A Rodgers (Sydney, AU, M)
- 09:09 QUADRO - A single 4-drug combination in hypertension**
S Taddei (Pisa, IT, M)
- 09:21 VERONICA-Nigeria - deliVERy of Optimal blood pressure coNtrol in afrICA**
D Ojji (Abuja, NG, M)
- 09:33 Discussant review - GMRx2, QUADRO and VERONICA-Nigeria**
P Taub (Rancho Santa Fe, US, F)
- 09:41 Panel discussion - GMRx2, QUADRO and VERONICA-Nigeria**

Learning Objectives:

Categories: Online Live

Great Debates: catheter ablation for persistent atrial fibrillation - is it better than medication and is pulmonary vein isolation sufficient?**Session Number: 164**Chairpersons: JL Merino (Madrid, ES) (M) - C Blomstrom-Lundqvist (Uppsala, SE) (F)

- 08:15 Persistent atrial fibrillation: ablation early and first beats antiarrhythmic medication - pro**
J Andrade (Vancouver, CA, M)
- 08:30 Persistent atrial fibrillation: ablation early and first beats antiarrhythmic medication - con**
J Kalman (Parkville, AU, M)
- 08:45 Persistent atrial fibrillation: ablation early and first beats antiarrhythmic medication - discussion**
M Gunawardene (Hamburg, DE, F)
- 09:00 Pulmonary vein isolation alone is not enough: a personalised approach is required in persistent atrial fibrillation patients - pro**
D Shah (Geneva, CH, M)
- 09:15 Pulmonary vein isolation alone is not enough: a personalised approach is required in persistent atrial fibrillation patients - con**
K Chun (Frankfurt, DE, M)
- 09:30 Pulmonary vein isolation alone is not enough: a personalised approach is required in persistent atrial fibrillation patients - discussion**
I Deisenhofer (Munich, DE, F)

Learning Objectives:

Categories: Online Live, Spotlight of the Congress

Patient and caregiver needs after an acute cardiac event**Session Number: 379**Chairpersons: R Mindham (London, GB) (M) - D Fitzsimons (Belfast, GB) (F)

08:15 Patients experience during an ICU admission - physician perspective
S Price (London, GB, F)

08:33 Patient experience during an ICU admission - patient perspective
R Veltrop (Gronsveld, NL, M)

08:51 Psychosocial support needs after discharge - physician perspective
M Abreu (Lisboa, PT, F)

09:09 Psychosocial support needs after discharge - patient perspective
M Van Heetvelde (Gent, BE, M)

09:27 Patient and caregiver needs after an acute cardiac event - discussion

Learning Objectives:

Categories: Includes a patient perspective

When the diet does not work: pharmacological options for obesity**Session Number: 236**Chairpersons: L Burrell (Melbourne, AU) (F) - B Gigante (Stockholm, SE) (F)**08:15 GIP and GLP-1 agonists for obesity**

C Lang (Dundee, GB, M)

08:33 SGLT2 inhibitors for obesity

J Eriksson (Uppsala, SE, M)

08:51 Impact of obesity on other drug therapy

B Rocca (Rome, IT, F)

09:09 Patient perspective on treatment of obesity

R Stephens (Stevenage, GB, M)

09:27 When the diet does not work: pharmacological options for obesity - discussion

J Kaski (London, GB, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Includes a patient perspective, Obesity Track, Online Live, Young Community Track

Calcium modification: optimising complexities in percutaneous coronary intervention

Session Number: 834

Chairpersons: J Siller-Matula (Vienna, AT) (F) - F Cuculi (Luzern, CH) (M)

- 08:15 State-of-the-art lecture on calcium modification: optimising the journey through coronary calcium**
A Kini (New York, US, F)
- 08:33 Rotational atherectomy versus orbital atherectomy for the treatment of calcified coronary lesions: a systematic review and meta-analysis of 81,873 patients**
M Abouzid (Poznan, PL, M)
- 08:51 Current application and results of the combined use of intravascular lithotripsy and rotational atherectomy for the treatment of calcified coronary lesions**
MJH Van Oort (Leiden, NL, M)
- 09:09 Comparison of different calcium modification strategies for coronary calcified nodules: insights from optical coherence tomography**
K Yasumura (New York, US, M)
- 09:27 Intravascular lithotripsy in the management of underexpanded stents**
M Sagris (Piraeus, GR, M)

Learning Objectives:

Categories: Online Live

Great Debates: acute stroke intervention - what's next after thrombectomy?**Session Number: 295**Chairpersons: F Pecoraro (Palermo, IT) (M) - A Halliday (Oxford, GB) (F)

- 08:15 Carotid stenting: pro**
P Widimsky (Prague, CZ, M)
- 08:30 Carotid stenting: con**
M Venermo (Helsinki, FI, F)
- 08:45 Carotid stenting - discussion**
B Rantner (Munich, DE, F)
- 09:00 Closing the atrial appendage: pro**
J Saw (Vancouver, CA, F)
- 09:15 Closing the atrial appendage: con**
E Gurol (Boston, US, M)
- 09:30 Closing the atrial appendage - discussion**
TS Potpara (Belgrade, RS, F)

Learning Objectives:

Categories: Online Live

Highlighted registries, observational, and other studies

Session Number: 1035

Chairpersons: A Rosengren (Gothenburg (Goteborg), SE) (F) - H Krumholz (New Haven, US) (M)

- 08:15 Nature-AGT: Using Causal AI to estimate the optimal timing of lowering SBP with an siRNA directed against angiotensinogen to reduce the lifetime risk of cardiovascular events**
BA Ference (Cambridge, GB, M)
- 08:26 Thirty-year cardiovascular outcomes in women based on C-reactive protein, LDL cholesterol, and lipoprotein(a)**
P Ridker (Boston, US, M)
- 08:37 Economic Toll of Cardiovascular Disease on Healthcare and Mortality in 50 ESC member countries**
R Luengo-Fernandez (Oxford, GB, M)
- 08:48 Incidental and progressive tobacco smoking from childhood through young adulthood with premature structural and functional cardiac damage in 1931 children: A 14-Year Longitudinal Study**
A O Agbaje (Kuopio, FI, M)
- 09:00 Global Pretest probability study of coronary artery disease**
LB Baskaran (Singapore, SG, M)
- 09:11 Black carbon: a novel indicator of the risk of acute myocardial infarction associated with short-term exposure to fine particulate matter**
S Kojima (Kumamoto, JP, M)
- 09:22 Incremental value of cardiac myosin binding protein C to high-sensitivity cardiac troponin for the early diagnosis of acute myocardial infarction**
P Lopez Ayala (Basel, CH, M)
- 09:33 Trial of switching high-sensitivity cardiac troponin assays in suspected acute coronary syndrome (TWITCH-ED)**
J Boeddinghaus (Edinburgh, GB, M)

Learning Objectives:

Categories:

Smaller trials, trial updates, and other studies on heart failure (2)

Session Number: 1036

Chairpersons: P Campbell (Craigavon, GB) (F)

- 08:15 Thoracentesis to alleviate pleural effusion in acute heart failure: results from the pragmatic, multi-centre, open-label, randomised controlled TAP-IT trial**
S Glargaard (Copenhagen, DK, F)
- 08:26 Impact of a pneumococcal vaccination incentive campaign in chronic heart failure patients in France: a randomized clinical trial**
F Roubille (Montpellier, FR, M)
- 08:37 Early in-hospital initiation of angiotensin-neprilysin inhibition in Japanese patients with acute heart failure: the investigator-initiated multicenter randomized PREMIER study**
A Tanaka (Saga, JP, M)
- 08:48 Intensive therapeutic education strategy by specialised nurses for patients with acute Heart Failure: results from the multicentre randomized controlled EDUSTRA-HF trial.**
A Cohen (Paris, FR, M)
- 09:00 Assessment of Digital consults in heart failure Management on cLINical Impact, SafeTy and Efficiency using a RCT (ADMINISTER) trial**
M Schuurin (Bussum, NL, M)
- 09:11 Carvedilol as single maintenance therapy for Heart Failure with Improved Ejection Fraction: an open-label randomized clinical trial CATHEDRAL-HF**
DSP Belfort (Sao Paulo, BR, F)
- 09:22 WITHDRAWal of Heart Failure Pharmacotherapy in Patients with Normalized Left Ventricular Function After AF Rhythm Control in Arrhythmia Induced Cardiomyopathy-The WITHDRAW-AF Randomized Clinical Trial**
L Segan (Melbourne, AU, F)
- 09:33 Assessment of non-inferiority of a hospital-at-home care pathway for patients with acute heart failure: FIL-EAS-ic**
JM Tartiere (Toulon Cedex, FR, M)

Learning Objectives:

Categories:

Obesity and pre-diabetes: where do we stand today on prevention and treatment?

Session Number: 837

Chairpersons: E Michos (Baltimore, US) (F) - M Halle (Munich, DE) (M)

08:15 State-of-the-art lecture on obesity and pre-diabetes: where do we stand today on prevention and treatment?
E Prescott (Copenhagen, DK, F)

08:33 Are metabolically healthy obese individuals really a benign cardiovascular group? An analysis of 162,590 participants with measures of arterial stiffness in UK BIOBANK
R Ananda (Melbourne, AU, M)

08:51 Association between normal range UACR and insulin resistance and prediabetes among US adults:
S Wu (Beijing, CN, F)

09:09 Exploratory mediation analysis of the effect of semaglutide on cardiovascular outcomes in people with overweight or obesity in the SELECT randomised trial

09:27 Cardiovascular prevention with GLP1 agonists in high or very-high cardiovascular risk irrespective of diabetes.
N del-Cuerpo-Salinas (San Juan De Alicante, ES, M)

Learning Objectives:

Categories:

Personalising care in congenital heart disease: a lifecycle perspective**Session Number: 315**Chairpersons: M Gatzoulis (London, GB) (M) - M Ladouceur (Geneva, CH) (F)**08:15 Living with congenital heart disease - patient perspective**

A Gombosova (Praha, CZ, F)

08:33 Adult congenital heart disease: tailored transition from paediatric to adult care

E Goossens (Leuven, BE, F)

08:51 Adult congenital heart disease: advising women about pregnancy

M Brida (Zagreb, HR, F)

09:09 Adult congenital heart disease: advice about sports participation

JW Roos-Hesselink (Rotterdam, NL, F)

09:27 Personalising care in congenital heart disease: a lifecycle perspective - discussion

S A Qureshi (London, GB, M)

Learning Objectives:

Categories: Includes a patient perspective, Spotlight of the Congress

Heart failure and valvular heart disease: imaging to the rescue**Session Number: 265**Chairpersons: J Dreyfus (Saint-Denis, FR) (M) - P Pellikka (Rochester, US) (F)

- 08:15** **Imaging to distinguish atrial from ventricular mitral regurgitation**
A Sannino (Naples, IT, F)
- 08:33** **Imaging to evaluate left ventricular function and hypertrophy in aortic stenosis**
M Dweck (Edinburgh, GB, M)
- 08:51** **Imaging to assess right ventricular function in tricuspid regurgitation**
A Duncan (London, GB, F)
- 09:09** **Imaging to aid timing of intervention in secondary mitral regurgitation**
J Separovic Hanzevacki (Zagreb, HR, F)
- 09:27** **Heart failure and valvular heart disease: imaging to the rescue - discussion**
R Hahn (New York, US, F)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Online Live, Young Community Track

Symposium	Saturday, 31 August 2024	08:15 - 09:45	Bern - Lecture room
-----------	--------------------------	---------------	---------------------

Diversity in cardiovascular care: effective, equitable, and empowering practice
Organised in collaboration with the British Association for Nursing in Cardiovascular Care (BANCC)

Session Number: 435

Chairpersons: M Lehane (Cork, IE) (F) - BM Delgado (Arcozelo, PT) (M)

- 08:15 Diversity in cardiovascular care: advancing health equity**
D Thompson (Belfast, GB, M)
- 08:33 Equality in the nursing workforce? Experiences of Black, Asian, and minority nurses in the UK**
J Pearson (Birmingham, GB, F)
- 08:51 Bridging the gap: ensuring equity, diversity, and inclusion in cardiovascular treatment**
J McDonagh (Yarramalong, AU, F)
- 09:09 Embedding clinical research in routine cardiovascular care: providing equitable opportunities to all patients**
- 09:27 Diversity in cardiovascular care: effective, equitable, and empowering practice - discussion**
H Eftekhari (Coventry, GB, F)

Learning Objectives:

Categories: Nurses and Allied Professionals track

The ESC Journal Family: focus on personalised care in different fields of cardiovascular medicine

Joint session with the European Heart Journal (EHJ)

Session Number: 412

Chairpersons: V Aboyans (Limoges, FR) (M) - A Gimelli (Pisa, IT) (F)

08:15 Digital health-digital twin: in-silico phenotyping for delivering precision medicine

N van Osta (Eindhoven, NL, M)

08:33 Prevention: personalising cardiovascular prevention

M Kavousi (Rotterdam, NL, F)

08:51 Arrhythmias: management of patients with long QT

KE Odening (Bern, CH, F)

09:09 Imaging: the role of cardiac imaging for personalised cardiovascular care

V Delgado (Barcelona, ES, F)

09:27 Translational science: turning medicines into lifelong cures

A Baker (Edinburgh, GB, M)

Learning Objectives: To provide an update on personalised medicine in specific cardiovascular fields including digital health, prevention, arrhythmias, imaging, and translational medicine.

Categories: Spotlight of the Congress

Artificial intelligence unleashed on digital biomarkers: a new era in personalised cardiovascular healthcare

Session Number: 370

Chairpersons: M Marketou (Heraklion, GR) (F) - G Hindricks (Berlin, DE) (M)

- 08:15 Retinal imaging for cardiovascular risk assessment**
S Park (Seoul, KR, M)
- 08:33 Speech analysis to detect acute decompensated heart failure**
W Abraham (Powell, US, M)
- 08:51 Patient stratification using digital biomarkers: a risky business**
FA Wenzl (Schlieren, CH, M)
- 09:09 Artificial intelligence-based management of arrhythmias**
R Schnabel (Hamburg, DE, F)
- 09:27 Artificial intelligence unleashed on digital biomarkers: a new era in personalised cardiovascular healthcare - discussion**
N Keser (Istanbul, TR, F)

Learning Objectives: This session aims to explore how artificial intelligence is transforming cardiovascular care with discussion about the implications of artificial intelligence-based speech analysis, automated ECG interpretation, face recognition, and risk prediction assessment; will provide the audience with state-of-the-art updates on digital health in cardiovascular medicine and to learn about the impact of automated data analysis on clinical practice.

Categories: Digital Health, Spotlight of the Congress

ESC Paul Hugenholtz Lecture in Innovation

Session Number: 400

Chairpersons: TF Luscher (London, GB) (M) - S Dimmeler (Frankfurt, DE) (F)

08:15 Presentation of the awardee

TF Luscher (London, GB, M)

08:20 Innovating biomaterials for tissue repair, advanced therapeutics and early disease detection

M Stevens (- , GB, F)

08:40 ESC Paul Hugenholtz Lecture in Innovation - Q&A

08:55 Award presentation

Learning Objectives:

Categories: Digital Health

Therapeutic modulation of the immune system in cardiovascular diseases**Session Number: 354**Chairpersons: F Leuschner (Heidelberg, DE) (M) - D Carnevale (Pozzilli, IT) (F)**08:15 Innate immunity mechanisms in heart failure**

S Epelman (Toronto, CA, M)

08:33 Immune therapeutic targets in vascular diseases

C Monaco (Oxford, GB, F)

08:51 T-cell therapeutic targets in heart failure

M Kallikourdis (Rozzano, IT, M)

09:09 Check-point inhibition: cardiovascular consequences and their prevention

J Moslehi (San Francisco, US, M)

09:27 Therapeutic modulation of the immune system in cardiovascular diseases - discussion

S Sattler (- , GB, F)

Learning Objectives:

Categories:

Personalised TAVI care in severe aortic stenosis

Session Number: 297

Joint session with the Asian Pacific Society of Cardiology (APSC)

Chairpersons: HS Kim (Seoul, KR) (M) - J Mascherbauer (Vienna, AT) (F)

08:15 Dilated aorta and bicuspid aortic valve stenosis: post-TAVI changes in the aorta over time

J Kang (Seoul, KR, M)

08:30 Aortic stenosis with concomitant coronary artery disease: strategies to access the coronary arteries

Y Ohno (Isehara, JP, M)

08:45 TAVI in patients with a small aortic annulus

S Windecker (Bern, CH, M)

09:00 Lifetime management of aortic stenosis: which prosthesis should we use first?

N Karam (Paris, FR, F)

Learning Objectives: This session aims to learn how to customise the TAVI procedure depending on the profiles of patients with severe aortic stenosis and to consider whether to use TAVI vs. SAVR taking into account that the most frequent and serious situations are bicuspid aortic stenosis with aortic dilatation or aortic stenosis with concomitant coronary artery disease.

Categories: Online Live, Spotlight of the Congress

High-sensitivity cardiac troponin assays: integrating evidence from clinical trials and implementation studies**Session Number: 3044**Chairpersons: S Zaman (Sydney, AU) (F) - H Katus (Heidelberg, DE) (M)

- 08:15 Troponin/creatinine kinase ratio for discrimination of type 1 and type 2 myocardial infarction**
J Lehmacher (Hamburg, DE, M)
- 08:27 Rapid rule-out of acute myocardial infarction using the 0/1-hour algorithm for cardiac troponins in emergency primary care: the OUT-ACS implementation study.**
TR Johannessen (Oslo, NO, F)
- 08:39 Clinical and experimental evidence for differences between cardiac troponin I and T in acute and chronic cardiovascular conditions**
T Zimmermann (Basel, CH, M)
- 08:51 Serial troponin sampling over 60-minutes allows early distinction between myocardial infarction and chronic myocardial injury in patients presenting to emergency departments.**
G Vimalaratnam (- , AU, F)
- 09:03 Acute kidney injury in relation to high-sensitivity cardiac troponin T levels in the emergency department**
L Cyon (Stocksund, SE, M)

Learning Objectives:

Categories:

New clinical insights from implantable loop recorders and smartphones**Session Number: 3014**Chairpersons: R Sigurjonsdottir (Goteborg, SE) (F) - H Puererfellner (Linz, AT) (M)

- 08:15 External validation of a machine learning based classification algorithm for ambulatory heart rhythm diagnostics using smartphone-photoplethysmography - the SMARTBEATS algorithm study**
J Fernstad (Stockholm, SE, M)
- 08:25 Implantable loop recorders in children and adolescents with Brugada syndrome: the YoungBruLoop study**
G Conte (Lugano, CH, M)
- 08:35 Dynamic QTc interval changes observed in real-world patients with implanted insertable cardiac monitors taking class III antiarrhythmic drugs**
G Rajagopal (Minneapolis, US, M)
- 08:45 Rates of therapeutic interventions in a large real-world cohort with insertable cardiac monitors**
- 08:55 Selective use of implantable loop recorders improves diagnostic potential for unexplained syncope**
E Oikonomou (Athens, GR, M)
- 09:05 Premature ventricular contraction burden measured by an insertable cardiac monitor and the incidence of ventricular tachycardia and fibrillation**
J Dukes (Ventura, US, M)

Learning Objectives:

Categories:

Unusual cardiomyopathies: do you know them all?

Session Number: 3066

Chairpersons: E Martins (Porto, PT) (F) - S Petersen (London, GB) (M)

- 08:15 ABLE-SCORE: a simplified risk score for major adverse cardiovascular outcomes in patients with left ventricular noncompaction**
L Liu (Beijing, CN, F)
- 08:25 AFFECT-HCM: quality of life and costs in hypertrophic cardiomyopathy**
SAC Schoonvelde (The Hague, NL, M)
- 08:35 Phenotypic and clinical evaluation of hypertrophic cardiomyopathy caused by the deep intronic variant MYBPC3:c.2308+227G>A**
S Rodriguez Diego (Cordoba, ES, F)
- 08:45 Phenotype progression in pediatric RASopathy-associated hypertrophic cardiomyopathy**
O Boleti (London, GB, F)
- 08:55 Impact of high intensity and long duration exercise in genetic arrhythmogenic left ventricular cardiomyopathy**
C Jean (- , FR, F)
- 09:05 Nexilin-related cardiomyopathy (NEXN-CMP) - an island's perspective**
M Cassar (- , MT, F)

Learning Objectives:

Categories:

Multifactorial risk in coronary heart disease**Session Number: 3091**Chairpersons: I Uchmanowicz (Wroclaw, PL) (F) - H Thiele (Leipzig, DE) (M)

- 08:15** **Prevalence of depression, anxiety and post-traumatic stress disorder (PTSD) after acute myocardial infarction: a systematic review and meta-analysis**
Y Hao (Singapore, SG, F)
- 08:30** **Estimating risk using the novel Particulate Matters years index (ePM-years index). A report from the nationwide EP-PARTICLES study**
L Kuzma (Bialystok, PL, M)
- 08:45** **The association between periodontal disease and coronary artery disease: insights from imaging, observational and genome-wide data**
M M Sanghvi (London, GB, M)
- 09:00** **Association of COVID-19 and influenza vaccinations and cardiovascular drugs with hospitalisation and mortality in COVID-19 and Long COVID: 2-year follow-up of 17 million individuals in England**
A Banerjee (London, GB, M)

Learning Objectives:

Categories:

Update on advanced plaque imaging with cardiac computed tomography**Session Number: 3007**

Chairpersons: W Chan (Hong Kong, HK) (F) - R Blankstein (Brigham And Women's Hospital Cardiovascu, US) (M)

- 08:15 Association of sodium-glucose cotransporter-2 inhibitor with regression of coronary plaque burden**
T Zhang (Beijing, CN, M)
- 08:25 Relationship between plaque burden and plaque vulnerability in patients with acute coronary syndromes versus chronic coronary syndrome**
D Kinoshita (Boston, US, M)
- 08:35 Predictors of debulking devices use by coronary artery calcification classification using cardiac CT**
Y Nakano (Fukuoka, JP, M)
- 08:45 Coronary plaque volume burden and composition in patients with non-hemodynamically significant coronary artery plaques and systemic inflammation**
P Martinez Vives (Madrid, ES, M)
- 08:55 Coronary CT angiography using photon counting CT for the detection of coronary artery stenoses and coronary atherosclerotic plaque: comparison of reconstructions with 0.2 mm and 0.4 mm slice thickness**
T Zuhair Kassem (Erlangen, DE, F)
- 09:05 Impact of ultra-high-resolution on cardiac CT assessment of coronary artery stenoses, plaque burden/composition, and pericoronary adipose tissue attenuation**
B Romanelli Scarpa Matuck (- , BR, F)

Learning Objectives:

Categories:

Adult congenital heart disease cases (2)**Session Number: 3328**Chairpersons: I Voges (Kiel, DE) (F) - C Stefanescu Schmidt (Boston, US) (F)**08:15 Adult congenital heart disease cases - get ready for the session****08:20 Necessity is the mother of ingenuity. Unconventional ventricular assist device to a Criss-cross heart.**

J Herrera (Cordoba, ES, M)

08:33 On an rare congenital heart disease: a patient with congenitally corrected transposition of the great arteries with advanced atrioventricular block and heart failure.

B Quintero Garzon (Mexico City, MX, M)

08:46 Severe outflow tract obstruction in a patient with previous repaired partial AVSD due to accessory papillary muscle

I Kasouridis (London, GB, M)

08:59 Non-corrected Tetralogy of Fallot in an elderly patient

G Valenzuela Valenzuela (Monterrey, MX, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals

Categories: Mobile App - Vote, Young Community Track

Imaging to the rescue

Session Number: 3354

Chairpersons: A Motoc (Brussels, BE) (F) - A Pazhenkottil (Zurich, CH) (M)

- 08:15 Clinical utility of thermographic imaging for monitoring extent and severity of driveline infection in left-ventricular-assist device patients**
V Drost (Rotterdam, NL, F)
- 08:27 Cardiac CT-derived fat attenuation index to assess evolution of inflammation degree in coronary vasculitis**
LM Becker (Nieuwegein, NL, F)
- 08:39 Holographic visualization with cloud-computing infrastructure for pre-procedural planning in a patient with severe mitral valve insufficiency and dextrocardia situs inversus**
K Piayda (Frankfurt, DE, F)
- 08:51 Late complications after coarctation repair – the importance of cardiac MRI**
N Chatrath (London, GB, M)
- 09:03 Multiparametric approach in the aetiological diagnosis of cardiomyopathies: a non-dilated left ventricular cardiomyopathy (NDLVC) case report**
A Milazzo (Florence, IT, F)

Learning Objectives:

Categories:

Supraventricular tachycardia (1)**Session Number: 3384**Chairpersons: M Gawalko (Warszawa, PL) (F) - P Papakonstantinou (Athens, GR) (M)

- 08:15 An interesting case of single loop macroreentrant biatrial tachycardia**
K Herzallah (Boston, US, M)
- 08:30 Cardiogenic shock caused by arrhythmia-induced cardiomyopathy from an unexpected source**
N Tsianakas (Offenbach, DE, M)
- 08:45 Single-shot ablation of atrial tachycardia, after atrial fibrillation cryoablation**
G Fotos (Athens, GR, M)
- 09:00 A congenital culprit of atrial fibrillation and cardiogenic stroke: anomalous left coronary artery arising from the pulmonary artery**
LH Qiu (Beijing, CN, M)

Learning Objectives:

Categories:

ESC Geoffrey Rose Lecture in Population Sciences

Session Number: 402

Chairpersons: M Piepoli (Piacenza, IT) (M) - N Kraenkel (Berlin, DE) (F)

- 09:15 Presentation of the awardee
N Kraenkel (Berlin, DE, F)
- 09:20 Making personalised prevention everyone's business
J Deanfield (London, GB, M)
- 09:40 ESC Geoffrey Rose Lecture in Population Sciences - Q&A
- 09:55 Award presentation

Learning Objectives:
Categories:

Tailored approaches in heart failure: insights from France and Spain**Session Number: 5101****Organised in collaboration with the French Society of Cardiology and the Spanish Society of Cardiology**Chairpersons: N Mewton (Bron, FR) (M) - S Mirabet Perez (Barcelona, ES) (F)**09:30 Bridging the gap: navigating the heart failure care continuum from diagnosis to management - insights from France**

E Berthelot (Le Kremlin Bicetre, FR, F)

09:42 Optimising the treatment of heart failure patients with reduced left ventricular ejection fraction and advanced renal failure - vision from Spain

A Recio Mayoral (Seville, ES, M)

09:54 Tailored approaches in heart failure: insights from France and Spain - discussion

N Girerd (Nancy, FR, M)

M Cobo Marcos (Madrid, ES, F)

Learning Objectives: To report practices in France regarding diagnosis and therapeutic management of heart failure and to relate the Spanish experience of using therapies and multidisciplinary coordination to manage heart failure patients with advanced renal failure.

Categories: Online Live, Spotlight of the Congress

Further Insights into SGLT2i treatment for heart failure

Session Number: 3026

Chairpersons: N Pavo (Wien, AT) (F) - M Abdelhamid (Cairo, EG) (M)**09:30 Effects of dapagliflozin according to QRS duration across the spectrum of LVEF: An analysis of DAPA-HF and DELIVER**

A Abdin (Homburg, DE, M)

09:40 Randomized trial assessing worsening renal function with dapagliflozin addition in acute decompensated heart failure: ROAD-ADHF trial

S Kawanami (Sakai, JP, M)

09:50 The effects of SGLT2 inhibitors on right ventricle functions in heart failure patients: update meta-analysis of the current literature**10:00 Effects of dapagliflozin on body composition and its relation to hemodynamics in heart failure with preserved ejection fraction: the CAMEO-DAPA randomized clinical trial**

JA Naser (Rochester, US, F)

10:10 Comparative outcomes between empagliflozin and dapagliflozin in heart failure: real world multi-center cohort study

S Bu (Gyeonggi-Do, KR, M)

10:20 Effectiveness of empagliflozin in patients with heart failure and COPD: Results from EMPEROR-Preserved and EMPEROR-Reduced

S von Haehling (Berlin, DE, M)

Learning Objectives:

Categories:

The heart in crisis after an acute myocardial infarction

Session Number: 3072

Chairpersons: M Lopes (Recife, BR) (F) - D Milasinovic (Belgrade, RS) (M)

- 09:30 Comparing predictive accuracy: systolic blood pressure to left ventricular end-diastolic pressure ratio versus TIMI score for short-term mortality after primary percutaneous coronary intervention**
N Yaqoob (Karachi, PK, M)
- 09:40 Trends in intracardiac thrombus formation in myocardial infarction patients after PCI: a nationwide analysis**
A Balaji (- , US, M)
- 09:50 A study of intracoronary thrombolytic agents in high thrombotic burden lesions during primary PCI**
V Palaparthi (Vijayawada, IN, M)
- 10:00 Modified quantitative gentle reperfusion method in patient with STEMI during PPCI**
JF He (Beijing, CN, M)
- 10:10 Prognosticating short-term outcomes in STE-ACS patients with intra-procedure slow flow/no-reflow: an analysis of predictive factors in primary percutaneous coronary revascularization**
U Safdar (Karachi, PK, F)
- 10:20 Intravascular imaging-guided PCI in patients with acute myocardial infarction and cardiogenic shock**
HS Joh (Seoul, KR, M)

Learning Objectives:

Categories:

Immunomodulation in cardiovascular disease

Session Number: 3127

Chairpersons: M Nosedá (London, GB) (F) - W Abplanalp (Frankfurt Am Main, DE) (M)

- 09:30 Malondialdehyde-specific natural IgM inhibit toll-like receptor 4 and peptidyl-arginine deiminase 4-dependent NETosis triggered by coronary extracellular vesicles of myocardial infarction patients**
A Ondracek (Vienna, AT, F)
- 09:40 Macrophage-T cell hybrid membrane-camouflaged biomimetic nanoparticles ameliorate autoimmune myocarditis via suppressing macrophage pyroptosis by target gene silencing**
Y Xiong (Beijing, CN, M)
- 09:50 Sex differences in dysregulation of inflammation- and remodeling-related miRNAs in the mouse model of CVB3 myocarditis-induced dilated cardiomyopathy**
- 10:00 Identification of pathogenic cytotoxic CD57-expressing T cells in viral myocarditis by single-cell multi-omics**
- 10:10 Epitranscriptional control of vascular immunomodulation and atherosclerosis progression in mice and humans by ADAR2**
M Amponsah-Offeh (Mannheim, DE, M)
- 10:20 Age-related decline in cardiac lymphatic vessels causes cardiac edema and macrophage accumulation**
J Wagner (Frankfurt Am Main, DE, M)

Learning Objectives:

Categories:

Daily cardiac problems in cancer patients

Session Number: 3101

Chairpersons: B Ky (Philadelphia, US) (F) - W Doehner (Berlin, DE) (M)

- 09:30** **The initial high-dose versus maintenance-dose anticoagulation therapy with direct oral anticoagulants for cancer-associated venous thromboembolism: from the COMMAND VTE Registry-2**
R Chatani (Kurashiki, JP, M)
- 09:40** **Understanding the impact of heart failure treatment on cancer growth**
C Civati (Antwerp, BE, F)
- 09:50** **Risk of cardiovascular disease in Hodgkin lymphoma patients**
SJ Godtfredsen (Aalborg, DK, U)
- 10:00** **Prediction of cancer therapy related cardiac dysfunction by using a machine learning approach with cardiac magnetic resonance images**
C Yu (Kiribilli, AU, M)
- 10:10** **Increased prevalence of coronary atherosclerosis in cancer survivors: a matched cross-sectional study with coronary CT angiography**
EAS Polomski (Leiden, NL, F)
- 10:20** **SGLT2 inhibitors in patients with amyloidosis and heart failure: a worldwide retrospective cohort study**
R Belo Nunes (Sao Paulo, BR, M)

Learning Objectives:

Categories:

**Innovations in cardiac health prediction: integrating deep learning
with multimodal data analysis****Session Number: 3114**Chairpersons: F Tjong (Amsterdam, NL) (F) - C Ross (Belfast, GB) (F)

- 09:30 Mobile single-lead ECG atrial fibrillation prediction enhancement integrated by standard ECG algorithm with Deep learning model**
KH Lee (Gwangju, KR, M)
- 09:40 ECGWiz: a unified and generalizable AI model for comprehensive ECG diagnosis**
I Vatsaraj (Baltimore, US, M)
- 09:50 Multi-modality deep learning prediction of heart age: insights from UK-Biobank.**
G Siontis (Bern, CH, M)
- 10:00 Detection and risk stratification of cardiac amyloidosis patients by integration of imaging and non-imaging data using a machine learning approach**
C Spielvogel (Vienna, AT, M)
- 10:10 Standardization of transthoracic impedance values for estimating heart failure and its utility**
D Nose (Fukuoka, JP, M)
- 10:20 Machine learning for prediction of incident heart failure and heart failure hospitalisation: multi-cohort development, validation and association with clinical phenotypes**
Y Nakao (- , JP, F)

Learning Objectives:

Categories:

Amyloidosis**Session Number: 3309**Chairpersons: A Martinez Naharro (London, GB) (F) - O Clerc (Boston, US) (M)**09:30 Amyloidosis - get ready for the session**

A Martinez Naharro (London, GB, F)

09:35 Transthyretin (ATTR) cardiac amyloidosis: a case report of feet paresthesia as a possible initial symptom and challenging diagnosis

L Xie (Hangzhou, CN, F)

09:48 Unveiling the veil: a case report of AL-amyloidosis

K Gkarmiris (Uppsala, SE, M)

10:01 Variant cardiac transthyretin amyloidosis presenting as hypertrophic cardiomyopathy with left ventricular outflow tract obstruction

V Hoeller (- , AT, F)

10:14 Bridge to candidacy: understanding the role of Impella 5.5 in cardiac amyloidosis and pulmonary hypertension

R Goswami (Jacksonville, US, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals

Categories: Mobile App - Vote, Young Community Track

Acute coronary syndromes (2)**Session Number: 3329**Chairpersons: T Nestelberger (Basel, CH) (M) - C Bonanad Lozano (Valencia, ES) (F)

- 09:30** **Pleuritic chest pain with diffuse ST-segment elevation as the initial manifestation of antiphospholipid syndrome-related acute myocardial infarction in a very young patient**
I Naoum (Haifa, IL, M)
- 09:42** **Acute coronary syndrome in cancer patient: what was the cause?**
P Radic (Zagreb, HR, F)
- 09:54** **A rare cause of ST-segment elevation myocardial infarction**
N Popa-Fotea (Bucharest, RO, F)
- 10:06** **Premature Myocardial Infarction (MI) Complicated with Cardiac Arrest Secondary to Essential Thrombocythemia (ET).**
A M Omar (Chelmsford, GB, M)
- 10:18** **ST-segment elevation myocardial infarction due to spontaneous coronary artery dissection in a young female - diagnostic and therapeutic challenges**
AR Luca (Iasi, RO, F)

Learning Objectives:

Categories:

Challenges in pacing**Session Number: 3377**Chairpersons: S Sze (Leicester, GB) (F) - M Gluhovic (Pale, BA) (M)

- 09:30 Cardiac resynchronization therapy after coronary sinus reducer implantation using a proximal venous tributary.**
J Costantino (Rome, IT, M)
- 09:42 Cracking the code – a case report of a pacemaker malfunction**
C Miguel Goncalves (Leiria, PT, F)
- 09:54 Pacemaker-induced apnea in a patient with cervical medullary trauma**
M Kaufmann (Lausanne, CH, F)
- 10:06 Comprehensive treatment of arrhythmia disorders in a patient with worsening heart failure due to atrial flutter with complete atrioventricular block**
L Tran (Ho Chi Minh City, VN, F)
- 10:18 Left bundle branch pacing in a patient with severe hypertrophic obstructive cardiomyopathy undergoing alcohol septal ablation followed by complete AV block: to kill two birds with one stone**
C Rodriguez-Lopez (Madrid, ES, M)

Learning Objectives:

Categories:

How to optimise contemporary treatment of STEMI patients: time and way of myocardial reperfusion, updated medication, and post infarction rehabilitation - insights from Ukraine and Poland
Organised in collaboration with the Ukrainian Association of Cardiology and the Polish Cardiac Society

Session Number: 5108

Chairpersons: M Sokolov (Kyiv, UA) (M) - R Gil (Warsaw, PL) (M)

- 10:30 Case 1 - changing the paradigm of reperfusion therapy for STEMI patients: vision from Ukraine**
S Chaichuk (Kyiv, UA, M)
- 10:40 Changing the paradigm of reperfusion therapy for STEMI patients: vision from Ukraine - discussion of guideline implementation**
L Sorokhtey (Lviv, UA, F)
- 10:52 Case 2 - Polish experience in post-reperfusion STEMI treatment for inpatients and outpatients**
M Jaguszewski (Gdansk, PL, M)
- 11:02 Polish experience in post-reperfusion STEMI treatment for inpatients and outpatients - discussion of guideline implementation**
A Blachut (Gliwice, PL, F)

Learning Objectives: To establish a dialogue during this 45-minute session between case presenters and experts about different approaches for inpatient and outpatient STEMI management in two large European countries.

Categories: Online Live

Risk factors, predictive models, and clinical outcomes in acute coronary conditions**Session Number: 3043**Chairpersons: A Lansky (New Haven, US) (F) - S Mehta (Hamilton, CA) (M)

- 10:45 Association of contemporary hormonal contraception and the risk of arterial thrombosis**
H Yonis (Aalborg, DK, M)
- 10:55 Comparing the ability of GRACE 2.0 scores for predicting mortality in patients with and without diabetes.**
B Soman (Norwich, GB, M)
- 11:05 The activation of cardiac sympathetic nervous system in the non-culprit lesion is a strong prognostic predictor in patients with acute myocardial infarction**
T Kondo (Sumiyoshi-Ku, JP, M)
- 11:15 Residual cardiovascular risk in patients with acute coronary syndromes: from hs-CRP and LDL-C to JCAD**
S Kraler (Zurich, CH, M)
- 11:25 Extent and impact of obesity in patients with diabetes and acute myocardial infarction - experience from a national cohort**
V Ritsinger (Stockholm, SE, F)
- 11:35 Management and outcomes of acute myocardial infarction in patients with Alzheimer's disease: a study of 2.7 million individuals with myocardial infarction, 2010 - 2020**
W Ozarek (- , GB, F)

Learning Objectives:

Categories:

**Integrated management of atrial fibrillation: addressing
comorbidities, risk factors, and lifestyle****Session Number: 3023**Chairpersons: S Al-Khatib (Durham, US) (F) - P Sanders (Adelaide, AU) (M)

- 10:45 Adherence to the ABC pathway improves prognosis in patients with AF: preliminary findings from an updated meta-analysis of 360,000 patients**
GF Romiti (Rome, IT, M)
- 10:55 Outcome and life expectancy associated with novel subgroups of atrial fibrillation: a data-driven cluster analysis**
Y Yu (Shanghai, CN, M)
- 11:05 Impact of blood pressure control on the risk of stroke and mortality in patients with atrial fibrillation across different ages: a nationwide population-based study**
M Jeong (Seoul, KR, F)
- 11:15 Body mass index may alter cardiovascular outcomes in patients with newly-diagnosed atrial fibrillation and previous stroke: an interaction analysis using longitudinal data from the GLORIA-AF registry**
SHM Lam (Liverpool, GB, M)
- 11:25 Diabetes mellitus and adverse clinical events in patients with atrial fibrillation: implications of insulin treatment: a report from the GLORIA-AF Registry Phase III**
B Huang (Liverpool, GB, M)
- 11:35 Effects of mineralocorticoid receptor antagonists on new-onset or recurrent atrial fibrillation: a Bayesian and frequentist network meta-analysis of randomized trials.**
P Karakasis (Kilkis, GR, M)

Learning Objectives:

Categories:

Natural course and novel techniques in aortic procedures

Session Number: 3069

Chairpersons: G Faerber (Jena, DE) (F) - C Nienaber (London, GB) (M)

- 10:45** **Distal ascending aortic dilatation portends a near 2-fold greater risk of cardiovascular mortality than proximal enlargement: results from 120,000 patients in a nationwide echocardiographic database**
E Paratz (Melbourne, AU, F)
- 10:55** **Comparative effectiveness of Castor single-branch stent and hybrid surgery for the left subclavian artery in managing acute Type B aortic dissection with an inadequate proximal landing zone**
- 11:05** **Short-term and long-term outcomes of advanced EVAR versus open surgery in management of complex abdominal aortic aneurysm: systematic review and meta-analysis**
A Putra (Bali, ID, M)
- 11:15** **Biological effects of radiation exposure in patients treated with X-ray guided endovascular aortic repair**
TT Yeong (London, GB, F)
- 11:25** **Variation in care in individuals hospitalised with abdominal aortic aneurysm in nine high-income countries: a cross-sectional cohort study**
L Pasea (London, GB, F)
- 11:35** **Study on screening and diagnosis of aortic dissection based on non-enhanced CT and deep learning**
Z Cheng (Fuzhou, CN, M)

Learning Objectives:

Categories:

Obesity and diabetes: risk assessment and prognosis**Session Number: 3090**Chairpersons: K Marx-Schuett (Aachen, DE) (F) - P Dendale (Hasselt, BE) (M)

- 10:45 Persistence and Adherence to GLP-1 RA treatment in Type 2 Diabetes Mellitus: a Nationwide registry study**
MCH Lassen (Copenhagen S, DK, M)
- 10:57 Cardiovascular disease risk in people with diabetes in the era of universal diabetes screening**
J Liang (Auckland, NZ, F)
- 11:09 Prognostic outcomes of masld and obesity in acute myocardial infarction**
G Kong (Singapore, SG, F)
- 11:21 Interleukin-6 and suPAR improves prediction of all-cause mortality in type 1 diabetes - the Thousand & 1 Study**
HSZ Bahrami (Copenhagen, DK, M)
- 11:33 Glucose lowering drugs with proven cardiovascular benefit following acute coronary syndrome in type 2 diabetes: treatment gaps and outcomes**
I Naoum (Haifa, IL, M)

Learning Objectives:

Categories:

Cutting-edge echocardiography for assessment of cardiac function

Session Number: 3001

Chairpersons: E Plonska-Gosciniak (Szczecin, PL) (F) - V Kamperidis (Thessaloniki, GR) (M)**10:45 Can examining shear wave elastography predict elevated filling pressures? - A comparative evaluation against the current guideline algorithm**

AE Werner (Rostock, DE, F)

10:55 Automated non-invasive quantification of myocardial work using 3D echocardiography and validation with invasive catheter measurements

S A Creamer (Auckland, NZ, M)

11:05 Combined 3D left ventricular-arterial coupling and 3D left atrial-ventricular coupling indices could better predict MACE in young patients with STEMI

AI Scarlatescu (Bucharest, RO, F)

11:15 Early detection of cardiac dysfunction using shear wave imaging: insights into reduced cardiorespiratory fitness in childhood cancer survivors

A Youssef (Leuven, BE, M)

11:25 Improving exercise cardiac reserve assessment using a novel cardiopulmonary and echocardiography testing protocol (CPET-ESE) based on individualised exercise intensity domains

D Dorobantu (Exeter, GB, M)

11:35 Comparison of different non-invasive estimates of right ventriculo-arterial coupling as outcome predictors in dilated cardiomyopathy

AI Scarlatescu (Bucharest, RO, F)

Learning Objectives:

Categories:

Cardio-oncology (2)**Session Number: 3319**Chairpersons: DM Costa-Dan (Sao Paulo, BR) (F) - C Sousa (Porto, PT) (F)**10:45 Cardio oncology - get ready for the session****10:50 A rare case of histiocytic sarcoma mimicking an acute pericarditis**

N Siviero (Padova, IT, M)

11:03 A rare case of cardiovascular toxicity caused by pembrolizumab leading to coronary vasospasm

I Pagliassotto (Turin, IT, F)

11:16 The frozen valves: multivalvular carcinoid heart disease arising from metastatic neuroendocrine tumour

H Wisanusattra (Bangkok, TH, F)

11:29 Primary cardiac undifferentiated B-cell lymphoma

F Guerra (Ancona, IT, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals

Categories: Mobile App - Vote, Young Community Track

Masses in the heart**Session Number: 3346**Chairpersons: W Rutsatz (Giessen, DE) (F) - N Boskovic (Belgrade, RS) (M)

- 10:45 An interesting case of richly vascular left atrial mass .**
T Mahdy (Sutton Coldfield, GB, M)
- 10:57 The management dilemma of a large left ventricular fibroma**
M Gomes (Perth, AU, M)
- 11:09 Clinical conundrum: cardiac metastases from pulmonary myxoid sarcoma to the left atrium**
N Gamarra Valverde (Lima, PE, F)
- 11:21 Recurrence of liposarcoma metastasis to cardiac interventriculat septum**
P Chnupa (Bratislava, SK, M)
- 11:33 An unusual case of syncope due to intravascular leiomyomatosis with intracardiac extension to the right heart cavities**
C Porras Bueno (Floridablanca, CO, M)

Learning Objectives:

Categories:

Coronary aneurysms: not so benign!**Session Number: 3370**Chairpersons: A Giannopoulos (Zurich, CH) (M)

- 10:45** **A giant mystery of chest pain- diagnosis of giant coronary artery aneurysms in a patient with hyper eosinophilic syndrome**
S Hyder (Hartford, US, F)
- 10:57** **Giant right coronary artery aneurysm**
M Abdelshafy (Galway, IE, M)
- 11:09** **Posterior descending coronary artery thrombosis in an adult with diffuse giant coronary artery aneurysms**
S Bagheri (Temecula, US, M)
- 11:21** **28-year old female patient with out-of-hospital cardiac arrest and thrombotically occluded, calcified giant coronary artery aneurysms**
T Thevathasan (Berlin, DE, M)
- 11:33** **Acute coronary syndrome and cardiac tamponade presentation in a potential Kawasaki disease-related coronary artery aneurysm with spontaneous dissection.**
A Khidhir (Buffalo, US, F)

Learning Objectives:

Categories:

HOT LINE 3

Session Number: 1012

Chairpersons: M Adamo (Brescia, IT) (F) - S Windecker (Bern, CH) (M) - JF Obadia (Lyon-Bron Cedex, FR) (M)

- | | |
|-------|--|
| 11:00 | RESHAPE-HF2 - Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure
S Anker (Berlin, DE, M) |
| 11:12 | Discussant review - RESHAPE-HF2
G Stone (New York, US, M) |
| 11:17 | Panel discussion - RESHAPE-HF2 |
| 11:22 | MATTERHORN - Transcatheter versus surgical mitral valve repair in patients with heart failure and secondary mitral regurgitation
V Rudolph (Bad Oeynhausen, DE, M) |
| 11:34 | Discussant review - MATTERHORN |
| 11:39 | Panel discussion - MATTERHORN |
| 11:44 | Tri.fr trial - Multicentric randomised evaluation of the transcatheter edge-to-edge repair in the treatment of severe isolated secondary tricuspid regurgitation
E Donal (Rennes, FR, M) |
| 11:56 | Discussant review - Tri.fr trial |
| 12:01 | Panel discussion - Tri.fr trial |

Learning Objectives:

Categories: Online Live

Treatment options for patients with atrial fibrillation and heart failure with preserved left ventricular function**Session Number: 179**Chairpersons: M Hocini (Pessac, FR) (F) - J Poole (Seattle, US) (F)

- 11:00 The role of catheter ablation for atrial fibrillation in atrial fibrillation patients with heart failure and preserved left ventricular ejection fraction**
P Sommer (Bad Oeynhausen, DE, M)
- 11:15 The role of AV nodal ablation and physiological pacing in atrial fibrillation patients with heart failure and preserved left ventricular ejection fraction**
M Brignole (Milan, IT, M)
- 11:30 The role of drug therapy in atrial fibrillation patients with heart failure and preserved left ventricular ejection fraction**
R Zakeri (London, GB, F)
- 11:45 Treatment options for patients with atrial fibrillation and heart failure with preserved left ventricular function - discussion**
D Packer (Murray, US, M)

Learning Objectives:

Categories:

Guidelines in Practice: chest pain and dyspnoea in a patient actively treated for cancer

Session Number: 194

Chairpersons: P Van Der Meer (Groningen, NL) (M) - S Salinger (Nis, RS) (F)

11:00 A patient receiving chemotherapy and an immune checkpoint inhibitor presents with chest pain and dyspnoea: case presentation
C Franssen (Edegem, BE, M)

11:15 A patient receiving chemotherapy and an immune checkpoint inhibitor presents with chest pain and dyspnoea: what do the guidelines say?
S Gevaert (Gent, BE, F)

11:30 A patient receiving chemotherapy and an immune checkpoint inhibitor presents with chest pain and dyspnoea: how to implement the guidelines and take-home messages
J Bergler-Klein (Vienna, AT, F)

Learning Objectives:

Categories: Clinical Implementation Track, Online Live

Guidelines in Practice: 2024 ESC Guidelines for the Management of Elevated Blood Pressure and Hypertension

Session Number: 1201

Case-based cardiovascular collaborations: working together for a better future?

Session Number: 299

Joint session with the European Society for Vascular Surgery (ESVS)

Chairpersons:

I Loftus (London, GB) (M) - B Rantner (Munich, DE) (F)

- 11:00 Optimising treatment of cardiac disease before major vascular surgery**
V Aboyans (Limoges, FR, M)
- 11:15 Case-based collaborations: aortic stenosis and large aneurysm repair - combined TAVI and EVAR or TAVI first?**
CFW Vermeulen (- , NL, F)
- 11:30 Artificial intelligence in managing aortic disease**
PH Kolh (Liege, BE, M)
- 11:45 Case-based cardiovascular collaborations: working together for a better future? - discussion**
KK Yeung (Amsterdam, NL, F)

Learning Objectives: This session aims to recognise the need for - and individual patient benefits of - close working relationships between vascular surgeons and cardiologists, as well as the future of vascular artificial intelligence.

Categories:

**Great Debate: mechanical circulatory support in cardiogenic shock -
'the course of true love never did run smooth'****Session Number: 103**Chairpersons: R Mehran (New York, US) (F) - M Gilard (Brest Cedex, FR) (F)

- 11:00 Mechanical circulatory support is of benefit in cardiogenic shock: pro**
N Kapur (Boston, US, M)
- 11:15 Mechanical circulatory support is of benefit in cardiogenic shock: con**
H Thiele (Leipzig, DE, M)
- 11:30 Mechanical circulatory support is of benefit in cardiogenic shock - discussion**
S Price (London, GB, F)

Learning Objectives:

Categories: Online Live

ESC Clinical Consensus Statement on Obesity and Cardiovascular Disease

Session Number: 452

Heart failure: recent breakers**Session Number: 118**Chairpersons: M Metra (Brescia, IT) (M) - M Jessup (Philadelphia, US) (F)

- 11:00** **Should we give beta-blockers post-myocardial infarction?**
M Packer (Dallas, US, M)
- 11:12** **A shock in the treatment of cardiogenic shock?**
M Crespo-Leiro (La Coruna, ES, F)
- 11:24** **Where do we stand with SGLT2i post-myocardial infarction?**
J Butler (Atlanta, US, M)
- 11:36** **Yet more promise for GLP-1 agonists in HFpEF?**
LMG Meems (Groningen, NL, F)
- 11:48** **Heart failure: recent breakers - discussion**
S Zieroth (Winnipeg, CA, F)

Learning Objectives:

Categories: Online Live

Clinical Case Management: athletes with cardiomyopathies

Session Number: 144

Chairpersons: M Sanz-de la Garza (Barcelona, ES) (F) - M Halle (Munich, DE) (M)

11:00 Case 1: an athlete with enlarged right ventricle
S Gati (London, GB, F)

11:20 Case 2: an athlete with enlarged left ventricle
F D'Ascenzi (Siena, IT, M)

11:40 Clinical Case Management: athletes with cardiomyopathies - discussion
A La Gerche (Fitzroy, AU, M)

V Maestrini (Roma, IT, F)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Young Community Track

Clinical Case Management: the valvular heart team at work

Session Number: 314

Chairpersons: V Falk (Berlin, DE) (M) - C Agatiello (Buenos Aires, AR) (F)

11:00 Case 1: my patient has severe symptomatic secondary mitral regurgitation despite optimal medical therapy

A Franzone (Naples, IT, F)

11:20 Case 2: my patient has symptomatic multivalvular heart disease

A Duncan (London, GB, F)

11:40 Clinical Case Management: the valvular heart team at work - discussion

L Conradi (Hamburg, DE, M)

N Ajmone Marsan (Leiden, NL, F)

Learning Objectives:

Categories:

The floor is yours: bring your questions on INOCA

Session Number: 260

Chairpersons: M Marwan (Erlangen, DE) (M) - E Cenko (Bologna, IT) (F) - M Rubini Gimenez (Valencia, ES) (F)

11:00 The floor is yours: bring your questions on INOCA - get ready for the session
M Rubini Gimenez (Valencia, ES, F)

11:05 The floor is yours: bring your questions on INOCA - expert panel
W Jaber (Cleveland, US, M)

J Schulz-Menger (Berlin, DE, F)

M Bhatia (New Dehli, IN, F)

C Berry (Glasgow, GB, M)

P Parwani (Redlands, US, F)

E Androulakis (London, GB, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Mobile App - Ask a Question, Young Community Track

		2024 update on Core Curriculum for Cardiovascular Nurses and Allied Professionals
		Organised in collaboration with the British Association for Nursing in Cardiovascular Care (BANCC)
Session Number:	436	
<u>Chairpersons:</u>	C Ross (Belfast, GB) (F) - AG van Driel (Strijen, NL) (M)	

- | | |
|--------------|--|
| 11:00 | The Core Curriculum for Cardiovascular Nurses and Allied Professionals: what is it and why do we need it?
L Neubeck (Edinburgh, GB, F) |
| 11:15 | Multidisciplinary teams, patient-centred care, and student engagement: what is the linking pin?
I Uchmanowicz (Wroclaw, PL, F) |
| 11:30 | The Core Curriculum and clinical practice: what are the patient's needs?
R Mindham (London, GB, M) |
| 11:45 | 2024 update on Core Curriculum for Cardiovascular Nurses and Allied Professionals - discussion
L Klompstra (Norrkoping, SE, F) |

Learning Objectives:

Categories: Includes a patient perspective, Nurses and Allied Professionals track

The EHJ's year in adult congenital heart disease, cardio-oncology, and valvular heart disease

Joint session with the European Heart Journal (EHJ)

Session Number: 413

Chairpersons: F Crea (Roma, IT) (M) - A Tybjaerg-Hansen (Copenhagen, DK) (F)

11:00 Adult congenital heart disease

M Brida (Zagreb, HR, F)

11:20 Cardio-oncology

RA De Boer (Rotterdam, NL, M)

11:40 Valvular heart disease

H Baumgartner (Muenster, DE, M)

Learning Objectives: To have the EHJ editors summarise game-changing studies published in the last year about adult congenital heart disease, cardio-oncology, and valvular heart disease.

Categories:

Latest advances in artificial intelligence applied to cardiovascular imaging

Session Number: 257

Chairpersons: J Grapsa (London, GB) (F) - W Kong (Singapore, SG) (M)

- 11:00 What is new in artificial intelligence applied to cardiac computed tomography?**
D Dey (Los Angeles, US, F)
- 11:15 What is new in artificial intelligence applied to echocardiography?**
P Sengupta (New Brunswick, US, M)
- 11:30 What is new in artificial intelligence applied to cardiac magnetic resonance imaging?**
L Fusini (Milano, IT, F)
- 11:45 Latest advances in artificial intelligence applied to cardiovascular imaging - discussion**
C Collet (Aalst, BE, M)

Learning Objectives:

Categories: Digital Health

Registries, observational, and other studies on frailty, falls, and sarcopenia

Session Number: 1054

Chairpersons: L Aguilar Iglesias (Burgos, ES) (F) - S von Haehling (Berlin, DE) (M)

- 11:00 Clinical frailty scale is independently associated with one-year mortality in a large cohort of patients with acute heart disease**
J Alfredsson (Norrköping, SE, M)
- 11:12 Relevance of frailty in patients with acute coronary syndrome**
JT Neumann (Hamburg, DE, M)
- 11:37 Impact of sarcopenia on the clinical course of older patients with peripheral artery disease**
VH Schmitt (Gau-Bischofsheim, DE, M)
- 11:50 History Of Falls is Associated with Management and Worse Prognosis in Patients with Atrial Fibrillation: An Analysis from the Prospective GLORIA-AF Registry Phase III**
GF Romiti (Rome, IT, M)
- 12:02 Feasibility and diagnostic yield of screening for atrial fibrillation with PPG in very old and frail patients. Results from the Dutch-GERAF study.**
LAR Zwart (Hoorn, NL, M)

Learning Objectives:

Categories:

The role of '-omics' in personalised cardiovascular medicine**Session Number: 355**Chairpersons: F Weidinger (Vienna, AT) (M) - S Steffens (Munich, DE) (F)**11:00 Proteomics and lipidomics in cardiovascular medicine**

P Ganz (San Francisco, US, M)

11:15 Genomic and metabolomics in cardiovascular medicine

T Zeller (Hamburg, DE, F)

11:30 Multiomic approaches in cardiovascular medicine

M Tomaszewski (Manchester, GB, M)

11:45 The role of '-omics' in personalised cardiovascular medicine - discussion

J Wojta (Vienna, AT, M)

Learning Objectives:

Categories: Spotlight of the Congress

Daily Highlights by the Asean Federation of Cardiology

Session Number: 5136

This session is brought to you by the Asean Federation of Cardiology and is not part of the official ESC programme

Chairpersons:

Learning Objectives:

Categories: Online Live

**Young Investigator Award Session in Heart Failure and
Cardiomyopathies****Session Number: 805**Chairpersons: A Bayes Genis (Badalona, ES) (M) - D Dawson (Aberdeen, GB) (F)Judges: CG Tocchetti (Napoli, IT) - T Lopez Fernandez (Madrid, ES) - M Sheppard (London, GB)

12:00 Acute kidney injury as a risk factor for heart failure hospitalisation after major non-cardiac surgery
R Kaufmann (Basel, CH, M)

12:15 Artificial intelligence for automated left ventricular systolic dysfunction detection using a wearable cardiac patch incorporated with synchronized phonocardiogram and electrocardiogram
WL Zhang (Shanghai, CN, F)

12:30 Associations of different definitions of iron deficiency with cardiac structure and function, congestion, exercise capacity and prognosis in heart failure
N Pugliese (Pisa, IT, M)

12:45 Proteomics-based computational modelling of myocardial metabolism for personalized phenotyping and outcome prediction in advanced heart failure
N Beyhoffs (Berlin, DE, M)

Learning Objectives:

Categories:

Young Investigator Award Session in Atherothrombosis, Coronary, Aortic and Peripheral Artery Disease

Session Number: 802

Chairpersons:

Judges: J Dumfarth (Innsbruck, AT) - J De Backer (Ghent, BE) - C Heiss (Guildford, GB)

12:00 The aortic paradox: a nationwide analysis of 523,994 individual echocardiograms exploring aortic dissection
E Paratz (Melbourne, AU, F)

12:15 Plasma protein profile associated with a family history of early-onset coronary heart disease
A Wahrenberg (Stockholm, SE, F)

12:30 Epidemiology of recurrent myocardial infarction in the reperfusion era
DM Christensen (Kobenhavn O, DK, M)

12:45 Dynamics and prognostic role of persistent angina in chronic coronary syndrome with clinical, angiographic and stress CMR evidence of ischemia
H Merenciano Gonzalez (L'eliana, ES, M)

Learning Objectives:

Categories:

Young Investigator Award Session in Population Science, Genetics and Epidemiology

Session Number: 807

Chairpersons: J Hopewell (Oxford, GB) (F) - J Kaski (London, GB) (M)

Judges: I Sudano (Zurich, CH) - K Haugaa (Oslo, NO) - D Blendea (Feleacu, US)

12:00 Genome-wide association analysis reveals insights into the molecular etiology of dilated cardiomyopathy
S Zheng (London, GB, M)

12:15 A novel digital twin strategy to enable the translation of evidence from randomized control trials to new populations
P Thangaraj (New Haven, US, F)

12:30 A population-based characterisation of the relationship between anatomical and electrical axes of the heart
M Kayyali (London, GB, M)

12:45 Proteome-wide associations of pulse pressure in the UK Biobank
M Dib (Philadelphia, US, F)

Learning Objectives:

Categories:

Young Investigator Award Session in Preventive Cardiology

Session Number: 808

Chairpersons: A Abreu (Lisboa, PT) (F) - M Halle (Munich, DE) (M)Judges: S Gati (London, GB) - EL Grove (Aarhus, DK) - B Gigante (Stockholm, SE)

12:00 Long-term weight change in midlife, cardiac magnetic resonance parameters, risk of atrial fibrillation: a large prospective cohort study
J Li (Shanghai, CN, M)

12:15 Composition of non-HDL cholesterol and residual cardiovascular risk in secondary prevention
M K Hansen (Aarhus, DK, F)

12:30 Lipoprotein (a), coronary artery disease risk, and MACE in individuals without standard modifiable risk factors in the UK Biobank
J Sangha (Hereford, GB, M)

12:45 Bidirectional relationship between kidney disease progression and cardiovascular events in type 2 diabetes: new Insights from the CANVAS Program and CREDENCE trial
B Neuen (Sydney, AU, M)

Learning Objectives:

Categories:

Endocarditis (1)

Session Number: 3315

Chairpersons: S Ersozlu (Zurich, CH) (F) - O Clerc (Boston, US) (M)

- 12:00 Endocarditis - get ready for the session**
O Clerc (Boston, US, M)
- 12:05 Destructive streptococcal left-sided, native valve, infective endocarditis.**
E Karapedi (Athens, GR, F)
- 12:18 Candida parapsilosis infective endocarditis with tricuspid valve obstruction**
C Powell (Carrigtwohill, IE, M)
- 12:31 An extremely rare case of aorto-mitral curtain abscess presenting with complete AV block progressing to a commando operation**
S Lian (Tainan, TW, F)
- 12:44 Brain vs heart: which comes first? Prioritizing treatment in complicated left-sided infective endocarditis with neurological complications**
M Rizzo (Siena, IT, F)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals

Categories: Mobile App - Vote, Young Community Track

Best Clinical Cases Awards Session**Session Number: 800**Chairpersons: M Rubini Gimenez (Valencia, ES) (F) - CJF Camm (Oxford, GB) (M)Judges: V Johnson (Giessen, DE) - D Benz (Zurich, CH) - R Vidal-Perez (A Coruna, ES)

12:00 Beyond surface ECG pattern: Brugada syndrome unveiled after evidence of typical atrial flutter and enhanced ventricular arrhythmias susceptibility in a young patient.
C Marallo (Arezzo, IT, M)

12:15 Spontaneous coronary artery dissection in a patient with vascular Ehler-Danlos syndrome
C Leung (Manhasset, US, M)

12:30 Multimodality imaging assessment of a patient presenting with symptomatic ventricular tachycardia secondary to a large, epicardial, lipomatous mass with myocardial infiltration.
R Varma (Southampton, GB, M)

12:45 Sudden cardiac arrest in an adolescent female - Long QT syndrome, arrhythmogenic cardiomyopathy or both?
G Davidsson (Reykjavik, IS, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals

Categories: Young Community Track

Complex adult congenital heart disease cases**Session Number: 3363**Chairpersons: S Moscatelli (Bologna, IT) (F) - D Dorobantu (Exeter, GB) (M)

- 12:00** **Insight into unilateral absence of a pulmonary artery: a 24-year journey**
R Quevedo Salazar (Monterrey, MX, F)
- 12:12** **A case of partially palliated univentricular heart in a young adult: Is it too late to fix a broken heart?**
AM Santos (Quezon City, PH, F)
- 12:24** **Significant Left-Right shunt due to partial anomalous pulmonary venous connection and patent foramen ovale**
N Jimidar (Antwerp, BE, M)
- 12:36** **The adult patient with cyanogenic congenital heart disease – a never ending story**
A Buta (Bucharest, RO, F)
- 12:48** **Serendipitous diagnosis of cor triatriatum sinister in a healthy man**
JL Jara Valderrama (Trujillo, PE, M)

Learning Objectives:

Categories:

Session Number:	117	Heart failure due to hypertension: innovative drug and device-based therapies
		Joint session with the Great Wall International Congress of Cardiology (GW-ICC)
<u>Chairpersons:</u>	J Liu (Beijing, CN) (M) - A Dominiczak (Glasgow, GB) (F)	

- | | |
|-------|---|
| 12:30 | The global contribution of hypertension to heart failure
ML Muiesan (Brescia, IT, F) |
| 12:45 | Blood pressure targets for patients with hypertension and heart failure
L Shen (Glasgow, GB, F) |
| 13:00 | Angiotensin receptor and neprilysin inhibition for the treatment of hypertension
J Wang (Shanghai, CN, M) |
| 13:15 | Heart failure and hypertension management today and tomorrow
F Ruschitzka (Zurich, CH, M) |

Learning Objectives:

Categories: Online Live

The best acute cardiovascular-care science

Session Number: 3040

Chairpersons: H Schaubroeck (Aalter, BE) (F) - A Sionis (Barcelona, ES) (M)

- 13:15** **Recreational drugs use as prognostic factor of major adverse cardiovascular and cerebrovascular events in patients hospitalised for acute cardiovascular events.**
R Mirailles (Paris, FR, M)
- 13:25** **Prognostic significance of the estimated pulse wave velocity in critically ill patients with coronary heart disease**
Y Gu (Beijing, CN, F)
- 13:35** **Echocardiographic evaluation of ventricular performance in VA-ECMO weaning: results from a observational monocentric prospective study**
G Tavazzi (Pavia, IT, M)
- 13:45** **European practices on antithrombotic management during percutaneous mechanical circulatory support in adults: insights from an international survey**
C Van Edom (Leuven, BE, F)
- 13:55** **Young patients in the cardiac intensive care unit: insights from the critical care cardiology trials network registry**
T Sharma (Valhalla, US, F)
- 14:05** **Novel scoring system specific for patients treated with micro-axial percutaneous left ventricular assist device**
J Mierke (Dresden, DE, M)

Learning Objectives:

Categories:

Sudden cardiac death: insight**Session Number: 3018**Chairpersons: E Marijon (Paris, FR) (M) - KE Odening (Bern, CH) (F)

- 13:15** **Role of ventricular tachycardia cycle length in the outcomes after catheter ablation or antiarrhythmic drugs in the SURVIVE-VT trial**
P Avila Alonso (Madrid, ES, M)
- 13:25** **High incidence of malignant arrhythmias and heart failure in patients with RBM20-associated cardiomyopathy: a multicenter cohort study and review of the literature**
M Tukker (Rotterdam, NL, M)
- 13:35** **Significance of J wave with inverted ST-T polarity induced by ill-timed atrial premature beats and its association with Torsade de Pointes in patients with acute acquired long QT syndrome**
H Ichiryu (Gifu, JP, M)
- 13:45** **Comorbidities and use of proarrhythmic drugs in patients with torsade de pointes arrhythmia**
K Nowinski (Stockholm, SE, F)
- 13:55** **Prevalence and characteristics of the catecholamine induced QT prolongation syndrome**
V Probst (Nantes, FR, M)
- 14:05** **Identification of genetic variants by using a whole exome sequencing approach in Taiwanese patients with Brugada Syndrome**
J Juang (Taipei, TW, M)

Learning Objectives:

Categories:

Tricuspid valve intervention: ready for prime time?**Session Number: 3059**Chairpersons: A Franzone (Naples, IT) (F) - BA Popescu (Bucharest, RO) (M)

- 13:15 Echocardiographic pulmonary vascular resistance in patients undergoing tricuspid annuloplasty: prognostic implications and reversibility**
J Zhang (Hong Kong, CN, M)
- 13:25 Characteristics and outcomes of patients with moderate multivalvular disease in the context of tricuspid regurgitation**
M Morosato (Milan, IT, M)
- 13:35 Ventricular interaction and clinical outcomes in patients undergoing transcatheter tricuspid valve repair**
T Tanaka (Bonn, DE, M)
- 13:45 Different right ventricular mechanics in atrial and ventricular secondary tricuspid regurgitation and their prognostic role. A multicentric three-dimensional echocardiography study**
BK Lakatos (Miskolc, HU, M)
- 13:55 Clinical outcomes according to clinical and surgical risk scores for tricuspid regurgitation**
S Gwak (Seoul, KR, F)
- 14:05 Mortality rates by therapeutic approaches for isolated severe tricuspid regurgitation: a systematic review.**
J Mesnier (Paris, FR, M)

Learning Objectives:

Categories:

Drugs and exercise performance in athletes**Session Number: 3084**Chairpersons: S Castelletti (Milan, IT) (F) - HT Jorstad (Amsterdam, NL) (M)

- 13:15 Heart rate response and recovery in bicycle exercise testing - reference values and association with mortality**
J Jou (Uppsala, SE, M)
- 13:25 A flattening systolic blood pressure response at the end of ramp exercise testing is not associated with all-cause mortality**
A Carlen (Linköping, SE, F)
- 13:35 Relation between wearable heart rate monitor derived training load and cardiac adaption in endurance athletes**
C Dausin (Perk, BE, M)
- 13:45 Peak oxygen pulse response during maximal cardiopulmonary exercise testing on a treadmill: applicability analysis of the FRIEND registry prediction equation in a Brazilian healthy sample**
M Milani (Hasselt, BE, M)
- 13:55 Effect of sacubitril/valsartan and dapagliflozin on athletic performance; can the popular cardiac medications of recent years be used as doping agents?**
S Asal (Istanbul, TR, M)
- 14:05 Comparative effects of ranolazine and trimetazidine on cardiac structure and exercise capacity in a healthy rat model: a new doping agent?**
S Kilic (- , TR, M)

Learning Objectives:

Categories:

Biotherapies in cardiovascular disease: from bench to bedside

Session Number: 3111

Chairpersons: A Caforio (Padua, IT) (F) - D Angiolillo (Jacksonville, US) (M)

- 13:15 CS585, a novel prostacyclin receptor agonist, demonstrates sustained efficacy in vivo in the prevention of thrombosis**
M Holinstat (Ann Arbor, US, M)
- 13:25 RKER-012, a novel modified ActRIIB ligand trap, attenuated right ventricular cardiomyopathy in a preclinical model of pulmonary arterial hypertension.**
P Jain (Lexington, US, M)
- 13:35 First-in-human study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of RBD4059, a GalNAc-siRNA drug targeting coagulation factor XI (FXI), in healthy subjects**
A Gabrielsen (Molndal, SE, M)
- 13:45 Preclinical characterisation and first-in-human results on the tolerability and pharmacodynamic effect of REGN9933, a monoclonal antibody targeting the factor XI/activated factor XI apple 2 domain**
A Kithcart (- , US, M)
- 13:55 Phase I results of both IV and oral administration for CG-0255: a novel fast-acting antiplatelet drug with a new activation pathway**
X Chen (Shanghai, CN, M)
- 14:05 Developing p21-activated kinase 1 (PAK1) activators to treat hypertrophic cardiomyopathy (HCM)**
Y He (Oxford, GB, F)

Learning Objectives:

Categories:

Implantable cardioverter defibrillator therapy**Session Number: 3316**Chairpersons: V Johnson (Giessen, DE) (F) - M Schoos (Klampenborg, DK) (M)**13:15 Implantable cardioverter defibrillator therapy - get ready for the session****13:20 The great dilemma: type-1 Brugada ECG pattern or right bundle branch block?**
S Latrofa (Pisa, IT, F)**13:33 Unexpected culprit: ventricular fibrillation triggered by ICD programming**
M Al Rawahi (Montreal, CA, M)**13:46 Electrical storm in a patient with Charcot-Marie-Tooth disease treated with radiofrequency ablation and subsequent serious complication of ICD implantation**
J Vrtal (Karvina, CZ, M)**13:59 Navigating out of hospital cardiac arrest in the young**
M Golian (Toronto, CA, M)**Learning Objectives:** This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals**Categories:** Mobile App - Vote, Young Community Track

Coronary anomalies**Session Number: 3330**Chairpersons: BCQ Caneiro-Queija (Vigo, ES) (F) - E Rafflenbeul (Hamburg, DE) (M)

- 13:15** **Coronary artery fistula: easy to diagnose using CT coronary angiography**
R Pantea (Brasov, RO, F)
- 13:30** **Pearl string coronary artery, better to keep it covered**
S Yadav (New Delhi, IN, M)
- 13:45** **Navigating Uncharted Waters: A Unique Encounter with Single Coronary Artery and Pulmonary Artery Fistula**
G Panichella (Florence, IT, F)
- 14:00** **Late presentation of Anomalous Origin of the Right Pulmonary Artery from the ascending aorta (AORPA)**
K Viriyanukulvong (Bangkok, TH, M)

Learning Objectives:

Categories:

Tricky treatments for endocarditis

Session Number: 3367

Chairpersons:

M Van Hemelrijck (Zurich, CH) (M) - B Uygur (Istanbul, TR) (F)

- 13:15 Two-step approach for managing severe tricuspid valve endocarditis sepsis: percutaneous debulking followed later by replacement.**
J Aziz (Columbus, US, F)
- 13:27 Strategic approaches to mitigate complications in infective endocarditis: a comprehensive inquiry**
S Duca (Iasi, RO, F)
- 13:39 A patchwork gone wrong-A rare complication after surgical repair of Tetralogy of Fallot**
A E Karanikola (Marousi, GR, F)
- 13:51 Unraveling the knot: exploiting delay for therapeutic advantage in complicated right heart endocarditis among intravenous drug users**
M Rizzo (Siena, IT, F)
- 14:03 Percutaneous thrombectomy assisted lead extraction: successful diagnosis and cure in a case of culture negative endocarditis**
S Khasnavis (The Bronx, US, M)

Learning Objectives:

Categories:

Ask the Trialists from Hot Line 2

Session Number: 1076

Chairpersons: IS Mackenzie (Dundee, GB) (F) - P Taub (Rancho Santa Fe, US) (F)

- 13:40 Ask the Trialist - BedMed and BedMed-Frail**
SR Garrison (Edmonton, CA, M)
- 13:48 Ask the Trialist - Meta-analysis of trials on HS dosing of antihypertensives**
R Turgeon (Vancouver, CA, M)
- 13:56 Ask the Trialist - QUADRO**
S Taddei (Pisa, IT, M)
- 14:04 Ask the Trialist - GMRx2**
A Rodgers (Sydney, AU, M)
- 14:12 Ask the Trialist - VERONICA-Nigeria**
D Ojji (Abuja, NG, M)

Learning Objectives:
Categories:

2024 ESC Guidelines for the Management of Chronic Coronary Syndromes

Session Number: 1002

Chairpersons: F Andreotti (Rome, IT) (F) - CJM Vrints (Edegem, BE) (M)

Management of atrial fibrillation: knowns and unknowns**Session Number: 176**Chairpersons: T Lewalter (Munich, DE) (M) - E Hylek (Boston, US) (F)**13:45 The three pillars of atrial fibrillation management**

GYH Lip (Liverpool, GB, M)

14:00 Why atrial fibrillation duration should be an endpoint in atrial fibrillation ablation trials

C Blomstrom-Lundqvist (Uppsala, SE, F)

14:15 Will left atrial appendage occlusion replace oral anticoagulation?

M Glikson (Jerusalem, IL, M)

14:30 Pulsed field ablation: should it replace radiofrequency and balloon cryoablation?

T De Potter (Aalst, BE, M)

14:45 Management of atrial fibrillation: knowns and unknowns - discussion

I Deisenhofer (Munich, DE, F)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Online Live, Young Community Track

Personalised management of patients with diabetes and coronary artery disease: unresolved issues**Session Number: 196**Chairpersons: C Hamm (Bad Nauheim, DE) (M) - A Kautzky-Willer (Vienna, AT) (F)

13:45 Glycaemic control in a patient with acute coronary syndrome: how and how much
A Sambola (Barcelona, ES, F)

14:00 Surgical vs. percutaneous revascularisation in multi-vessel disease
M Ruel (Ottawa, CA, M)

14:15 Anti-diabetes therapy beyond glycaemic control
K Marx-Schuett (Aachen, DE, F)

14:30 Should diabetes influence antithrombotic therapy decision-making?
P Gurbel (Baltimore, US, M)

14:45 Personalised management of patients with diabetes and coronary artery disease: unresolved issues - discussion
M Morice (Massy, FR, F)

Learning Objectives:

Categories: Spotlight of the Congress

Secondary causes of hypertension: mind the gap**Session Number: 217**Chairpersons: A Schutte (Sydney, AU) (F) - K Tsioufis (Athens, GR) (M)

- 13:45 Primary hyperaldosteronism and pheochromocytoma**
S Monticone (Torino, IT, F)
- 14:00 Renal artery stenosis and fibromuscular dysplasia**
D Staub (Basel, CH, M)
- 14:15 Sleep apnoea**
D Linz (Maastricht, NL, M)
- 14:30 Non-adherence to medication**
IS Mackenzie (Dundee, GB, F)
- 14:45 Secondary causes of hypertension: mind the gap - discussion**
M Camafort (Barcelona, ES, M)

Learning Objectives:

Categories: Online Live

Mastering complexity: advanced PCI strategies for challenging lesions**Session Number: 285**Chairpersons: K Kearney (Seattle, US) (F) - A Colombo (Milan, IT) (M)

- 13:45 Chronic total occlusions unveiled: when antegrade? when retrograde?**
M McEntegart (Glasgow, GB, F)
- 14:00 Calcified lesions in focus: from scoring balloons to lithotripsy, and laser to orbital atherectomy**
J Escaned (Madrid, ES, M)
- 14:15 Tackling the bifurcation challenge: how I keep it safe and swift**
A Neylon (Paris, FR, F)
- 14:30 When stents fail (and CABG is not an option): drug-coated balloons or drug-eluting stents?**
RA Byrne (Dublin, IE, M)
- 14:45 Mastering complexity: advanced PCI strategies for challenging lesions - discussion**
M Roffi (Geneva, CH, M)

Learning Objectives:

Categories: Online Live

Great Debate: assessment of myocardial viability - a bygone era**Session Number: 266**Chairpersons: F Asch (Washington, US) (M) - M Bhatia (New Dehli, IN) (F)

13:45 Myocardial viability evaluation with advanced imaging is no longer relevant for heart team discussions: pro
M Westwood (London, GB, M)

14:05 Myocardial viability evaluation with advanced imaging is no longer relevant for heart team discussions: con
A Gimelli (Pisa, IT, F)

14:25 Myocardial viability evaluation with advanced imaging is no longer relevant for heart team discussions - discussion
R Nijveldt (Nijmegen, NL, M)

Learning Objectives:

Categories: Online Live

**Registries, observational, and other studies on coronary disease
including intervention and surgery**

Session Number: 1037

Chairpersons: P Avanzas Fernandez (Gijon, ES) (M)

- 13:45 Temporal trends in the use of drug-coated balloons**
R Januszek (Krakow, PL, M)
- 13:57 Ticagrelor monotherapy or DAPT after drug-eluting coronary stenting in patients with or without acute coronary syndrome: a patient-level meta-analysis of randomized controlled trials**
M Valgimigli (Lugano, CH, M)
- 14:10 Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents**
VV Daphne (Enschede, NL, F)
- 14:22 Major adverse cardiovascular events, new diagnoses, prescription redemptions and outpatient visits in patients one year after evaluation for symptoms suggestive of chronic coronary syndrome**
M Bottcher (Egaa, DK, M)
- 14:35 The trajectory of functional recovery after cardiac surgery: a prospective observational cohort study**
J Spence (Hamilton, CA, F)
- 14:47 Survival after PCI or CABG for multivessel disease in NSTEMI-ACS: a report from the SWEDEHEART registry**
E Omerovic (Gothenburg, SE, M)

Learning Objectives:

Categories:

Diagnosis of heart failure: towards better phenotyping

Session Number: 828

Chairpersons: C Fonseca (Oeiras, PT) (F) - JR Gonzalez Juanatey (Santiago De Compostela, ES) (M)

13:45 State-of-the-art lecture on diagnosis of heart failure: towards better phenotyping

T McDonagh (London, GB, F)

14:03 Undetected heart failure in tertiary care: prevalence, predictors and outcomes

K Rumora (Basel, CH, F)

14:22 A streamlined protocol for exercise right heart catheterisation for the diagnosis of heart failure with preserved ejection fraction

M Selvadurai (- , AU, F)

14:41 The diagnostic value of endomyocardial biopsy in the era of precision medicine: data from over 8,000 patients with comprehensive biopsy diagnostics

C Baumeier (Berlin, DE, M)

Learning Objectives:

Categories:

Refining risk stratification: what works best in primary prevention?**Session Number: 143**Chairpersons: E Yang (Mercer Island, US) (M) - N Kraenkel (Berlin, DE) (F)

- 13:45 Which biomarkers are useful to risk stratify in primary prevention?**
R Laaksonen (Espoo, FI, M)
- 14:00 When is calcium scoring useful to risk stratify in primary prevention?**
B Lopez Melgar (Madrid, ES, F)
- 14:15 When is cardiopulmonary fitness useful to risk stratify in primary prevention?**
M Guazzi (Milano, IT, M)
- 14:30 Do genetic scores help risk stratify in primary prevention?**
M Kavousi (Rotterdam, NL, F)
- 14:45 Refining risk stratification: what works best in primary prevention? - discussion**
E Gianos (New York, US, F)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Young Community Track

Tricuspid regurgitation and intervention: what are the limits?

Session Number: 832

Chairpersons: M Sitges (Barcelona, ES) (F) - R Ribeiras (Sintra -Lisbon, PT) (F)

- 13:45 State-of-the-art lecture on tricuspid regurgitation and intervention: what are the limits?**
F Praz (Bern, CH, M)
- 14:00 A decade of follow-up: atrial fibrillation, pulmonary pressure, and the progression of tricuspid regurgitation**
A Sabbag (Ramat Gan, IL, M)
- 14:15 The prognostic impact of tricuspid regurgitation improvement after left-sided valvular interventions**
I Von Der Heide (Hamburg, DE, F)
- 14:30 Effective RV ejection fraction by CMR: a new index of RV function in patients with severe TR.**
R Hinojar Baydes (Madrid, ES, F)
- 14:45 Improvement of endorgan function following tricuspid edge-to-edge repair**
U Jorde (Bronx, US, M)

Learning Objectives:

Categories: Online Live

Clinical Case Management: aortic stenosis and morbid obesity

Session Number: 258

Chairpersons: T Edvardsen (Oslo, NO) (M) - L Gargani (Pisa, IT) (F)

13:45 Case 1 - diagnostic challenges in aortic stenosis and morbid obesity: from non-invasive to invasive assessment
MA Clavel (Quebec, CA, F)

14:07 Case 2 - what treatment comes first in aortic stenosis and morbid obesity: weight loss or valve replacement?
AB Cid Alvarez (Santiago De Compostela, ES, F)

14:29 Clinical Case Management: aortic stenosis and morbid obesity - discussion
R Thamman (Pittsburgh, US, F)

J Bermejo Thomas (Madrid, ES, M)

Learning Objectives:

Categories: Obesity Track

Session Number: 437
Optimising healthcare delivery in cardiovascular patients: will artificial intelligence help?
Organised in collaboration with the British Association for Nursing in Cardiovascular Care (BANCC)
Chairpersons: I Gibson (Galway, IE) (F) - R Khatib (Leeds, GB) (M)

- 13:45 Optimising healthcare delivery by artificial intelligence?**
D Fitzsimons (Belfast, GB, F)
- 14:00 Role of new technologies in communication between patients and healthcare professionals**
P Dendale (Hasselt, BE, M)
- 14:15 Can artificial intelligence reduce the burden of clinical data?**
G Lee (Cork, IE, F)
- 14:30 Optimising healthcare delivery in cardiovascular patients: will artificial intelligence help? - patient perspective**
P McGreavy (Hope Valley, GB, M)
- 14:45 Optimising healthcare delivery in cardiovascular patients: will artificial intelligence help? - discussion**
A Stromberg (Linkoping, SE, F)

Learning Objectives:
Categories: Digital Health, Includes a patient perspective, Nurses and Allied Professionals track

Revolutionary new cardiovascular disease therapies: future now

Session Number: 414 **Joint session with the European Heart Journal (EHJ) - Cardiovascular Research**

Chairpersons: I Fleming (Frankfurt Am Main, DE) (F)

13:45 Genetic therapy to cure the heart: inherited cardiomyopathies
H C Watkins (Oxford, GB, M)

14:00 RNA-based therapies for cardiovascular disease
S Zacchigna (Trieste, IT, F)

14:15 Targeted therapeutic gene delivery to the cardiovascular system

14:30 Monoclonal antibodies, gene silencing, and gene editing (CRISPR) therapies for the treatment of hyperlipidaemia
KK Ray (London, GB, M)

14:45 RNA interference for treating hypertension
A Desai (Boston, US, M)

Learning Objectives: To present therapies and cures that are changing clinical practice in cardiovascular medicine.

Categories:

Digital technology to personalise a heart-healthy lifestyle**Session Number: 135**Chairpersons: J Niebauer (Salzburg, AT) (M) - I Frederix (Rotselaar, BE) (F)

13:45 Digital health tools to support and sustain personalised exercise prescription
V Cornelissen (Leuven, BE, F)

14:00 Patient's perspective on digital tools: what's in it for me?
C Mersa (Timisoara, RO, M)

14:15 Do digital patient educational programmes work?
M Back (Gothenburg, SE, F)

14:30 Tele-rehabilitation: alternative and/or adjunct to conventional cardiac rehabilitation?
M Ciuca-Pana (Bucharest, RO, F)

14:45 Digital technology to personalise a heart-healthy lifestyle - discussion
EG Caiani (Milano, IT, M)

Learning Objectives:

Categories: Digital Health, Includes a patient perspective

Gene editing and gene therapies to cure cardiovascular diseases**Session Number: 341**Chairpersons: J van der Velden (Amsterdam, NL) (F) - S Heymans (Maastricht, NL) (M)

- 13:45** **Gene editing to correct monogenic cardiomyopathies**
E Van Rooij (Utrecht, NL, F)
- 14:00** **Gene therapies for inherited channelopathies**
SG Priori (Pavia, IT, F)
- 14:15** **Gene/base editing as therapy for common cardiovascular disorders**
S Lebek (Regensburg, DE, M)
- 14:30** **Towards clinical translation of gene editing into cardiovascular care**
M Giacca (London, GB, M)
- 14:45** **Gene editing and gene therapies to cure cardiovascular diseases - discussion**
C Kupatt (Munich, DE, M)

Learning Objectives:

Categories:

Daily Highlights by the Pakistan Cardiac Society

Session Number: 5128

**This session is brought to you by the Pakistan Cardiac Society
and is not part of the official ESC programme**

Chairpersons:

Learning Objectives:

Categories: Online Live

Ask the Trialists from Hot Line 3

Session Number: 1078

Chairpersons: G Stone (New York, US) (M)

- 14:30 **Ask the Trialist - RESHAPE-HF2**
S Anker (Berlin, DE, M)

- 14:40 **Ask the Trialist - MATTERHORN**
V Rudolph (Bad Oeynhausen, DE, M)

- 14:50 **Ask the Trialist -Tri.fr trial**
E Donal (Rennes, FR, M)

Learning Objectives:
Categories:

Markers for the severity of worsening heart failure**Session Number: 3038**Chairpersons: C Angermann (Wurzburg, DE) (F) - D Knappe (Hamburg, DE) (F)

- 14:30 Blood plasma metabolites and heart failure risk: insights from Mendelian randomization analysis**
Z Ma (Heidelberg, DE, M)
- 14:40 Comparing de novo heart failure and acute decompensated heart failure using a proteomic approach**
A Dieden (Malmoe, SE, F)
- 14:50 Prognostic impact of systemic immune-inflammation index in patients with acute decompensated heart failure with preserved ejection fraction -PURSUIT-HFpEF Registry-**
Y Kokubu (Osaka, JP, M)
- 15:00 Low admission T3 serum levels in acute decompensated heart failure hospitalizations: an unrecognized hidden enemy? A propensity matching tale.**
- 15:10 VExUS score improvement is associated with better outcomes in acute decompensated heart failure**
M Saadi (Porto Alegre, BR, F)
- 15:20 Serial shock severity assessment within seventy-two hours after diagnosis: a cardiogenic shock working group report**
V Ton (Boston, US, F)

Learning Objectives:

Categories:

TAVI: technical aspects in special populations**Session Number: 3076**Chairpersons: A Petronio (Pisa, IT) (F) - H Herrmann (Philadelphia, US) (M)

- 14:30** **Procedural and clinical outcomes according to ultrasound-guided access in TAVI: a propensity-matched comparative sub-analysis from the PULSE registry**
D Grundmann (Hamburg, DE, M)
- 14:40** **Comparison of the effects of pre-dilatation with conventional versus larger balloon sizes on clinical outcomes in transcatheter aortic valve implantation with self-expandable valves**
N Takahashi (Tokyo, JP, M)
- 14:50** **Procedure-related radiation and contrast use during TAVI procedures with balloon-expandable versus self-expanding devices**
J Andreka (Pomaz, HU, F)
- 15:00** **Flow adjusted predicted prosthesis patient mismatch in patients undergoing transcatheter aortic valve implantation**
D Tomii (Bern, CH, M)
- 15:10** **Impact of SAPIEN3 Ultra RESILIA on improvement of valve performance: Insights from the multicenter registry: a propensity-score matched analysis**
N Takahashi (Tokyo, JP, M)
- 15:20** **Safety and efficacy of transcatheter aortic valve implantation (TAVI) in patients with previous TAVI; a systematic review and meta-analysis**
N Ktenopoulos (Athens, GR, M)

Learning Objectives:

Categories:

Hypertension phenotypes and cardiovascular risk**Session Number: 3082**Chairpersons: AMG Almeida (Lisbon, PT) (F) - G Gnanaraj (Chennai, IN) (M)

- 14:30** **Influence of orthostatic blood pressure changes on the effects of intensive blood pressure control in patients with type 2 diabetes**
M Zhao (Beijing, CN, F)
- 14:40** **Clustering analysis based on clinically available data for improving risk stratification and outcome prediction of hypertension**
E Rauseo (Gerrards Cross, GB, F)
- 14:50** **Prevalence and prediction of masked uncontrolled hypertension in patients recently hospitalised for an acute coronary syndrome**
H Hellqvist (Stockholm, SE, M)
- 15:00** **Optimal blood pressure values to reduce arterial stiffness, an analysis from UK Biobank**
A Shantsila (Liverpool, GB, F)
- 15:10** **One-year risk of all-cause death and major cardiovascular events in patients presenting with hypertensive crisis. A report from a global federated research health network.**
T Bucci (Castelnuovo Di Porto, IT, M)
- 15:20** **Association between the cumulative excessive systolic blood pressure and left ventricular mass index**
Y Lee (Guri, KR, M)

Learning Objectives:

Categories:

Renal failure: special aspects for the cardiologist**Session Number: 3098**Chairpersons: H Hanssen (Basel, CH) (M) - N Sattar (Glasgow, GB) (M)

- 14:30 Interpretable machine learning model for predicting long-term cardiovascular mortality risk in chronic kidney disease patients using SHAP explainers**
W Wu (Guangzhou, CN, F)
- 14:42 Correlation between postdialysis blood pressure assessed at different time points and home blood pressure monitoring**
W Nadruz (Campinas, BR, M)
- 14:54 Guideline-directed medical therapy and in-hospital mortality in acute coronary syndrome patients with advanced renal dysfunction**
Z Jin (- , CN, M)
- 15:06 Electronic nudges to increase influenza vaccination in patients with chronic kidney disease: a prespecified analysis of NUDGE-FLU-CHRONIC**
KG Skaarup (Copenhagen, DK, M)
- 15:18 Surgical reduction of a high-flow dialysis fistula has long-term positive effects of the heart**
A Valerianova (Prague, CZ, F)

Learning Objectives:

Categories:

Transforming population health through mobile technology

Session Number: 3115

Chairpersons: A Pearsons (Edinburgh, GB) (F) - RMA Van Der Boon (Rotterdam, NL) (M)

- 14:30 Comparison between smartphone 6-lead ECGs and 12-lead ECGs in athletes**
JJ Orchard (Sydney, AU, F)
- 14:40 The impact of daily step count with mobile health apps on clinical outcomes among general population**
Y Takeji (Kanazawa, JP, M)
- 14:50 Smartphone motion sensor based detection of atrial fibrillation in populations referred to cardiology**
J Blomster (Turku, FI, M)
- 15:00 Prevention of dementia using mobile phone applications (PRODEMOS): a multinational randomised controlled effectiveness-implementation trial**
E Moll van Charante (Bosch En Duin, NL, M)
- 15:10 Design and implementation of digital home blood pressure monitoring based on Bluetooth and WeChat App in the FAIR-Pilot study**
Y Li (Beijing, CN, M)
- 15:20 Remote monitoring of patients with chronic heart failure class II-III (NYHA) using the mobile application 'M-cardio' in residents of Kyrgyzstan**
A Rustambekova (Bishkek, KG, F)

Learning Objectives:

Categories:

Peripheral artery disease**Session Number: 3321**Chairpersons: I Desormais (Limoges, FR) (F) - AN Calik (Istanbul, TR) (M)

- 14:30** **Peripheral artery disease - get ready for the session**
I Desormais (Limoges, FR, F)
- 14:35** **Young man with inflammatory vascular neck pain**
F Belcastro (Buenos Aires, AR, M)
- 14:48** **Type A Aortic Dissection and Fibromuscular dysplasia**
D Banerji (Waltham, US, F)
- 15:01** **Successful clinical outcome after PCI for rapidly progressed bilateral ostial coronary lesions in a patient with Takayasu arteritis who was treated with timeous immunosuppressive combination therapy**
R Fukuoka (Tokyo, JP, M)
- 15:14** **Renal fractional flow reserve guided stenting in renovascular hypertension with extremely tortuous renal artery**
YX Chang (Beijing, CN, F)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals

Categories: Mobile App - Vote, Young Community Track

Management in congenital heart disease**Session Number: 3351**Chairpersons: FJ Ruperti Repilado (Basel, CH) (M) - R Luna (Madrid, ES) (F)

- 14:30 Complex aortic coarctation with dilation of the aortic root in a patient with a bicuspid aortic valve**
B Quintero Garzon (Mexico City, MX, M)
- 14:45 Cor triatriatum dexter - not a simple membrane, but a small red flag to take a closer look at the heart**
R Vornicu (Bucuresti, RO, F)
- 15:00 Enormous ASD presenting with severe right heart failure**
E Orchard (Oxford, GB, F)
- 15:15 Twisting the fate of ACHD case: from hopeless to curable disease**
C Maneesopit (Bangkok, TH, M)

Learning Objectives:

Categories:

Complex complications in pericarditis**Session Number: 3372**Chairpersons:

B Weber (Boston, US) (F) - S Khalaf (Cleveland Heights, US) (F)

- 14:30 Pediatric constrictive pericarditis: a case report and imaging findings**
MF Egas (- , EC, F)
- 14:42 Pericardial mesothelioma in pregnancy: a rare clinical presentation**
S Laterza (- , IT, F)
- 14:54 Unraveling complexity: recurrent pericarditis in a patient with post-cardiac injury syndrome, primary pulmonary hypertension, and the confluence of hypertrophic cardiomyopathy and atrial flutter**
D Dodita (Bucharest, RO, F)
- 15:06 The hidden mimic: tuberculous pericarditis unraveling as heart failure**
T Lertnimittham (Khon Kaen, TH, F)
- 15:18 Restrictive cardiomyopathy after aortic coarctation repaired in childhood: beyond cardiovascular hemodynamics.**
J Vila Garcia (Madrid, ES, F)

Learning Objectives:

Categories:

Percutaneous treatment of tricuspid regurgitation

Session Number: 330

Joint session with the Saudi Heart Association (SHA)

Chairpersons: M Balghith (Riyadh, SA) (M) - N Karam (Paris, FR) (F)

14:45 Clinical evaluation and optimal medical management of tricuspid regurgitation

15:00 Imaging of tricuspid regurgitation
R Hahn (New York, US, F)

15:15 Transcatheter edge-to-edge repair (TEER) for tricuspid regurgitation is a good alternative to surgical repair
S Samargandy (Riyadh, SA, F)

15:30 When transcatheter edge-to-edge repair (TEER) is not a good treatment option for tricuspid regurgitation
F Alqahtani (Riyadh, SA, M)

Learning Objectives: This session aims to learn how to choose the type of percutaneous therapy for severe tricuspid regurgitation (TR); to learn how to select and do transcatheter edge-to-edge repair (TEER) for tricuspid regurgitation; and to learn how to select and do TricValve.

Categories: Clinical Implementation Track, Online Live

Coronary computed tomography angiograms for diagnosis and risk stratification**Session Number: 3050**Chairpersons: L Shaw (New York, US) (F) - A Saraste (Turku, FI) (M)

- 15:45** **Number of inflamed coronary vessels in prediction of cardiac death and MACE among patients undergoing routine CCTA: the Oxford Risk Factors And Non-Invasive Imaging (ORFAN) Study**
K Chan (London, GB, M)
- 15:55** **Impact of coronary CT angiography on the hospital outcome among patients admitted with AMI undergoing revascularization procedures in theUS**
S Shoar (Largo, US, M)
- 16:05** **Low density lipoprotein cholesterol and cardiovascular disease risk in patients with absence of coronary artery calcification: a multicenter cohort study**
MH Andersen (Aarhus N, DK, F)
- 16:15** **Association between high versus low cardiovascular risk in individuals with corresponding unexpected absent versus severe subclinical coronary atherosclerosis, a nationwide, multicenter study**
M Johansson (Malmo, SE, F)
- 16:25** **Real world data after the implementation of coronary computed tomography angiography in Swedish primary care to rule out coronary artery disease, a cross-sectional study based on pre-test probability**
E Stertman (- , SE, M)
- 16:35** **Assessment of surgical revascularization completeness with quantitative myocardial blood flow distribution derived from CCTA in severe coronary artery disease**
P W Serruys (Galway, IE, M)

Learning Objectives:

Categories:

Heart and kidney in heart failure: no end to the dangerous liaison**Session Number: 3032**Chairpersons: ML Muiesan (Brescia, IT) (F) - E Jankowska (Wroclaw, PL) (F)

- 15:45 Implications of incorporating cystatin C into estimated glomerular filtration rate equations in patients with heart failure**
P Tolomeo (Ferrara, IT, M)
- 15:55 Heart failure and advanced chronic kidney disease: differences in characteristics, treatment and outcomes in patients with glomerular filtration rate greater or less than 30 ml/minute/m²**
A Recio Mayoral (Seville, ES, M)
- 16:05 Chronic kidney disease in patients with heart failure in German primary care practices: the InspeCKD study**
- 16:15 Validation of existing risk scores for worsening renal function in patients with newly diagnosed heart failure: a longitudinal population cohort study**
I Mordi (Dundee, GB, M)
- 16:25 The impact of comorbidities on therapy-optimization and their prognostics role among hospitalized patients with heart failure with reduced ejection fraction**
B Muk (Budapest, HU, M)
- 16:35 Kidney status and events preceding death in heart failure: A real world data study on 18,456 patients with heart failure**
D Zahir (Hellerup, DK, F)

Learning Objectives:

Categories:

Inflammation in heart failure

Session Number: 3121

Chairpersons: F Leuschner (Heidelberg, DE) (M) - P Alcaide (Boston, US) (F)

- 15:45** **Role of inflammation and macrophages in the formation of the atrial cardiomyopathy associated with obesity**
N Suffee (Paris, FR, F)
- 15:55** **The myocardium of human dilated nonischemic cardiomyopathy harbors unique tissue-resident lymphocyte subsets**
F Alkhunaizi (New York, US, F)
- 16:05** **Loss of IDH1 and IDH2 in macrophages induces pathological phenotypes in cardiomyocytes**
P Pennoyer (Frankfurt Am Main, DE, F)
- 16:15** **Snip3 promotes the release of mitochondria-derived extracellular vesicles in cardiac fibroblasts to exacerbate inflammation response after myocardial infarction**
Y Hu (Nanjing, CN, F)
- 16:25** **Photobiomodulation mitigates diastolic dysfunction, reduces perivascular fibrosis and inflammation, and enhances mitochondrial metabolism and angiogenesis in a mouse model of HFpEF**
D Nachman (Jerusalem, IL, M)
- 16:35** **Macrophage-mediated interleukin-6 signaling drives ryanodine receptor-2 calcium leak in postoperative atrial fibrillation**
X Wehrens (Houston, US, M)

Learning Objectives:

Categories:

Models and aspects of care delivery in patients with cardiovascular conditions**Session Number: 3108**Chairpersons: R Wynne (Melbourne, AU) (F) - R Khatib (Leeds, GB) (M)

- 15:45 The introduction of a dedicated cardiology clinic including a clinical scientist led pathway for women with turner's syndrome**
R Macrae (London, GB, F)
- 15:55 Nurse led assessment of congestion in outpatient heart failure patients: remote dielectric sensing versus lung ultrasound comparison**
A Abbo (Haifa, IL, M)
- 16:05 Beyond telehealth in heart failure, how a nurse-led mobile team unit improves management and reduces re-admission in elderly patients living in a rural area.**
O Soussi (Rabat, MA, F)
- 16:15 Shared care in heart failure management is linked with physical and mental health by perceived control in patient-caregiver dyads**
ML Chung (Lexington, US, F)
- 16:25 Safe transition home after transcatheter aortic valve implantation feasibility (START-F) study: Very early self-reported function and recovery status after early discharge**
S Lauck (Vancouver, CA, F)
- 16:35 The trajectory of self-care over a 12-month period in patients with heart failure, comparing those with consistently good and poor self-care.**
L Klompstra (Norrkoping, SE, F)

Learning Objectives:

Categories:

**Exploring valvular and congenital heart disease with cardiac
magnetic resonance****Session Number: 3011**Chairpersons: G Vinco (Verona, IT) (F) - A Altes (Lille, FR) (M)

- 15:45 Severe aortic stenosis is associated with left atrial prothrombotic flow changes that persists despite successful aortic valve replacement**
M Spartera (Oxford, GB, M)
- 15:57 Right atrial and ventricular function in risk stratification of patients with pulmonary artery hypertension**
J Guo (Sichuan, CN, F)
- 16:09 Impact of epicardial adipose tissue and atrial functional impairment in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement**
J Gronwald (Goettingen, DE, F)
- 16:21 LV reverse remodeling after SAVR in patients with severe symptomatic aortic stenosis: impact on the clinical outcome**
MRL Lima (Lisbon, PT, F)
- 16:33 Fenofibrate modulates cardiac energy metabolism in moderate-severe aortic stenosis: a mechanistic double-blinded randomised controlled MR trial**
S Monga (Swindon, GB, F)

Learning Objectives:

Categories:

Spontaneous coronary artery dissection**Session Number: 3301**Chairpersons: J Boeddinghaus (Edinburgh, GB) (M) - E Rafflenbeul (Hamburg, DE) (M)

- 15:45 Spontaneous coronary artery dissection - get ready for the session**
J Boeddinghaus (Edinburgh, GB, M)
- 15:50 A case of multi-vessel SCAD in association with aortic dissection**
A Abdullah (Dudley, GB, M)
- 16:13 An unorthodox cause of spontaneous coronary artery dissection (SCAD)**
TH Nyi (Norwich, GB, M)
- 16:26 Spontaneous coronary artery dissection: a diagnostic dilemma**
A Butt (Rochester, US, M)
- 16:39 Successful management of familial spontaneous coronary artery dissection with massive thrombosis originating proximal to the left anterior descending artery and extending to the left main coronary**
M Cap (Diyarbakir, TR, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals

Categories: Mobile App - Vote, Young Community Track

Percutaneous coronary intervention

Session Number: 3333

Chairpersons: G Tzanis (Athens, GR) (M) - C Fraccaro (Padova, IT) (F)

- 15:45 Stent stripped off balloon during ST elevation myocardial infarction**
S Aalaei Andabili (Baltimore, US, M)
- 15:57 Stent in the middle of nowhere. A Persistent-Aneurysm as cause of an inferior STEMI.**
H Alexy (Bremen, DE, M)
- 16:09 A missing coronary guidewire mimicking aortic dissection**
Z Arow (Jatt, IL, M)
- 16:21 A patient with multiple in-stent restenosis and polyneuropathy. What are we missing?**
M Del Rio Lopez (Elche, ES, F)
- 16:33 Coronary wire complete fracture-When "all hell break loose in a cath lab"**
APN De Vas Goonewardane (Polonnaruwa, LK, M)

Learning Objectives:

Categories:

Unusual causes of aortic pathology

Session Number: 3380

Chairpersons: P Paolisso (Naples, IT) (M) - M Alasnag (Jeddah, SA) (F)

15:45 **IgG4-related aortitis simulating intramural hematoma in asymptomatic woman**
JP Fescina (Buenos Aires, AR, M)

16:00 **Intimal tear of ascending aorta caused myocardial infarction**
Z Zhu (Changsha, CN, M)

16:15 **Severe coronary artery disease in a patient mwith Takayasu arteritis**
C Rivera Avalos (Mexico City, MX, M)

16:30 **Acute aortic dissection in a young woman caused by a rare disease**
A Apostu (Bucharest, RO, F)

Learning Objectives:

Categories:

Daily Highlights by the Hungarian Society of Cardiology

Session Number: 5123

This session is brought to you by the Hungarian Society of Cardiology and is not part of the official ESC programme

Chairpersons:

Learning Objectives:

Categories: Online Live

HOT LINE 4

Session Number: 1013

Chairpersons: A Zientara (Freiburg, DE) (F) - S Verma (Toronto, CA) (M) - R Gil (Warsaw, PL) (M)

- 16:15** **ASSURE DES - Perioperative antiplatelet therapy in patients with coronary stents before non-cardiac surgery**
J Ahn (- , KR, M)
- 16:27** **Discussant review - ASSURE DES**
- 16:32** **Panel discussion - ASSURE DES**
- 16:37** **SWEDEGRAFT - No-touch vein grafts in coronary artery bypass grafting**
S James (Uppsala, SE, M)
- 16:49** **Discussant review - SWEDEGRAFT**
V Falk (Berlin, DE, M)
- 16:54** **Panel discussion - SWEDEGRAFT**
- 16:59** **TIGHT-K - Potassium supplementation and the prevention of atrial fibrillation after cardiac surgery**
B O'Brien (Berlin, DE, M)
- 17:11** **Discussant review - TIGHT-K**
F Zannad (Paris, FR, M)
- 17:16** **Panel discussion - TIGHT-K**

Learning Objectives:
Categories: Online Live

Updates for everyone in electrophysiology and arrhythmias**Session Number: 181**Chairpersons: JC Deharo (Marseille Cedex 05, FR) (M) - J Vogler (Luebeck, DE) (F)**16:15 Update on atrial cardiomyopathy**

A Goette (Paderborn, DE, M)

16:30 Update on atrial cardiomyopathy - discussion

D Tomasoni (Brescia, IT, F)

16:35 Practical guide to antiarrhythmic drug therapy

JL Merino (Madrid, ES, M)

16:50 Practical guide to antiarrhythmic drug therapy - discussion

AJ Camm (London, GB, M)

16:55 Certifying physicians and allied professionals in cardiac implantable electronic device therapy and invasive cardiac electrophysiology

S Trines (Leiden, NL, M)

17:10 Certifying physicians and allied professionals in cardiac implantable electronic device therapy and invasive cardiac electrophysiology - discussion

S Al-Khatib (Durham, US, F)

Learning Objectives:

Categories:

Dealing with obesity in the cardiac care unit: practical solutions**Session Number: 190**Chairpersons: K Huber (Vienna, AT) (M) - A Porter (Ganey Tiqua, IL) (F)**16:15 Impact of obesity on acute cardiovascular outcomes**

C Magnussen (Hamburg, DE, F)

16:35 Optimising medical therapy and interventions for patients with obesity in the cardiac care unit

A Sambola (Barcelona, ES, F)

16:55 Anti-obesity medications in the acute setting: when should we start, stop, or continue?

S Leonardi (Pavia, IT, M)

Learning Objectives:

Categories: Clinical Implementation Track, Obesity Track

Personalised hypertension management

Session Number: 222

Joint session with the European Society of Hypertension (ESH)

Chairpersons: T Weber (Wels, AT) (M) - RM Bruno (Paris, FR) (F)

16:15 Should sex differences be considered in hypertension management?
E Gerdtts (Bergen, NO, F)

16:30 What is the role of genetic testing and biomarkers in hypertension management?
T Guzik (Glasgow, GB, M)

16:45 How to personalise drug treatment in hypertension management
J Brguljan (Ljubljana, SI, F)

17:00 When to use renal denervation in hypertension management
K Tsioufis (Athens, GR, M)

Learning Objectives:

Categories: Online Live, Spotlight of the Congress

Invasive treatment of peripheral arterial disease: these boots are made for walking**Session Number: 287**Chairpersons: C Espinola-Klein (Mainz, DE) (F) - M Venermo (Helsinki, FI) (F)

- 16:15 Open surgery or endovascular approach as first-line treatment for chronic limb ischaemia: review of evidence from BEST-CLI and BASIL-2 and more**
P Krishnan (Manhattan, US, M)
- 16:35 A case of a patient with critical limb ischaemia: first-line treatment decisions**
I Baumgartner (Bern, CH, F)
- 16:55 Invasive treatment of peripheral arterial disease: these boots are made for walking - discussion**
M Brodmann (Graz, AT, F)

Learning Objectives:

Categories:

2024 ESC Guidelines for the Management of Chronic Coronary Syndromes: Ask the Guidelines Task Force

Session Number: 1102

**Trial updates and other studies on percutaneous coronary
intervention**

Session Number: 1038

Chairpersons: R Colleran (Dublin, IE) (F) - G Tarantini (Padua, IT) (M)

- 16:15 Clopidogrel following 1-month aspirin-free low-dose prasugrel monotherapy versus aspirin following 1-month DAPT after PCI for patients with ACS or HBR: Final 1-year results from the STOPDAPT-3**
H Watanabe (Hirakata, JP, M)
- 16:27 Long-Term Outcomes with PCI Guided by Fractional Flow Reserve**
C Collet (Aalst, BE, M)
- 16:39 Titanium-nitride-oxide-coated vs drug-eluting stents in acute coronary syndromes during five-year follow-up: an individual patient data meta-analysis**
T Mahendiran (Lausanne, CH, M)
- 16:51 Physiology-guided complete versus culprit-only PCI in older MI patients**
Sim Biscaglia (Cona, Ferrara, IT, M)
- 17:03 A comparison of prolonged anticoagulation versus no anticoagulation after primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction**
Y Yan (Beijing, CN, F)

Learning Objectives:

Categories:

The end of ejection fraction: novel alternative imaging indices in heart failure**Session Number: 107**Chairpersons: M Worme (, CA) (F) - S Solomon (Boston, US) (M)

- 16:15 Imaging in heart failure: what about ventricular deformation?**
E Bossone (Lauro, IT, M)
- 16:30 Imaging in heart failure: what about atrial size and function?**
J Grapsa (London, GB, F)
- 16:45 Imaging in heart failure: what about myocardial fibrosis?**
S Rosch (Mainz, DE, M)
- 17:00 The end of ejection fraction: novel alternative imaging indices in heart failure - discussion**
J Celutkiene (Vilnius, LT, F)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Online Live, Young Community Track

Cardiovascular disease management in patients with cancer

Session Number: 156

**Joint session with the European Society for Medical Oncology
(ESMO)**

Chairpersons: S Banerjee (London, GB) (F) - T Suter (Bern, CH) (M)

- 16:15 Baseline cardiovascular risk assessment before cardiotoxic cancer treatment**
E de Azambuja (Brussels, BE, M)
- 16:30 Novel targeted cancer therapies which can cause cardiovascular complications**
V Guarneri (Padova, IT, F)
- 16:45 Cardiovascular complications and surveillance in cancer survivors: who, when, and how?**
J Bergler-Klein (Vienna, AT, F)
- 17:00 Cardiovascular disease management in patients with cancer - patient perspective**
R Stephens (Stevenage, GB, M)

Learning Objectives: This session aims to understand baseline cardiovascular risk assessment before cardiotoxic cancer treatment and to be aware of novel targeted cancer therapies with cardiovascular complications; will focus on learning how to manage cardiovascular toxicities and how to implement cardiovascular surveillance for cancer survivors: who? when? and how?

Categories: Includes a patient perspective

Great Debate: treatment of multivalvular heart disease**Session Number: 324**Chairpersons: J Seeger (Ulm, DE) (F) - S Bartus (Krakow, PL) (M)

16:15 Treatment of multivalvular heart disease should be surgical: pro
M Borger (Leipzig, DE, M)

16:30 Treatment of multivalvular heart disease should be surgical: con
M Urena (Paris, FR, F)

16:45 Treatment of multivalvular heart disease should be surgical - discussion
G Faerber (Jena, DE, F)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Online Live, Young Community Track

**Guidelines in practice: imaging in hypokinetic non-dilated
cardiomyopathy**

Session Number: 250

Chairpersons: K Haugaa (Oslo, NO) (F) - R Manka (Zurich, CH) (M)

- 16:15 A patient with hypokinetic non-dilated cardiomyopathy and an arrhythmia: case presentation**
A Baritussio (Padova, IT, F)
- 16:30 A patient with hypokinetic non-dilated cardiomyopathy and an arrhythmia: what do the guidelines say?**
J Kaski (London, GB, M)
- 16:45 A patient with hypokinetic non-dilated cardiomyopathy and an arrhythmia: how to implement the guidelines and take-home messages**
E Perez-David (Majadahonda, ES, F)

Learning Objectives:

Categories: Clinical Implementation Track, Online Live

Patient care in atrial fibrillation: how to develop excellence

Session Number: 438

Organised in collaboration with the British Association for Nursing in Cardiovascular Care (BANCC)

Chairpersons: K Wood (Atlanta, US) (F) - I Jones (Liverpool, GB) (M)

16:15 Models of care delivery in atrial fibrillation: why change current practice?

J Hendriks (Sittard, NL, M)

16:30 Cardiac rehabilitation or secondary prevention in patients with atrial fibrillation: is there a difference?

S Risom (Copenhagen S, DK, F)

16:45 Patient engagement: why is it as crucial and fundamental in models of care delivery?

J Dwight (Bromley, GB, M)

17:00 Patient care in atrial fibrillation: how to develop excellence - discussion

G Lee (Cork, IE, F)

Learning Objectives:

Categories: Includes a patient perspective, Nurses and Allied Professionals track, Spotlight of the Congress

The EHJ's year in heart failure, ischaemic heart disease and acute cardiovascular care, dyslipidaemias

Joint session with the European Heart Journal (EHJ)

Session Number: 415

Chairpersons: P Libby (Boston, US) (M) - L Badimon (Barcelona, ES) (F)

16:15 Heart failure
J Bauersachs (Hannover, DE, M)

16:35 Ischaemic heart disease
S Price (London, GB, F)

16:55 Dyslipidaemias
A Catapano (Milan, IT, M)

Learning Objectives: To have the EHJ editors summarise game-changing studies published in the last year about heart failure, ischaemic heart disease, acute cardiovascular care, and dyslipidaemias.

Categories:

**The floor is yours: bring your questions on medical device regulation
in digital health**

Session Number: 380

Chairpersons: N Keser (Istanbul, TR) (F) - A Fraser (Cardiff, GB) (M) - K Malaczynska-Rajpold
(London, GB) (F)

**16:15 The floor is yours: bring your questions on medical device regulation in digital
health - get ready for the session**
K Malaczynska-Rajpold (London, GB, F)

**16:20 The floor is yours: bring your questions on medical device regulation in digital
health - expert panel**
ET Locati (Milano, IT, F)

G Holborow (Whitchurch, GB, M)

RA Byrne (Dublin, IE, M)

D Fitzsimons (Belfast, GB, F)

EG Caiani (Milano, IT, M)

R Ladeiras-Lopes (Porto, PT, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals
particularly relevant for young professionals.

Categories: Digital Health, Mobile App - Ask a Question, Young Community Track

Memorial lecture for Alain Cribier

Session Number: 407

Chairpersons: M Gilard (Brest Cedex, FR) (F) - S Windecker (Bern, CH) (M)

16:15 Introduction: Memorial lecture for Alain Cribier
M Gilard (Brest Cedex, FR, F)

16:20 Memorial lecture for Alain Cribier
H Eltchaninoff (Rouen Cedex, FR, F)

16:40 Plaque presentation

Learning Objectives:

Categories:

Novel players in atrial fibrillation: looking outside the box**Session Number: 345**Chairpersons: C Schmidt (Heidelberg, DE) (F) - AM Gomez (Orsay, FR) (F)

- 16:15 The role of mitochondrial dysfunction in atrial fibrillation**
N Voigt (Goettingen, DE, M)
- 16:30 Epicardial adipose tissue: a modulator of atrial fibrillation?**
B Westenbrink (Groningen, NL, M)
- 16:45 Role of inflammation and reactive oxygen species in atrial fibrillation: new therapeutic targets?**
B Casadei (Oxford, GB, F)
- 17:00 Novel players in atrial fibrillation: looking outside the box - discussion**
D Linz (Maastricht, NL, M)

Learning Objectives:

Categories:

Treatment of heart failure in Bulgaria and Germany: implementation of 2023 ESC Guidelines - Focused Update on Heart Failure**Organised in collaboration with the German Cardiac Society and the Bulgarian Society of Cardiology****Session Number: 5110**Chairpersons: S von Haehling (Berlin, DE) (M) - V Traykov (Sofia, BG) (M)

17:00 Case 1 - treatment of HFrEF beyond the fantastic four: the German perspective
K Marx-Schuett (Aachen, DE, F)

17:10 Treatment of HFrEF beyond the fantastic four: the German perspective - discussion of guideline implementation
R Wachter (Leipzig, DE, M)

17:22 Case 2 - multimorbid patient with heart failure: the Bulgarian experience
A Kisheva (Varna, BG, F)

17:32 Multimorbid patient with heart failure: the Bulgarian experience - discussion of guideline implementation
M Tokmakova (Plovdiv, BG, F)

Learning Objectives: To understand treatment of HFimpEF, acute decompensation, indications for device implantation, and recompensation using standard heart-failure medication.

Categories: Online Live

Delving deeper into HFpEF

Session Number: 3027

Chairpersons: P Campbell (Craigavon, GB) (F) - C Tschoepe (Berlin, DE) (M)

- 17:00 The added value of cardiopulmonary exercise testing in the diagnosis of heart failure with preserved ejection fraction**
L Massa (Milan, IT, F)
- 17:10 Echocardiographic predictors of cardiovascular outcome in heart failure with preserved ejection fraction**
N Wang (Sydney, AU, M)
- 17:20 Chronotropic incompetence as a critical predictor for cardiovascular outcomes in heart failure with preserved ejection function**
T Lin (Hsin-Chu, TW, M)
- 17:30 Clinical correlates and prognostic impact of cognitive decline in patients with heart failure and preserved ejection fraction: insights from PARAGON-HF**
L Shen (Glasgow, GB, F)
- 17:40 Exosome-like nanovesicle targeting visceral adipose tissue inflammation mitigates heart failure with preserved ejection fraction**
Yao Jiang (Beijing, CN, F)
- 17:50 Effect and mechanism of Adipokine Omentin-1 on cardiac hypertrophy in heart failure with preserved ejection fraction**
Q Li (Beijing, CN, F)

Learning Objectives:

Categories:

Diversities and disparities in cardiac surgery**Session Number: 3071**Chairpersons: G Gerosa (Padova, IT) (M) - J De Backer (Ghent, BE) (F)

- 17:00 Racial, ethnic, and sex disparities in the utilization and outcomes of tricuspid valve surgery**
M Ismayl (Rochester, US, M)
- 17:10 Surgical treatment of tricuspid valve infective endocarditis: tricuspid valve repair versus replacement.**
M Laimoud (Cairo, EG, M)
- 17:20 The fate of coronary artery bypass grafting in the elderly: treat and forget**
F Barili (Milan, IT, M)
- 17:30 Do obese patients undergoing extracorporeal membrane oxygenation have a higher mortality ? a systematic review and meta-analysis.**
S Picado-Loaiza (Curridabat, CR, F)
- 17:40 Sex-specific prognosis of right ventricular size measured by 3D echocardiography following isolated tricuspid valve surgery**
Y Liu (Shanghai, CN, M)
- 17:50 Transcatheter mitral replacement: what are the outcomes of un-eligible patients compared to treated?**
E Zancanaro (Milano, IT, M)

Learning Objectives:

Categories:

Acute pulmonary embolism: new approaches for an old killer**Session Number: 3055**Chairpersons: A Sharp (Cardiff, GB) (M) - C Becattini (Perugia, IT) (F)

- 17:00 Efficacy and safety of reduced-dose and slow-infusion intravenous alteplase regimen in patients with acute pulmonary embolism at intermediate-high-risk**
B Kultursay (Istanbul, TR, M)
- 17:10 Elective endovascular reperfusion therapies in intermediate-high risk pulmonary embolism after PERT assesment**
I Cigalini (Rosario, AR, M)
- 17:20 Impact of a blood return system on mechanical thrombectomy in treatment of acute pulmonary embolism: a retrospective cohort study comparing 30-day mortality and need for blood transfusion**
D Patel (- , US, M)
- 17:30 Intracranial haemorrhage following treatment for pulmonary embolism: analysis of the german nationwide inpatient sample**
K C Christodoulou (Mainz, DE, M)
- 17:40 White Smoke in the Intermediate risk PE debate, could POPE be the solution?**
A Martins (Lisbon, PT, F)
- 17:50 Interleukin 21, plasminogen activator inhibitor 1 and fractalkine improve risk stratification in elderly patients with pulmonary embolism**
MA Matter (Zurich, CH, M)

Learning Objectives:

Categories:

Lipids as cardiovascular risk factors and treatment options

Session Number: 3085

Chairpersons: A Kautzky-Willer (Vienna, AT) (F) - M Guazzi (Milano, IT) (M)

- 17:00 Intraindividual variability in lipoprotein(a): the value of a repeat measure for reclassifying individuals at intermediate-risk**
T Harb (Baltimore, US, M)
- 17:12 Lipoprotein(a) metabolomic and proteomic features and atherosclerotic cardiovascular disease in young, asymptomatic adults**
S Goonewardena (Ann Arbor, US, M)
- 17:24 Combination therapy with GalNAc-siRNA drugs targeting both PCSK9 and APOC3 resulted in enhanced lipid lowering in mice**
J Wikstrom (- , SE, M)
- 17:36 Reduction of triglyceride-rich lipoproteins with retatrutide in type 2 diabetes may be explained by concurrent reduction in ANGPTL3/8 levels**
G Ruotolo (Indianapolis, US, M)
- 17:48 Metabolomic profiling of the entire UK Biobank enables interpretation of familial hypercholesterolemia mutations and prediction of severe cardiovascular outcomes**
J Barrett (Helsinki, FI, M)

Learning Objectives:

Categories:

Computed tomography assessment of myocardial disease revisited

Session Number: 3006

Chairpersons: A Reid (Liverpool, GB) (F) - W Chan (Hong Kong, HK) (F)

- 17:00** **Computed tomography-derived myocardial extracellular volume: a diagnostic marker for cardiac amyloidosis in transcatheter aortic valve implantation patients with biopsy confirmation**
K Matsushita (Yokohama, JP, M)
- 17:10** **Morphologic differences in atrial and ventricular secondary tricuspid regurgitation by computed tomography**
APA Chua (Leiden, NL, F)
- 17:20** **Extra-cellular volume fraction analysis on cardiac CT is useful for predicting the prognosis of hypertrophic cardiomyopathy**
S Aoki (Chiba, JP, M)
- 17:30** **Late iodine enhancement quantification by computed tomography: a comparison study against cardiac magnetic resonance imaging**
P Martinez Vives (Madrid, ES, M)
- 17:40** **Associate variables of coronary computed tomographic angiography-derived extracellular volume fraction and cardiac magnetic resonance-derived late-gadolinium enhancement**
H Ueno (Tsuchiura, JP, M)
- 17:50** **Assessment of coronary blood volume to left ventricular mass ratio: a comparative study among endurance athletes, hypertrophic cardiomyopathy patients and healthy controls**
A Hamdan (Petach Tikva, IL, M)

Learning Objectives:

Categories:

Valvulopathies**Session Number: 3311**Chairpersons: A Chiodini (Zurich, CH) (F) - C Besler (Leipzig, DE) (M)**17:00 Valvulopathies - get ready for the session****17:05 An insidious case of dynamic mitral regurgitation**

G Nemola (Milano, IT, F)

17:20 The lower the patient clicks, the higher the gradient peaks

V Villarmin Martin (Madrid, ES, U)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals

Categories: Mobile App - Vote, Young Community Track

Mechanical circulatory support

Session Number: 3332

Chairpersons: C Bonanad Lozano (Valencia, ES) (F) - M Wallner (Graz, AT) (M)

- 17:00** **Peripheral veno-arterial extracorporeal membrane oxygenation as a bridge to cardiac transplantation in a patient with ischaemic ventricular septal defect**
H Yong (Glasgow, GB, M)
- 17:12** **ST-elevation myocardial infarction with unexpected ventricular septal defect, covered rupture & pericardial tamponade managed by combined percutaneous circulatory support as bridge to surgical repair**
M Poudel (Bielefeld, DE, M)
- 17:24** **Cardiac rupture post-acute myocardial infarction: management of the cardiogenic shock**
R Filipescu (- , RO, M)
- 17:36** **Echo and hemodynamic-guided ramp test in a LVAD carrier with right ventricular failure and aortic regurgitation: unveiling the Scylla and Charybdis of durable mechanical circulatory support**
E Ravetti (Turin, IT, M)
- 17:48** **The unusual cause of cardiomyopathy: a sudden sniffing death syndrome**
M Vassara (Nonthaburi, TH, F)

Learning Objectives:

Categories:

Cardiovascular disease in pregnancy cases**Session Number: 3379**Chairpersons: K Kupczynska (Lodz, PL) (F) - G Halasz (Lugano, CH) (M)

- 17:00 Myocardial work assessment as a prognostic tool in peripartum cardiomyopathy**
M Malek-Elikowska (Poznan, PL, F)
- 17:12 Hidden perils: heart failure and venous thromboembolism during pregnancy**
NY Sari (Indonesia, ID, F)
- 17:24 A case report of prenatal ultrasound diagnosis of ectopic cardiac pulmonary venous drainage**
- 17:36 Long QT syndrome type 2 and overdue pregnancy**
J Lueg (Berlin, DE, F)
- 17:48 Pregnancy-Associated Ventricular Tachycardia: Unraveling the Rarity of Right Ventricular Outflow Tract (RVOT) VT as a Recognizable Culprit**
A Shive Gowda (Buffalo, US, M)

Learning Objectives:

Categories:

**Smaller trials, trial updates, and other studies: atrial fibrillation
detection, prevention and treatment**

Session Number: 1039

Chairpersons: S Al-Khatib (Durham, US) (F) - D Shah (Geneva, CH) (M)

- 17:30 Catheter ablation in persistent atrial fibrillation: long term outcomes of the CAPLA multicentre randomised trial of pulmonary vein isolation(PVI) vs PVI plus posterior left atrial wall isolation(PWI)**
P Kistler (Melbourne, AU, M)
- 17:42 Randomized evaluation of decision support interventions for atrial fibrillation: Anticoagulant adherence after shared decision making interventions for stroke prevention in atrial fibrillation**
E Jackson (Birmingham, US, F)
- 17:54 Predictors and Outcomes of Atrial Fibrillation Progression in Patients with Device-Detected Subclinical AF: Insights from the ARTESiA Trial**
G Boriani (Castenaso, IT, M)
- 18:06 Biomolecule-based prediction of sinus rhythm and interaction with early rhythm control: EAST-AFNET 4 biomolecule study**
L Fabritz (Hamburg, DE, F)
- 18:18 The Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation Extend**
A Tang (London, CA, M)

Learning Objectives:

Categories:

Guidelines in Practice: 2024 ESC Guidelines for the Management of Chronic Coronary Syndromes

Session Number: 1202

Personalising antithrombotic therapy in patients with cancer: what every cardiologist should know**Session Number: 241**Chairpersons: A Rubboli (Ravenna, IT) (M) - S Gevaert (Gent, BE) (F)

17:30 Individual anticoagulation choices for patients with cancer and atrial fibrillation
T Lopez Fernandez (Madrid, ES, F)

17:45 Anticoagulation choices in patients with cancer, acute coronary syndrome, and percutaneous coronary intervention
D Gorog (London, GB, F)

18:00 Anticoagulation choices in patients with cancer and venous thromboembolism
S Szmit (Warsaw, PL, M)

18:15 Personalising antithrombotic therapy in patients with cancer: what every cardiologist should know - discussion

Learning Objectives:

Categories: Online Live, Spotlight of the Congress

Hot topics in stroke for cardiologists**Session Number: 293**Chairpersons: E Gurol (Boston, US) (M) - I Grunwald (, GB) (F)

- 17:30 Managing stroke patients with indications for both anticoagulant and antiplatelet treatment**
R Schnabel (Hamburg, DE, F)
- 17:45 The best workup for embolic stroke of undetermined source**
G Ntaios (Larisa, GR, M)
- 18:00 Cerebral microbleeds are common: what do cardiologists need to know about the bleeding risk with antithrombotic therapies?**
C Gibson (Boston, US, M)
- 18:15 Hot topics in stroke for cardiologists - discussion**
C Meyer-Zurn (Basel, CH, F)

Learning Objectives: This session will discuss personalised care: where, for example, stroke, carotid stenosis, or cerebral amyloid angiopathy complicate the treatment process and need individual approaches and solutions.

Categories:

Great Debate: hypertrophic cardiomyopathy and sport - restrict or rethink?**Session Number: 145**Chairpersons: S Gati (London, GB) (F) - HT Jorstad (Amsterdam, NL) (M)

17:30 Patients with hypertrophic cardiomyopathy: should be restricted from sport - pro
M Sanz-de la Garza (Barcelona, ES, F)

17:45 Patients with hypertrophic cardiomyopathy: should be restricted from sport - con
M Papadakis (London, GB, M)

18:00 Patients with hypertrophic cardiomyopathy: should be restricted from sport - discussion
A Baggish (Lausanne, CH, M)

Learning Objectives:

Categories: Online Live

Smaller trials, trial updates, and other studies on hypertension

Session Number: 1040

Chairpersons: S Brouwers (Aalst, BE) (F) - B Williams (London, GB) (M)

- 17:30 Renal denervation lowers all-cause and cardiovascular mortality in patients with uncontrolled arterial hypertension: a randomised, sham-controlled study.**
MJ Heradien (Kuils River, ZA, M)
- 17:42 Effects of Intensive vs Standard Blood Pressure Control on Cardiovascular Outcomes in Cancer Survivors: Results from the SPRINT Randomized Trial**
Y Xiao (Changsha, CN, M)
- 17:54 A machine learning algorithm for personalizing intensive blood pressure treatment: derivation from SPRINT/ACCORD-BP trials and validation in CRHCP, a pragmatic implementation trial**
Y Sun (Shenyang, CN, M)
- 18:06 Long-term outcomes of intensive blood-pressure control in older patients with hypertension: final six-year results of the STEP trial**
S Song (Beijing, CN, F)
- 18:18 Fractional flow reserve to determine the appropriateness of percutaneous renal artery intervention in atherosclerotic renovascular hypertension patients: a randomized trial**
J Li (Beijing, CN, M)

Learning Objectives:

Categories:

The floor is yours: bring your questions on heart failure. 'Heart's failing secrets unveiled: thy burning queries expertly resolved'

Session Number: 108

Chairpersons: F Ruschitzka (Zurich, CH) (M) - T McDonagh (London, GB) (F) - D Hashemi (Berlin, DE) (M)

17:30 The floor is yours: bring your questions on heart failure. 'Heart's failing secrets unveiled: thy burning queries expertly resolved' - get ready for the session
D Hashemi (Berlin, DE, M)

17:35 The floor is yours: bring your questions on heart failure. 'Heart's failing secrets unveiled: thy burning queries expertly resolved' - expert panel
JJV McMurray (Glasgow, GB, M)

LW Stevenson (Nashville, US, F)

M Packer (Dallas, US, M)

F Zannad (Paris, FR, M)

M Costanzo (Naperville, US, F)

A Cannata (London, GB, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Mobile App - Ask a Question, Young Community Track

Liver and lipids in cardiometabolic syndrome

Session Number: 153

Joint session with the European Atherosclerosis Society (EAS)

Chairpersons: M Benn (Hellerup, DK) (F) - A Zirlik (Graz, AT) (M)

17:30 Steatotic liver disease and lipids in cardiometabolic syndrome

S Romeo (Gothenburg, SE, M)

17:45 Is there a specific treatment for cardiometabolic syndrome?

B Verges (Dijon, FR, M)

18:00 Treatment of dyslipidaemia in cardiometabolic syndrome: how far should you go?

M Acevedo (Santiago, CL, F)

18:15 Inflammation and cardiometabolic syndrome: what is the link?

E Osto (Zurich, CH, F)

Learning Objectives: This session aims to increase understanding of cardiometabolic syndrome including its definition and why it is a risk factor for cardiovascular disease; will delve into the relationships among steatotic liver disease, mixed dyslipidaemia, and isolated hypertriglyceridemia; to improve treatment of cardiometabolic syndrome – i.e. are there specific treatments or do we simply reduce all other known cardiovascular risk factors?; and will discuss how cardiometabolic dyslipidaemia is treated – i.e. is the treatment like that of any other dyslipidaemia or should we also focus on lowering plasma triglycerides?

Categories:

Personalised therapy for pericardial disease: the right treatment for the right patient**Session Number: 322**Chairpersons: M Imazio (Udine, IT) (M) - S Benyoussef (Marsa, TN) (F)**17:30 Personalised therapy for pericarditis and the role of genetic testing**

G Lazaros (Athens, GR, M)

17:50 State-of-the-art management of pericardial effusion

D Fairweather (Jacksonville, US, F)

18:10 Personalised treatments for constrictive pericarditis

A Klein (Cleveland, US, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Clinical Implementation Track, Spotlight of the Congress, Young Community Track

Case conundrum: personalised imaging in asymptomatic severe regurgitant valve disease**Session Number: 259**Chairpersons: LD Gillam (Morristown, US) (F) - B lung (Paris, FR) (M)**17:30 When to treat asymptomatic severe aortic regurgitation: too early, too late, and everything in between**

T Pilgrim (Bern, CH, M)

17:50 Asymptomatic severe primary mitral regurgitation: what is new?

J Bax (Leiden, NL, M)

18:10 Asymptomatic severe tricuspid regurgitation: what is the right timing of intervention?

P Mahia (Madrid, ES, F)

Learning Objectives:

Categories: Spotlight of the Congress

The floor is yours: bring your questions on optimal management of very high-risk acute coronary syndromes

Session Number: 191

Chairpersons: I Ahrens (Cologne, DE) (M) - M Aleksic (Belgrade, RS) (F) - H Schaubroeck (Aalter, BE) (F)

17:30 The floor is yours: bring your questions on optimal management of very high-risk acute coronary syndromes - get ready for the session

H Schaubroeck (Aalter, BE, F)

17:35 The floor is yours: bring your questions on optimal management of very high-risk acute coronary syndromes - expert panel

C Hassager (Copenhagen, DK, M)

U Zeymer (Ludwigshafen, DE, M)

J Poess (Leipzig, DE, F)

K Krychtiuk (Vienna, AT, M)

A Tycinska (Bialystok, PL, F)

A Viana Tejedor (Madrid, ES, F)

Learning Objectives: This session will delve into very high acute coronary syndrome scenarios treated in the cardiac intensive care unit such as cardiogenic shock, intractable heart failure or arrhythmias, VT storm, severe coronary aortic disease, mechanical complications, and bleeding complications.

This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Mobile App - Ask a Question, Young Community Track

Global approach to hypertension management and cardiovascular risk reduction

Joint session with the World Hypertension League (WHL) and the World Health Organization (WHO)

Session Number: 221

Chairpersons:

K Sliwa (Cape Town, ZA) (F) - PK Whelton (New Orleans, US) (M) - J Farrington (Copenhagen, DK) (F)

17:30 Modifiable cardiovascular risk factors: global trends and regional differences

C Magnussen (Hamburg, DE, F)

17:45 Blood pressure measurement: global recommendations, challenges, and solutions

G Parati (Milano, IT, M)

18:00 WHO HEARTS Initiative: scope, status, and experience to date

J Farrington (Copenhagen, DK, F)

18:15 Global approach to hypertension management and cardiovascular risk reduction - discussion

Learning Objectives: This session will focus on understanding what the essential elements for clinically valid BP measurements in office and out-of-office settings, as well as being aware of elements of the WHO HEARTS Initiative and the extent to which it is successful in achieving target BPs in regions/countries where it is being applied.

Categories: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.
Online Live, Young Community Track

Session Number:	417	Spotlight on innovation: top publications in the European Heart Journal - Digital Health 2023-2024 Joint session with the European Heart Journal - Digital Health (EHJ - DH)
<u>Chairpersons:</u>	N Bruining (Rotterdam, NL) (M) - AS Mihailidou (Sydney, AU) (F)	

17:30	External validation of a deep learning algorithm for automated echocardiographic strain measurements P Myhre (Oslo, NO, M)
-------	--

17:42	International evaluation of an artificial intelligence-powered electrocardiogram model detecting acute coronary occlusion in myocardial infarction R Herman (Wien, AT, M)
-------	---

17:54	Premature atrial and ventricular contractions detected on wearable-format electrocardiograms and prediction of cardiovascular events M Orini (London, GB, M)
-------	--

18:06	Short-term prediction of atrial fibrillation from ambulatory monitoring ECG using a deep neural network J Singh (Boston, US, M)
-------	---

18:18	Spotlight on innovation: top publications in the European Heart Journal - Digital Health 2023-2024 - discussion I Kardys (Rotterdam, NL, F)
-------	---

Learning Objectives:	To learn about the latest developments about digital health published in the European Heart Journal – Digital Health in 2023 and 2024.
Categories:	Digital Health

ESC Florence Nightingale Lecture in Nurse-Led Research

Session Number: 404

Chairpersons: L Klompstra (Norrköping, SE) (F) - P Moons (Leuven, BE) (M)

17:30 Presentation of the awardee
P Moons (Leuven, BE, M)

17:35 Building research capacities in clinical nurse-led research: patient-reported outcomes at the core
TM Norekval (Bergen, NO, F)

17:55 ESC Florence Nightingale Lecture in Nurse-Led Research - Q&A

18:10 Award presentation

Learning Objectives:

Categories:

Anti-inflammatory therapies: from bench to bedside**Session Number: 357**Chairpersons: S Steffens (Munich, DE) (F) - R De Caterina (Pisa, IT) (M)

17:30 Novel pharmacological anti-inflammatory approaches: beyond IL-1 inhibition
P Libby (Boston, US, M)

17:45 Novel non-pharmacological anti-inflammatory approaches: bioelectronics
P Olofsson (Stockholm, SE, M)

18:00 Targeting the right patient for precision therapy
S Dimmeler (Frankfurt, DE, F)

18:15 Anti-inflammatory therapies: from bench to bedside - discussion
G Caligiuri (Paris, FR, F)

Learning Objectives:

Categories: Online Live

HOT LINE 5

Session Number: 1014

Chairpersons: G Dangas (New York, US) (M) - D Tchetche (Toulouse, FR) (M)

- 17:35 NOTION-3 - Percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation**
J Thomsen Loenborg (Copenhagen, DK, M)
- 17:47 Discussant review - NOTION-3**
S Mehta (Hamilton, CA, M)
- 17:52 Panel discussion - NOTION-3**
- 17:57 POPular PAUSE TAVI - Continuation or interruption of oral anticoagulation during TAVI?**
DJ van Ginkel (Nieuwegein, NL, M)
- 18:09 Discussant review - POPular PAUSE TAVI**
- 18:14 Panel discussion - POPular PAUSE TAVI**
- 18:19 RHEIA - Transcatheter versus surgical aortic valve replacement in women with severe aortic stenosis**
H Eltchaninoff (Rouen Cedex, FR, F)
- 18:31 Discussant review - RHEIA**
A Petronio (Pisa, IT, F)
- 18:36 Panel discussion - RHEIA**

Learning Objectives:

Categories: Online Live

Daily Highlights by the Argentine Society of Cardiology

Session Number: 5129

This session is brought to you by the Argentine Society of Cardiology and is not part of the official ESC programme

Chairpersons:

Learning Objectives:

Categories: Online Live

Daily Highlights by the Azerbaijan Society of Cardiology

Session Number: 5124

This session is brought to you by the Azerbaijan Society of Cardiology and is not part of the official ESC programme

Chairpersons:

Learning Objectives:

Categories: Online Live

Daily Highlights by the Korean Society of Cardiology**Session Number: 5130****This session is brought to you by the Korean Society of Cardiology
and is not part of the official ESC programme**Chairpersons:

- 07:15 Exercise stress test in HFpEF: when and how?**
- 07:26 Right ventricular-predominant heart failure and cardiogenic shock in the cardiac
intensive care unit**
- 07:37 Microvascular dysfunction and prognosis after heart transplantation**
- 07:48 Daily Highlights by the Korean Society of Cardiology - panel discussion**

Learning Objectives:

Categories: Online Live

HOT LINE 6

Session Number: 1015

Chairpersons: C Gibson (Boston, US) (M)

- 08:15 **STEEER-AF - Stroke prevention and rhythm control therapy**
D Kotecha (Birmingham, GB, M)
- 08:30 **Discussant review - STEEER-AF**
CB Granger (Durham, US, M)
- 08:35 **Panel discussion - STEEER-AF**
- 08:40 **OCEANIC-AF - Asundexian versus apixaban in patients with atrial fibrillation**
M Patel (Durham, US, M)
- 09:00 **Discussant review - OCEANIC-AF**
E Hylek (Boston, US, F)
- 09:08 **Panel discussion - OCEANIC-AF**
- 09:16 **EPIC-CAD - Edoxaban monotherapy vs. dual antithrombotic therapy for atrial fibrillation and stable coronary artery disease**
GB Nam (Seoul, KR, M)
- 09:31 **Discussant review - EPIC-CAD**
M Valgimigli (Lugano, CH, M)
- 09:36 **Panel discussion - EPIC-CAD**

Learning Objectives:
Categories: Online Live

Subclinical and device-detected atrial fibrillation: fact and fiction**Session Number: 168**Chairpersons: T Glotzer (Tenafly, US) (F) - H Puererfellner (Linz, AT) (M)**08:15 Progression of device-detected atrial fibrillation to clinical atrial fibrillation: should we worry?**

C Sticherling (Basel, CH, M)

08:33 Atrial fibrillation burden and association with incident stroke

TS Potpara (Belgrade, RS, F)

08:51 My smartwatch says I am in atrial fibrillation: now what?

A Goette (Paderborn, DE, M)

09:09 Reducing stroke risk in patients with atrial high-rate episodes (AHRE)

G Boriani (Castenaso, IT, M)

09:27 Subclinical and device-detected atrial fibrillation: fact and fiction - discussion

IC Van Gelder (Groningen, NL, F)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Online Live, Young Community Track

Smaller trials, trial updates, and other studies on coronary artery disease

Session Number: 1041

Chairpersons: O Manfrini (Bologna, IT) (F)

- 08:15** **Effects of Beta-Blockers on Quality of Life and Well-being in Patients with Myocardial Infarction and Preserved Left Ventricular Function - a prespecified substudy from REDUCE-AMI**
R Hofmann (Stockholm, SE, M)

- 08:26** **Short- and long-term effects of beta-blockers on symptoms of anxiety and depression in patients with myocardial infarction and preserved left ventricular function: prespecified substudy from REDUCE-AM**
P Leissner (Uppsala, SE, M)

- 08:37** **Coronary computed tomography angiography guided management of patients with stable chest pain: 10-year outcomes from the SCOT-HEART trial**
MC Williams (Edinburgh, GB, F)

- 08:48** **Adherence to Nordic and Mediterranean dietary patterns may be associated with a lower absolute risk of incident atherosclerotic cardiovascular disease**
C Bork (Skoerping, DK, M)

- 09:00** **Cardiorenal effects and safety of initiation of empagliflozin after acute myocardial infarction**
D Bhatt (Scarsdale, US, M)

- 09:11** **Cardiovascular Risk Scoring or CT Angiography for Lifestyle and Risk Factor Modification in Primary Prevention of Cardiovascular Disease The SCOT-HEART 2 IMPACT Study**
M Mcdermott (Glasgow, GB, M)

- 09:22** **Rehabilitation at home using mobile health in older adults after hospitalization for ischemic heart disease**
J Dodson (- , US, M)

- 09:33** **Cost-effectiveness and safety of the CADScorSystem in patients with symptoms suggestive of stable coronary artery disease.**
K W Skak-Hansen (Copenhagen, DK, M)

Learning Objectives:

Categories:

Hot papers in hypertension 2023/2024

Session Number: 220

Chairpersons: A Dominiczak (Glasgow, GB) (F) - J Wang (Shanghai, CN) (M)

08:15 **Hot papers on risk factors and comorbidities in hypertension**
J Brguljan (Ljubljana, SI, F)

08:33 **Hot papers on drugs for hypertension**
A Desai (Boston, US, M)

08:51 **Hot papers on device-based treatment of hypertension**
D Hering (Gdansk, PL, F)

09:09 **Hot papers on digital health in hypertension**
F Charchar (Ballarat, AU, M)

09:27 **Hot papers in hypertension 2023/2024 - discussion**
F Mahfoud (Homburg, DE, M)

Learning Objectives:

Categories:

Cath lab tsunami: managing complications**Session Number: 282**Chairpersons: G Dangas (New York, US) (M) - S Banerjee (Reigate, GB) (F)**08:15 Annulus rupture: now what?**

T Modine (Bordeaux, FR, M)

08:33 The vessel unzips: now what?

A McInerney (Beaumont Hospital Cardiology Department, IE, F)

08:51 No reflow, large thrombus burden: now what?

D Cao (Milan, IT, M)

09:09 Lost equipment: now what?

S Biswas (Melbourne, AU, F)

09:27 Cath lab tsunami: managing complications - discussion

N Curzen (Southampton, GB, M)

Learning Objectives:

Categories: Online Live

Great Debates: new implantable cardiac device technologies - ready for prime time?**Session Number: 178**Chairpersons: A Sultan (Cologne, DE) (F) - M Spartalis (Athens, GR) (M)

- 08:15 Conduction system pacing should replace cardiac resynchronisation: pro**
J Joza (Montreal, CA, F)
- 08:30 Conduction system pacing should replace cardiac resynchronisation: con**
K Vernooij (Maastricht, NL, M)
- 08:45 Conduction system pacing should replace cardiac resynchronisation - discussion**
C Leclercq (Rennes Cedex, FR, M)
- 09:00 Patients with an ICD but no indication for bradycardia pacing should receive an extravascular ICD: pro**
L Boersma (Nieuwegein, NL, M)
- 09:15 Patients with an ICD but no indication for bradycardia pacing should receive an extravascular ICD: con**
J Poole (Seattle, US, F)
- 09:30 Patients with an ICD but no indication for bradycardia pacing should receive an extravascular ICD - discussion**
H Burri (Geneva, CH, M)

Learning Objectives:

Categories: Online Live

Trial updates and other studies in hypertrophic cardiomyopathy and aortic stenosis

Session Number: 1042

Chairpersons: PM Elliott (London, GB) (M)

- 08:15 Effect of Aficamten on Cardiac Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy: The SEQUOIA-HCM CMR Trial**
A Masri (Portland, US, M)
- 08:26 Effect of Aficamten on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy: Results from SEQUOIA-HCM**
J Spertus (Kansas City, US, M)
- 08:37 Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy**
S Hegde (Boston, US, F)
- 08:48 Safety and Outcomes of Standard of Care Medications Withdrawal in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Aficamten in FOREST-HCM Trial**
A Masri (Portland, US, M)
- 09:00 Aortic valve replacement versus conservative treatment in asymptomatic severe aortic stenosis**
M Banovic (Belgrade, RS, M)
- 09:11 Sex-specific outcomes after transcatheter or surgical treatment of aortic valve stenosis: A subanalysis from the DEDICATE-DZHK6 trial**
S Bleiziffer (Bad Oeynhausen, DE, F)
- 09:22 Transcatheter or surgical treatment of aortic valve stenosis in patients with chronic kidney disease: an analysis from the randomized DEDICATE-DZHK 6 trial**
M Abdel-Wahab (Leipzig, DE, M)
- 09:33 Development and validation of the ASGARD-S risk score for optimal timing of echocardiograms in asymptomatic patients with non-severe aortic valve stenosis: the SEAS and SALTIRE II trials**
E Hadziselimovic (Frederiksberg, DK, F)

Learning Objectives:

Categories:

Worsening heart failure: are we winning the war?**Session Number: 112**Chairpersons: N Sato (Saitama, JP) (M) - S Nalbantgil (Izmir, TR) (F)

08:15 Worsening heart failure: unmet needs
M Arrigo (Zurich, CH, M)

08:33 Worsening heart failure: achieving decongestion
JM Ter Maaten (Groningen, NL, F)

08:51 Worsening heart failure: optimisation of guideline-recommended medical therapy
HGC Van Spall (Hamilton, CA, F)

09:09 Worsening heart failure: when to refer for advanced therapies
M Crespo-Leiro (La Coruna, ES, F)

09:27 Worsening heart failure: are we winning the war? - discussion
P Ponikowski (Wroclaw, PL, M)

Learning Objectives:

Categories:

How to personalise lipid-lowering therapy with so many choices**Session Number: 147**Chairpersons: M Kayikcioglu (Istanbul, TR) (F) - H Schunkert (Muenchen, DE) (M)**08:15 Genetic scores are the future of personalised lipid-lowering**

A Tybjaerg-Hansen (Copenhagen, DK, F)

08:33 Imaging to personalise lipid-lowering

M Budoff (Torrance, US, M)

08:51 Biomarkers to personalise lipid-lowering

P Taub (Rancho Santa Fe, US, F)

09:09 Personalised lipid-lowering: bringing it all together with artificial intelligence

BA Ference (Cambridge, GB, M)

09:27 How to personalise lipid-lowering therapy with so many choices - discussion

M Benn (Hellerup, DK, F)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Online Live, Spotlight of the Congress, Young Community Track

Novel therapies for hypertrophic cardiomyopathy: recent developments and future prospects

Session Number: 833

Chairpersons: E Hutt (Cleveland, US) (F) - H C Watkins (Oxford, GB) (M)

- 08:15 State-of-the-art lecture on novel therapies for hypertrophic cardiomyopathy: recent developments and future prospects**
C Ho (Boston, US, F)
- 08:33 Long-term safety and efficacy of mavacamten in obstructive hypertrophic cardiomyopathy: up to 3.5-year follow-up results of the EXPLORER cohort of MAVA-Long-Term Extension study**
P Garcia-Pavia (Madrid, ES, M)
- 08:51 Clinical application of biomarkers in obstructive hypertrophic cardiomyopathy: insights from SEQUOIA-HCM**
CJ Coats (Glasgow, GB, F)
- 09:09 Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in preclinical individuals with an HCM sarcomeric gene mutation**
B Van Driel (Amsterdam, NL, M)
- 09:27 Aficamten in patients with obstructive hypertrophic cardiomyopathy: an integrated safety analysis**
A Masri (Portland, US, M)

Learning Objectives:

Categories: Online Live

Deep dive into aortic stenosis: new imaging insights

Session Number: 821

Chairpersons: C Bucciarelli-Ducci (London, GB) (F) - W Zoghbi (Houston, US) (M)

- 08:15 State-of-the-art lecture on aortic stenosis: new imaging insights**
P Pibarot (Quebec, CA, M)
- 08:33 Computed tomography-derived myocardial extracellular volume as a prognosis predictor in patients with severe aortic stenosis**
R Reis Santos (Leiria, PT, F)
- 08:51 Prognostic significance of pre-procedure wall shear stress in the ascending aorta in patients with aortic stenosis undergoing transcatheter aortic valve replacement**
T Hamaya (Sapporo, JP, M)
- 09:09 Left ventricular flow dynamics and energetics derived from 4D flow CMR in patients with low gradient severe aortic stenosis**
YS Wang (Shanghai, CN, F)
- 09:27 Phenotype of patients with severe aortic stenosis and small aortic annulus: how does it impact on hemodynamics and on transcatheter aortic valve implantation outcomes**
L Niro (Ferrazzano, IT, M)

Learning Objectives:

Categories:

Cardiovascular disease management in the UK versus other European countries

Organised in collaboration with the Primary Care Cardiovascular Society (PCCS)

Session Number: 430

Chairpersons: S Dragan (Timisoara, RO) (F) - A Fuat (Darlington, GB) (M)

- 08:15 Cardiovascular disease prevention in the UK**
HJ Williams (Llandysul, GB, F)
- 08:33 Cardiovascular disease prevention according to ESC Clinical Practice Guidelines**
A Lupi (Novara, IT, M)
- 08:51 Lipid guidelines: comparison between National Institute for Health and Care Excellence (NICE) and ESC guidance**
KK Ray (London, GB, M)
- 09:09 Is vaping better than smoking? Differences between the UK and European countries**
D Richter (Athens, GR, M)
- 09:27 Cardiovascular disease management in the UK versus other European countries - discussion**
A Warren (Haywards Heath, GB, F)

Learning Objectives: This session will provide a critical appraisal of the differences between smoking and vaping on the cardiovascular system as part of an overview of current management of cardiovascular disease across the UK and Europe, including a review of lipid guidelines from the UK (NICE) and the ESC.

Categories: General Cardiology for Physicians, Technicians and General Practitioners

Fixing the obesity crisis

Session Number: 451

**Joint session with the American College of Cardiology (ACC) and the
American Heart Association (AHA)**

Chairpersons: F Weidinger (Vienna, AT) (M) - C Biga (Darien, US) (F) - K Churchwell (New Haven, US) (M)

08:15 The origins of the obesity epidemic

N Sattar (Glasgow, GB, M)

08:35 We can reduce cardiovascular risk by treating obesity

H Wilson (Charlotte, US, M)

08:55 The economics of obesity: can we afford to treat it? Can we afford not to?

D Kazi (Boston, US, M)

09:15 Fixing the obesity crisis - discussion

LMG Meems (Groningen, NL, F)

C Kramer (Charlottesville, US, M)

S Khan (Chicago, US, F)

Learning Objectives:

Categories: Obesity Track

Integration of artificial intelligence in electrocardiography: state of the art

Session Number: 841

Chairpersons: R Khera (New Haven, US) (M) - I Kardys (Rotterdam, NL) (F)

- 08:15** **Integration of artificial intelligence in electrocardiography: state-of-the art lecture**
F Lopez-Jimenez (Rochester, US, M)
- 08:33** **An artificial intelligence-enabled electrocardiogram model outperforms the revised cardiac risk index score for predicting major adverse cardiovascular events in patients undergoing noncardiac surgery**
A Estrada-Magana (Rochester, US, M)
- 08:51** **Prognostic assessment based on the trajectory of artificial intelligence-enabled electrocardiograms for age estimation**
T Hwang (Seoul, KR, M)
- 09:09** **A smartphone based AI model to detect left ventricular systolic dysfunction on 12-lead ECG**
A Demolder (Ghent, BE, M)
- 09:27** **Incident atrial fibrillation prediction using ECG-based deep learning at a specialized tertiary cardiac care center**
G Jabbour (Montreal, CA, M)

Learning Objectives:

Categories: Digital Health

The European Research Council: funding for frontier research in Europe

Session Number: 457

Chairpersons: N El Mjiyad (Brussels, BE) (F)

08:15 The European Research Council: funding opportunities and latest updates on evaluation criteria
N El Mjiyad (Brussels, BE, F)

08:35 Testimonial from a European Research Council grantee and former panel member

08:45 The European Research Council: funding for frontier research in Europe - questions and answers

Learning Objectives:

Categories:

Basic and Translational Late-Breaking Science

Session Number: 1043

Chairpersons: V Puntmann (Frankfurt, DE) (F)

- 08:15 Gut Microbiota and Associated Metabolites Play a Key Role in the Pathogenesis of the Obesity Phenotype of Heart Failure With Preserved Ejection Fraction**
R Asleh (Haifa, IL, M)
- 08:26 Distinct cellular and molecular trajectories leading to subclinical diastolic dysfunction and the progression to HFpEF**
E Lara-Pezzi (Madrid, ES, M)
- 08:37 Different cardiovascular outcomes of vascular ageing proteomic phenogroups in normotensive and hypertensive individuals: results from the UK Biobank.**
M Lemoli (Brescia, IT, M)
- 08:48 Polygenic traits and cardiac remodelling contribute to a markedly increased risk of atrial fibrillation in former elite endurance athletes**
A La Gerche (Fitzroy, AU, M)
- 09:00 Echocardiographic screening for cardiac amyloidosis using artificial intelligence: A multi-site study for algorithm training and external validation.**
P Pellikka (Rochester, US, F)
- 09:11 An isocaloric high fat diet enriched with saturated compared to polyunsaturated fat has a more detrimental effect on clinical cardiometabolic risk factors in healthy humans**
N Srnica (Oxford, GB, M)
- 09:22 The role of uremic toxin indoxyl sulfate in aggravated aortic valve stenosis under uremic conditions**
P Duesing (Bonn, DE, M)
- 09:33 The individual fibrinolytic potential predicts efficacy of ultrasound-assisted catheter-directed thrombolysis in patients with acute pulmonary embolism**
D Draxler (- , AT, M)

Learning Objectives:

Categories:

Personalising HFpEF care

Session Number: 115 Joint session with the Japanese Circulation Society (JCS)

Chairpersons: T Ishizu (Ibaraki, JP) (F) - AM Shah (London, GB) (M)

- 08:15 What on earth is HFpEF?
B Heidecker (Berlin, DE, F)
- 08:30 Stress echocardiography for diagnosis and risk stratification in HFpEF
M Obokata (Maebashi, JP, M)
- 08:45 Prevention of sudden cardiac death in HFpEF: role of multimodality cardiac imaging
M Amano (Suita, JP, M)
- 09:00 Personalising HFpEF treatment
N Pavo (Wien, AT, F)

Learning Objectives: This session will discuss the potential risk stratification of HFpEF from the insights of non-invasive cardiac imaging.

This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Online Live, Spotlight of the Congress, Young Community Track

Epidemiology of Takotsubo syndrome and acute coronary syndromes: focus on gender, cardiorenal syndrome and cancer**Session Number: 3047**Chairpersons: D Dawson (Aberdeen, GB) (F) - R Vidal-Perez (A Coruna, ES) (M)

- 08:15 Trends in Takotsubo syndrome**
V Schweiger (Zurich, CH, M)
- 08:27 Difference in long-term mortality after takotsubo syndrome. The role of gender, socioeconomic profile, and psychological distress**
P Palm (Holte, DK, F)
- 08:39 Cardio-renal syndromes in patients admitted with ST-elevation myocardial infarctions: Incidence and impact on renal and overall outcome**
J Schmucker (Bremen, DE, M)
- 08:51 Time trends in mortality, incidence and case-fatality of acute myocardial infarction in Norway - do we see the end of the coronary heart disease epidemic?**
KH Bonaa (Trondheim, NO, M)
- 09:03 Myocardial infarction risk across cancer subtypes - nationwide registry study**
J Shanmuganathan (Randers C, DK, M)

Learning Objectives:

Categories:

'Shocking' news on implantable cardioverter defibrillators**Session Number: 3017**Chairpersons: A Russo (Moorestown, US) (F) - GL Botto (Rho, IT) (M)

- 08:15** **Insights from an international clinic survey on CIED patient management practices and perceptions**
E Martens (Grafelfing, DE, M)
- 08:25** **Comparison of ICD implantation approach in children. The IChildRen study.**
V Probst (Nantes, FR, M)
- 08:35** **Risk for appropriate ICD intervention and complications in patients implanted after an out-hospital cardiac arrest compared to patients implanted for primary and other secondary prevention indication**
E Baldi (Pavia, IT, M)
- 08:45** **Similar incidence of ICD-shocks in diabetic compared to non-diabetic patients receiving implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D)**
S Haxha (Hilleroed, DK, F)
- 08:55** **Risk stratification for a primary prevention ICD: Performance of the MADIT-ICD Benefit Score in contemporary real world patients**
DJ Dzikowicz (Rochester, US, M)
- 09:05** **Incidence of systolic heart failure and need for implantable cardiac defibrillators in patients with atrial fibrillation who had catheter ablation versus antiarrhythmic medical therapy**
B Ali (Cleveland, US, M)

Learning Objectives:

Categories:

Immune and genetic factors in myocarditis: not just a common cold!**Session Number: 3064**Chairpersons: A Lewis (Oxford, GB) (M) - A Caforio (Padua, IT) (F)

- 08:15 Incidence and risk of autoimmune disease in patients with a previous diagnosis of myocarditis - a nationwide Danish register-based cohort study**
NLO Lundgren (Aalborg, DK, U)
- 08:25 Peripheral blood immune cells distribution in biopsy-proven myocarditis: etiology and prognostic correlates**
C Vicenzetto (Padua, IT, F)
- 08:35 Effect of extracellular vesicles derived from inflammatory H9C2 cardiomyocytes on the polarization of macrophages and its mechanism**
B Han (Jinan, CN, F)
- 08:45 Ringlike late gadolinium enhancement: prevalence, association with cardiac phenotype, and patient outcome in an unselected cohort referred for cardiovascular magnetic resonance imaging**
D Filomena (Rome, IT, M)
- 08:55 Prevalence of pathogenic variants in cardiomyopathy-associated genes in acute myocarditis: a systematic review and meta-analysis**
E Monda (Marigliano, IT, M)
- 09:05 Acute myocarditis presentation and intra-hospital prognosis: results of the multicenter prospective MYOCARDITIRM study.**
C Bouleti (Paris, FR, F)

Learning Objectives:

Categories:

The broad spectrum of cardiovascular risk**Session Number: 3093**Chairpersons: M Gulati (Los Angeles, US) (F) - A Rakisheva (Almaty, KZ) (F)

- 08:15 Heterogeneous effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular events among people with type 2 diabetes: an application of machine learning to target trial emulation**
Y Mori (Kyoto, JP, M)
- 08:25 Red cell distribution width as a predictor of cardiovascular events in high-risk patients with statin intolerance: post-hoc analysis of the CLEAR Outcomes trial**
P Moriarty (Kansas City, US, M)
- 08:35 High physical activity relates to higher risk of incident carotid plaque components**
L Zuo (Rotterdam, NL, M)
- 08:45 Estimation of individual lifetime cardiovascular disease risk and treatment benefit in patients with established atherosclerotic cardiovascular disease: the updated SMART-REACH2 model**
J Holtrop (Utrecht, NL, M)
- 08:55 Sex-differences in prescription patterns of secondary prevention pharmacotherapy in patients with acute myocardial infarction: a 20-year perspective**
H Rickli (St Gallen, CH, M)
- 09:05 Association of insulin resistance with cardiovascular disease and all-cause mortality in type 1 diabetes mellitus: systematic review and meta-analysis**
R Sun (Beijing, CN, F)

Learning Objectives:

Categories:

**Imaging to improve diagnosis and risk-stratification of
cardiomyopathies****Session Number: 3002**Chairpersons: F Graziani (Rome, IT) (F) - J Ako (Sagamihara, JP) (M)

- 08:15 Long-term outcomes of patients with apical hypertrophic cardiomyopathy: incorporation of a novel risk score.**
M Desai (Cleveland, US, M)
- 08:25 Identification and validation of ventricular rhythmic risk subgroups in hypertrophic cardiomyopathy by clustering analysis including left ventricular strain analysis**
A Al wazzan (Rennes, FR, M)
- 08:35 Automated deep learning approach for identifying etiologies of hypertrophic phenocopies by echocardiography**
PH Su (Taipei, TW, M)
- 08:45 Artificial intelligence-guided screening of under-recognized cardiomyopathies adapted for point-of-care echocardiography**
EK Oikonomou (New Haven, US, M)
- 08:55 Extra cellular volume by computed tomography is useful for prediction of prognosis in cardiac sarcoidosis**
Y Nishikawa (Chiba, JP, M)
- 09:05 Arrhythmogenic right ventricular cardiomyopathy: the importance of biventricular strain in risk-stratification**
APA Chua (Leiden, NL, F)

Learning Objectives:

Categories:

Atrial fibrillation cases**Session Number: 3324**Chairpersons: L Rottner (Hamburg, DE) (F) - M Manninger (Graz, AT) (M)

- 08:15 Atrial fibrillation cases - get ready for the session**
M Manninger (Graz, AT, M)
- 08:20 Intercoronary collateral arteries adjacent to left atrial pulmonary veins in patient with AF and ARCAPA**
I Tonchev (Varna, BG, M)
- 08:33 Electrical anomaly during digoxin loading in the setting of atrial fibrillation**
RP Amier (Amsterdam, NL, F)
- 08:46 Complex left atrial appendage closure using 3D printing system in a patient with recurrent embolism and previous mitral prosthetic valve implantation**
R Tarantini (Pavia, IT, M)
- 08:59 Ventricular fibrillation risk during left atrial pulsed field ablation**
S Valcher (Lodi, IT, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals

Categories: Mobile App - Vote, Young Community Track

Ablation of ventricular tachycardia**Session Number: 3341**Chairpersons: S Castelletti (Milan, IT) (F) - N Schaerli (Basel, CH) (M)

- 08:15 Left ventricle reconstruction and aneurysmectomy as a treatment for recurrent and refractory ventricular tachycardia in a patient suffering from ischemic myocardial disease**
PGS Guimaraes Silva (Sao Paulo, BR, M)
- 08:27 Anatomical approach for left parahissian ventricular arrhythmia ablation to reduce atrioventricular block risk.**
F Vannini (Rome, IT, M)
- 08:39 Chagas myocardiopathy: a case of ventricular tachycardia in a non-endemic setting.**
M Carvalho (Leiria, PT, F)
- 08:51 Electrical storm due to polymorphic tachycardia and ventricular fibrillation triggered by premature ventricular complexes originating in the Purkinje fibers adjacent to the moderator band.**
N Campo (Cali, CO, F)
- 09:03 Ablation of Purkinje fibers as therapy for idiopathic ventricular fibrillation.**
J Adamek (- , SK, M)

Learning Objectives:

Categories:

Valve cases

Session Number: 3362

Chairpersons:

F Ilardi (Naples, IT) (F) - G Tsaban (Rochester, US) (M)

- 08:15** **A rare case of double peri-commissural mitral flail: double horn sign**
F Vagnarelli (Bologna, IT, M)
- 08:27** **A new serological marker in the diagnostic-therapeutic management of valvulopathies. When blood tests can still guide us in the Imaging Era**
E Tommasi (Florence, IT, F)
- 08:39** **A rare case of congenitally corrected transposition of great arteries with severe degenerative aortic stenosis submitted to TAVR**
M Sobral Domingues (Lisboa, PT, M)
- 08:51** **HIKICOM Bailout technique: Bailout method using trans atrial septal approach for guidewire removal from the left ventricle during sapien s3 implantation in TAVR**
T Kokawa (Komatsushima, JP, M)
- 09:03** **Isolated tricuspid valve dysplasia leading to functional pulmonary atresia: a rare clinical entity without clear guidelines for intervention**
E Tham (Edmonton, CA, F)

Learning Objectives:

Categories:

ESC Rene Laennec Lecture in Clinical Cardiology

Session Number: 401

Chairpersons: H Baumgartner (Muenster, DE) (M) - C Espinola-Klein (Mainz, DE) (F)

- 09:15 **Presentation of the awardee**
H Baumgartner (Muenster, DE, M)
- 09:20 **Personalised approaches to managing heritable thoracic aortic disease**
J De Backer (Ghent, BE, F)
- 09:40 **ESC Rene Laennec Lecture in Clinical Cardiology - Q&A**
- 09:55 **Award presentation**

Learning Objectives:
Categories:

From valvular heart disease to heart failure: bringing guidelines into personalised patient care - Israeli and Swiss perspectives**Organised in collaboration with the Swiss Society of Cardiology and the Israel Heart Society****Session Number: 5100**Chairpersons: B Veragut Davies (Carouge, CH) (F) - A Segev (Tel Hashomer, IL) (M)**09:30 Hypertrophic obstructive cardiomyopathy and mitral regurgitation: 'clipping' two birds with one stone - the Israeli perspective**

E Shaked (Ashdod, IL, F)

09:42 Aortic stenosis in 2024 - the Swiss perspective**09:54 From valvular heart disease to heart failure: bringing guidelines into personalised patient care - Israeli and Swiss perspectives - discussion**

GB Pedrazzini (Lugano, CH, M)

I Barbash (Ramat Gan, IL, M)

Learning Objectives: To discuss cases in the context of current guidelines, highlighting standards, interpretations, and adaptations tailored to individual patients.**Categories:** Online Live, Spotlight of the Congress

Modern views on worsening heart failure

Session Number: 3037

Chairpersons: E Goncalvesova (Bratislava, SK) (F) - D Milicic (Zagreb, HR) (M)

- 09:30 Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: a participant level pooled analysis of CREDENCE and CANVAS**
S Chatur (Boston, US, F)
- 09:40 Safety of COVID-19 vaccines regarding cardiovascular events: a systematic review and meta-analysis**
I Khaeshi (Tehran, IR, M)
- 09:50 International cooperation in cardiogenic shock is key to improving outcomes: Cardiogenic Shock Working Group impacts a single-center in a developing country.**
JA Ortega-Hernandez (Df, MX, M)
- 10:00 Associations of nutritional status and comorbidities with long-term survival among patients with acute heart failure**
Q Zhou (Beijing, CN, F)
- 10:10 The impact of the 2022 definition of pulmonary hypertension on long-term clinical outcomes in patients with heart failure with preserved ejection fraction**
F Sera (Suita, JP, F)
- 10:20 Remote management of worsening heart failure events and subsequent rate of emergency department admission**
J Florence (Clermont-Ferrand, FR, M)

Learning Objectives:

Categories:

Hypertension in special circumstances**Session Number: 3083**Chairpersons: T Kahan (Stockholm, SE) (M) - G Rivasi (Florence, IT) (F)

- 09:30 Gender differences in cardiovascular outcomes related to systolic blood pressure time in target range: insights from the SPRINT trial**
- 09:42 Association of hypertension and the risk of cancer: a study based on the UK Biobank**
H Wu (Guangzhou, CN, M)
- 09:54 Regional variation of age-related blood pressure trajectories and their association with blood pressure control rates, disability-adjusted life years and death**
J Nolde (Freiburg, DE, M)
- 10:06 Gender difference in the association of serum triglyceride level with hypertension: analysis of the NHANEs 2017-2020**
P Wattanachayakul (Orange, US, M)
- 10:18 Autonomous cortisol secretion in patients with primary aldosteronism is associated with left ventricular hypertrophy and diastolic dysfunction**
CH Tsai (Taipei City, TW, M)

Learning Objectives:

Categories:

Epigenetic targets in cardiovascular disease

Session Number: 3129

Chairpersons: D Fernandez-Twinn (Cambridge, GB) (F) - W Linke (Muenster, DE) (M)

- 09:30 Targeting BRD4-HK2 reverses the meta-inflammatory shift in perivascular adipose tissue and rescues cardiometabolic vascular dysfunction.**
A Mengozzi (Pisa, IT, M)
- 09:40 Targeting the histone methyltransferase SETD7 rescues diabetes-induced impairment of angiogenic response by transcriptional repression of semaphorin 3G**
SA Mohammed (Zurich, CH, M)
- 09:50 Chromatin remodeling by the histone methyltransferase SETD2 drives cardiometabolic heart failure with preserved ejection fraction**
S Costantino (Zurich, CH, F)
- 10:00 Epigenetic BET inhibitor apabetalone counters inflammatory and fibrotic processes in activated cardiac fibroblasts providing insight into reduced hospitalizations for heart failure in BETonMACE trial**
E Kulikowski (Calgary, CA, F)
- 10:10 The BET inhibitor Apabetalone protects against heart failure with preserved ejection fraction by suppressing myocardial inflammation**
E Gorica (Zurich, CH, F)
- 10:20 RBM20 promotes doxorubicin-induced cardiotoxicity by Atp6v0a1 alternative splicing**
Z Qiu (Shanghai, CN, M)

Learning Objectives:

Categories:

Risk prediction and treatment options in cardio-oncology

Session Number: 3102

Chairpersons: T Lopez Fernandez (Madrid, ES) (F) - N Lang (Glasgow, GB) (M)

- 09:30 Integrative STE for the early detection and prediction of CTRCD**
C Xing (Xi'an, CN, M)
- 09:40 Adverse cardiovascular events in patients with cancer: a biomarker-enhanced clinical risk score**
S Kraler (Zurich, CH, M)
- 09:50 Sex differences in cancer incidence amongst people with cardiovascular disease: a large British population study.**
R Thuemmler (Aberdeen, GB, F)
- 10:00 Effects of SGLT2 inhibitors on the cardiovascular outcomes in patients with cancer: a systematic review and meta-analysis**
L Liu (Hsinchu, TW, M)
- 10:10 An analysis of the virtual cardio-oncology research initiative (VICORI) resource: bleeding risk among cancer patients beyond 1-year post-myocardial infarction**
K W Ow (Leicester, GB, M)
- 10:20 Unveiling the heartbeat of hope: exploring cardiovascular morbidity, mortality, and socioeconomic threads in 65,173 Child, Adolescent, and Young Adult (caya) cancer patients.**
J Sodling (Norrkoping, SE, M)

Learning Objectives:

Categories:

Innovations in heart failure management: insights from clinical practice and healthcare data**Session Number: 3117**Chairpersons: LW Stevenson (Nashville, US) (F) - A Shah (Edinburgh, GB) (M)

- 09:30 Traditional dual-chamber right ventricular pacing versus conduction system pacing in the US medicare population**
P Vijayaraman (Wilkes Barre, US, M)
- 09:40 Response patterns in self-reported medical conditions: insights from the National Health and Nutrition Examination Survey (NHANES)**
G Siontis (Bern, CH, M)
- 09:50 THIRST Alert: a randomised controlled trial and feasibility study of an electronic health record alert in patients with heart failure and fluid overload**
Y Chen (London, GB, M)
- 10:00 Impact of heart failure diagnosis on recorded healthcare resource use by older people in Wales; is primary care shouldering a hidden burden?**
E Rees (Swansea, GB, F)
- 10:10 Impact of a clinician-to-clinician electronic consultation program in heart failure patients with previous hospitalization. Implications for heart failure multidisciplinary management.**
D Garcia Vega (Santiago De Compostela, ES, M)
- 10:20 Integrating artificial intelligence into a real-world clinical pathway to facilitate clinician treatment optimisation in patients with HFrEF on suboptimal medical therapy**
Mya Win (Dundee, GB, F)

Learning Objectives:

Categories:

Cardiac pacing cases**Session Number: 3325**Chairpersons: V Johnson (Giessen, DE) (F) - A Naraen (Aughton, GB) (F)**09:30 Cardiac pacing cases - get ready for the session****09:35 Performance improvement in elderly athlete with pacemaker: The importance of optimizing device parameters during exercise**

R Rios (Sao Paulo, BR, F)

09:48 Myocardial bridging presenting as exercise-induced sinus node dysfunction in a young patient

A Fonseca Vazao (Leiria, PT, F)

10:01 Extraction of an aveir leadless pacemaker using the loop wire technique

K Yano (Tokyo, JP, M)

10:15 Simultaneous left bundle branch pacing and right ventricular pacing in a patient with surgically corrected tetralogy of Fallot and severe biventricular failure

H Eldeeb (Leicester, GB, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals**Categories:** Mobile App - Vote, Young Community Track

Rare causes of heart failure

Session Number: 3340

Chairpersons: I Cabac-Pogorevici (Chisinau, MD) (F) - V Sullivan (Ireland, IE) (F)

09:30 Mapping the pathway: understanding an aorto-atrial fistula in a patient with heart failure.

R Carvalho (Lisbon, PT, F)

09:42 A case of infiltrative cardiomyopathy: Loeffler Endocarditis

BM Ulker (Bursa, TR, M)

09:54 Seeing behind the diagnosis of acute myocardial infarction in a postpartum woman with premature birth

A Breazu (Bucharest, RO, M)

10:06 Hoofbeats approaching: horses or zebras?

A Kazay (Budapest, HU, M)

10:18 Spectacular and unexpected a rare case of a giant thrombosed left ventricular aneurysm after silent myocardial infarction - challenging differential diagnosis of true or false aneurysms

M Poudel (Bielefeld, DE, M)

Learning Objectives:

Categories:

Team up for endocarditis

Session Number: 3368

Chairpersons:

C Sousa (Porto, PT) (F) - G Benetos (Athens, GR) (M)

- 09:30** **It takes a village – importance of endocarditis teams in patients who inject drugs**
A Coulis (Philadelphia, US, F)
- 09:42** **Endocarditis-induced rapidly progressive glomerulonephritis mimicking vasculitis**
M Candia Ramirez (Ciudad De Mexico, MX, M)
- 09:54** **Pericardial effusion as an unusual manifestation of infective endocarditis. What do we know about cardiac complications?**
A Hernandez Fonseca (- , MX, M)
- 10:06** **A giant pseudoaneurysm of mitral-aortic intervalvular fibrosa presenting as recent-onset angina and cardiac arrest due to ventricular fibrillation**
F Vagnarelli (Bologna, IT, M)
- 10:18** **To be or not to be endocarditis or the congenital disease patient's story**
A Buta (Bucharest, RO, F)

Learning Objectives:

Categories:

2023 ESC Guidelines on Acute Coronary Syndromes: Great Britain and Ireland perspectives**Organised in collaboration with the Irish Cardiac Society and the British Cardiovascular Society****Session Number: 5105**Chairpersons: PP McKeown (Belfast, GB) (M) - J Greenwood (Leeds, GB) (M)**10:30 Case 1 - contemporary management of NSTEMI-ACS: the Ireland perspective**

RA Byrne (Dublin, IE, M)

10:40 Contemporary management of NSTEMI-ACS: the Ireland perspective - discussion of guideline implementation

N Johnston (Belfast, GB, F)

10:52 Case 2 - contemporary investigation and management of MINOCA: the UK perspective

V Kunadian (Newcastle Upon Tyne, GB, F)

11:02 Contemporary investigation and management of MINOCA: the UK perspective - discussion on guideline implementation

C Berry (Glasgow, GB, M)

Learning Objectives: To discuss experiences related to current diagnostic methods and treatment strategies for NSTEMI-ACS and MINOCA, with an emphasis on clinical practice in the UK and Ireland.

Categories: Online Live

The best science in cardiac arrest and cardiogenic shock

Session Number: 3041

Chairpersons: C Malta Hansen (Copenhagen, DK) (F) - J Belohlavek (Praha, CZ) (M)

- 10:45** **Impact of extracorporeal cardiopulmonary resuscitation with ECPELLA on improvement of short-term survival in patients with refractory cardiac arrest**
T Inamori (Kumamoto, JP, M)
- 10:55** **Increased miRNA-related inflammation markers and pro-inflammatory circulating cell profile in patients with poor neurological outcome after out-of-hospital cardiac arrest**
F Jimenez Trinidad (Barcelona, ES, M)
- 11:05** **Sex-specific prediction of cardiogenic shock complicating acute coronary syndromes: the SEX-SHOCK score**
Y Wang (Zurich, CH, F)
- 11:15** **The majority of 30-days survivors return to work one-year after in-hospital cardiac arrest**
H Yonis (Aalborg, DK, M)
- 11:25** **The effects of targeting mild hypercapnia on right ventricular function after out-of-hospital cardiac arrest. A sub-study of the TAME trial.**
M Baumann Melberg (Oslo, NO, M)
- 11:35** **Clinical significance of residual ischemia in acute myocardial infarction complicated by cardiogenic shock undergoing VA-ECMO**
O Kim (Seoul, KR, F)

Learning Objectives:

Categories:

Stroke risk management in atrial fibrillation registries: key take-home messages for clinicians**Session Number: 3025**Chairpersons: I Savelieva (London, GB) (F) - A Sztaniszlav (Orebro, SE) (M)

- 10:45** **How much does elective cardioversion increase the risk of ischaemic stroke compared to the baseline risk in atrial fibrillation? A nationwide study.**
S Itainen-Stromberg (Helsinki, FI, F)
- 10:57** **Stratification of residual thromboembolic risk among anticoagulated atrial fibrillation patients: a hierarchical cluster analysis from a global, real-world population**
B Huang (Liverpool, GB, M)
- 11:09** **Cluster-specific risk factors for suboptimal thromboprophylaxis in contemporary European cohort of patients with atrial fibrillation: the EHRA-PATHS Project**
M Mihajlovic (Belgrade, RS, M)
- 11:21** **Temporal trends in initiation of oral anticoagulants and stroke-free survival among elderly and very elderly patients with new onset atrial fibrillation - a 20-year perspective.**
M Elmegaard (Frederiksberg, DK, F)
- 11:33** **Is atrial fibrillation associated with increased risk of stroke after transient ischaemic attack?**
K Al-Chaer (Copenhagen, DK, F)

Learning Objectives:

Categories:

The different faces of mitral regurgitation**Session Number: 3060**Chairpersons: A Marciniak (London, GB) (F) - D Messika Zeitoun (Ottawa, CA) (M)

- 10:45 Atrial and ventricular mitral regurgitation in the general population**
L Keil (Hamburg, DE, F)
- 10:55 Elevated mitral valve pressure gradient following transcatheter edge-to-edge repair is independently associated with inferior outcomes in atrial, but not in ventricular secondary mitral regurgitation**
B Koell (Hamburg, DE, M)
- 11:05 Prognostic impact of cardiac events in asymptomatic mitral regurgitation**
E Girdauskas (Augsburg, DE, M)
- 11:15 Prognostic implications of right ventricular dysfunction in degenerative mitral regurgitation**
Y Bohbot (Amiens, FR, M)
- 11:25 Incidence and factors associated with mitral valve reoperation in patients undergoing intervention for mitral regurgitation: a nationwide cohort study**
S Truong (Copenhagen, DK, F)
- 11:35 Prevalence, mechanisms and prognostic impact of dynamic mitral regurgitation unmasked by handgrip exercise in patients with hypokinetic non-dilated and dilated cardiomyopathy**
N Guenther (Duesseldorf, DE, M)

Learning Objectives:

Categories:

Novel biomarkers for cardiovascular risk prediction

Session Number: 3097

Chairpersons: M Kavousi (Rotterdam, NL) (F) - V Vassiliou (Cambridge, GB) (M)

- 10:45 Serum amyloid A-low-density-lipoprotein complex and cause-specific mortality in patients with suspected or known coronary artery disease: The ANOX Study**
M Suzuki (Wako, JP, M)
- 10:55 Associations between neutrophil-percentage-to-albumin ratio level and all-cause mortality and cardiovascular disease-cause mortality in general population: evidence from nhanes 1999-2010**
Z Qiu (Beijing, CN, M)
- 11:05 Remnant cholesterol is associated with platelet reactivity for patients with coronary artery disease underwent percutaneous coronary intervention**
J Li (Beijing, CN, F)
- 11:15 A direct comparison of non-invasive blood markers of liver fibrosis as associates of cardiovascular risk. The Athens cardiometabolic registry**
S Athanasopoulos (- , GR, M)
- 11:25 Cystatin C predicts cardiovascular events in patients with coronary artery disease both among patients with and among those without type 2 diabetes**
A Vonbank (Feldkirch, AT, M)
- 11:35 Novel insights of phenylalanine in Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) and cardiovascular complications**
J Liu (Oxford, GB, F)

Learning Objectives:

Categories:

Novel assessment of cardiovascular risk using computed tomography**Session Number: 3005**Chairpersons: Q Truong (New York, US) (F) - E Nicol (Abingdon, GB) (M)

- 10:45 Coronary inflammation stratifies risk in patients undergoing coronary CT angiography: the Oxford Risk Factors and Non-Invasive Imaging (ORFAN) study**
K Chan (London, GB, M)
- 10:55 Comparison between coronary calcium score and segment involvement score when used in clinical routine**
H Lofmark (Stockholm, SE, M)
- 11:05 Prevalence of high-risk plaque features on cardiac computed tomography scans in patients with a coronary artery calcium score of zero**
K Miszalski-Jamka (Zabrze, PL, M)
- 11:15 A novel marker of cardiovascular risk stratification: the role of total cardiovascular calcium score using cardiac CT**
I Miranda (Lisboa, PT, F)
- 11:25 Role of pericoronary adipose tissue inflammation at CCTA after heart transplantation as non-invasive diagnostic tool of cardiac rejection and predictor of major adverse cardiovascular events**
D Cavallo (Bologna, IT, M)
- 11:35 CT-perfusion quantitation of cardiac infarct size - a novel technique**
KT Ho (Singapore, SG, M)

Learning Objectives:

Categories:

Cardiogenic shock**Session Number: 3302**Chairpersons: C Vandenbriele (Leuven, BE) (M) - E Karagiannidis (Thessaloniki, GR) (M)**10:45 Cardiogenic shock - get ready for the session**

10:50 Cardiogenic shock in a patient diagnosed with Diffuse Large B Cell Lymphoma (dlbcl) infiltrating the right ventricle, with secondary Takotsubo cardiomyopathy and arrhythmogenic instability
H Abramovich Yoffe (Petah Tikva, IL, F)

11:03 Broken heart with burning feet: tailored care for neurologically complicated cardiogenic shock
SIR INNUPAT (Bangkok, TH, M)

11:16 Recurrent cardiogenic shock in a young woman: is myocarditis the cause or the epiphenomenon ?
A Minervini (Bologna, IT, F)

11:29 Management of cardiogenic shock complicating acute myocardial infarction: no room for intra-aortic balloon pump?
R Simamora (Jakarta Pusat, ID, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals

Categories: Mobile App - Vote, Young Community Track

MINOCA (1)

Session Number: 3334

Chairpersons:

J Boeddinghaus (Edinburgh, GB) (M) - C Plesoianu (Iasi, RO) (F)

10:45 A pregnant women with acute coronary syndrome: the vasospasm over the myocardial bridging.

M Palmieri (Genoa, IT, M)

10:57 Cannabis-induced left main coronary artery vasospasm

H Ahmed (Omaha, US, M)

11:09 Unraveling the clinical enigma: from recurring stress cardiomyopathy to pheochromocytoma

AC Cristea (Valladolid, ES, F)

11:21 A challenging case of spontaneous coronary artery dissection

M Centola (Milan, IT, M)

11:33 Look before you leap - unveiling a case of myocardial infarction with non-obstructive coronary arteries

C Miguel Goncalves (Leiria, PT, F)

Learning Objectives:

Categories:

All the facets of cardioimmunology**Session Number: 3374**Chairpersons:

D Tomasoni (Brescia, IT) (F) - S Reinstadler (Innsbruck, AT) (M)

- 10:45** **An uncommon cause of restrictive cardiomyopathy in a 16 years old teenage girl**
MD CHOWDHURY (Dhaka, BD, M)
- 10:57** **Chronic heart failure and ventricular arrhythmias in a young patient with hypertrophic cardiac phenotype: the multiple shades of myocardial inflammation**
A Giordani (Padova, IT, M)
- 11:09** **Immune checkpoint inhibitor (ICI)-related complicated acute myocarditis associated with myositis in a woman with advanced ovarian cancer.**
N Conti (Bergamo, IT, F)
- 11:21** **Desmoplakin cardiomyopathy presenting as fulminant myocarditis with negative endomyocardial biopsies**
WB He (Melbourne, AU, M)
- 11:33** **Another systemic heart disease. Right decisions.**
M Garbayo Bugada (Madrid, ES, F)

Learning Objectives:

Categories:

HOT LINE 7

Session Number: 1016

Chairpersons: M Crespo-Leiro (La Coruna, ES) (F) - M Boehm (Homburg, DE) (M) - W Mullens (Genk, BE) (M)

- 11:00 FINEARTS-HF - Finerenone in heart failure with mildly reduced and preserved ejection fraction**
S Solomon (Boston, US, M)
- 11:12 Discussant review - FINEARTS-HF**
T McDonagh (London, GB, F)
- 11:17 Panel discussion - FINEARTS-HF**
- 11:22 MRAs in heart failure - An individual patient data meta-analysis of randomised trials**
P Jhund (Glasgow, GB, M)
- 11:34 Discussant review - MRAs in heart failure**
M Cikes (Zagreb, HR, F)
- 11:39 Panel discussion - MRAs in heart failure**
- 11:44 FINE-HEART - Participant-level pooled analysis of finerenone in heart failure and chronic kidney disease trials**
M Vaduganathan (Boston, US, M)
- 11:56 Discussant review - FINE-HEART**
J Ferreira (Nancy, FR, M)
- 12:01 Panel discussion - FINE-HEART**

Learning Objectives:

Categories: Online Live

Restore or preserve ventricular synchrony: when and why to use conduction system pacing**Session Number: 180**Chairpersons: D Nair (Jonesboro, US) (F) - R Hatala (Bratislava, SK) (M)

- 11:00 Biventricular pacing (cardiac resynchronisation therapy): when is it preferred?**
L Marcantoni (Rovigo, IT, F)
- 11:15 Conduction system pacing: efficacy and safety - when and why to use?**
M Glikson (Jerusalem, IL, M)
- 11:30 Future perspectives and open questions?**
H Burri (Geneva, CH, M)
- 11:45 Restore or preserve ventricular synchrony: when and why to use conduction system pacing - discussion**
C Leclercq (Rennes Cedex, FR, M)

Learning Objectives:

Categories: Online Live

Personalised management of the patient on mechanical circulatory support in the cardiac care unit**Session Number: 199**Chairpersons: A Tycinska (Bialystok, PL) (F) - A Combes (Paris, FR) (M)**11:00 How to personalise vaso-active drugs in the patient on mechanical circulatory support**

A Sionis (Barcelona, ES, M)

11:20 How to personalise antithrombotic treatment in the patient on mechanical circulatory support

C Van Edom (Leuven, BE, F)

11:40 Maximising imaging modalities to personalise management of the patient on mechanical circulatory support

G Tavazzi (Pavia, IT, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Spotlight of the Congress, Young Community Track

Targeting lipids above and beyond statins: key new players**Session Number: 242**Chairpersons: AG Semb (Oslo, NO) (F) - L Badimon (Barcelona, ES) (F)

11:00 PCSK9 inhibition: new insights
L Raber (Bern, CH, M)

11:12 Strategies to inhibit Lp(a)
F Kronenberg (Innsbruck, AT, M)

11:24 Targeting triglycerides: is it worth it? lessons from recent trials
G Liuzzo (Rome, IT, F)

11:36 Additional cholesterol synthesis inhibition, CETP inhibitors, and cholesterol-efflux enhancer therapies
U Landmesser (Berlin, DE, M)

11:48 Targeting lipids above and beyond statins: key new players - discussion
H Drexel (Feldkirch, AT, M)

Learning Objectives:

Categories: Online Live

The year in review: top trials in coronary interventions impacting guidelines and patient care**Session Number: 301**Chairpersons: M Morice (Massy, FR) (F) - D Capodanno (Catania, IT) (M)

- 11:00 Microaxial flow pump or standard care in infarct-related cardiogenic shock: the DanGer shock trial**
C Hassager (Copenhagen, DK, M)
- 11:12 A placebo-controlled trial of percutaneous coronary intervention for stable angina: the ORBITA-2 trial**
R Al-Lamee (London, GB, F)
- 11:24 ILUMIEN IV: optical coherence tomography-guided vs. angiography-guided PCI**
Z Ali (St Francis, US, M)
- 11:36 Paclitaxel-coated balloon vs. uncoated balloon for coronary in-stent restenosis: the AGENT IDE randomised clinical trial**

R Yeh (Boston, US, M)
- 11:48 The year in review: top trials in coronary interventions impacting guidelines and patient care - discussion**

Learning Objectives:

Categories:

Great Debate: assessing the risk of sudden death in hypertrophic cardiomyopathy should include myocardial fibrosis imaging**Session Number: 319**Chairpersons: C Ho (Boston, US) (F) - J Schulz-Menger (Berlin, DE) (F)**11:00 Sudden death risk assessment in hypertrophic cardiomyopathy should include myocardial fibrosis imaging: pro**

C Kramer (Charlottesville, US, M)

11:15 Sudden death risk assessment in hypertrophic cardiomyopathy should include myocardial fibrosis imaging: con

A Kammerlander (Vienna, AT, M)

11:30 Sudden death risk assessment in hypertrophic cardiomyopathy should include myocardial fibrosis imaging - discussion

L Sierra-Galan (Mexico City, MX, F)

E Arbelo (Barcelona, ES, F)

Learning Objectives:

Categories: Online Live

Smaller trials and other studies on atherosclerosis

Session Number: 1044

Chairpersons: P Taub (Rancho Santa Fe, US) (F) - S Nicholls (Clayton, AU) (M)

- 11:00 Effects of Coronary Artery Calcium-Guided Statin Therapy on Atherosclerotic Progression in Intermediate-Risk People with Familial Coronary Artery Disease**
N Nerlekar (Hawthorn, AU, M)
- 11:12 Functional Improvement of non-infarct related coronary artery stenosis by Extensive LDL-C Reduction with a PCSK9 Antibody**
FB Mensink (Nijmegen, NL, M)
- 11:24 Treatment of periodontitis and progression of subclinical atherosclerosis: a randomized controlled clinical trial**
F D'Aiuto (London, GB, M)
- 11:36 Primary Results of SLICE-CEA CardioLink-8: A Randomized Trial of Evolocumab on Carotid Artery Atherosclerotic Plaque Characteristics in People with Asymptomatic High-Risk Carotid Stenosis**
CD Mazer (Toronto, CA, M)
- 11:48 Quantified characterization of atherosclerotic plaques by optical coherence tomography attenuation imaging**
Y Chen (Beijing, CN, F)

Learning Objectives:

Categories:

**Guidelines in Practice: implementing the 2023 Focused Update on
Heart Failure - target, treat, and titrate**

Session Number: 106

Chairpersons: E Jankowska (Wroclaw, PL) (F) - P Ponikowski (Wroclaw, PL) (M)

11:00 Decompensated heart failure: case presentation

K Cerlinskaite-Bajore (Vilnius, LT, F)

11:15 Decompensated heart failure: what do the guidelines say?

RS Gardner (Linthgow, GB, M)

**11:30 Decompensated heart failure: how to implement the guidelines and take-home
messages**

A Mebazaa (Paris, FR, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Clinical Implementation Track, Online Live, Young Community Track

The impact of obesity management on cardiovascular outcomes

Session Number: 155

Joint session with the European Association for the Study of Obesity (EASO)

Chairpersons: M Haykowsky (Edmonton, CA) (M) - A Ciudin (Barcelona, ES) (F)

- 11:00 Metabolic bariatric surgery as first-line therapy to improve outcomes**
G Fruhbeck (Pamplona, Navarra, ES, F)
- 11:15 GLP-1 RA as first-line therapy to improve outcomes?**
P Sbraccia (Rome, IT, M)
- 11:30 Lifestyle intervention in HFpEF with obesity to improve outcomes**
E Van Craenenbroeck (Edegem, BE, F)
- 11:45 HFpEF patients with obesity and atrial fibrillation: role of exercise and ablation**
S Wernhart (Essen, DE, M)

Learning Objectives: This session aims to recognise that obesity is a chronic relapsing disease that has a multifactorial aetiology and multiple health consequences and with the objective to be aware that certain obesity treatments can benefit the cardiovascular health of patients living with obesity (PLWO).

Categories: Obesity Track

Shaping the future management of pulmonary hypertension

Session Number: 327

Joint session with the European Respiratory Society (ERS)

Chairpersons: A Vonk Noordegraaf (Amsterdam, NL) (M) - M Escribano Subias (Madrid, ES) (F)

11:00 Inclusion of the patient perspective in new trials in pulmonary hypertension
P Ferrari (Udine, IT, F)

11:15 Novel concepts in trial design: a trialist's view
M Humbert (Le Kremlin-Bicetre, FR, M)

11:30 Will omics finally fulfil the promise of personalised medicine in pulmonary hypertension?
M Wilkins (London, GB, M)

11:45 What is the state of the art of reverse remodelling strategies for the treatment of pulmonary arterial hypertension?
M Delcroix (Leuven, BE, F)

Learning Objectives: This session will focus on the recent progress made in the field of pulmonary hypertension from bench to bedside including novel concepts and learning points involving genetic and omics profiles of the different types of pulmonary hypertension and how this knowledge can be translated to a personal approach; and will provide insights in novel platform adaptive trial designs to test drugs in rare diseases.

Categories: Includes a patient perspective

Use of imaging in electrophysiology**Session Number: 264**Chairpersons: GE Mandoli (Siena, IT) (F) - J Aranyo (Badalona, ES) (F)**11:00 Imaging to select candidates for atrial fibrillation ablation**

BLM Gerber (Woluwe-St. Lambert, BE, M)

11:15 Imaging to select candidates for ventricular tachycardia ablation

M De Riva Silva (Leiden, NL, F)

11:30 Imaging for atrial and ventricular device optimisation

I Stankovic (Belgrade, RS, M)

11:45 Use of imaging in electrophysiology - discussion

A Rinaldi (London, GB, M)

Learning Objectives:

Categories:

Clinical Case Management: case studies from primary care

Session Number: 432

Organised in collaboration with the Primary Care Cardiovascular Society (PCCS)

Chairpersons: L Guasti (Varese, IT) (F) - J Moore (Cheltenham, GB) (M)

11:00 Case 1: how do I diagnose and manage HFpEF?

P Campbell (Craigavon, GB, F)

11:20 Case 2: how do I manage chronic kidney disease as a generalist?

R Thakkar (High Wycombe, GB, M)

11:40 Clinical Case Management: case studies from primary care - discussion

T Kumler (Herlev, DK, M)

Learning Objectives: This session will provide practical advice to general clinicians on diagnosing and managing HFpEF and chronic kidney disease.

Categories: General Cardiology for Physicians, Technicians and General Practitioners

The floor is yours: bring your questions on renal denervation in hypertension management - when? how? and who?

Session Number: 216

Chairpersons: M Boehm (Homburg, DE) (M) - C Meyer-Zurn (Basel, CH) (F) - E Lioudaki (London, GB) (F)

11:00 The floor is yours: bring your questions on renal denervation in hypertension management - when? how? and who? - get ready for the session
E Lioudaki (London, GB, F)

11:05 The floor is yours: bring your questions on renal denervation in hypertension management - when? how? and who? - expert panel
A Pathak (Monte Carlo, MC, M)

S Brouwers (Aalst, BE, F)

M Azizi (Paris, FR, M)

TD Wang (Taipei City, TW, M)

D Hering (Gdansk, PL, F)

A Kasiakogias (Athens, GR, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Clinical Implementation Track, Mobile App - Ask a Question, Young Community Track

Digital tools to inform decisions in aortic stenosis

Session Number: 311

Chairpersons: A Baumbach (London, GB) (M) - J Wykrzykowska (Groningen, NL) (F)

11:00 **Deep learning to predict progression of aortic stenosis**
EK Oikonomou (New Haven, US, M)

11:20 **TAVI vs. SAVR: a decision model**
S Bleiziffer (Bad Oeynhausen, DE, F)

11:40 **Artificial intelligence-assisted techniques to optimise aortic valve intervention**

Learning Objectives:

Categories: Digital Health, Online Live

ESC Andreas Grüntzig Lecture in Interventional Cardiology

Session Number: 406

Chairpersons: M Roffi (Geneva, CH) (M) - J Mehilli (Landshut, DE) (F)

11:00 Presentation of the awardee
J Mehilli (Landshut, DE, F)

11:05 Cardiogenic shock complicating acute myocardial infarction - current evidence and future strategies
H Thiele (Leipzig, DE, M)

11:25 ESC Andreas Grüntzig Lecture in Interventional Cardiology - Q&A

11:40 Award presentation

Learning Objectives:

Categories:

Personalised treatment of cardiac arrhythmias: novel insights from the bench

Session Number: 343

Chairpersons: CA Remme (Amsterdam Z0, NL) (F) - J Jalife (Madrid, ES) (M)

- 11:00 Human models to investigate atrial arrhythmia mechanisms**
T Christ (Hamburg, DE, M)
- 11:15 Novel personalised therapies of long QT and short QT syndromes**
KE Odening (Bern, CH, F)
- 11:30 Digital twins for precision rhythmology: ready for prime time?**
J Heijman (Graz, AT, M)
- 11:45 Personalised treatment of cardiac arrhythmias: novel insights from the bench - discussion**
B Rodriguez (Oxford, GB, F)

Learning Objectives:
Categories: Spotlight of the Congress

Session Number: 5131	Daily Highlights by The Heart Association of Thailand
<u>Chairpersons:</u>	This session is brought to you by The Heart Association of Thailand and is not part of the official ESC programme

Learning Objectives:

Categories: Online Live

Young Investigator Award Session in Valvular Heart Disease

Session Number: 809

Chairpersons: M Gilard (Brest Cedex, FR) (F) - A Vahanian (Vincennes, FR) (M)

Judges: Gry Dahle (Oslo, NO) - IM Lang (Vienna, AT) - G Giannakoulas (Thessaloniki, GR)

- 12:00 The prevalence and impact of changes in the severity of secondary TR during hospitalization in acute heart failure**
T Kobayashi (Tokyo, JP, M)
- 12:15 Residual tricuspid regurgitation after transcatheter tricuspid valve edge-to-edge repair: the EuroTR Registry**
L Stolz (Munich, DE, M)
- 12:30 Bacteremia after transcatheter aortic valve implantation: a nationwide cohort study.**
K Hadji-Turdeghal (Frederiksberg, DK, F)
- 12:45 Multi-modal artificial intelligence-based prediction for cardiovascular mortality after transcatheter aortic valve implantation: a time-to-event survival prediction**
I Shiri (Bern, CH, M)

Learning Objectives:

Categories:

Nursing and Allied Professions Investigator Awards

Session Number: 810

Chairpersons: M Kyriakou (Larnaca, CY) (F) - J Hendriks (Sittard, NL) (M)

Judges: AF Gomes (Aveiro, PT) - M Back (Gothenburg, SE) - H Eftekhari (Coventry, GB)

- 12:00** **A nurse-led intervention improves quality of life and reduces arrhythmic recurrences in patients undergoing atrial fibrillation ablation. Results of the NURSECAT-AF randomized clinical trial.**
A Cano Valls (Barcelona, ES, F)
- 12:15** **Impact of agitation status during intensive care on functional outcomes and mortality in patients with cardiovascular disease**
S Soeda (Sagamihara, JP, M)
- 12:30** **Cardiovascular disease history as a predictor for adverse outcomes in frail older adults admitted to acute geriatric settings: 12-month outcomes from an Australian frailty registry.**
J McDonagh (Yarramalong, AU, F)
- 12:45** **CARD-SARC: mixed-method study to develop a disease-specific health-related quality of life tool for cardiac sarcoidosis**
JC Quijano-Campos (London, GB, M)

Learning Objectives:

Categories:

Cases of cardiovascular disease in pregnancy**Session Number: 3327**Chairpersons: D Gencheva (Plovdiv, BG) (F) - K Von Klemperer (London, GB) (F)

- 12:00 Cases of cardiovascular disease in pregnancy - get ready for the session**
D Gencheva (Plovdiv, BG, F)
- 12:05 Joining forces : a complex cardio-obstetric case**
A Radhakrishna (Dublin, IE, M)
- 12:18 Management of pregnancy in univentricular heart and pulmonary hypertension**
P F D'Andria (Milano, IT, M)
- 12:31 One tumour; two patients: cardiac myxoma causing acute mitral regurgitation in pregnancy**
L Aildasani (Bournemouth, GB, F)
- 12:44 Overcoming the odds: successful management of peripartum EGPA-induced cardiomyopathy through multidisciplinary care**
A Li (Indianapolis, US, F)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals

Categories: Mobile App - Vote, Young Community Track

Endocarditis (2)**Session Number: 3337**Chairpersons: V Reskovic Luksic (Zagreb, HR) (F) - L Koechlin (Basel, CH) (M)

- 12:00 The case of the rarest restrictive cardiomyopathy ever – Loeffler Endocarditis**
D Beliaieva (Kyiv, UA, F)
- 12:12 Loeffler endocarditis as a rare manifestation of chronic eosinophilic leukemia with FIP1L1-PDGFR α rearrangement**
R Faraj (Rabat, MA, M)
- 12:24 A case of pulmonic valve endocarditis requiring surgical intervention**
R Castro (New York, US, F)
- 12:36 A challenging case of a complicated TAVI endocarditis in a young patient with alveolar haemorrhages and thrombocytopaenia**
ML Dikou (London, GB, F)
- 12:48 Anterior mitral leaflet perforation and infective endocarditis after deep transcatheter aortic valve implantation**
I Sharabi (Holon, IL, M)

Learning Objectives:

Categories:

Cases with the European Heart Journal - Case Reports Editors

Session Number: 3385

Chairpersons: D Duncker (Hannover, DE) (M)

- 12:00 Aortic regurgitation, it is not always what it seems.**
V Tassi (Athens, GR, F)
- 12:15 Low fetal heart rate, a potentially ominous finding**
A Afana (Craiova, RO, F)
- 12:30 Two rare syndromes in one patient – determining the cause of sudden cardiac arrest**
A Haney (Mosbach, DE, F)
- 12:45 Challenges in diagnosis and management of aortobronchial fistula**
MH Abaydi (Tangier, MA, M)

Learning Objectives: Four cases amongst the top-rated ones have been selected by the Editorial Team of the EHJ-CR and offered the opportunity to be published in the European Heart Journal – Case Reports, free of charge.

Categories:

		Personalised dual antiplatelet therapy (DAPT) after acute coronary syndromes: difficult decisions	
Session Number: 204		Joint session with the Cardiological Society of India (CSI)	
<u>Chairpersons:</u>		S Tewari (Lucknow, IN) (M) - M Rubini Gimenez (Valencia, ES) (F)	

- | | |
|--------------|---|
| 12:30 | De-escalation vs. early cessation of DAPT for patients at high bleeding risk
PC Rath (Hyderabad, IN, M) |
| 12:45 | When should we prolong DAPT beyond 12 months?
M Das (Kolkata, IN, M) |
| 13:00 | Is aspirin the preferred monotherapy after DAPT?
B Rocca (Rome, IT, F) |
| 13:15 | Machine learning to determine the optimal mode and duration of DAPT
B Vogel (New York, US, F) |

Learning Objectives:

Categories: Online Live, Spotlight of the Congress

Functional testing in coronary artery disease

Session Number: 3049

Chairpersons: M Gulati (Los Angeles, US) (F) - P Ong (Stuttgart, DE) (M)

- 13:15 Clinical value of single projection angiography-derived FFR in non-infarct related artery**
SH Lee (Gwangju, KR, M)
- 13:25 Influence of pathophysiological patterns of coronary artery disease on the safety and efficacy of percutaneous coronary intervention**
D Munhoz (Aalst, BE, M)
- 13:35 Prognostic implications of microvascular resistance reserve in symptomatic patients with intermediate coronary stenosis**
JM Lee (Seoul, KR, M)
- 13:45 VERMONT non-optimised: can baseline diagnostic catheter images be used to measure angiography based CAAS-vFFR?**
D Akrawi (Campbelltown, AU, M)
- 13:55 Fractional flow reserve versus solely angiography-guided revascularisation in coronary artery disease, systematic review and meta-analysis.**
M Blaziak (Wroclaw, PL, M)
- 14:05 Antiplatelet agents in patients with intermediate coronary artery stenosis and deferred revascularization**
D Hong (Seoul, KR, M)

Learning Objectives:

Categories:

**Understanding and improving clinical outcomes after catheter
ablation****Session Number: 3012**Chairpersons: S Ernst (London, GB) (F) - E Fengsrud (Orebro, SE) (M)

- 13:15 Ablation of tachyarrhythmias with zero fluoroscopy technique in patients under 18 years of age. 4-year follow-up**
CA Chavez Gutierrez (Zapopan, MX, M)
- 13:25 Clinical characteristic and zero-fluoroscopy ablation outcomes of tachyarrhythmias in pregnant: a single center study**
A Abdrakhmanov (Astana, KZ, M)
- 13:35 Clinical findings from a large endo-epicardial atrial arrhythmia ablation registry**
K Manoharan (London, GB, M)
- 13:45 Cardioneuroablation for the treatment of carotid sinus syndrome**
JR Gonzalez Juanatey (Santiago De Compostela, ES, M)
- 13:55 Digital health in the EP lab: routine implementation of remote access and technical support for complex ablation procedures**
SS Popescu (Luebeck, DE, M)
- 14:05 Effect of selective renal denervation guided by renal nerve stimulation on atrial remodeling**
D Li (Chongqing, CN, F)

Learning Objectives:

Categories:

Novel metrics to improve outcomes in congenital heart disease

Session Number: 3068

Chairpersons: B Cupido (Cape Town, ZA) (F) - G Di Salvo (Padua, IT) (M)

- 13:15 Invasive testing leads to significantly altered (surgical) management strategy in coronary anomalies with interarterial course: 3 year interim analysis of MuSCAT**
DBH Verheijen (Leiden, NL, M)
- 13:25 Ventriculo-arterial coupling parameters by cardiac magnetic imaging are associated with outcome in patients with a systemic right ventricle**
K Wustmann (Munich, DE, F)
- 13:35 Variability in patient-reported outcomes among different congenital heart defects: a comparative analysis of 7,498 patients from 32 countries**
P Moons (Leuven, BE, M)
- 13:45 The ratios of ultrasound parameters in normal fetal heart-- a multi-center retrospective cross-sectional study**
Y He (Beijing, CN, F)
- 13:55 A new model utilizing an optimal parameter set for prenatal screening of critical congenital heart disease**
X Gu (Beijing, CN, F)
- 14:05 A novel risk score based on exercise capacity to predict all-cause mortality in adults with congenital heart disease**
S Skogby (Umea, SE, F)

Learning Objectives:

Categories:

Risk scores in different populations

Session Number: 3096

Chairpersons: P MORRIS (Mount Pleasant, US) (F) - I Graham (Wicklow, IE) (M)

- 13:15 Association of lifes essential 8 and mortality among adults with and without CVD**
O Kobo (Rakefet, IL, M)
- 13:24 Adding ethnicity to cardiovascular risk prediction: external validation and model updating of SCORE2 using data from the multiethnic HELIUS population cohort**
JAN Van Apeldoorn (- , NL, M)
- 13:33 LE8 score in relation to cardiovascular disease and mortality in individuals with diabetes**
Z Chen (Changsha, CN, F)
- 13:42 Prediction of 10-year risk for recurrent atherosclerotic cardiovascular events in a secondary prevention population: Insights from CHART-2 and Suita studies in the Japanese population**
K Oyama (Sendai, JP, M)
- 13:52 Implications of five different risk models in primary prevention guidelines**
M Sud (Toronto, CA, M)
- 14:01 Polygenic prediction of coronary artery disease among 130,000 Mexican adults**
T Liu (Oxford, GB, F)
- 14:10 SCORE2 Asia-Pacific risk prediction algorithms: revised models to estimate 10-year risk of cardiovascular disease in the Asia-Pacific Region**
S Johar (Bandar Seri Begawan, BN, M)

Learning Objectives:

Categories:

Prognostication in left ventricular hypertrophy: role of cardiac magnetic resonance imaging**Session Number: 3008**Chairpersons: A Meave (Mexico City, MX) (F) - BLM Gerber (Woluwe-St. Lambert, BE) (M)

- 13:15 Incremental prognostic value of late gadolinium enhancement granularity in patients with hypertrophic cardiomyopathy**
J Florence (Clermont-Ferrand, FR, M)
- 13:25 Revisiting risk stratification in hypertrophic cardiomyopathy after the recent guidelines - LGE remains tough to beat**
R Amador (Lisbon, PT, F)
- 13:35 Left atrioventricular coupling index is an independent associate of new-onset AF and stroke in hypertrophic cardiomyopathy: a CMR study**
M De Raffele (Ferrara, IT, F)
- 13:45 CMR-derived pulmonary artery to aorta ratio as a predictor of adverse outcome in patients with cardiac transthyretin amyloidosis**
C Kronberger (Vienna, AT, F)
- 13:55 The prognostic and incremental value of T1 mapping for predicting adverse events in hypertrophic cardiomyopathy**
J Wang (Chengdu, CN, M)
- 14:05 A4300G mitochondrial mutation case series: a rare case of mitochondrial disease or hypertrophic cardiomyopathy?**
A Akhtar (London, GB, M)

Learning Objectives:

Categories:

Heart failure with reduced left ventricular ejection fraction / acute heart failure**Session Number: 3305**Chairpersons: H Arfsten (Vienna, AT) (F) - M Ciuca-Pana (Bucharest, RO) (F)

- 13:15 Heart failure with reduced left ventricular ejection fraction / acute heart failure - get ready for the session**
- 13:20 Using the familiar to diagnose the rare: from electrocardiogram to cardiac storage disease**
MA Van Diepen (Amsterdam, NL, M)
- 13:33 From epigastric pain to heart transplant: navigating DRESS-induced myocarditis**
S Ama (Detroit, US, F)
- 13:46 The Heart of the Matter- Late cardiotoxicity with severe biventricular dysfunction in a young patient with non-Hodgkin Lymphoma treated with R-CHOP**
I Caramihai (Bucharest, RO, F)
- 13:59 Mushroom-induced reversible acute heart failure**
N Hadjigeorgiou (Paphos, CY, F)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals

Categories: Mobile App - Vote, Young Community Track

Myocarditis (1)**Session Number: 3350**Chairpersons: I Grike (Riga, LV) (F) - M Sampaio De Sousa Lira (Sao Paulo, BR) (F)

- 13:15 Eosinophilic myocarditis complicated by early onset prosthetic mitral valve thrombosis in a young patient**
L Stoiber (London, DE, M)
- 13:27 Confronting giant cell myocarditis: a challenging clinical encounter**
R Goswami (Jacksonville, US, M)
- 13:39 Postpartum ventricular arrhythmia with perimyocarditis**
L Bacud (Quezon City, PH, F)
- 13:51 Ventricular tachycardia as first manifestation of systemic sclerosis: acute myocarditis strikes.**
M Palazzini (Dalmine, IT, M)
- 14:03 A patient with non-dilated left ventricle cardiomyopathy (NDLVC) phenotype presenting with recurrent ventricular arrhythmia and myocarditis: the importance of suspicion and genetic testing.**
N S V Nunes (Niteroi, BR, F)

Learning Objectives:

Categories:

Pulmonary hypertension (2)**Session Number: 3365**Chairpersons: J Adler (Koeln, DE) (F) - L Lauder (Homburg, DE) (M)

- 13:15 Role of cardiac magnetic resonance in the management of complex congenital heart diseases**
M Abbate (Naples, IT, F)
- 13:27 Eisenmenger syndrome complicated by the presence of an aneurysm of pulmonary trunk and compression of the left main coronary artery.**
M Blaziak (Wroclaw, PL, M)
- 13:39 Pulmonary arterial hypertension associated with double intracardiac shunt**
E Palacios (Monterey, MX, F)
- 13:51 Pulmonary veno-occlusive disease: getting the timing right for transplantation**
H Nashat (London, GB, F)
- 14:03 Use of riociguat as front-line therapy in a patient with high-risk pulmonary arterial hypertension and right ventricular failure.**
J Gamez Jimenez (Monterey, MX, M)

Learning Objectives:

Categories:

Ask the Trialists from Hot Line 5

Session Number: 1079

Chairpersons: A Petronio (Pisa, IT) (F)

13:35 Ask the Trialist- NOTION-3
J Thomsen Loenborg (Copenhagen, DK, M)

13:43 Ask the Trialist - POPular PAUSE TAVI

13:51 Ask the Trialist - RHEIA
H Eltchaninoff (Rouen Cedex, FR, F)

Learning Objectives:

Categories:

2024 ESC Guidelines for the Management of Atrial Fibrillation

Session Number: 1003

Chairpersons:

IC Van Gelder (Groningen, NL) (F) - D Kotecha (Birmingham, GB) (M)

The dilemma of sudden cardiac death prediction in low-risk populations

Session Number: 825

Chairpersons: J Poole (Seattle, US) (F) - P Lambiase (London, GB) (M)

13:45 State-of-the-art lecture on the dilemma of sudden cardiac death prediction in low-risk populations

L Crotti (Pavia, IT, F)

14:03 Diabetes and sudden cardiac death in a nationwide, unselected population

T Skjelbred (Copenhagen, DK, M)

14:22 A risk score for ventricular arrhythmia in mitral valve prolapse

J Diamond (Chapel Hill, US, M)

14:41 The association between exercise-induced ventricular premature contractions and long-term mortality in patients without coronary artery disease

L Pay (Istanbul, TR, M)

Learning Objectives:

Categories:

Treatment of angina in chronic coronary syndromes: where do we stand?**Session Number: 192**Chairpersons: N Gonzalo Lopez (Madrid, ES) (F) - FJ Neumann (Bad Krozingen, DE) (M)**13:45 How effective are medications for angina?**

P Steg (Paris, FR, M)

14:00 How effective is revascularisation for angina? Lessons learnt from the ORBITA trials

J Tamis-Holland (Cleveland, US, F)

14:15 What is the burden and clinical impact of residual angina?

E Navarese (Sassari, PL, M)

14:30 Therapeutic options beyond medications and revascularisation

TF Luscher (London, GB, M)

14:45 Treatment of angina in chronic coronary syndromes: where do we stand? - discussion

Y Appelman (Amsterdam, NL, F)

Learning Objectives:

Categories: Online Live

The future of personalised medicine in cardiology practice**Session Number: 237**Chairpersons: C Lang (Dundee, GB) (M) - O Manfrini (Bologna, IT) (F)**13:45 Personalised medicine: how we can do this in practice**

EF Magavern (London, GB, F)

14:00 Personalised medicine approaches in cardiomyopathy

FW Asselbergs (Amsterdam, NL, M)

14:15 Personalised medicine in hypertension

A Dominiczak (Glasgow, GB, F)

14:30 Overcoming challenges to deliver of personalised medicine in cardiology

R De Caterina (Pisa, IT, M)

14:45 The future of personalised medicine in cardiology practice - discussion

B Gigante (Stockholm, SE, F)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Spotlight of the Congress, Young Community Track

From evolution to disruption: it is all about understanding the natural course of aortic disease**Session Number: 291**Chairpersons: Gry Dahle (Oslo, NO) (F) - V Aboyans (Limoges, FR) (M)**13:45 It is all about understanding the natural course: new thoughts about aortic disease**

A Haverich (Hannover, DE, M)

14:00 Ascending aortic length: the new key consideration regarding treatment

A Della Corte (Naples, IT, M)

14:15 Initial diameter increase in acute aortic pathology: what is expected and what is pathologic?

A Zientara (Freiburg, DE, F)

14:30 Differences and similarities in acute aortic syndromes between Asian and White patients

J Dumfarth (Innsbruck, AT, F)

14:45 From evolution to disruption: it is all about understanding the natural course of aortic disease - discussion

Learning Objectives:

Categories:

Great Debate: blood pressure thresholds in hypertension - treat the cardiovascular risk, not the number!**Session Number: 215**Chairpersons: F Mahfoud (Homburg, DE) (M) - I Sudano (Zurich, CH) (F)

13:45 **Treat the cardiovascular risk, not the number: pro**
J Mcevoy (Galway, IE, M)

14:05 **Treat the cardiovascular risk, not the number: con**
B Williams (London, GB, M)

14:25 **Treat the cardiovascular risk, not the number - discussion**
E Lonn (Hamilton, CA, F)

K Rahimi (Oxford, GB, M)

Learning Objectives:

Categories: Online Live

Registries, observational, and other studies on lipids

Session Number: 1045

Chairpersons: KK Ray (London, GB) (M)

- 13:45** **LDL-Cholesterol levels and lipid lowering therapy in secondary prevention patients: preliminary data from BRING-UP Prevention Study**
AP Maggioni (Milano, IT, M)
- 14:00** **Suboptimal Lipid Measurement and Statin Use after Percutaneous Coronary Intervention is associated with Increased Mortality: Results of a Real World Registry of 76,264 Patients in NW London**
M Akhtar (London, GB, M)
- 14:15** **Intensive, early and sustained lowering of atherogenic lipoproteins after myocardial infarction and long-term prognosis: a nationwide cohort study of myocardial infarction patients**
J Schubert (Uppsala, SE, F)
- 14:30** **Association of early versus late use of combination lipid-lowering therapy with major cardiovascular outcomes after myocardial infarction: data from the SWEDEHEART registry**
M Leosdottir (Malmo, SE, F)
- 14:45** **A global perspective of Lp(a) levels in patients with coronary heart disease - Implications for risk factor control & future trials from the INTERASPIRE Study**
KK Ray (London, GB, M)
- 15:00** **Optimising oral lipid-lowering therapy regimens in high and very high-risk statin intolerant patients with dyslipidaemia: A French real-world simulation**
F Schiele (Besancon, FR, M)

Learning Objectives:

Categories:

Heart failure with secondary mitral and tricuspid regurgitation**Session Number: 119**Chairpersons: J Grapsa (London, GB) (F) - L Lund (Stockholm, SE) (M)

- 13:45 Pathophysiology of secondary mitral and tricuspid regurgitation**
C Bleakley (London, GB, F)
- 14:00 What should optimal heart failure therapy look like?**
J Bauersachs (Hannover, DE, M)
- 14:15 What is the evidence for TEER in mitral regurgitation?**
S Anker (Berlin, DE, M)
- 14:30 What is the evidence for TEER in tricuspid regurgitation?**
R Hahn (New York, US, F)
- 14:45 Heart failure with secondary mitral and tricuspid regurgitation - discussion**
M Metra (Brescia, IT, M)

Learning Objectives:

Categories:

How to manage a patient with obesity and HFpEF**Session Number: 131**Chairpersons: E Van Craenenbroeck (Edegem, BE) (F) - M Haykowsky (Edmonton, CA) (M)

13:45 HFpEF patient with obesity and exercise intolerance: case presentation
E Tessitore (Geneve, CH, F)

14:03 Exercise intervention in HFpEF patients with obesity
A Rakisheva (Almaty, KZ, F)

14:22 Dietary intervention in HFpEF patients with obesity
M Lee (Glasgow, GB, M)

14:41 Optimal medical therapy in HFpEF patients with obesity
M Piepoli (Piacenza, IT, M)

Learning Objectives:

Categories: Clinical Implementation Track, Obesity Track, Online Live

Mitral valve prolapse: a new look at an old disease**Session Number: 313**Chairpersons: M Enriquez-Sarano (Minneapolis, US) (M) - K Haugaa (Oslo, NO) (F)**13:45 Clinical heterogeneity in mitral valve prolapse: what the cardiologist needs to know**

J Hung (Boston, US, F)

14:00 Multimodality imaging to identify arrhythmogenic mitral valve prolapse

V Delgado (Barcelona, ES, F)

14:15 The genetics of mitral valve prolapse

N Bouatia-Naji (Paris, FR, F)

14:30 Managing mitral valve prolapse in 2024

P Lancellotti (Liege, BE, M)

14:45 Mitral valve prolapse: a new look at an old disease - discussion

R Bonow (Chicago, US, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Online Live, Young Community Track

Great Debate: cardiac computed tomography in primary prevention - too much or just enough?**Session Number: 256**Chairpersons: L Murphy (Dublin 7, IE) (F) - P Maurovich-Horvat (Budapest, HU) (M)

- 13:45 Cardiac computed tomography is essential for my cardiovascular primary prevention practice: pro**
P Parwani (Redlands, US, F)
- 14:00 Cardiac computed tomography is essential for my cardiovascular primary prevention practice: con**
A Reid (Liverpool, GB, F)
- 14:15 Would cardiac computed tomography make me more likely to take a statin? - patient perspective**
A Gesztes (Budapest, HU, M)
- 14:30 Cardiac computed tomography is essential for my cardiovascular primary prevention practice - discussion**
G Pontone (Milan, IT, M)

Learning Objectives:

Categories: Includes a patient perspective, Online Live

Practical seminar for general clinicians

Session Number: 431

Organised in collaboration with the Primary Care Cardiovascular Society (PCCS)

Chairpersons: R Thakkar (High Wycombe, GB) (M) - L Tokgozoglu (Ankara, TR) (F)

- 13:45 How do I get patients to secondary care lipid targets?**
S Nistri (Altavilla Vicentina, IT, M)
- 14:00 How can I use lifestyle medicine to change patient behaviour?**
S Raman (London, GB, F)
- 14:15 How do I manage refractory hypertension?**
M Ferrini (Lyon, FR, M)
- 14:30 How to manage frailty in patients with cardiovascular disease?**
L Guasti (Varese, IT, F)
- 14:45 Practical seminar for general clinicians - discussion**
S Zaidi (Essex, GB, F)

Learning Objectives: This session will provide practical advice on getting patients to secondary care lipid targets; on managing refractory hypertension and frailty in patients with cardiovascular disease; as well as a discussion about the use of lifestyle medicine by clinicians.

Categories: Clinical Implementation Track, General Cardiology for Physicians, Technicians and General Practitioners

The Lancet Cardiology Commissions: advancing cardiac care

Session Number: 418

Joint session with The Lancet

Chairpersons: F Geraldes (London, GB) (F) - R Horton (London, GB) (M)

13:45 The Lancet Cardiology Commissions: advancing cardiac care - introduction

13:50 Update from The Lancet Commission To Reduce the Global Burden of Sudden Cardiac Death
E Marijon (Paris, FR, M)

14:05 Update from The Lancet Women and Cardiovascular Disease Commission
R Mehran (New York, US, F)

14:20 Interim presentation from The Lancet Commission on Atherosclerotic Heart Disease
R Al-Lamee (London, GB, F)

14:45 Announcement of The Lancet Regional Health–Europe Commission on inequalities and disparities in cardiovascular health
R Bugiardini (Bologna, IT, M)

14:50 Announcement of The Lancet Commission on the Cardiovascular Disease Burden in Asia-Pacific
C Lam (Singapore, SG, F)

S Nicholls (Clayton, AU, M)

Learning Objectives: To explore/discuss advances in cardiac care stemming from the unique format of the Lancet Commissions.

Categories:

Environmental impacts on heart health

Session Number: 372

Chairpersons: F Pinto (Lisbon, PT) (M) - D Fitzsimons (Belfast, GB) (F)

- 13:45 The increasing impact of climate change on global health**
P Prabhakaran (New Delhi, IN, F)
- 14:00 Microplastics and nanoplastics in carotid atheroma**
D Grobbee (Utrecht, NL, M)
- 14:15 Climate change as a driver of obesity. Can digital tools help?**
E Placzkiewicz-Jankowska (Krakow, PL, F)
- 14:30 Health data from earth observation satellites: insights from the European Space Agency (ESA)**
S Ferretti (Frascati, IT, M)
- 14:45 Environmental impacts on heart health - discussion**
AF Gomes (Aveiro, PT, F)

Learning Objectives:

Categories: Digital Health

New treatment targets for personalised therapy in genetic cardiomyopathies

Session Number: 344

Chairpersons: PM Elliott (London, GB) (M) - C Basso (Padua, IT) (F)

- 13:45 Myosin activators for cardiomyopathy: all is not lost**
Z Papp (Debrecen, HU, M)
- 14:00 Myosin inhibitors as novel drugs for hypertrophic cardiomyopathy**
J van der Velden (Amsterdam, NL, F)
- 14:15 Targeting desmosomal adhesion to treat arrhythmogenic cardiomyopathy**
C Schinner (Basel, DE, F)
- 14:30 Targeting titin in dilated cardiomyopathy**
W Linke (Muenster, DE, M)
- 14:45 New treatment targets for personalised therapy in genetic cardiomyopathies - discussion**
K Gehmlich (Birmingham, GB, F)

Learning Objectives:

Categories: Spotlight of the Congress

Daily Highlights by the Maltese Cardiac Society

Session Number: 5122

This session is brought to you by the Maltese Cardiac Society and is not part of the official ESC programme

Chairpersons:

Learning Objectives:

Categories: Online Live

Ask the Trialists from Hot Line 4

Session Number: 1080

Chairpersons: V Falk (Berlin, DE) (M) - F Zannad (Paris, FR) (M)

- 14:10

Ask the Trialist - ASSURE DES
J Ahn (- , KR, M)
- 14:18

Ask the Trialist- SWEDEGRAFT
S James (Uppsala, SE, M)
- 14:26

Ask the Trialist- The TIGHT-K trial
B O'Brien (Berlin, DE, M)

Learning Objectives:

Categories:

Deeper phenotyping in heart failure: race- and sex-related differences

Session Number: 3033

Chairpersons: CI Saldarriaga (Medellin, CO) (F) - S Solomon (Boston, US) (M)

- 14:30 Race in heart failure: a pooled participant-level analysis of the global PARADIGM-HF and PARAGON-HF trials**
H Lu (Lausanne, CH, M)
- 14:40 Sex-related differences in health-related quality-of-life measured using the EuroQol 5-Dimension questionnaire across the LVEF spectrum in DAPA-HF and DELIVER**
M Yang (Glasgow, GB, M)
- 14:50 Gender disparities in the association of low dietary protein intake with congestive heart failure: an analysis of the NHANES database 2017-2020**
P Wattanachayakul (Orange, US, M)
- 15:00 Sex-specific association of NT-proBNP with clinically inapparent structural heart disease in the general population: results from the STAAB study**
C Morbach (Wuerzburg, DE, F)
- 15:10 Gender disparity in heart failure: does it matter?**
G Kaur (Hemet, US, F)
- 15:20 Sex-specific clinical outcomes and healthcare resource utilization in the 5 years following hospitalization for heart failure**
T Averbuch (- , CA, M)

Learning Objectives:

Categories:

TAVI in different ages and sizes

Session Number: 3078

Chairpersons: V Paradies (Rotterdam, NL) (F) - MK Kaluzna-Oleksy (Poznan, PL) (F)

- 14:30** **Temporal trends of aortic valve replacement modalities by age group in the united states 2015 - 2023**
M Barghout (Providence, US, M)
- 14:40** **Transcatheter versus surgical aortic valve replacement in patients younger than 65 years: analysis from the national inpatient sample database**
M Ismayl (Rochester, US, M)
- 14:50** **Impact of age on health status after TAVI or SAVR in low risk patients with severe aortic stenosis: results from the PARTNER 3 Trial**
M Brener (New York City, US, M)
- 15:00** **Long-term outcomes after transcatheter aortic valve implantation: derivation and validation of the long-TAVI prediction model**
FA Wenzl (Schlieren, CH, M)
- 15:10** **Meta-analysis of clinical and hemodynamic outcomes between transcatheter and surgical aortic valve replacement in patients with severe aortic stenosis and a small aortic annulus.**
E Moras (New York, US, M)
- 15:20** **Transcatheter aortic valve replacement with balloon-expandable and self-expandable valves in Japanese patients with large annulus: the OCEAN-TAVI registry**
K Onishi (Osaka, JP, M)

Learning Objectives:

Categories:

Novel mechanisms of arrhythmogenic cardiac disease

Session Number: 3125

Chairpersons: C Bezzina (Amsterdam, NL) (F) - L Fabritz (Hamburg, DE) (F)

- 14:30 Serum exosomal long non-coding RNA H19 as a theragnostic target for atrial fibrillation**
JY Kang (Seoul, KR, F)
- 14:40 The CNP analogue vosoritide reduces arrhythmia in diabetic cardiomyopathy via cGMP-dependent PDE2 stimulation on cellular and organ level**
R Firneburg (Dresden, DE, F)
- 14:50 Investigating the role of an orphan nuclear receptor NR4A1 in atrial fibrillation**
CHK Yiu (Oxford, GB, M)
- 15:00 Role of common variants and new genes associated with arrhythmogenic cardiomyopathy**
J barc (Nantes, FR, M)
- 15:10 Characterization of knock-in zebrafish models with a novel SLC4A3 variant identified in a short QT syndrome family**
M Zhu (Osaka, JP, F)
- 15:20 The H222P-Lamin mutation induces heart failure via impaired mitochondrial calcium uptake in human cardiac laminopathy**
J Hulot (Paris, FR, M)

Learning Objectives:

Categories:

Coronary artery disease in kidney patients: from genes to treatment

Session Number: 3103

Chairpersons: S Apostolovic (Beograd, RS) (F) - D Duprez (Minneapolis, US) (M)

- 14:30** **Characterization of individuals with atherosclerotic cardiovascular disease, with and without chronic kidney disease: results from a UK electronic health record database**
N Sattar (Glasgow, GB, M)
- 14:40** **Coronary artery disease screening in renal transplant candidates: insights from a large prospective cohort**
L Giovachini (Paris, FR, M)
- 14:50** **The effect of the combined treatment with dulaglutide and dapagliflozin in arterial elasticity, cardiac function, albuminuria and endothelial thickness in type 2 diabetes mellitus after 12 months**
I Ikonomidis (Chaidari Athens, GR, M)
- 15:00** **Renal hyperfiltration as risk factor of major adverse cardiovascular events in patients with acute myocardial infarction**
W Kim (Seoul, KR, M)
- 15:10** **Mapping renal impairment and cardiac structure and function: observation and genetic insights from 30,000 cardiac magnetic resonance images**
X Lu (Guangzhou, CN, M)
- 15:20** **Much ado about nothing: the impact of coronary angiography on kidney function in individuals with chronic kidney disease**
O Dirir (Sheffield, GB, M)

Learning Objectives:

Categories:

Novel drugs for cardiovascular diseases

Session Number: 3110

Chairpersons: E Osto (Zurich, CH) (F) - R De Silva (London, GB) (M)**14:30 Zibotentan in microvascular angina: a randomized, placebo-controlled, crossover trial**

A Morrow (Glasgow, GB, M)

14:40 Inhibition of ceramide de novo synthesis mitigates atherosclerosis

SY Chong (Singapore, SG, F)

14:50 Experimental evidence on colchicine's mode of action in human carotid artery plaques

I Steenbuck (Freiburg, DE, F)

15:00 The short-term prognosis of salvianolate use during hospitalization in patients with acute myocardial infarction

R Guo (Tianjin, CN, F)

15:10 Safety, tolerability, and basic pharmacokinetic parameters of AUX-001, a once-daily extended release nicorandil in healthy volunteers under fasting and fed conditions

U Tigoer (Saratoga Springs, US, M)

15:20 SHR-1918, a monoclonal antibody against angiopoietin-like 3, in healthy subjects: a randomized, double-blind, placebo-controlled, phase 1 study

C Lv (Shanghai, CN, M)

Learning Objectives:

Categories:

Monogenetic cardiac diseases**Session Number: 3320**Chairpersons: CM van Duijn (Oxford, GB) (F) - D Haroun (Enschede, NL) (M)**14:30 Monogenetic cardiac diseases - get ready for the session**

CM van Duijn (Oxford, GB, F)

14:35 RYR2 gene exon 3 deletion as a cause of convergent polymorphic catecholaminergic ventricular tachycardia and cardiomyopathy characterized by LV systolic dysfunction.

J Segura-Aumente (Jaen, ES, M)

14:52 Fukutin-related protein (FKRP) dilated cardiomyopathy preceding a diagnosis of limb girdle muscular dystrophy

J Tomlinson (Bristol, GB, M)

15:10 A case of disappearing hypertrophic cardiomyopathy in Costello syndrome

E Tham (Edmonton, CA, F)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals

Categories: Mobile App - Vote, Young Community Track

End-stage heart failure and left ventricular assist devices**Session Number: 3344**Chairpersons:

LX van Nunen (Nijmegen, NL) (M) - T Thevathasan (Berlin, DE) (M)

- 14:30 Myocardial recovery necessitating left ventricular assist device explant in peripartum cardiomyopathy – when is the right time to wait ?**
A Sharma (- , US, F)
- 14:42 When LVAD addresses the unmet needs for heart transplantation, a bright future for recovery.**
K Shaker (Sohag, EG, M)
- 14:54 Reverse remodeling in late presenter peripartum cardiomyopathy after 4-months sacubitril/valsartan treatment. Longitudinal strain and myocardial work index analysis**
M Hendiperdana (Bandung, ID, M)
- 15:06 Heartmate 3 left ventricular assistive device acute thrombosis after noncardiac surgery**
M Hidalgo (Makati, PH, F)
- 15:18 ECMO bridging to an emergency heart transplant for a rare cardiomyopathy in a 15-year-old teenage girl: the worst of the worst**
A Ariyachaipanich (Bangkok, TH, M)

Learning Objectives:

Categories:

Challenges in the diagnosis and treatment of athletes**Session Number: 3358**Chairpersons: E Cavarretta (Rome, IT) (F) - A Vaquer Segui (Inca, ES) (F)

- 14:30** **Ventricular arrhythmia in an endurance runner: is it early arrhythmogenic cardiomyopathy or exercise-induced arrhythmogenic cardiomyopathy?**
N Jayaratne (London, GB, F)
- 14:42** **The fall of a marathon runner**
CW Lai (Hong Kong, HK, F)
- 14:54** **Do not cheat at the gym. The importance of medical history in toxic-induced cardiomyopathy**
R Martinez Gonzalez (Madrid, ES, M)
- 15:06** **Multiple roads for a master cyclist.**
O Perez Fernandez (Bogota, CO, M)
- 15:18** **Exercise-induced cardiac troponin I in an individual with progressive coronary artery disease**
I Hove (Stavanger, NO, F)

Learning Objectives:

Categories:

Ask the Trialists from Hot Line 7**Session Number: 1081**Chairpersons: M Cikes (Zagreb, HR) (F) - J Ferreira (Nancy, FR) (M)

14:45 Ask the Trialist - FINEARTS-HF
S Solomon (Boston, US, M)

14:53 Ask the Trialist - MRAs in heart failure
P Jhund (Glasgow, GB, M)

15:01 Ask the Trialist - FINE-HEART
M Vaduganathan (Boston, US, M)

Learning Objectives:

Categories:

The spectrum of cardiomyopathies: genetics to HIV

Session Number: 333 Joint session with the South African Heart Association (SA Heart)

Chairpersons: B Cupido (Cape Town, ZA) (F) - I Olivotto (Firenze, IT) (M)

14:45 Genetic polymorphisms and dilated cardiomyopathy
N Tsabedze (Johannesburg, ZA, M)

15:00 HIV and the heart: detection of subclinical disease by cardiac MRI
PS Robbertse (Cape Town, ZA, M)

15:15 Genetics of arrhythmogenic cardiomyopathies
V Parikh (- , US, F)

15:30 Contemporary treatment of hypertrophic cardiomyopathy
C Ho (Boston, US, F)

Learning Objectives: This session aims to apply the lessons learned in South Africa and Africa to the broader group of patients with myocardial dysfunction.

Categories: Online Live

Outcomes in coronary artery disease

Session Number: 3053

Chairpersons: A McInerney (Beaumont Hospital Cardiology Department, IE) (F) - M Milojevic (Rotterdam, NL) (M)

15:45 Correlation between short-term quality of life improvement and clinical outcomes - a post-hoc ISCHEMIA trial analysis

T Caldonazo (Jena, DE, M)

15:55 One-year results from the REDUCER-I multi-center real-world clinical trial of the treatment of refractory angina with the coronary sinus Reducer

S Verheye (Antwerp, BE, M)

16:05 Outcomes by race and ethnicity in patients undergoing percutaneous coronary intervention of chronic total occlusion

M Petrovic (Belgrade, RS, F)

16:15 Prognostic impact of the presence and absence of angina on mortality and cardiovascular outcomes in the ISCHEMIA trial

A Singh (Los Angeles, US, F)

16:25 Multi-modality deep learning model for prediction of chronic obstructive coronary artery disease

R Trivedi (Los Angeles, US, M)

16:35 Relationship between coronary artery calcium score and plaque vulnerability in patients with established coronary artery disease

D Fujimoto (Brookline, US, M)

Learning Objectives:

Categories:

Collateral damage in heart failure: comorbidities and their treatment

Session Number: 3028

Chairpersons: A Rakisheva (Almaty, KZ) (F) - E Jankowska (Wroclaw, PL) (F)

- 15:45** **Prevalent and incident anemia in PARAGON-HF**
H Lu (Lausanne, CH, M)
- 15:55** **Ferric derisomaltose versus usual care in patients with heart failure, reduced ejection fraction, and iron deficiency: a short-term UK cost-utility analysis based on the IRONMAN RCT**
RF Pollock (Harpenden, GB, M)
- 16:05** **Impact of various iron deficiency definitions on mortality risk in chronic heart failure across the spectrum of left ventricular ejection fraction spectrum.**
A Mohamed (Gentofte, DK, M)
- 16:15** **Predictors of worsening kidney function and their relation to SGLT2 inhibitor dapagliflozin administration in type 2 diabetes mellitus patients with chronic heart failure**
AE Berezin (Salzburg, AT, M)
- 16:25** **Non-linear causal effects of kidney function on the risk of heart failure: a Mendelian randomization study**
Jin Liu (Guang Zhou, CN, M)
- 16:35** **Development and validation of a risk prediction model for worsening renal function in patients with incident heart failure**
C Lang (Dundee, GB, M)

Learning Objectives:

Categories:

The 50 shades of TAVI

Session Number: 3057

Chairpersons: M Urena (Paris, FR) (F) - D Pedicino (Roma, IT) (F)

- 15:45** **Prevalence of multiple native valvular heart disease in TAVR patients: a multicenter study assessing the impact of staged transcatheter edge-to-edge repair**
B Al-Kassou (Bonn, DE, M)
- 15:55** **Transcatheter valve replacement as rescue treatment for heart failure in infective endocarditis. A multinational series.**
N Fernandez Hidalgo (Barcelona, ES, F)
- 16:05** **Survival penalty in patients undergoing transcatheter versus surgical aortic valve replacement: is it just a question of frailty? Insights from a large cohort with demographic matching**
M Boute (Brussels, BE, M)
- 16:15** **Two different hybrid vascular access closure strategies post transcatheter aortic valve implantation**
MS Abdelaziz (Bad Segeberg, DE, M)
- 16:25** **Outcomes of percutaneous coronary interventions after transcatheter aortic valve replacement**
CA Pivato (Milano, IT, M)
- 16:35** **Independent association between radial secondary access and stroke in patients undergoing transcatheter aortic valve implantation**
M Potratz (Bad Oeynhausen, DE, M)

Learning Objectives:

Categories:

Updates on cardiac rehabilitation

Session Number: 3107

Chairpersons: G Lee (Cork, IE) (F) - J Hendriks (Sittard, NL) (M)

- 15:45** **Exercise intolerance at hospital discharge as a predictor for readmission and mortality after aortic aneurysm repair**
M Shibuya (Sagamihara, JP, F)
- 15:57** **Impact of inpatient cardiac rehabilitation on hospital-associated disability for older patients undergoing transcatheter aortic valve implantation: insight from the JROAD/JROAD-DPC database**
S Katano (Sapporo, JP, F)
- 16:09** **Assessing the use of activity trackers in clinical practice: a survey of cardiac rehabilitation clinicians from Australia, Brazil, and Canada**
T Pettersen (Kleppesto, NO, M)
- 16:21** **Differences in symptoms of anxiety and depression among out-of-hospital cardiac arrest survivors and their relatives, paired results from the DANCAS survey**
D Bekker-Jensen (Odense, DK, F)
- 16:33** **Associations between cardiac rehabilitation and clinical outcomes in patients with heart failure and cognitive frailty**
K Nozaki (Sagamihara, JP, M)

Learning Objectives:

Categories:

Ischaemia and inflammation: the role of cardiac PET in diagnosis and prognosis**Session Number: 3004**Chairpersons: D Neglia (Pisa, IT) (M) - M Al Mallah (Pearland, US) (M)

- 15:45 Improvement of myocardial lipolysis in iodine-123-beta-methyl-P-iodophenyl-pentadecanoic acid scintigraphy in patients with idiopathic triglyceride deposit cardiomyovascuopathy treated with Tricaprin**
H MIYAUCHI (Chiba, JP, M)
- 15:55 Perfusion metabolism mismatch predicts short-term complications in Takotsubo syndrome**
T Sato (Tokyo, JP, M)
- 16:05 Residual post-infarct myocardial inflammation detected by 68Ga-DOTATATE PET/MRI predicts long-term adverse cardiac remodelling**
A Corovic (Cambridge, GB, M)
- 16:15 Evaluation of 18F FOL a PET tracer targeting folate receptor beta in a rat model of myocardial infarction**
I Iqbal (Turku, FI, M)
- 16:25 Sex differences in coronary atherosclerotic plaque activity using 18F-sodium fluoride positron emission tomography**
J Kwiecinski (Wejherowo, PL, M)
- 16:35 Identification of ischemia with no obstructive coronary arteries using 13N-ammonia positron emission tomography-derived myocardial strain ratio**
A Sakai (Tokyo, JP, F)

Learning Objectives:

Categories:

Pulmonary embolism**Session Number: 3318**Chairpersons: A Garcia-Alvarez (Barcelona, ES) (F) - M Pazdernik (Praha, CZ) (M)**15:45 Pulmonary embolism - get ready for the session**

M Pazdernik (Praha, CZ, M)

15:50 The timely implementation of catheter-based thrombectomy and VA-ECMO in high-risk pulmonary embolism

W Wangpermpoon (Bangkok, TH, M)

16:03 Isolated tricuspid valve Libman-Sacks endocarditis in acute pulmonary embolism

I Vranic (Belgrade, RS, F)

16:16 Cardiovascular conundrums in massive pulmonary embolism

MH Ohn (London, MM, F)

16:29 Beyond the clots: charting a new course with thromboaspiration in complex pulmonary embolism management

V Myftari (Rome, IT, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals

Categories: Mobile App - Vote, Young Community Track

Stroke and hypertension**Session Number: 3343**Chairpersons: T Stegmann (Leipzig, DE) (F) - D Terentes-Printzios (Athens, GR) (M)

- 15:45 Unraveling the complexity: exploring multifactorial causes of stroke in a single patient**
M Manzur Barbur (Bogota, CO, F)
- 15:57 An unusual cause of hypertension-Nutcracker syndrome**
M Ivascu (Brasov, RO, F)
- 16:09 Concurrent myocardial infarction and ischemic stroke: an unexpected source of embolism**
AM Mihail (Bucharest, RO, F)
- 16:21 ALCAPA in young adult after an ischemic stroke**
M Voitsekhivska (- , UA, F)
- 16:33 A rare case of ischemic stroke and pulmonary embolism in a young patient**
T Georgopoulou (Athens, GR, F)

Learning Objectives:

Categories:

Cardio-oncology (3)

Session Number: 3383

Chairpersons:

M Hemmat Gaber (Alexandria, EG) (F) - M Falter (Hasselt, BE) (M)

- 15:45** **Early isolated myopericarditis induced by all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia**
E Galli (Rennes, FR, F)
- 15:57** **A Hodgkin's lymphoma presenting with left ventricular dilation and systolic dysfunction**
A Piermartiri (Bologna, IT, M)
- 16:09** **An exceptionally rare cause of pyrexia and polyarthralgia.**
W Camilleri (Sliema, MT, M)
- 16:21** **Beyond the headache - a rare case of multifocal cardioembolic stroke and atrial myxoma**
I Iancu (Salford, GB, F)
- 16:33** **Multidisciplinary approach in cardio-oncology: putting words into action**
A Pons Riverola (Barcelona, ES, F)

Learning Objectives:

Categories:

Session Number: 5125	Daily Highlights by the Moroccan Society of Cardiology
<u>Chairpersons:</u>	This session is brought to you by the Moroccan Society of Cardiology and is not part of the official ESC programme

Learning Objectives:

Categories: Online Live

HOT LINE 8

Session Number: 1017

Chairpersons: R Mehran (New York, US) (F) - RA Byrne (Dublin, IE) (M)

- 16:15 SENIOR RITA - Older patients with non-ST segment elevation myocardial infarction randomised interventional treatment trial**
V Kunadian (Newcastle Upon Tyne, GB, F)
- 16:27 Discussant review - SENIOR RITA**
Sim Biscaglia (Cona, Ferrara, IT, M)
- 16:32 Panel discussion - SENIOR RITA**
- 16:37 EARTH-STEMI - Complete vs. culprit-only revascularization in older STEMI patients**
G Campo (Cona, IT, M)
- 16:49 Discussant review - EARTH-STEMI**
R Schnabel (Hamburg, DE, F)
- 16:54 Panel discussion - EARTH-STEMI**
- 16:59 SCOFF - Fasting or no fasting before cardiac catheterisation procedures**
D Ferreira (Wantirna, AU, M)
- 17:11 Discussant review - SCOFF**
A Kini (New York, US, F)
- 17:16 Panel discussion - SCOFF**

Learning Objectives:

Categories: Online Live

A practical guide to personalised treatment of non-cardiac syncope**Session Number: 177**Chairpersons: P Kulakowski (Warsaw, PL) (M) - S Ernst (London, GB) (F)

- 16:15 An algorithm to identify the mechanism of non-cardiac syncope**
M Brignole (Milan, IT, M)
- 16:30 The patient with hypotensive phenotype: 'de-prescription' and blood pressure raising drugs**
G Rivasi (Florence, IT, F)
- 16:45 The patient with bradycardic phenotype: pacing and cardioneuroablation**
J Joza (Montreal, CA, F)
- 17:00 A practical guide to personalised treatment of non-cardiac syncope - discussion**
A Fedorowski (Stockholm, SE, M)

Learning Objectives:

Categories: Online Live, Spotlight of the Congress

The heart restarts: what's next after cardiac arrest?

Session Number: 203

Joint session with the European Resuscitation Council (ERC)

Chairpersons: N Nikolaou (Athens, GR) (M) - A Sambola (Barcelona, ES) (F)

16:15 Brain protection after cardiac arrest
C Sandroni (Roma, IT, M)

16:30 Sedation, analgesia, and seizure control after cardiac arrest
C Malta Hansen (Copenhagen, DK, F)

16:45 Invasive and non-invasive cardiac management after cardiac arrest
T Patterson (London, GB, F)

17:00 Pulmonary management after cardiac arrest
M Skrifvars (Helsinki, FI, M)

Learning Objectives: This session will discuss the reason why optimising haemodynamic support, oxygenation, ventilation, and suppression of ictal activity have not met with the expected benefit for patients after cardiac arrest, as well as looking into the future of these interventions in post-resuscitation care.

Categories:

Managing hypertension through lifestyle modifications: an important consideration

Session Number: 223

Joint session with the International Society of Hypertension (ISH)

Chairpersons:

B Williams (London, GB) (M) - RM Bruno (Paris, FR) (F)

16:15 Lifestyle management of hypertension: eat

M Tadic (Ulm, DE, F)

16:30 Lifestyle management of hypertension: drink

M Tomaszewski (Manchester, GB, M)

16:45 Lifestyle management of hypertension: move

H Hanssen (Basel, CH, M)

17:00 Lifestyle management of hypertension: chill, sleep, and be mindful

F Charchar (Ballarat, AU, M)

Learning Objectives: This session will provide an update on lifestyle management for hypertension in line with the recent position paper of the International Society of Hypertension, covering both established and new directions in non-drug management and prevention of high blood pressure - from reduction in sodium intake to meditation and yoga; will put particular emphasis on a holistic approach to management of hypertension, providing a unique international perspective on differences between regions/countries and offering guidance on implementation.

Categories: Online Live

Surgery or re-intervention: tips and tricks**Session Number: 289**Chairpersons: Gry Dahle (Oslo, NO) (F) - J Granada (Orangeburg, US) (M)

16:15 TAVI has failed: TAVI explant or valve-in-valve
H Eltchaninoff (Rouen Cedex, FR, F)

16:35 Transcatheter edge-to-edge repair (TEER) is failing in the mitral: re-intervention or surgical rescue
R Kornowski (Petach-Tikva, IL, M)

16:55 Transcatheter edge-to-edge repair (TEER) is failing in the tricuspid: re-intervention or surgical rescue
H Treede (Mainz, DE, M)

Learning Objectives:

Categories: Clinical Implementation Track

2024 ESC Guidelines for the Management of Atrial Fibrillation: Ask the Guidelines Task Force

Session Number: 1103

Smaller trials: cardiac function and remodelling

Session Number: 1046

Chairpersons: K Sliwa (Cape Town, ZA) (F) - S Petersen (London, GB) (M)

- 16:15 Strain sUrveillance during Chemotherapy for improving Cardiovascular Outcomes: Results of a Randomized Trial of Cardioprotection for Reduced Myocardial Strain (SUCCOUR-MRI)**
T Marwick (Melbourne, AU, M)
- 16:27 Catheter Ablation versus Medical Rate Control in Atrial Fibrillation with Left Ventricular Systolic Dysfunction and Myocardial Fibrosis - The CAMERA-MRI II Randomized Trial**
S Prabhu (Melbourne, AU, M)
- 16:39 Sacubitril/valsartan compared to valsartan in regressing myocardial fibrosis in stage B heart failure: the REVERSE-LVH Trial**
C Chin (Singapore, SG, M)
- 16:51 Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction**
J Carberry (Glasgow, GB, F)
- 17:03 Sacubitril/valsartan in primary prevention of cancer-therapy related cardiac dysfunction in breast cancer patients.**
Y Hsu (Tainan, TW, F)

Learning Objectives:

Categories:

Interventions for arrhythmia through the heart failure lens**Session Number: 104**Chairpersons: JGF Cleland (Glasgow, GB) (M) - M Cikes (Zagreb, HR) (F)**16:15 Medical anti-arrhythmic strategies in patients with heart failure**

P Van Der Meer (Groningen, NL, M)

16:30 Atrial fibrillation ablation in heart failure: where are we?

C Linde (Stockholm, SE, F)

16:45 Ablation of ventricular tachycardias in heart failure: is there enough evidence?

F Ruschitzka (Zurich, CH, M)

17:00 Interventions for arrhythmia through the heart failure lens - discussion

LW Stevenson (Nashville, US, F)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Young Community Track

Guidelines in Practice: cardio-renal protection in patients with diabetes

Session Number: 158

Chairpersons: R Ajjan (Leeds, GB) (M) - B Rocca (Rome, IT) (F)

16:15 Patient with diabetes, heart failure with reduced ejection fraction, and impaired kidney function: case presentation

A Kautzky-Willer (Vienna, AT, F)

16:30 Patient with diabetes, heart failure with reduced ejection fraction, and impaired kidney function: what do the guidelines say?

D McGuire (Dallas, US, M)

16:45 Patient with diabetes, heart failure with reduced ejection fraction, and impaired kidney function: how to implement the guidelines and take-home messages

N Marx (Aachen, DE, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Clinical Implementation Track, Young Community Track

Personalising cardiovascular care in congenital heart disease

Session Number: 326

**Joint session with the Association for European Paediatric and
Congenital Cardiology (AEPC)**

Chairpersons: JS Dua (Altrincham, GB) (M) - MHS El Sayed (Cairo, EG) (F)

16:15 Personalised approach to resynchronisation therapy in congenital heart disease

J Janousek (Prague, CZ, M)

16:30 The use of biomarkers to personalise treatment in congenital heart disease

L Coats (Newcastle-Upon-Tyne, GB, F)

16:45 Genetics in congenital heart disease: are we ready?

J De Backer (Ghent, BE, F)

17:00 Advanced imaging to personalise intervention in congenital heart disease

S Babu-Narayan (London, GB, F)

Learning Objectives: This session will discuss whether biomarkers for heart failure can be used to evaluate the effectiveness of personalised medicine and will look into which congenital heart defects might benefit from resynchronisation and how it should be implemented.

Categories: Spotlight of the Congress

Imaging in cardiomyopathies: my most challenging case!

Session Number: 251

Chairpersons: A Timoteo (Lisboa, PT) (F) - P Parwani (Redlands, US) (F)

16:15 Imaging in hypertrophic cardiomyopathy
J Moon (London, GB, M)

16:35 Imaging in dilated cardiomyopathy
E Galli (Rennes, FR, F)

16:55 Imaging in restrictive cardiomyopathy
C Van De Heyning (Antwerpen, BE, F)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Online Live, Young Community Track

ESC Clinical Practice Guidelines 2022 and 2023 for General Practice and General Cardiology: where do we stand?

Organised in collaboration with the Primary Care Cardiovascular Society (PCCS)

Session Number: 433

Chairpersons: B Bostock (Hereford, GB) (F) - K Toutouzas (Athens, GR) (M)

16:15 2022 ESC Guidelines on Cardio-Oncology: case presentation

T Lopez Fernandez (Madrid, ES, F)

16:27 2022 ESC Guidelines on Cardio-Oncology: what do the guidelines say and how to implement the guidelines?

R Asteggiano (Turin, IT, M)

16:45 2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes: case presentation

F Dievart (Dunkerque, FR, M)

16:57 2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes: what do the guidelines say and how to implement the guidelines?

R Christodorescu (Timisoara, RO, F)

Learning Objectives: This session will review for general clinicians the ESC Guidelines on Cardio-Oncology and Management of Cardiovascular Disease in Patients with Diabetes.

Categories: General Cardiology for Physicians, Technicians and General Practitioners, Online Live

Nature Medicine: 2024 highlights in personalised cardiovascular medicine

Session Number: 419

Joint session with Nature Medicine

Chairpersons: L Tokgozoglu (Ankara, TR) (F) - M Basson (, US) (M)

- 16:15 Development and validation of a new algorithm for improved cardiovascular risk prediction**
J Hippisley-Cox (Oxford, GB, F)
- 16:30 An evidence-based screening tool for heart failure with preserved ejection fraction: the HFpEF-ABA score**
Y Reddy (Rochester, US, M)
- 16:45 Proteomic analysis of cardiorespiratory fitness for prediction of mortality and multi-system disease risks**
A Perry (- , US, M)
- 17:00 Artificial intelligence-enabled electrocardiography alert intervention and all-cause mortality: a pragmatic randomised clinical trial**
CL Lin (Taipei, TW, M)

Learning Objectives:

Categories: Spotlight of the Congress

Great Debate: the pros and cons of artificial intelligence in cardiology

Session Number: 375

Chairpersons: N Bruining (Rotterdam, NL) (M) - MC Williams (Edinburgh, GB) (F)

- 16:15 Artificial intelligence is important in cardiology: pro
J Singh (Boston, US, M)
- 16:30 Artificial intelligence is important in cardiology: con
A Bhatt (Boston, US, F)
- 16:45 Artificial intelligence is important in cardiology - discussion
FE Rademakers (Leuven, BE, M)

Learning Objectives:

Categories: Digital Health

Special Event	Sunday, 1 September 2024	16:15 - 17:15	Helsinki - Lecture room
---------------	--------------------------	---------------	-------------------------

Awards ceremony

Session Number: 5001

Chairpersons: JJV McMurray (Glasgow, GB) (M)

Learning Objectives:

Categories:

The molecular hallmarks of cardiovascular health**Session Number: 353**Chairpersons: C Emanuelli (London, GB) (F) - L Kirshenbaum (Winnipeg, CA) (M)

16:15 The protective power of exercise on cardiovascular health
C Lerchenmueller (Zurich, CH, F)

16:30 Metabolic control of cardiovascular health
S Bibli (- , DE, F)

16:45 Organelle quality control in cardiac health
J Sadoshima (Newark, US, M)

17:00 The molecular hallmarks of cardiovascular health - discussion
J Wagner (Frankfurt Am Main, DE, M)

Learning Objectives:

Categories:

**Case-based implementation of the 2023 ESC Guidelines for the
Management of Endocarditis: insights from Egypt and Georgia**
**Organised in collaboration with the Egyptian Society of Cardiology
and the Georgian Society of Cardiology**

Session Number: 5111

Chairpersons: NF Farag (Cairo, EG) (M) - A Chukhrukidze (Tbilisi, GE) (M)

- 17:00 Case 1 - intervention in endocarditis, guidelines and beyond: the Egyptian perspective**
MSM Meshael (Cairo, EG, F)
- 17:10 Intervention in endocarditis, guidelines and beyond: the Egyptian perspective - discussion of guideline implementation**
SM Shaheen (Cairo, EG, M)
- 17:22 Case 2 - frontiers of infective endocarditis in Georgia**
R Agladze (Tbilisi, GE, F)
- 17:32 Frontiers of infective endocarditis in Georgia - discussion of guideline implementation**
ZK Kereselidze (Tbilisi, GE, M)

Learning Objectives: To have cardiologists from different countries share their experiences about how to:

- identify signs and symptoms that may indicate presence of infective endocarditis (IE);
- evaluate patients for causative pathogens based on risk factors associated with IE;
- assess a patient for IE based on clinical presentation and diagnostic testing; and
- design treatment plans for patients with IE.

Categories: Online Live

Advances in amyloidosis

Session Number: 3031

Chairpersons: K Klingel (Tuebingen, DE) (F) - M Merlo (Trieste, IT) (M)

- 17:00 Patient journey from the appearance of red flags to the diagnosis of transthyretin cardiac amyloidosis (ATTR-CM) in Japan: a nationwide retrospective study using a medical claims database**
H Abe (- , JP, M)
- 17:12 Long-term all-cause and cardiovascular-related mortality in patients with ATTR-CM treated with continuous tafamidis vs placebo to tafamidis by NAC stage at baseline**
M Fontana (London, GB, F)
- 17:24 Tafamidis for the treatment of transthyretin cardiac amyloidosis (ATTR-CM) - Real-world data from a tertiary center.**
R Carvalho (Lisbon, PT, F)
- 17:36 Long-term effects of patisiran on survival and cardiac parameters in patients with transthyretin-mediated cardiac amyloidosis: post hoc analysis of APOLLO-B and cardiac subpopulation of APOLLO OLE**
O Lairez (Toulouse, FR, M)
- 17:48 Long-term safety and efficacy of antibody ALXN2220 for depletion of cardiac amyloid transthyretin: results of treatment beyond 12 months in the open-label extension of study NI006-101**
P Van Der Meer (Groningen, NL, M)

Learning Objectives:

Categories:

Decision-making for revascularisation of multivessel disease

Session Number: 3074

Chairpersons: J Mehilli (Landshut, DE) (F) - K Al-Shaibi (Jeddah, SA) (M)

- 17:00 Clinical outcome based on functional complete revascularization in patients with three-vessel coronary artery disease: The FAME 3 Trial**
H Otsuki (- , JP, M)
- 17:10 Performance and safety of complex percutaneous coronary intervention in centres without on-site cardiac surgery: a multi-centre australian registry study.**
N Dayawansa (Melbourne, AU, M)
- 17:20 Percutaneous coronary intervention versus coronary arterial bypass grafting in patients with left main coronary artery disease and chronic kidney disease: a systematic review and meta-analysis**
I Gialamas (Athens, GR, M)
- 17:30 Impact of preoperative quantitative flow ratio on long term coronary artery bypass grafts patency**
J Andreka (Pomaz, HU, F)
- 17:40 Ten-year comparative long-term outcomes of PCI versus CABG in multi-vessel coronary artery disease**
- 17:50 Comparison of ridaforolimus-eluting and zotarolimus-eluting coronary stents: 5-Year outcomes from the BIONICS and NIREUS trials**
L Zornitzki (Tel Aviv, IL, M)

Learning Objectives:

Categories:

Cardiovascular treatment: protecting the brain and the limbs

Session Number: 3079

Chairpersons: M Bahit (Rosario, AR) (F) - M Bonaca (Aurora, US) (M)

- 17:00** **Remnant cholesterol, not LDL cholesterol, explains peripheral artery disease risk conferred by apolipoprotein B: a cohort study**
B Nilsson Wadstrom (Copenhagen, DK, M)
- 17:12** **The evolution of carotid atherosclerotic plaque composition: a prospective study**
L Zuo (Rotterdam, NL, M)
- 17:24** **Extracranial systemic embolic events in patients with atrial fibrillation: an individual patient-level meta-analysis of 71 683 patients randomized to NOAC vs warfarin from the COMBINE-AF study**
S Al Said (Boston, US, M)
- 17:36** **The influence of concomitant antiplatelet therapy in venous thromboembolism patients treated with anticoagulants in the DOAC era: insight from the COMMAND VTE Registry-2**
K Kaneda (Kyoto, JP, M)
- 17:48** **Drug-eluting devices versus angioplasty in infrapopliteal artery disease:an updated systematic review and meta-analysis**
E Katsuyama (Sao Paulo, BR, M)

Learning Objectives:

Categories:

Caring for the elderly in cardiology: special clinical aspects

Session Number: 3100

Chairpersons: J Niebauer (Salzburg, AT) (M) - A Salzwedel (Potsdam, DE) (F)

- 17:00** **Usefulness of preoperative NT-proBNP for prediction of acute heart failure, perioperative myocardial infarction/injury and mortality after non-cardiac surgery**
D Gualandro (Basel, CH, F)
- 17:12** **Subclinical myocardial fibrosis is almost ubiquitous in the hearts of older British persons: 'MyoFit46' cardiovascular sub-study of the NSHD**
M Webber (London, GB, M)
- 17:24** **Delirium and risk of incident cardiovascular events in elderly: data from a global health research network**
M Proietti (Milan, IT, M)
- 17:36** **Insights into cardiac amyloidosis screening in TAVI from a Greek/Cypriot Cohort: the GRECA-TAVI registry**
- 17:48** **Characteristics associated with prevalent atrial fibrillation and risk profile for future atrial fibrillation among those in sinus rhythm in an elderly population in the ELSA Brasil Study**
E Pianca (Porto Alegre, BR, M)

Learning Objectives:

Categories:

Disparities: insights into socioeconomic factors and cardiovascular health**Session Number: 3119**Chairpersons: JJ Orchard (Sydney, AU) (F) - H Naci (London, GB) (M)

- 17:00** **Area-level socioeconomic inequalities in mortality in China: a nationwide cohort study based on the ChinaHEART project**
W Peng (Beijing, CN, F)
- 17:10** **Cost differences between oral anticoagulation therapies in atrial fibrillation patients**
O Lehtonen (Kuopio, FI, M)
- 17:20** **Embedding a text message recall system to increase the uptake of cardiovascular screening in Australian general practice. Results of the Text to Detect randomised controlled trial**
N Raffoul (Sydney, AU, F)
- 17:30** **Independent associations of educational attainment and its joint associations with LE8 score for risk of cardiovascular disease incidence and mortality among Chinese people**
Z Chen (Changsha, CN, F)
- 17:40** **Disparities by region, age, and sex in cardiovascular disease burden attributable to high fasting plasma glucose in China, 2010-2018: a nationwide, population-based study.**
X Cao (Beijing, CN, F)
- 17:50** **Cost-effectiveness of semaglutide for secondary prevention of cardiovascular disease in the United States**
S Hennessy (San Francisco, US, F)

Learning Objectives:

Categories:

Transcatheter aortic valve interventions**Session Number: 3304**Chairpersons: BCQ Caneiro-Queija (Vigo, ES) (F) - N Majunke (Leipzig, DE) (M)**17:00 Transcatheter aortic valve interventions - get ready for the session**

17:05 Sutures or not, it can be fixed... Greece's first-ever valve in valve TAVI of a supra-annular transcatheter valve replacing a sutureless, bioprosthetic surgical one in aortic position
F Toulgaridis (Athens, GR, M)

17:18 Urgent transcatheter aortic valve implantation (TAVI) in the context of cardiogenic shock complicated by cardiac arrest due to critically severe aortic stenosis
H Alghamdi (Riyadh, SA, M)

17:32 Valve-in-valve transcatheter aortic valve replacement in a patient with severe left ventricular systolic dysfunction in previous Bentall procedure
S Janorkar (Pune, IN, M)

17:35 Aorto-right ventricular fistula after Transcatheter Aortic Valve Implantation (TAVI)
JH Lee (Wonju, KR, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals

Categories: Mobile App - Vote, Young Community Track

More to learn in cardiomyopathies

Session Number: 3356

Chairpersons: G Vinco (Verona, IT) (F) - SF Stampfli (Lucerne, CH) (M)

- 17:00** **Challenging diagnosis of an incidental echocardiographic finding in an asymptomatic patient**
B A Nita (Bucharest, RO, F)
- 17:15** **Orthostatic syncope in an elderly patient with restrictive pathophysiology and orthostatic mid-cavity obliteration.**
L Ordine (Napoli, IT, M)
- 17:30** **Heartbreak and healing : a tale of pity partner**
K Pakpian (Bangkok, TH, M)
- 17:45** **Dynamic left ventricular outflow tract obstruction in wild-type transthyretin cardiac amyloidosis**
N Kubinova (Praha, CZ, U)

Learning Objectives:

Categories:

Unusual cases of conduction deficits

Session Number: 3378

Chairpersons: I Zeljkovic (Zagreb, HR) (M) - D Duncker (Hannover, DE) (M)

- 17:00 Posture is everything: postural heart block in the setting of esophageal mass**
G Hagan (Rochester, US, F)
- 17:12 Takotsubo syndrome as a rare cause of complete heart block, more significant than the benign broken-heart syndrome we once thought?**
H Procter (Leeds, GB, M)
- 17:24 Unveiling the impact of atrio-ventricular block: exertional dyspnea in the elderly**
T Donisan (Rochester, US, F)
- 17:36 Paradoxical effect of isoprenaline in patient with paroxysmal atrio-ventricular block**
L Salerno (Rome, IT, M)
- 17:48 Intriguing syncope: insights from the intersection of cardiovascular pathology and neuro-oncology**
I Martins Moreira (Vila Real, PT, F)

Learning Objectives:

Categories:

Ask the Trialists from Hot Line 6

Session Number: 1087

Chairpersons: CB Granger (Durham, US) (M) - E Hylek (Boston, US) (F) - M Valgimigli (Lugano, CH) (M)

17:20 Ask the Trialist - STEER-AF

17:30 Ask the Triaist - OCEANIC-AF
M Patel (Durham, US, M)

17:40 Ask the Trialist - EPIC-CAD
DW Park (Seoul, KR, M)

GB Nam (Seoul, KR, M)

Learning Objectives:

Categories:

Guidelines in Practice: 2024 ESC Guidelines for the Management of Atrial Fibrillation

Session Number: 1203

Guidelines in Practice: a patient with recent non-ST elevation myocardial infarction and percutaneous coronary intervention requiring cancer surgery

Session Number: 198

Chairpersons: E Barbato (Roma, IT) (M) - M Morice (Massy, FR) (F)

- 17:30 A patient with recent non-ST elevation myocardial infarction and percutaneous coronary intervention requiring cancer surgery: case presentation**
D Angiolillo (Jacksonville, US, M)
- 17:45 A patient with recent non-ST elevation myocardial infarction and percutaneous coronary intervention requiring cancer surgery: what do the guidelines say?**
V Kunadian (Newcastle Upon Tyne, GB, F)
- 18:00 A patient with recent non-ST elevation myocardial infarction and percutaneous coronary intervention requiring cancer surgery: how to implement the guidelines and take-home messages**
S Halvorsen (Oslo, NO, F)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Clinical Implementation Track, Online Live, Young Community Track

Anti-inflammatory drugs in cardiovascular disease: current and novel approaches

Session Number: 231

Chairpersons: P Ridker (Boston, US) (M) - C Christersson (Uppsala, SE) (F)

17:30 Anti-inflammatory treatment for recurrent pericarditis
M Imazio (Udine, IT, M)

17:50 Anti-inflammatory treatment for coronary artery disease
F Roubille (Montpellier, FR, M)

18:10 Anti-inflammatory treatment for myocarditis
B Heidecker (Berlin, DE, F)

Learning Objectives:

Categories: Online Live

Intracoronary imaging and physiology in 2024: 'eyes wide open'**Session Number: 281**Chairpersons: M Alasnag (Jeddah, SA) (F) - A Kirtane (Demarest, US) (M)

17:30 Intracoronary physiology in the cath lab: state of the art - IFR, FFR, and QFR
J Escaned (Madrid, ES, M)

17:50 Evaluation of microvascular disease in the cath lab: the toolbox
J Tremmel (Stanford, US, F)

18:10 Intravascular imaging to optimise PCI, IVUS, OCT, and more...
DW Park (Seoul, KR, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Clinical Implementation Track, Young Community Track

Great Debate: 'fire and forget' beats personalised lipid-lowering treatment**Session Number: 139**Chairpersons: L Tokgozoglul (Ankara, TR) (F) - KC Koskinas (Bern, CH) (M)**17:30 'Fire and forget' beats personalised lipid-lowering treatment: pro**
KK Ray (London, GB, M)**17:45 'Fire and forget' beats personalised lipid-lowering treatment: con**
E Gianos (New York, US, F)**18:00 'Fire and forget' beats personalised lipid-lowering treatment - discussion**
A Zirlik (Graz, AT, M)**Learning Objectives:** This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.**Categories:** Online Live, Spotlight of the Congress, Young Community Track

Smaller trials, trial updates, and other studies on coronary artery disease and coronary revascularisation

Session Number: 1047

Chairpersons: T Rudolph (Bad Oeynhausen, DE) (F)

- 17:30 Assessment of the microvascular resistance reserve for predicting the effect of revascularization in patients with moderate coronary stenoses.**
LD Rasmussen (Aalborg, DK, M)
- 17:45 Long-term effect of biodegradable versus durable polymer drug-eluting stents on neoatherosclerosis among STEMI patients: the international CONNECT randomized controlled intracoronary OCT trial**
J Haener (Bern, CH, M)
- 18:00 Glycoprotein IIb/IIIa Inhibitors in patients with acute myocardial infarction and angiographic no-reflow: the randomized REVERSE-FLOW trial**
I Eitel (Luebeck, DE, M)
- 18:15 Evaluation of ambulatory electrocardiographic monitoring of patients after high-risk acute coronary syndrome. A randomized trial.**
JM De La Torre Hernandez (Santander, ES, M)

Learning Objectives:

Categories:

What cardiologists need to know about frailty

Session Number: 240

Joint session with the European Geriatric Medicine Society (EuGMS)

Chairpersons: A Benetos (Vandoeuvre Cedex, FR) (M) - A Janmohamed (London, GB) (F)

17:30 Assessing frailty helps therapeutic decision-making
A Ungar (Florence, IT, M)

17:45 How to screen for frailty
I Rodriguez-Sanchez (Madrid, ES, F)

18:00 Incorporating frailty assessment in daily clinical practice
S Sze (Leicester, GB, F)

18:15 Educating healthcare professionals about the basics of geriatrics: a European call to action by PROGRAMMING CA 21122
M Kotsani (Nice, FR, F)

Learning Objectives:

Categories: Clinical Implementation Track

Precision pathways to diabetes management in individuals with cardiovascular disease

Joint session with the European Association for the Study of Diabetes (EASD)

Session Number: 157

Chairpersons: M Lettino (Milano, IT) (F) - M Petrie (Glasgow, GB) (M)

- 17:30 Precision pathways to glucose management in patients with diabetes and cardiovascular disease: the in-patient setting**
J Mader (Graz, AT, F)
- 17:45 Precision pathways to glucose management in patients with diabetes and cardiovascular disease: the out-patient setting**
T Vilsboll (Copenhagen, DK, F)
- 18:00 Optimising cardiovascular risk factors beyond glucose management in patients with diabetes and cardiovascular disease**
S Gielen (Detmold, DE, M)
- 18:15 Introducing digital tools for patients with diabetes and cardiovascular disease: challenges and pitfalls**
AB Gevaert (Antwerp, BE, M)

Learning Objectives: This session aims to ensure adequate and proactive use of modern glucose-lowering medications in the treatment of T2D for both in- and out-patient settings and will provide an overview of the efficacy and benefits of currently available compounds, reviewing the results from recent large-scale CVOTs in a clinical context with suggestions on improving the implementation of GLP-1 RA therapy across specialties to improve overall patient selection and to attain optimal treatment.

Categories: Clinical Implementation Track, Spotlight of the Congress

**Personalising treatment strategies for aortic valve stenosis:
matching therapies to patients**

**Joint session with the European Association for Cardio-Thoracic
Surgery (EACTS)**

Session Number: 332

Chairpersons: V Falk (Berlin, DE) (M) - H Eltchaninoff (Rouen Cedex, FR) (F)

17:30 Is Ross the gold standard aortic valve replacement in the young?

M Jahangiri (London, GB, F)

17:45 Bioprosthetic or mechanical valve replacement: what do the data tell us?

A Zientara (Freiburg, DE, F)

18:00 Bioprosthetic or mechanical aortic valve replacement: patient expectations

G Meltzer (Tel Aviv, IL, M)

**18:15 Percutaneous shockwave therapy for calcific aortic stenosis: a new kid on the
block?**

E Messas (Paris, FR, M)

Learning Objectives: This session aims to understand the pros and cons of each treatment modality for aortic stenosis, what factors should influence the choice of modality, and future perspectives.

Categories: Includes a patient perspective, Online Live, Spotlight of the Congress

**Clinical Case Management: the diagnostic challenge of combined
valvular stenosis and regurgitation**

Session Number: 269

Chairpersons: E Diaz Pelaez (Badalona, ES) (F) - H Mahmoud-Elsayed (Aswan, EG) (M)

17:30 Case 1: concomitant aortic regurgitation and aortic stenosis
E Donal (Rennes, FR, M)

17:50 Case 2: concomitant mitral regurgitation and aortic stenosis
M Garbi (Cambridge, GB, F)

**18:10 Clinical Case Management: the diagnostic challenge of combined valvular
stenosis and regurgitation - discussion**
N Ajmone Marsan (Leiden, NL, F)

J Cavalcante (Minneapolis, US, M)

Learning Objectives:

Categories: Clinical Implementation Track

Personalised cardiovascular disease prevention in primary care

Session Number: 154

**Joint session with the European Primary Care Cardiovascular
Society (EPCCS)**

Chairpersons: L Guasti (Varese, IT) (F) - R Hobbs (Oxford, GB) (M)

- 17:30 Chronic kidney disease and cardiovascular risk prevention: how important and how to identify patients?**
S Seidu (Leicester, GB, M)
- 17:45 Atrial fibrillation screening: is it worthwhile and does it influence atrial fibrillation management across the life span?**
J Mant (Cambridge, GB, M)
- 18:00 Personalised lipid-lowering therapy in different patient populations**
V Bittner (Birmingham, US, F)
- 18:15 Personalised blood pressure control in different patient populations**
C Ingul (Trondheim, NO, F)

Learning Objectives: This session will explore the impact of chronic kidney disease and atrial fibrillation on patients and health systems; aims to better understand the evidence base on atrial fibrillation screening and chronic kidney disease identification; and will discuss the implications for public health and primary care.

Categories: Spotlight of the Congress

Applied innovations in cardiovascular care

Session Number: 378

**Joint session with the International Society for Cardiovascular
Translational Research (ISCTR)**

Chairpersons: J Bax (Leiden, NL) (M) - S Dimmeler (Frankfurt, DE) (F)

- 17:30 The innovation ecosystem for cardiovascular disease**
N Dib (Phoenix, US, M)
- 17:42 Emerging approaches to prevent sudden cardiac death**
SG Priori (Pavia, IT, F)
- 17:54 Incorporating innovations into clinical practice**
A De-Maria (San Diego, US, M)
- 18:06 Evolving role for transcatheter intervention for stable angina**
R Al-Lamee (London, GB, F)
- 18:18 Applied innovations in cardiovascular care - discussion**

Learning Objectives:

Categories:

**ChatGPT, Copilot, and other large language models (LLMs):
transforming cardiovascular education, care, and science****Session Number: 381**Chairpersons: N Keser (Istanbul, TR) (F) - G Hindricks (Berlin, DE) (M)**17:30 What are large language models (LLMs)?**

MJ Boonstra (Hilversum, NL, F)

17:42 LLMs impact on cardiovascular education

S Fournier (Lausanne, BE, M)

17:54 Improving patient care with LLMs

RMA Van Der Boon (Rotterdam, NL, M)

18:06 Challenges and opportunities of LLMs in scientific publishing

T Guzik (Glasgow, GB, M)

**18:18 ChatGPT, Copilot, and other large language models (LLMs): transforming
cardiovascular education, care, and science - discussion**

R Mehran (New York, US, F)

Learning Objectives: To explain LLMs by exploring their roles in clinical decision-making, patient care, research, and scientific writing, as well as their implications for peer review.

Categories: Digital Health

Circadian rhythm alterations in cardiovascular diseases

Session Number: 349

Chairpersons: D Aksentijevic (London, GB) (F) - I Rabinovich-Nikitin (Winnipeg, CA) (F)

17:30 Circadian medicine: a critical aspect of cardiac care
T Martino (Guelph, CA, F)

17:45 Circadian regulation of cardiometabolism
C Greco (Milan, IT, F)

18:00 Circadian rhythmicity and cardiac ageing
P Dierickx (Bad Nauheim, DE, M)

18:15 Circadian rhythm alterations in cardiovascular diseases - discussion
L Van Laake (Utrecht, NL, F)

Learning Objectives:

Categories:

HOT LINE 9

Session Number: 1018

Chairpersons: E Svennberg (Stockholm, SE) (F) - P Sanders (Adelaide, AU) (M)

- 17:35 STROKESTOP II - Randomised systematic NT-proBNP and ECG screening for atrial fibrillation among 75 year-olds**
K Kemp Gudmundsdottir (Reykjavik, IS, F)
- 17:50 GUARD-AF - ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals**
RD Lopes (Durham, US, M)
- 18:02 Discussant review - STROKESTOP II and GUARD-AF**
GYH Lip (Liverpool, GB, M)
- 18:09 Panel discussion - STROKESTOP II and GUARD-AF**
- 18:14 MIRACLE-AF - A Novel Model of IntegRATED Care of OLdEr Patients with Atrial Fibrillation in rural China**
M Chen (Nanjing, CN, M)
- 18:26 Discussant review - MIRACLE-AF**
IC Van Gelder (Groningen, NL, F)
- 18:31 Panel discussion MIRACLE-AF**

Learning Objectives:

Categories: Online Live

Ask the Trialists from Hot Line 8

Session Number: 1088

Chairpersons: Sim Biscaglia (Cona, Ferrara, IT) (M) - R Schnabel (Hamburg, DE) (F) - A Kini (New York, US) (F)

18:00 **Ask the Trialist - SENIOR RITA**
V Kunadian (Newcastle Upon Tyne, GB, F)

18:10 **Ask the Trialist - EARTH-STEMI**
G Campo (Cona, IT, M)

18:20 **Ask the Trialist - SCOFF**
D Ferreira (Wantirna, AU, M)

Learning Objectives:

Categories:

Daily Highlights by the Mexican Society of Cardiology

Session Number: 5132

This session is brought to you by the Mexican Society of Cardiology and is not part of the official ESC programme

Chairpersons:

Learning Objectives:

Categories: Online Live

**Daily Highlights by the Chilean Society of Cardiology and
Cardiovascular Surgery**

**This session is brought to you by the Chilean Society of
Cardiology and Cardiovascular Surgery and is not part of the
official ESC programme**

Session Number: 5137

Chairpersons:

Learning Objectives:

Categories: Online Live

Daily Highlights by the Taiwan Society of Cardiology

Session Number: 5133

This session is brought to you by the Taiwan Society of Cardiology and is not part of the official ESC programme

Chairpersons:

Learning Objectives:

Categories: Online Live

2024 ESC Guidelines for the Management of Peripheral Arterial and Aortic Diseases

Session Number: 1004

Chairpersons: L Mazzolai (Lausanne, CH) (F) - J Rodriguez Palomares (Barcelona, ES) (M)

Weighty matters! Deciding the best care for atrial fibrillation patients with obesity**Session Number: 172**Chairpersons: P Lambiase (London, GB) (M) - M Middeldorp (Norwood, NL) (F)**08:15 Atrial fibrillation: obesity matters**

D Gupta (Liverpool, GB, M)

08:33 Weight reduction to improve outcomes after atrial fibrillation ablation in patients with obesity

M Gunawardene (Hamburg, DE, F)

08:51 Optimal oral anticoagulation in atrial fibrillation patients with obesity

V Roldan-Schilling (Murcia, ES, F)

09:09 Obstructive sleep apnoea: does treatment prevent atrial fibrillation?

P Sanders (Adelaide, AU, M)

09:27 Weighty matters! Deciding the best care for atrial fibrillation patients with obesity - discussion

JL Merino (Madrid, ES, M)

Learning Objectives:

Categories: Obesity Track, Online Live

Personalised management after primary PCI for ST elevation myocardial infarction: unresolved issues**Session Number: 201**Chairpersons: F Weidinger (Vienna, AT) (M) - B Vogel (New York, US) (F)

- 08:15** **When to use a pharmaco-invasive approach rather than primary PCI**
A Kastrati (Munich, DE, M)
- 08:33** **Should everyone receive complete revascularisation after primary PCI?**
BE Stahli (Zurich, CH, F)
- 08:51** **Should 12 months of dual antiplatelet therapy still be the default recommendation after primary PCI?**
S James (Uppsala, SE, M)
- 09:09** **How useful are risk scores in determining bleeding risk and antithrombotic therapy duration after primary PCI?**
R Colleran (Dublin, IE, F)
- 09:27** **Personalised management after primary PCI for ST elevation myocardial infarction: unresolved issues - discussion**
V Kunadian (Newcastle Upon Tyne, GB, F)

Learning Objectives:

Categories: Spotlight of the Congress

Repurposing anti-diabetic pharmacotherapy: the new cure for all evils?

Session Number: 839

Chairpersons: S Verma (Toronto, CA) (M) - H Drexel (Feldkirch, AT) (M)

- 08:15 State-of-the-art lecture on repurposing of diabetic medications: the new cure for all evils?**
A Navar (Dallas, US, F)
- 08:33 Impact of SGLT2 inhibitors on liver-related outcomes in patients with heart failure - a population-based study in HK**
H Yang (Hong Kong, HK, F)
- 08:52 Combined sodium-glucose-transporters inhibitors (SGLT2i) and glucagon-like-peptide receptor agonist (GLP1ra) compared with SGLT2i or GLP1ra alone improves survival: a Real-World Registry**
D Garcia Vega (Santiago De Compostela, ES, M)
- 09:11 Risk of Incident colorectal carcinoma in patients with type 2 diabetes on SGLT-2 inhibitor users: a population-based cohort study**
Gwo Jong (Taichung, TW, M)

Learning Objectives:

Categories: Online Live

Coronary revascularisation in patients undergoing TAVI: why? when? and how?**Session Number: 280**Chairpersons:

M Leon (New York, US) (M) - M Gilard (Brest Cedex, FR) (F)

08:15 Indication for revascularisation in patients undergoing aortic valve replacement

A Abizaid (Sao Paulo, BR, M)

08:33 Timing of revascularisation in patients undergoing TAVI: before? during? or after?

T Rudolph (Bad Oeynhausen, DE, F)

08:51 Physiology-guided revascularisation in patients undergoing TAVI

C De Biase (Toulouse, FR, F)

09:09 PCI after TAVI: tricks and toolbox

Z Piroth (Budapest, HU, M)

09:27 Coronary revascularisation in patients undergoing TAVI: why? when? and how? - discussion

A Petronio (Pisa, IT, F)

Learning Objectives:

Categories: Clinical Implementation Track

Great Debates: diagnosis and management of chronic coronary syndromes**Session Number: 195**Chairpersons: D Hasdai (Petah-Tikva, IL) (M) - J Mehilli (Landshut, DE) (F)

- 08:15** **Coronary CT angiography should be the first-line imaging tool for diagnosis of coronary artery disease: pro**
L Shaw (New York, US, F)
- 08:30** **Coronary CT angiography should be the first-line imaging tool for diagnosis of coronary artery disease: con**
J Knuuti (Turku, FI, M)
- 08:45** **Coronary CT angiography should be the first-line imaging tool for diagnosis of coronary artery disease - discussion**
A Gimelli (Pisa, IT, F)
- 09:00** **Asymptomatic severe coronary artery disease should be managed conservatively regardless of left ventricular function: pro**
D Perera (London, GB, M)
- 09:15** **Asymptomatic severe coronary artery disease should be managed conservatively regardless of left ventricular function: con**
A Lansky (New Haven, US, F)
- 09:30** **Asymptomatic severe coronary artery disease should be managed conservatively regardless of left ventricular function - discussion**
G Montalescot (Paris, FR, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Online Live, Young Community Track

Smaller trials and trial updates on shock, surgery, and other interventions

Session Number: 1048

Chairpersons: M Rubini Gimenez (Valencia, ES) (F) - H Bueno (Madrid, ES) (M)

- 08:15 Extracorporeal life support for acute myocardial infarction complicated by cardiogenic shock - 12 months results of the ECLS-SHOCK trial**
S Desch (Leipzig, DE, M)
- 08:26 Impact of baseline surgical risk on the treatment effect of PCI and CABG in ischemic left ventricular systolic dysfunction: results of the REVIVED-BCIS2 and STICH randomized controlled trials**
G Marquis Gravel (Montreal, CA, M)
- 08:37 Empagliflozin for prevention of acute kidney injury in patients with type 2 diabetes mellitus undergoing extracorporeal on-pump CABG: The POST-CABGDM trial**
FG Pitta (Sao Paulo, BR, M)
- 08:48 Comparative Effectiveness of Percutaneous and Surgical Revascularisation in Ischaemic Left Ventricular Systolic Dysfunction: Combined Patient-Level Analysis of the REVIVED-BCIS2 and STICH Trials**
M Ryan (London, GB, M)
- 09:00 Temporary mechanical circulatory support in infarct-related cardiogenic shock - An individual patient data meta-analysis of all randomized trials with 6-month follow-up**
H Thiele (Leipzig, DE, M)
- 09:11 Urgent surgery compared to fibrinolytic therapy for the treatment of left-sided mechanical valve thrombosis (SAFE-PVT): a randomized controlled trial**
G Karthikeyan (New Dehli, IN, M)
- 09:22 Apixaban versus ClopidoGRel on a background of aspirin in patient undergoing InfraPoPliteal angioplasty for critical limb ischemial**
R Biagioni (- , BR, M)
- 09:33 Cardiac magnetic resonance imaging vs invasive coronary angiography as primary strategy in heart failure with reduced ejection fraction - A diagnostic randomized trial**
G Gueder (Wuerzburg, DE, F)

Learning Objectives:

Categories:

Contemporary epidemiology of worsening heart failure

Session Number: 827

Chairpersons: E Jankowska (Wroclaw, PL) (F) - G Filippatos (Athens, GR) (M)

- 08:15 State-of-the-art lecture on contemporary epidemiology of worsening heart failure**
M Jessup (Philadelphia, US, F)
- 08:33 Modern epidemiology of heart failure with reduced and preserved ejection fraction in population-wide linked electronic health records: a study of 208815 heart failure patients in England**
R Fletcher (Cambridge, GB, M)
- 08:51 Comprehensive machine learning models for prediction of heart failure in 476,393 women and men from the UK Biobank reveal sex differences and underutilized risk factors**
T F Kok (Rotterdam, NL, M)
- 09:09 Clinical and financial implications of inpatient and outpatient management strategies for worsening heart failure**
SJ Greene (Durham, US, M)
- 09:27 Temporal trends in sudden cardiac death after acute decompensation in HFrEF patients: a 13-year Japanese multicentre registry study**
R Fukuoka (Tokyo, JP, M)

Learning Objectives:

Categories:

How to manage acute cardiac problems in patients with cancer**Session Number: 132**Chairpersons: A Rubboli (Ravenna, IT) (M) - B Ky (Philadelphia, US) (F)

08:15 New onset of heart failure in patients with cancer: what to monitor? how to treat?
N Lang (Glasgow, GB, M)

08:33 New onset carcinoid heart disease in metastatic cancer: from diagnosis to treatment
T Lopez Fernandez (Madrid, ES, F)

08:51 New onset of atrial fibrillation in patients with cancer: risk-benefit appraisal of anticoagulants
G Boriani (Castenaso, IT, M)

09:09 Acute coronary syndrome in patients with cancer: what to consider
S Gevaert (Gent, BE, F)

09:27 How to manage acute cardiac problems in patients with cancer - discussion
S Dent (Hillsborough, US, F)

Learning Objectives:

Categories: Online Live

Structural intervention meets adult congenital heart disease**Session Number: 321**Chairpersons: MHS El Sayed (Cairo, EG) (F) - S Saito (Kamakura City, JP) (M)

08:15 TAVI in adult congenital heart disease
B Bouma (Amsterdam, NL, M)

08:33 Mitral and tricuspid edge-to-edge repair in adult congenital heart disease
P Guerin (Nantes Cedex 1, FR, M)

08:51 Percutaneous coronary revascularisation in adult congenital heart disease
J Bouchardy Clement (Lausanne, CH, F)

09:09 Interventional training pathways in adult congenital heart disease
R Bedair (Bristol, GB, F)

09:27 Structural intervention meets adult congenital heart disease - discussion
S A Qureshi (London, GB, M)

Learning Objectives:

Categories:

From screening to digital twin models in valvular heart disease: the new imaging frontiers

Session Number: 268

Chairpersons: S Little (Houston, US) (M) - S Mulvagh (Halifax, CA) (F)

- 08:15 New tools for screening valvular heart disease**
P Pellikka (Rochester, US, F)
- 08:33 Artificial intelligence for quantification of valvular heart disease**
T Marwick (Melbourne, AU, M)
- 08:51 Phenotyping valvular heart disease: what we learn from machine learning**
J Bermejo Thomas (Madrid, ES, M)
- 09:09 Digital twin models: planning and predicting response to treatment in valvular heart disease**
B Rodriguez (Oxford, GB, F)
- 09:27 From screening to digital twin models in valvular heart disease: the new imaging frontiers - discussion**
M Garbi (Cambridge, GB, F)

Learning Objectives:

Categories: Digital Health

Smaller trials, trial updates, and other studies: devices, cardiac arrest and atrial fibrillation ablation

Session Number: 1049

Chairpersons: M De Riva Silva (Leiden, NL) (F) - C Leclercq (Rennes Cedex, FR) (M)

- 08:15 Consistent ATP, defibrillation, and safety performance of the extravascular ICD: final results from the global EV-ICD Pivotal Study**
F Murgatroyd (London, GB, M)
- 08:27 Pacing Performance of the First Leadless Pacemaker Communicating with an SICD from the full cohort of the MODULAR ATP study**
L Mont (Barcelona, ES, M)
- 08:40 Death and Neurological Outcome in Patients Delivered to a Cardiac Arrest Centre: Pre-specified secondary analyses of the ARREST Trial**
T Patterson (London, GB, F)
- 08:53 Resynchronization/defibrillation for Ambulatory heart Failure Trial in patients with Permanent Atrial Fibrillation**
A Tang (London, CA, M)
- 09:06 Pulsed Electric Field versus Cryoballoon to Treat Paroxysmal Atrial Fibrillation (PERFECT-PAF) Randomized Trial: a Periprocedural Clinical and Cost Analysis**
GB Chierchia (Jette, BE, M)
- 09:19 Using computed tomogram atrial myocardial thickness maps in cryoballoon pulmonary vein isolation: a randomized clinical trial**
D Kim (Seoul, KR, M)
- 09:32 Conduction system pacing vs biventricular resynchronization therapy in systolic dysfunction and wide QRS: CONSYST-CRT.**
M Pujol-Lopez (Barcelona, ES, F)

Learning Objectives:

Categories:

Enhancing personalised cardiovascular care with artificial intelligence

Joint session with JAMA and JAMA Cardiology

Session Number: 420

Chairpersons: L Neubeck (Edinburgh, GB) (F) - K Bibbins-Domingo (Chicago, US) (F) - R Khera (New Haven, US) (M)

08:15 Artificial intelligence-powered discoveries to achieve precision in cardiovascular care
R Khera (New Haven, US, M)

08:30 Enabling disease diagnosis at scale: deploying novel artificial intelligence in consumer devices for community cardiovascular screening
D Adedinsowo (Jacksonville, US, F)

08:45 Making each contact count: enhancing the value of cardiac CT and MRI for detecting hidden disease and cardiovascular risk
MC Williams (Edinburgh, GB, F)

09:00 Enhanced disease phenotyping and novel care signatures: arming routine clinical data to personalise care globally
A Banerjee (London, GB, M)

09:15 Laboratories of the present and care of the future: foundation models for multimodality data in the EHRs
D Kotecha (Birmingham, GB, M)

09:30 Implementation and regulation of artificial intelligence-enabled precision care solutions

Learning Objectives: To present a detailed evaluation of AI-driven innovation in all facets of cardiovascular care spanning precision in diagnosis, risk stratification, and personalised treatment including:
- concepts in AI technology grounded in clinical examples;
- the quality of data available for various AI interventions; and
- emerging innovations in personalised care, as well as the relevant regulatory processes.

Categories: Digital Health, Spotlight of the Congress

Digitising heart failure: from diagnosis to treatment**Session Number: 102**Chairpersons: H Krumholz (New Haven, US) (M) - HGC Van Spall (Hamilton, CA) (F)**08:15 Use of artificial intelligence for diagnosis of heart failure: ECG**

A Jordan (Mexico, MX, M)

08:30 Use of artificial intelligence for diagnosis of heart failure: echo

P Kaul (Edmonton, CA, F)

08:45 Digital tools to help treat heart failure

A Hernandez (Durham, US, M)

09:00 Digital solutions for monitoring therapy in heart failure

I Kardys (Rotterdam, NL, F)

09:15 Digitising heart failure - patient perspective

R Mindham (London, GB, M)

09:30 Digitising heart failure: from diagnosis to treatment - discussion

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Digital Health, Includes a patient perspective, Online Live, Young Community Track

ESC William Harvey Lecture in Basic Science

Session Number: 405

Chairpersons: J van der Velden (Amsterdam, NL) (F) - H C Watkins (Oxford, GB) (M)

08:15 Presentation of the awardee
H C Watkins (Oxford, GB, M)

08:20 Sudden cardiac death and autopsy in the era of molecular medicine
C Basso (Padua, IT, F)

08:40 ESC William Harvey Lecture in Basic Science - Q&A

08:55 Award presentation

Learning Objectives:

Categories:

Epigenetic regulators and tools

Session Number: 843

Chairpersons: R Madonna (Pisa, IT) (F) - S Rickert-Sperling (Berlin, DE) (F)

- 08:15 State-of-the-art lecture on epigenetic regulators and tools**
S Heymans (Maastricht, NL, M)
- 08:33 An epigenetic editor targeting human PCSK9 efficiently and durably lowers Low Density Lipoprotein Cholesterol (LDL-C) in non-human primates**
F Tremblay (Boston, US, M)
- 08:51 Epi-Allele: CRISPR-mediated allele-specific epigenetic editing alleviates hypertrophic cardiomyopathy**
Z Wang (Shanghai, CN, M)
- 09:09 Intronic regulatory sequences regulate epicardial gene expression and EMT during heart development**
J Nunes Vieira (London, GB, M)
- 09:27 The orchestration of coding and non-coding genes at the CDH13 locus in coronary artery disease**
Z Chen (Munich, DE, F)

Learning Objectives:

Categories:

Heart failure management in low/middle-income countries

Session Number: 116 Joint session with the Philippine Heart Association (PHA)

Chairpersons: R Tiongco (Manila, PH) (M) - M Farrero Torres (Barcelona, ES) (F)

- 08:15 The global burden of heart failure
DJ Pineiro (Buenos Aires, AR, M)
- 08:30 Challenges to heart failure management in low/middle-income countries
G Gervacio (Taguig City, PH, F)
- 08:45 Tackling an emerging problem in heart failure: cancer
R Jimenez (Taguig City Metro Manila, PH, M)
- 09:00 Emerging solutions for equitable treatment of heart failure in low/middle-income countries
K Sliwa (Cape Town, ZA, F)

Learning Objectives: This session will provide a broad perspective on factors that influence the management of chronic heart failure with a focus on management of cancer and chemotherapy-related cardiomyopathy in developing countries; and will delve into both the adaptability and availability of device therapies for chronic heart failure patients in developing countries.

Categories: Online Live

Fine-tuning prognostication after acute coronary syndromes

Session Number: 3048

Chairpersons: M Aleksic (Belgrade, RS) (F) - S-L Chen (Nanjing, CN) (M)

- 08:15** **Coronary artery plaque characteristics in smokers assessed by intracoronary multi-modality imaging: a NIRS-IVUS guided PROSPECT II substudy**
A Dahlgren (Lund, SE, M)
- 08:25** **Advancing prognostic insights in STEMI patients through microvascular resistance reserve evaluation**
T Tsai (Taipei, TW, M)
- 08:35** **Association of PCSK6 rs1531817(C/A) polymorphism with the prognosis and coronary stenosis in premature myocardial infarction patients: a prospective cohort study**
J Gao (Tianjin, CN, F)
- 08:45** **Angiography-based index of microcirculatory resistance as a novel tool to predict the morbidity of new-onset atrial fibrillation in patients with MINOCA**
S Huang (- , CN, M)
- 08:55** **Prognostic implications of p2y12 inhibitor pre-treatment in non-st segment elevation acute coronary syndromes undergoing late invasive strategy - a national registry analysis**
A Fonseca Vazao (Leiria, PT, F)
- 09:05** **Minimal coronary microvascular resistance: agreement between continuous and bolus thermodilution**
T Mahendiran (Lausanne, CH, M)

Learning Objectives:

Categories:

**Atrial fibrillation management and outcomes in high-risk atrial
fibrillation populations****Session Number: 3022**Chairpersons: E Hylek (Boston, US) (F) - GYH Lip (Liverpool, GB) (M)

- 08:15 Predictors and outcomes of intracranial hemorrhage in 58,000 patients with atrial fibrillation on oral anticoagulation: insights from COMBINE-AF**
M Tannu (Durham, US, F)
- 08:27 Anticoagulation and stroke in hospitalized patients newly diagnosed with secondary atrial fibrillation: a population-based cohort study**
H Abdel-Qadir (Toronto, CA, M)
- 08:39 Post-operative atrial fibrillation during cardiac rehabilitation: incidence and long-term prognostic value.**
S Rastelli (- , IT, M)
- 08:51 Use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation across five stages of chronic kidney diseases**
T Chao (Taipei, TW, M)
- 09:03 Risk of thromboembolic and haemorrhagic events associated with anticoagulation among 11,355 patients with non-valvular atrial fibrillation and thrombocytopenia**
TK Tam (Shatin, HK, M)

Learning Objectives:

Categories:

Cardiomyopathies uncovered

Session Number: 3030

Chairpersons: C Angermann (Wurzburg, DE) (F) - M Senni (Bergamo, IT) (M)

- 08:15 Fabry cardiomyopathy: myocardial fibrosis, inflammation and reduced mannose6phosphate receptors cause low accessibility to enzyme therapy.**
A Frustaci (Rome, IT, M)
- 08:25 Global and national insights into the decline of hypertrophic cardiomyopathy as a cause of sudden death in the young**
D Nelson (Melbourne, AU, M)
- 08:35 Proteomic profiling of extracellular vesicles in takotsubo syndrome**
E Zulfaj (Orkelljunga, SE, M)
- 08:45 Changes in blood metabolomes as potential biomarkers for severity and prognosis in doxorubicin-induced heart failure: a study in HER2-positive and HER2-negative breast cancer patients**
C Thonusin (Chiang Mai, TH, F)
- 08:55 Clinical validated risk prediction model for development of heart failure after contemporary breast cancer treatment**
A Barac (Fairfax, US, F)
- 09:05 Association of genetically predicted human metabolomic gene expression with incident heart failure**
H Ahn (London, GB, M)

Learning Objectives:

Categories:

Non-classical risk factors for heart disease revisited

Session Number: 3094

Chairpersons: J Bergler-Klein (Vienna, AT) (F) - T Suter (Bern, CH) (M)

- 08:15 Interplay between family History and polygenic risk for coronary heart disease: a cohort study among over 60 thousand individuals**
C Iribarren (Oakland, US, M)
- 08:25 Association of Life's Essential 8 metrics with mortality outcomes in US cancer survivors**
W Chen (Beijing, CN, M)
- 08:35 Non-lipid metabolomic biomarkers are associated with adverse cardiac remodelling and cardiovascular outcomes**
M M Sanghvi (London, GB, M)
- 08:45 AI-enhanced detection of coronary inflammation predicts 10-year risk for cardiac mortality and MACE in individuals with no or minimal coronary atherosclerosis on routine CCTA**
K Chan (London, GB, M)
- 08:55 Remnant cholesterol and mortality in 37.559 patients from LIPIDOGram 2004, 2006 and 2015 studies.**
M Banach (Lodz, PL, M)
- 09:05 Identifying clinical phenotype clusters for coronary artery disease: a novel approach using clustering by unsupervised machine learning**
J Holtrop (Utrecht, NL, M)

Learning Objectives:

Categories:

**The power of cardiac magnetic resonance in dilated
cardiomyopathies****Session Number: 3009**Chairpersons: AMG Almeida (Lisbon, PT) (F) - R Licordari (Messina, IT) (M)

- 08:15 Myocardial parametric mapping in patients with suspected acute myocarditis: a prognosis study**
Y Wang (Beijing, CN, F)
- 08:27 Prognostic impact of the concept of late gadolinium enhancement granularity in non-ischaemic dilated cardiomyopathy**
T Goncalves (Paris, FR, F)
- 08:39 Cardiac MRI traits linked to cardiomyopathy mutations in phenotype naive carriers**
P Croon (Amsterdam, NL, M)
- 08:51 Cardiovascular magnetic resonance to differentiate veteran athlete's heart with cavity dilatation and mild dilated cardiomyopathy**
W Javed (Leeds, GB, M)
- 09:03 Quantifying late gadolinium enhancement improved sudden cardiac death risk prediction in non-ischemic dilated cardiomyopathy**
Y Li (Sichuan, CN, M)

Learning Objectives:

Categories:

Aortic disease**Session Number: 3323**Chairpersons: A Zientara (Freiburg, DE) (F) - O Ozden Kayhan (Istanbul, TR) (F)**08:15 Aortic disease - get ready for the session**

A Zientara (Freiburg, DE, F)

08:20 A rare case of intramural hematoma with aortic dissection in a young female with a large cell vasculitis (Takayasu arteritis)

C Masaga (San Juan Metro Manila, PH, M)

08:38 A devil in disguise : gigantic aortic pseudoaneurysm presenting with inferior wall st-elevation myocardial infarction

T Kittiboonya (Bangkok, TH, M)

08:56 Hemorrhagic pericardial effusion after removal of pericardial drain in penetrating atherosclerotic ulcer of the ascending aorta with pseudoaneurysm

T Poruban (Kosice, SK, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals

Categories: Mobile App - Vote, Young Community Track

Ventricular tachycardia (2)

Session Number: 3348

Chairpersons: M Schoos (Klampenborg, DK) (M) - M Ebert (Dresden, DE) (F)

- 08:15 **Unraveling a rare case of bundle branch reentry ventricular tachycardia**
C Srisakvarakul (Maung, TH, M)
- 08:27 **Experience sharing of one-stage endo-epicardial 3D mapping for localization of VT origin during LV diverticulum repair surgery**
L Chen (Kaohsiung, TW, M)
- 08:39 **Staying afloat during the storm - A difficult case of VT storm provoked by ischemic scar**
K Akkineni (New Delhi, IN, M)
- 08:51 **Sudden cardiac death abortion as a clinical presentation of long QT syndrome**
D Cardoso (Monterrey, MX, M)
- 09:03 **When a thunderstorm turns into a hurricane; the longest ventricular tachycardia you have ever seen.**
J Cruz Leon (Ciudad De Mexico, MX, M)

Learning Objectives:

Categories:

Heartfelt genetics

Session Number: 3357

Chairpersons: M Cvijic (Ljubljana, SI) (F) - M Isgandar (Baku, AZ) (F)**08:15 Preventing a second cardiac arrest in the same family: are genetics enough?**

M Casian (Bucharest, RO, M)

08:27 Unexpected Diagnosis of CASQ2-Catecholaminergic Polymorphic Ventricular Tachycardia in an Adult Athlete

F Amata (Rozzano, IT, M)

08:39 Beyond age limits: successful management of pediatric dilated cardiomyopathy with rare PLEKHM2 mutation in an adult hospital

S Bendayan (Montreal, CA, M)

08:51 Cardiac Contractility Modulation as bailout in a patient with Phospholamban p.Arg14del related cardiomyopathy intolerant to medication

F Verelst (Antwerp, BE, F)

09:03 Successful heart transplantation in a young patient diagnosed with polyglucosan body myopathy type 1

F Naghashzadeh (Tehran, IR, F)

Learning Objectives:

Categories:

Ask the Trialists from Hot Line 9

Session Number: 1085

Chairpersons: IC Van Gelder (Groningen, NL) (F) - GYH Lip (Liverpool, GB) (M)

09:15 **Ask the Trialist - STROKESTOP II**
K Kemp Gudmundsdottir (Reykjavik, IS, F)

09:28 **Ask the Trialist - GUARD-AF**
RD Lopes (Durham, US, M)

09:41 **Ask the Trialist - MIRACLE-AF**
M Chen (Nanjing, CN, M)

Learning Objectives:

Categories:

Session Number:	5104	Management of complex patients in Lebanon and Czech Republic
		Organised in collaboration with the Lebanese Society of Cardiology and the Czech Society of Cardiology
<u>Chairpersons:</u>	A El sayed (Beirut, LB) (M) - J Belohlavek (Praha, CZ) (M)	

09:30	The Lebanese experience in subcutaneous defibrillators
	B Harbieh (Jounieh, LB, M)

09:42	Extracorporeal membrane oxygenation (ECMO) in cardiogenic shock: the Czech perspective
	P Ostadal (Prague, CZ, M)

09:54	Management of complex patients in Lebanon and Czech Republic - discussion
	Z Motovska (Prague, CZ, F)
	M Khatib (Zahle, LB, M)

Learning Objectives:	Subcutaneous defibrillators: the Lebanese experience will highlight the significance of implementing cutting-edge technologies such as S-ICDs (subcutaneous implantable cardioverter-defibrillators) despite the multifaceted challenges of a developing nation.
	Extracorporeal membrane oxygenation (ECMO) in cardiogenic shock: the Czech perspective will focus on selection of patients who may profit from mechanical circulatory support.
Categories:	Online Live, Spotlight of the Congress

Tailored approaches to cardiovascular therapy in acute coronary syndromes**Session Number: 3045**Chairpersons: J Kubica (Osielsko, PL) (M) - A Kitsiou (Athens, GR) (F)

- 09:30 Effect of alirocumab on coronary plaque stratified by atherothrombotic risks**
Y Ueki (Matsumoto, JP, M)
- 09:42 Lesion-level changes induced by low-density lipoprotein cholesterol lowering therapy in patients with acute myocardial infarction: the pre-specified PACMAN-AMI lesion-level analysis.**
FG Biccire (- , CH, M)
- 09:54 Real-world evidence supports superior efficacy of prasugrel over ticagrelor in individuals with acute coronary syndrome**
N Kruger (Munich, DE, M)
- 10:06 Post-PCI anticoagulation with unfractionated heparin in acute coronary syndrome: insight from the STOPDAPT-3 trial**
H Watanabe (Hirakata, JP, M)
- 10:18 A liberal blood transfusion strategy is safe in patients with myocardial infarction, anemia, and heart failure: lessons from MINT**
AM Goldsweig (West Hartford, US, M)

Learning Objectives:

Categories:

Advances in left atrial appendage and patent foramen ovale closure

Session Number: 3077

Chairpersons: R Theotonio (Lisboa, PT) (F) - M Grygier (Poznan, PL) (M)

- 09:30 Intracardiac vs transesophageal echocardiography for percutaneous LAA occlusion: a meta-analysis**
E Beneki (Athens, GR, F)
- 09:40 Impact of left atrial appendage closure on left atrial function: insights from the OCEAN-LAAC registry**
HN Nonaka (Brisbane, AU, M)
- 09:50 Venous thrombo-embolic events as the probable cause of arterial ischemic event in patients with patent foramen ovale**
P Guedeney (Paris, FR, M)
- 10:00 Prevalence, determinants, and impact of significant shunt after percutaneous patent foramen ovale closure**
P Guedeney (Paris, FR, M)
- 10:10 Neurologic recurrence after transcatheter PFO closure in patients with cryptogenic stroke**
B Goessinger (Vienna, AT, F)
- 10:20 Transcatheter patent foramen ovale closure in patients with and without documented nickel hypersensitivity**
A Apostolos (Athens, GR, M)

Learning Objectives:

Categories:

Novel risk predictors in hypertrophic cardiomyopathy

Session Number: 3062

Chairpersons: H C Watkins (Oxford, GB) (M) - M Michels (Rotterdam, NL) (F)

- 09:30 Prediction of family inheritance in non-sarcomeric hypertrophic cardiomyopathy using clinical variables and 12-lead electrocardiogram artificial intelligence models**
M Tremblay-Gravel (Montreal, CA, M)
- 09:40 Improving the prediction of major adverse cardiovascular events in patients with hypertrophic cardiomyopathy by adding plasma SVEP1 to conventional clinical model including NT-proBNP**
I Osawa (New York, US, M)
- 09:50 Genotype predicts heart failure independent of left ventricular ejection fraction and NT-proBNP levels in hypertrophic cardiomyopathy**
A Bakalakos (London, GB, M)
- 10:00 Impaired myocardial energetics in both sarcomere positive and negative HCM are linked to arrhythmic risk**
Z Ashkir (Leicester, GB, M)
- 10:10 Myocardial scar in end-stage hypertrophic cardiomyopathy: correlation with systolic function and prognostic significance.**
R Ditaranto (Bologna, IT, M)
- 10:20 Effectiveness of contemporary risk stratification in patients with hypertrophic cardiomyopathy: a pilot study**
M Jensovsky (Prague, CZ, M)

Learning Objectives:

Categories:

Challenges when caring for cancer patients with heart disease

Session Number: 3104

Chairpersons: G Novo (Palermo, IT) (F) - CJ Plummer (Newcastle Upon Tyne, GB) (M)

- 09:30** **Therapeutic benefits of tofacitinib on steroid-resistant immune checkpoint inhibitor-associated myocarditis: long-term cardiac and oncological outcomes**
- 09:40** **Early rhythm control of atrial fibrillation in cancer survivors: a nationwide population-based cohort study**
S Han (Seoul, KR, M)
- 09:50** **The prognostic value of advanced lung cancer inflammation index in cancer survivors complicated with cardiovascular disease**
Y Zhang (Changsha, CN, M)
- 10:00** **Cardiovascular and non-cardiovascular adverse events in patients with hematologic malignancies treated with BTK inhibitors: a real-world analysis**
R Belo Nunes (Sao Paulo, BR, M)
- 10:10** **Machine learning and traditional analysis of the interaction between cardiovascular diseases and hematological malignancies**
T Itkin (Tel Aviv, IL, M)
- 10:20** **Cardiovascular outcomes of Sodium-glucose cotransporter-2 inhibitors in cancer patients receiving Anthracycline chemotherapy: a systematic review and meta-analysis**
Z Jarito-Vergara (Cebu City, PH, F)

Learning Objectives:

Categories:

Novel mechanisms in arrhythmogenic cardiac diseases

Session Number: 3122

Chairpersons: K Dibb (Manchester, GB) (F) - C Schmidt (Heidelberg, DE) (F)

- 09:30** **Reduced Na current in dystrophin-deficient ventricular cardiomyocytes is rescued by tenascin-C inhibition**
J Marksteiner (Wien, AT, F)
- 09:40** **The suppression of RCAN1 alleviated lipid accumulation and mitochondrial fission in diabetic cardiomyopathy**
S Shu (Beijing, CN, M)
- 09:50** **MRPL44 haploinsufficient mouse spontaneously develops hypertrophic cardiomyopathy and shows systolic dysfunction after aldosterone treatment**
R Okamoto (Tsu, JP, M)
- 10:00** **A novel murine model of stress-induced cardiomyopathy achieved by chemogenetic stimulation of the locus coeruleus-norepinephrine system**
S Ministrini (Zurich, CH, M)
- 10:10** **Phosphoproteomics of PLN R14del heart tissue reveals major myocyte degenerate phenotype, and is attenuated by PLN antisense treatment in vitro**
FE Deiman (Groningen, NL, M)
- 10:20** **Burst-like transcription of MYH7, allelic and contractile imbalance already in early stage hiPSC-cardiomyocytes indicate these as pathogenic factors in Hypertrophic Cardiomyopathy**
T Kraft (Hannover, DE, F)

Learning Objectives:

Categories:

Cardiomyopathies**Session Number: 3313**Chairpersons: E Cavarretta (Rome, IT) (F) - A Cannata (London, GB) (M)**09:30 Cardiomyopathies - get ready for the session**

E Cavarretta (Rome, IT, F)

09:35 Butterfly apex, huge cardiac lipomatosis: potential diagnostic pitfalls in a patient referred for arrhythmogenic cardiomyopathy

L Brugiattelli (Jesi, IT, M)

09:48 Stress cardiomyopathy due to multiple aetiologies in a young man

H Abid (Birmingham, GB, F)

10:01 Late-onset combined cardiomyopathy: Fabry disease and hypertrophic cardiomyopathy with atypical cmr findings

K Sriudomporn (Bangkok, TH, M)

10:14 Metabolic myocardial storage cardiomyopathie and sudden death due to a pathogenic variant in the PRKAG2 gene. non-sarcomeric hypertrophic cardiomyopathy associated with Wolff Parkinson White syndrome.

R Villa Fernandez (Lomas De Zamora, AR, F)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals**Categories:** Mobile App - Vote, Young Community Track

Traumatic heart disease

Session Number: 3347

Chairpersons: I Jonauskiene (Kaunas, LT) (F) - F Tanner (Zurich, CH) (M)

- 09:30** **Acquired Gerbode defect following penetrating chest trauma**
DA Ocampo Gomez (Medellin, CO, M)
- 09:42** **Unconventional presentation of Takotsubo cardiomyopathy during a terrorist attack scenario.**
A Star (Beer Sheva, IL, M)
- 09:54** **Cardiogenic shock in puerperal woman secondary to pheochromocytoma**
M Gonzalez Arribas (Bilbao, ES, M)
- 10:06** **Unmasking of Brugada syndrome by high-voltage electric shock**
M Castellaneta (Rio De Janeiro, BR, F)
- 10:18** **A young man with recurrent massive haemoptysis**
S Nasrin (Dhaka, BD, F)

Learning Objectives:

Categories:

The zebras of hypertrophic cardiomyopathy: rare and challenging**Session Number: 3373**Chairpersons:

D Hiestand (Zurich, CH) (F) - A Chaloupka (Brno, CZ) (F)

- 09:30 The tale of a tough and jittery heart- a case of lately detected PRKAG2 cardiomyopathy associated with novel mutation**
GK KINTADA (New Delhi, IN, M)
- 09:45 Unravelling a rare cardiomyopathy phenotype as part of the syndrome of mitochondrial encephalo-myopathy with lactic acidosis and stroke-like episodes**
D Vronsky (Tel Aviv, IL, F)
- 10:00 Dynamic scenery of familial hypertrophic cardiomyopathy**
U OFONG (Eastleigh, GB, F)
- 10:15 Hypertensive crisis following Mavacamten introduction in severe obstructive Hypertrophic Cardiomyopathy and arterial hypertension**
N Maurizi (Florence, IT, M)

Learning Objectives:

Categories:

Prospects for implementation and effectiveness assessment of national protocols for acute coronary syndromes in Kazakhstan and Kyrgyzstan: challenges and opportunities**Organised in collaboration between the Kyrgyz Society of Cardiology and the Association of Cardiologists of Kazakhstan****Session Number: 5107**Chairpersons: E Mirrakhimov (Bishkek, KG) (M) - S Berkinbayev (Almaty, KZ) (M)

10:30 Case 1 - integration of the 2023 ESC Guidelines on Acute Coronary Syndromes into clinical practice in Kazakhstan: key points for mortality reduction
O Sakhov (Almaty, KZ, M)

10:40 Integration of the 2023 ESC Guidelines on Acute Coronary Syndromes into clinical practice in Kazakhstan: key points for mortality reduction - discussion of guideline implementation
G Junusbekova (Almaty, KZ, F)

10:52 Case 2 - analysis of mortality from acute coronary syndrome in the Kyrgyz Republic and measures aimed at reducing mortality

11:02 Analysis of mortality from acute coronary syndrome in the Kyrgyz Republic and measures aimed at reducing mortality - discussion of guideline implementation

Learning Objectives: To discuss management and treatment of acute coronary syndromes, as well as how European recommendations have been implemented into clinical practices in Kazakhstan and Kyrgyzstan.

Categories: Online Live

Risk stratification for midterm outcome after acute coronary syndromes**Session Number: 3054**Chairpersons: R Al-Lamee (London, GB) (F) - AK Gitt (Ludwigshafen, DE) (M)

- 10:45 Effects of restrictive vs liberal transfusion strategies on mortality in patients with acute myocardial infarction and anemia: The 6-month follow up primary results of the MINT trial**
T Simon (Paris, FR, F)
- 10:55 Safety of beta-blocker discontinuation in patients after acute coronary syndromes and preserved left ventricular ejection fraction: long-term clinical outcomes from the SPUM-ACS cohort**
N Johner (Geneva, CH, M)
- 11:05 Impact of dapagliflozin on cardiometabolic outcomes after myocardial infarction according to baseline left ventricular ejection fraction: a DAPA-MI substudy**
D Erlinge (Lund, SE, M)
- 11:15 Albumin creatinine index added to the grace score increases its discriminative capacity for mortality at 12 years of follow-up in patients with acute coronary syndrome**
C Higa (Capital Federal, AR, M)
- 11:25 Microcirculatory resistance after primary percutaneous coronary intervention predicts residual myocardial damage: a post hoc analysis from the CLEVER-ACS trial**
A Candreva (Zurich, CH, M)
- 11:35 Impact of baseline thrombocytopenia on outcomes in hospitalizations for acute coronary syndrome and non-elective percutaneous coronary intervention: meta-analysis**
S Senapati (El Paso, US, M)

Learning Objectives:

Categories:

**Fighting ventricular dyssynchrony: cardiac resynchronisation
therapy vs. conduction-system pacing****Session Number: 3016**Chairpersons: D Nair (Jonesboro, US) (F) - M Glikson (Jerusalem, IL) (M)

- 10:45 Impact of QRS complex fragmentation on all-cause mortality before and after cardiac resynchronization therapy**
C Rodriguez-Lopez (Madrid, ES, M)
- 10:55 Comparative study of the effects of preferential left ventricular and biventricular pacing on echocardiographic and cardiorespiratory indices and clinical status of heart failure patients: preliminary**
P Xydis (Athens, GR, M)
- 11:05 Mechanical dyssynchrony and response to cardiac resynchronization therapy in heart failure patients with right ventricular pacing: a pre-specified subgroup analysis of the BUDAPEST CRT Upgrade trial**
A Fabian (Budapest, HU, F)
- 11:15 Beat-to-beat measurement of R-wave peak time for left bundle branch area pacing: man versus machine using a novel automated algorithm**
A Spadotto (Bologna, IT, M)
- 11:25 Conduction-System pacing Italian Network Group (C-SING): insights from a Nationwide Multicenter Observational Study**
G Dell'Era (Novara, IT, M)
- 11:35 Left bundle branch area pacing efficacy, feasibility, and long-term outcomes: a prospective cohort study**

Learning Objectives:

Categories:

Pharmacotherapy for worsening heart failure

Session Number: 3036

Chairpersons: M Farrero Torres (Barcelona, ES) (F) - I Planinc (Zagreb, HR) (M)

- 10:45 Left ventricular dysfunction, pulmonary congestion, or both and cardiovascular risk after acute myocardial infarction**
JT Tavares Nunes (Toronto, CA, M)
- 10:55 Diuretic therapy strategies in decompensated acute heart failure: a systematic review and network metanalysis**
G Anastasia (Grottaglie, IT, M)
- 11:05 Clinical outcomes of dapagliflozin in acute heart failure with reduced ejection fraction: a randomized controlled trial (CODA-HFrEF)**
H Hussein (Cairo, EG, M)
- 11:15 Acetazolamide for patients with acute decompensated heart failure: a systematic review and meta-analysis of randomised controlled trials**
M Kritya (Pune, IN, M)
- 11:25 Acute hemodynamic effect of oral ketones in patients with acutely decompensated heart failure and low cardiac output syndrome: a prospective randomized study.**
M Sramko (Prague, CZ, M)
- 11:35 Paracetamol and adverse cardiovascular outcomes in patients with heart failure**
QW Ren (- , CN, F)

Learning Objectives:

Categories:

Epidemiology of cardiovascular risk and disease

Session Number: 3095

Chairpersons: E Gianos (New York, US) (F) - F D'Ascenzi (Siena, IT) (M)

10:45 Cardiovascular disease burden and risk factor management in cancer survivors: insights from a large-scale East London cohort
L Szabo (Budapest, HU, F)

10:55 Heterogeneous associations of traditional atherosclerotic risk factors and long-term events in different arterial territories: the EPIC Norfolk prospective population cohort
M van den Bogaart (Amsterdam, NL, F)

11:05 LDL-cholesterol and CRP as predictors of CV morbidity and mortality - a comprehensive analysis of data from the UK Biobank
MRP Markus (Greifswald, Hansestadt, DE, M)

11:15 Independent and joint associations of urinary potassium excretion with cardiovascular death: a national population-based cohort study
C Lin (Beijing, CN, F)

11:25 The projected global burden of modifiable risk factors on cardiovascular disease from 2025 to 2100
B Chong (Singapore, SG, M)

11:35 Applicability of VICTORION-1 PREVENT Criteria to the US Population
R Aggarwal (Boston, US, M)

Learning Objectives:

Categories:

Innovations in telemedicine, robotics, and digital health interventions

Session Number: 3112

Chairpersons: I Uchmanowicz (Wroclaw, PL) (F) - J Granada (Orangeburg, US) (M)

- 10:45 Electronic consultation from primary care to a cardiology department improves outcomes in patients with cancer.**
JR Gonzalez Juanatey (Santiago De Compostela, ES, M)
- 10:55 The role of digital health intervention in improving physical activity in cardiac rehabilitation center: a randomised controlled trial**
SE Kizilkilic (Hasselt, BE, F)
- 11:05 Impact on healthcare costs of adding telemedicine to a multidisciplinary disease management program for heart failure: a sub-analysis of the iCOR trial**
H Morillas Climent (Valencia, ES, M)
- 11:15 Feasibility of novel robot-assisted, remotely-performed echocardiographic examination**
J Atherton (Brisbane, AU, M)
- 11:25 Effectiveness of telephone clinics for assessment of new onset chest pain - a retrospective single-centre observational study**
M Faizur Rahman (Rotherham, GB, M)
- 11:35 Hypertensive myocardial disease screening in low-income settings using smartphone-based technologies: a prospective multicenter trial**
N Maurizi (Florence, IT, M)

Learning Objectives:

Categories:

MINOCA (2)**Session Number: 3303**Chairpersons: M Verdoia (Biella, IT) (F) - A Greco (Catania, IT) (M)**10:45 MINOCA - get ready for the session**

M Verdoia (Biella, IT, F)

10:50 The invisible culprit: decoding vasospasm in MINOCA with a multimodality approach

R Terzi (Milan, IT, M)

11:03 A diagnostic dilemma: Commotio cordis, Takotsubo syndrome or MINOCA?

R Pang (Singapore, SG, F)

11:16 MINOCA due to coronary spasm associated with apical hypertrophic cardiomyopathy

GAB Boros (Jundiai, BR, M)

11:29 Acute non-fulminant myocarditis presenting as a STEMI-mimick due to suspected vasospastic angina/INOCA - a Matryoshka doll case.

E Altintac (Ingolstadt, DE, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals

Categories: Mobile App - Vote, Young Community Track

Takotsubo syndrome**Session Number: 3331**Chairpersons: I Kotlar (Skopje, MK) (F) - S Raposeiras Roubin (Pontevedra, ES) (M)

- 10:45 Chest pain after elective percutaneous coronary intervention as trigger of Takotsubo syndrome**
V Castiglione (Pisa, IT, M)
- 10:57 Takotsubo syndrome in heart transplant recipient under a high intensity immunosuppression**
E Flores Gonzalez (Berlin, DE, M)
- 11:09 Empowering early action: the role of impella 5.5 in Takotsubo cardiomyopathy complicated by cardiogenic shock**
R Goswami (Jacksonville, US, M)
- 11:21 Patient with gender dysphoria diagnosed with multiple sclerosis following takotsubo syndrome and ventricular arrhythmia: a case report and systematic literature review**
S Yamanaka (- , JP, M)
- 11:33 Takotsubo cardiomyopathy post pericardiocentesis in a patient with cardiac tamponade**
A Bhatti (Redhill, GB, F)

Learning Objectives:

Categories:

All shapes and forms of pericarditis**Session Number: 3371**Chairpersons: M Sampaio De Sousa Lira (Sao Paulo, BR) (F) - IT Colluoglu (Karabuk, TR) (F)

- 10:45 Tuberculous pericarditis secondary to latent tuberculosis**
J A Quintero-Martinez (Miami, US, M)
- 10:57 An unusual case of purulent pericarditis**
A Pandolfi (Urgnano, IT, M)
- 11:09 Unlocking the power of corticosteroids: revolutionising treatment of purulent effusive-constrictive pericarditis**
J Willis (Chapel Hill, US, F)
- 11:21 Hemopericardium and acute type A aortic dissection: tips and tricks from initial clinical presentation to recovery**
I Burazor (Belgrade, RS, F)
- 11:33 Eat your heart out: a case of pyopneumopericarditis secondary to a gastropericardial fistula.**
M Stefil (Adelaide, AU, F)

Learning Objectives:

Categories:

HOT LINE 10

Session Number: 1019

Chairpersons: K Chun (Frankfurt, DE) (M)

- 11:00 **SHAM-PVI - A randomised sham-controlled study of pulmonary vein isolation in symptomatic atrial fibrillation**
R Dulai (London, GB, M)
- 11:12 **Discussant review - SHAM-PVI**
- 11:17 **Panel discussion - SHAM-PVI**
- 11:22 **SUPPRESS-AF - The efficacy of low-voltage-area ablation on atrial tachyarrhythmias recurrence in patients with persistent atrial fibrillation**
M Masuda (Nishinomiya-Shi, JP, M)
- 11:34 **Discussant review - SUPPRESS-AF**
H Puererfellner (Linz, AT, M)
- 11:39 **Panel discussion - SUPPRESS-AF**
- 11:44 **CRABL-HF - Cryoballoon vs. Radiofrequency Ablation of AF in Patients with Heart Failure**
K Kusano (Suita, JP, M)
- 11:56 **Discussant review - CRABL-HF**
- 12:01 **Panel discussion - CRABL-HF**

Learning Objectives:

Categories: Online Live

Risk stratification and advanced therapies in channelopathies**Session Number: 167**Chairpersons: SG Priori (Pavia, IT) (F) - ER Behr (London, GB) (M)

- 11:00 Living with channelopathies - patient perspective**
A Verstrael (Antwerpen, BE, M)
- 11:10 Does genetic testing aid risk-stratification in channelopathies?**
L Crotti (Pavia, IT, F)
- 11:22 Interventional therapy for refractory arrhythmias in channelopathies**
K Shivkumar (Los Angeles, US, M)
- 11:34 Gene therapy in channelopathies: ready for prime time?**
KE Odening (Bern, CH, F)
- 11:46 Risk stratification and advanced therapies in channelopathies - discussion**
V Probst (Nantes, FR, M)

Learning Objectives:

Categories: Includes a patient perspective

Diagnosis and management of acute Takotsubo cardiomyopathy in the intensive cardiac care unit**Session Number: 208**Chairpersons: K Huber (Vienna, AT) (M) - A Lansky (New Haven, US) (F)

- 11:00** **Diagnosis of Takotsubo cardiomyopathy: biomarkers, electrocardiogram, non-invasive, and invasive imaging**
JR Ghadri (Zurich, CH, F)
- 11:20** **Management of Takotsubo cardiomyopathy with haemodynamic instability or incessant arrhythmias**
J Poess (Leipzig, DE, F)
- 11:40** **Treatment of acute, uncomplicated Takotsubo cardiomyopathy: if, what, and for how long?**
H Bueno (Madrid, ES, M)

Learning Objectives:

Categories: Clinical Implementation Track, Online Live

Clinical Case Management: impact of comorbidities on personalised care for hypertension

Session Number: 219

Chairpersons: K Ngu Blackett (Guildford, GB) (F) - E Yang (Mercer Island, US) (M)

- 11:00 Case 1: a patient with hypertension, obesity, and HFpEF**
ML Muiesan (Brescia, IT, F)
- 11:20 Case 2: a patient with hypertension during cancer therapy**
G Kuster (Basel, CH, F)
- 11:40 Clinical Case Management: impact of comorbidities on personalised care for hypertension - discussion**
TJ Jafar (Singapore, SG, F)
- M Camafort (Barcelona, ES, M)

Learning Objectives:

Categories: Spotlight of the Congress

Heart-brain interactions: sex differences and impact on cognition

Session Number: 300

Joint session with the European Academy of Neurology (EAN)

Chairpersons: W Doechner (Berlin, DE) (M) - V Caso (Perugia, IT) (F)

11:00 Sex differences in heart-brain interactions: a neurology perspective
M Endres (Berlin, DE, M)

11:15 Sex differences in heart-brain interactions: a cardiology perspective
C Gebhard (Zurich, CH, F)

11:30 Cardiac disease and cognition: a neurology perspective
G Tsivgoulis (Athens, GR, M)

11:45 Cardiac disease and cognition: a cardiology perspective
I Grunwald (- , GB, F)

Learning Objectives: This session will discuss the pathophysiological mechanisms of brain-heart interactions and their important clinical implications (Takotsubo, stroke-heart syndrome, etc.) from the perspective of sex and gender, as well as mechanisms of cognitive decline and the development of dementia due to heart disease, keeping in mind the considerable comorbidity between neurological and cardiological diseases.

Categories:

2024 ESC Guidelines for the Management of Peripheral Arterial and Aortic Diseases: Ask the Guidelines Task Force

Session Number: 1104

Smaller trials, trial updates, and other studies on lipid therapy

Session Number: 1050

Chairpersons: KC Koskinas (Bern, CH) (M)

- 11:00 Apolipoprotein A-I infusions and cardiovascular outcomes in patients with acute myocardial infarction and hyperlipidemia**
C Gibson (Boston, US, M)
- 11:12 Cardiovascular Efficacy of Evolocumab in Patients with Obesity: Updates from FOURIER Trial**
Y Kang (Boston, US, F)
- 11:24 Alternative LDL cholesterol lowering strategy vs. high-intensity statin strategy: An individual patient data meta-analysis from the randomized RACING and LODESTAR trials**
M Hong (Seoul, KR, M)
- 11:36 A randomised, placebo-controlled phase 3 study of plzasiran in patients with familial chylomicronemia syndrome**
G Watts (Nedlands, AU, M)
- 11:48 ApoA-I Infusions and Burden of Ischemic Events after Acute Myocardial Infarction**

Learning Objectives:

Categories:

Metabolic rewiring of the heart

Session Number: 356

Chairpersons: S Pullamsetti (Bad Nauheim, DE) (F) - M Abdellatif (Paris, FR) (M)

- 11:00 Metabolic rewiring in HFpEF**
P Liu (Ottawa, CA, M)
- 11:15 Iron metabolism in heart failure**
S Lakhal-Littleton (Oxford, GB, F)
- 11:30 Lipid metabolism rewiring of the heart**
I Fleming (Frankfurt Am Main, DE, F)
- 11:45 Metabolic rewiring of the heart - discussion**
AM Shah (London, GB, M)

Learning Objectives:

Categories:

Doping: cause of sudden cardiac death in athletes?**Session Number: 137**Chairpersons: S Sharma (London, GB) (M) - K Esefeld (Muenchen, DE) (F)

- 11:00 Current doping practices and the risk of cardiovascular disease and sudden death**
A La Gerche (Fitzroy, AU, M)
- 11:15 Potential cardiovascular risks of energy drinks and caffeinated beverages**
E Cavarretta (Rome, IT, F)
- 11:30 Potential cardiovascular risks of performance-enhancing drugs**
E Kouidi (Thessaloniki, GR, F)
- 11:45 Doping: cause of sudden cardiac death in athletes? - discussion**

Learning Objectives:

Categories: Online Live

Personalising the management of coronary artery disease in patients undergoing transcatheter aortic interventions

Session Number: 334

Chairpersons: J Mascherbauer (Vienna, AT) (F) - M Leon (New York, US) (M)

- 11:00 Risk stratification of coronary artery disease in TAVI patients: clinical, anatomical, and physiological assessment**
G Stefanini (Milan, IT, M)
- 11:15 PCI in TAVI: before, during, and after**
D Wood (Vancouver, CA, M)
- 11:30 Patient-based strategies: valve choice and technical issues**
T Rudolph (Bad Oeynhausen, DE, F)
- 11:45 Personalising the management of coronary artery disease in patients undergoing transcatheter aortic interventions - discussion**
C GANDOLFO (Palermo, IT, F)

Learning Objectives:

Categories: Online Live, Spotlight of the Congress

Guidelines in Practice: imaging in prosthetic valve endocarditis

Session Number: 252

Chairpersons: N Ajmone Marsan (Leiden, NL) (F) - B Cosyns (Brussels, BE) (M)

11:00 A patient with a prosthetic valve and fever: case presentation
LE Sade (Ankara, TR, F)

11:15 A patient with a prosthetic valve and fever: what do the guidelines say?
P Erba (Bergamo, IT, F)

11:30 A patient with a prosthetic valve and fever: how to implement the guidelines and take-home messages
G Habib (Marseille, FR, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Clinical Implementation Track, Online Live, Young Community Track

The floor is yours: bring your questions on stroke prevention in clinical and subclinical atrial fibrillation

Session Number: 170

Chairpersons: T Glotzer (Tenafly, US) (F) - AJ Camm (London, GB) (M) - K Triantafyllou (Thessaloniki, GR) (M)

11:00 The floor is yours: bring your questions on stroke prevention in clinical and subclinical atrial fibrillation - get ready for the session
K Triantafyllou (Thessaloniki, GR, M)

11:05 The floor is yours: bring your questions on stroke prevention in clinical and subclinical atrial fibrillation - expert panel
P Kirchhof (Hamburg, DE, M)

J Healey (Hamilton, CA, M)

GYH Lip (Liverpool, GB, M)

E Hylek (Boston, US, F)

TS Potpara (Belgrade, RS, F)

M Schoos (Klampenborg, DK, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Mobile App - Ask a Question, Young Community Track

Circulation: the full spectrum

Session Number: 421 Joint session with Circulation

Chairpersons: J Hill (Dallas, US) (M) - IM Lang (Vienna, AT) (F)

- 11:00 **Introduction: Circulation**
J Hill (Dallas, US, M)
- 11:03 **Coronary and interventional research in Circulation**
P Steg (Paris, FR, M)
- 11:09 **Acute coronary syndrome research in Circulation**
S James (Uppsala, SE, M)
- 11:15 **Imaging research in Circulation**
V Delgado (Barcelona, ES, F)
- 11:21 **Social media in Circulation**
P Myhre (Oslo, NO, M)
- 11:27 **Genetic epidemiology in Circulation**
W Post (Baltimore, US, F)
- 11:33 **Cardiac diagnostics in Circulation**
NL Mills (Edinburgh, GB, M)
- 11:39 **Advances in HFrEF and HFpEF in Circulation**
NAB Ntusi (Cape Town, ZA, M)
- 11:45 **Preclinical and translational studies in Circulation**
G Schiattarella (Berlin, DE, M)
- 11:51 **Biomarker research in Circulation**
T Omland (Oslo, NO, M)

Learning Objectives:

Categories:

Help or hindrance: ChatGPT and chatbots?

Session Number: 373

Chairpersons: CJ Plummer (Newcastle Upon Tyne, GB) (M) - T Jaarsma (Norrköping, SE) (F)

11:00 Only seven minutes per patient: could chatbots enhance patient consultations?

L Neubeck (Edinburgh, GB, F)

11:15 Is the patient comfortable using ChatGPT?

M Verbakel (Nijmegen, NL, F)

11:30 Large language models and other foundation models will soon disrupt clinical care

D Duncker (Hannover, DE, M)

11:45 Help or hindrance: ChatGPT and chatbots? - discussion

L Koltowski (Warsaw, PL, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Digital Health, Includes a patient perspective, Young Community Track

EHRA-PATHS: developing a systematic approach of patients with atrial fibrillation and multimorbidity

Session Number: 440

Chairpersons: JL Merino (Madrid, ES) (M) - E Svennberg (Stockholm, SE) (F)

- 11:00 A new software tool to track presence and management of comorbidities in patients with atrial fibrillation**
H Heidbuchel (Antwerp, BE, M)
- 11:15 Development and evaluation of a new software tool to address comorbidities in atrial fibrillation: lessons learned on how to navigate the EU's Medical Device Regulation (MDR)**
L Desteghe (Edegem, BE, F)
- 11:30 The ongoing clinical trial testing whether the EHRA-PATHS software tool improves detection and management of comorbidities in atrial fibrillation**
M Rienstra (Groningen, NL, M)

Learning Objectives:

Categories:

International partnership to nurture future cardiovascular research leaders in Europe

Session Number: 450

Chairpersons: M Avkiran (London, GB) (M) - S Dimmeler (Frankfurt, DE) (F) - R Schouten (The Hague, NL) (F)

- 11:00 Mechanisms of right heart failure in pulmonary hypertension (PROMETHEUS Project)**
F De Man (Amsterdam, NL, F)
- 11:15 Role of platelets in microvascular dysfunction in HFpEF (MegaCardiocyte project)**
M Brittan (Edinburgh, GB, F)
- 11:30 Intercellular communication in atherogenesis and plaque destabilisation (PLAK-TALK Project)**
J Tarkin (Cambridge, GB, M)
- 11:45 Translational proteomics for cardiovascular disease (Prot4CVD Project)**
C Langenberg (Berlin, DE, F)

Learning Objectives: This session will highlight a strategic partnership between funders in the UK (British Heart Foundation; BHF), Germany (Deutsches Zentrum für Herz-Kreislauf-Forschung E.V.; DZHK) and the Netherlands (Dutch Heart Foundation Hartstichting; DHF) targeted at supporting mid-career researchers in order to nurture future cardiovascular research leaders in Europe; will profile four international teams of mid-career researchers who are currently funded and give them a platform to share their progress and plans in different areas of cardiovascular research.

Categories:

Session Number: 5134	Daily Highlights by the Japanese Circulation Society
<u>Chairpersons:</u>	This session is brought to you by the Japanese Circulation Society and is not part of the official ESC programme

Learning Objectives:

Categories: Online Live

Therapeutic targets for myocardial infarction

Session Number: 3124

Chairpersons: RT Smolenski (Gdansk, PL) (M) - M Nosedá (London, GB) (F)

- 12:00 Inhibition of fractalkine signalling in patients with acute myocardial infarction - First results from the FRACTAL trial**
I Spyridopoulos (Newcastle Upon Tyne, GB, M)
- 12:10 From bench to bedside and back to bench: investigating the role of platelet heterogeneity in coronary artery disease**
D Bongiovanni (Augsburg, DE, M)
- 12:20 NPM1-mediated suppression of OXPHOS reprogramming in reparative macrophages impairs cardiac repair post-myocardial infarction**
Z Zhan (Shanghai, CN, F)
- 12:30 Downregulation of CPEB3 exacerbates cardiac injury by inhibiting cardiomyocyte adaptive metabolic reprogramming after myocardial infarction**
Z Tao (Nanjing, CN, F)
- 12:40 Lipin1 prevents ischemic heart disease by regulating lipid homeostasis**
J Guo (San Francisco, US, F)
- 12:50 Oxct1 regulates cardiomyocyte PANoptosis in acute myocardial infarction via succinylating Tfam**
X Li (Nanjing, CN, F)

Learning Objectives:

Categories:

The guardians of clotting: exploring antiplatelet strategies**Session Number: 3073**Chairpersons: R Colleran (Dublin, IE) (F) - A Oliva (Milano, IT) (M)

- 12:00** **Reduction of thrombus burden by cangrelor in ticagrelor-loaded st-elevation myocardial infarction patients with high residual platelet reactivity: the imaging sub-study of the ERMIT randomized trial**
F Beygui (Caen, FR, M)
- 12:10** **Association of ticagrelor vs clopidogrel with net adverse clinical events in patients with mild thrombocytopenia undergoing PCI**
K Chen (Tianjin, CN, M)
- 12:20** **Disparities in the proportion of ticagrelor and prasugrel-eligible patients with NSTEMI-ACS in a real-world registry**
- 12:30** **The safety and efficacy of indobufen or aspirin combined with clopidogrel in patients with acute myocardial infarction after percutaneous coronary intervention**
W Dai (Tianjin, CN, M)
- 12:40** **Respective impact of bleeding and ischemic complications of mortality after percutaneous coronary interventions: substudy from the FRANCE-PCI registry**
P Guedeney (Paris, FR, M)
- 12:50** **Complex versus non-complex, should we adjust the antiplatelet strategy to the type of percutaneous coronary intervention? Results from a real world PCI population**
ECI Woelders (Nijmegen, NL, F)

Learning Objectives:

Categories:

Cardiac myosin inhibitors for treatment of hypertrophic obstructive cardiomyopathy**Session Number: 3065**Chairpersons: B Raman (Oxford, GB) (F) - J Kaski (London, GB) (M)

- 12:00** **Serial changes in left and right ventricular global longitudinal strain in symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten: insights from VALOR-HCM trial**
M Desai (Cleveland, US, M)
- 12:15** **Exploring the effects of mavacamten through hemodynamic force analysis in patients with obstructive hypertrophic cardiomyopathy**
A Milazzo (Florence, IT, F)
- 12:30** **A comprehensive evaluation of available evidence of mavacamten in obstructive HCM: a meta-analysis of randomised controlled trials.**
A Elmorsy (Tanta, EG, M)
- 12:45** **Mavacamten in a real-world hypertrophic cardiomyopathy population: how many may be eligible?**
MRL Lima (Lisbon, PT, F)

Learning Objectives:

Categories:

Mental stress, nutrition, pregnancy, and cancer: risk factors for heart disease**Session Number: 3086**Chairpersons: E Cavarretta (Rome, IT) (F) - T Suter (Bern, CH) (M)

- 12:00 Predictive value of Type D personality combined with unhealthy cardiovascular behaviors for the long-term adverse cardiovascular events in ACS patients**
Y Wang (Harbin, CN, F)
- 12:10 Associations between subjective and objective well-being and risk of cardiometabolic disease**
Y Hou (Beijing, CN, F)
- 12:20 Ultra-processed food consumption and risk of cardiovascular mortality in Australia: preliminary results from prospective observational study**
S Gauci (Melbounre, AU, F)
- 12:30 External validation of the HFA-ICOS risk stratification tool for prediction of cardiovascular complications after cancer treatment**
MN Gynnild (Trondheim, NO, F)
- 12:40 Insights into the aetiology and temporal trends in cardiac mortality in the young: a 21-year review of national and registry data in the united kingdom**
R Bhatia (London, GB, M)
- 12:50 Pregnancy complications and long-term risk of cardiovascular events in women with heart disease**
E Taufer Cederlof (Huddungeby, SE, F)

Learning Objectives:

Categories:

Cardiovascular trends: hospitalisations, trials, and genetic therapies

Session Number: 3120

Chairpersons: I Kardys (Rotterdam, NL) (F) - K Kotseva (London, GB) (F)

- 12:00 Trends in cardiovascular-related hospitalizations, costs, and procedures from the national inpatient sample, 2016-2020**
A Haidar (Los Angeles, US, M)
- 12:12 Reassessing pharmacological trials with positive composite outcome driven by reduction in nonfatal myocardial infarction: a systematic review and meta-analysis**
H Sun (- , CN, M)
- 12:24 Association between autonomic dysfunction, 12-year mortality and 10-year incident cardiovascular disease**
B Hernandez (Dublin, IE, F)
- 12:36 First trimester maternal infections and offspring congenital heart defects: a systematic review and meta-analysis**
HM Su (Leuven, BE, F)
- 12:48 Phase I gene therapy clinical trial design of RP-A601 in adult patients with PKP2-arrhythmogenic cardiomyopathy (PKP2-ACM)**
M Coggins (- , US, M)

Learning Objectives:

Categories:

Myocarditis (2)**Session Number: 3312**Chairpersons: C Graeni (Bern, CH) (M) - A Caforio (Padua, IT) (F)

- 12:00 Myocarditis - get ready for the session**
C Graeni (Bern, CH, M)
- 12:05 Immunotherapy-mediated myocarditis and concurrent vasospastic angina in a patient with established ischaemic heart disease: a clinical conundrum**
J Ko (Melbourne, AU, M)
- 12:23 Cardiac conundrum: a case of fulminant myocarditis, refractory ventricular tachycardia and the enigma of ring-like fibrosis.**
KE Gil (Columbus, US, F)
- 12:41 Giant cell myocarditis presenting as a clinical syndrome of heart failure progressing to cardiogenic shock: the role of endomyocardial biopsy and advanced heart failure therapy**
W Srisuwanwattana (Bangkok, TH, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals

Categories: Mobile App - Vote, Young Community Track

Rare, rarer, and unique cardiomyopathies**Session Number: 3355**Chairpersons:

V Sullivan (Ireland, IE) (F) - C Nitsche (Vienna, AT) (M)

- 12:00 Emotional stress-induced hot-phases in a patient with a desmoplakin-associated arrhythmogenic cardiomyopathy?**
A Caputo (Rome, IT, F)
- 12:12 Spasms that choked the heart - an interesting case of tetanus presenting with stress cardiomyopathy**
GK KINTADA (New Delhi, IN, M)
- 12:24 Difficult management of electrical storm in hypertrophic cardiomyopathy with arrhythmogenic features of channelopathies: a novel overlapping syndrome is possible?**
A Palmieri (- , IT, M)
- 12:36 A novel likely pathogenic DSP mutation, p. Glu1892Argfs*38, in a family with arrhythmogenic cardiomyopathy**
R Mitran (Bucharest, RO, F)
- 12:48 Rare presentation of fulminant AI cardiac Amyloidosis.**
C Santos Aragao (Aracaju, BR, M)

Learning Objectives:

Categories:

Tumours in the heart**Session Number: 3361**Chairpersons: A Neto (Penafiel, PT) (F) - L Szabo (Budapest, HU) (F)

- 12:00** **Massive pericardial effusion caused by primary effusion lymphoma of the pericardium**
M SOH (Suwon, KR, M)
- 12:15** **Endomyocardial fibrosis due to hypereosinophilic syndrome mimicking apical hypertrophic cardiomyopathy.**
S Mustafaeva (Baku, AZ, F)
- 12:30** **A rare case of restrictive cardiomyopathy in a young patient with advanced heart failure**
A E Karanikola (Marousi, GR, F)
- 12:45** **What do bradycardias hide? A rare mediastinal tumor invading the adjacent structures**
A Teodorescu (Bucharest, RO, F)

Learning Objectives:

Categories:

ESC Ordinary General Assembly

Session Number: 5002

Chairpersons:

12:30 ESC Ordinary General Assembly

Learning Objectives:

Categories:

Challenges in acute and chronic heart failure: implementing guidelines and beyond - insights from Greece and Cyprus
Organised in collaboration with the Hellenic Cardiological Society and the Cyprus Society of Cardiology

Session Number: 5109

Chairpersons: G Filippatos (Athens, GR) (M) - M Karakiriou (Nicosia, CY) (F)

- 12:30 Case 1 - medical therapy in acute heart failure: vision from Cyprus**
T Christodoulides (Nicosia, CY, M)
- 12:40 Medical therapy in acute heart failure: vision from Cyprus - discussion of guideline implementation**
P Agathangelou (Nicosia, CY, M)
- 12:52 Case 2 - HFpEF: how to monitor and treat - Greek perspectives**
C Chrysohoou (Athens, GR, F)
- 13:02 HFpEF: how to monitor and treat - Greek perspectives - discussion of guideline implementation**
KK Naka (Ioannina, GR, F)

Learning Objectives: To discuss medical therapies and limitations of multimodal management for acute decompensated heart failure in neighbouring Greece and Cyprus in the context of their different healthcare systems and implementation of ESC Guidelines into their respective clinical practices.

Categories: Online Live

	Management and prognostication in acute myocardial infarction cardiogenic shock
--	--

Session Number: 3046

Chairpersons: M Alasnag (Jeddah, SA) (F) - RA Byrne (Dublin, IE) (M)

- 13:15 **Influence of hospital ownership on patient outcomes in STEMI-induced cardiogenic shock undergoing revascularization: a retrospective cohort study**
J Sequeira Gross (Fort Myers, US, M)
- 13:27 **The effect of treatment strategy for acute myocardial infarction complicated by cardiac shock using Impella in accordance with institutional protocol**
T Tada (Kurashiki, JP, M)
- 13:39 **Evaluation of repeated machine learning-based phenotyping in patients with cardiogenic shock**
E Zweck (Duesseldorf, DE, M)
- 13:51 **Patient characteristics and clinical outcome in acute myocardial infarction related cardiogenic shock according to vascular access site for PCI**
E Peters (Amsterdam, NL, F)
- 14:03 **Influence of timing of impella insertion on the prognosis of acute myocardial infarction complicated with cardiogenic shock requiring ECPELLA**
K Shimamoto (Kyoto, JP, M)

Learning Objectives:
Categories:

The interplay between atrial fibrillation and heart failure: implications for clinicians**Session Number: 3024**Chairpersons: T Hovakimyan (Yerevan, AM) (F) - D Gaita (Timisoara, RO) (M)

- 13:15 Incidence of atrial fibrillation detected by an insertable cardiac monitor in a large real-world cohort of heart failure patients with reduced and preserved ejection fraction**
S Sarkar (Moundsvew, US, M)
- 13:25 Heart failure risk assessment using biomarkers in patients with atrial fibrillation: analysis of 32,041 patients from the COMBINE-AF study**
PM Haller (Boston, US, M)
- 13:35 Long-term risk of heart failure and postoperative atrial fibrillation following noncardiac surgery: not so different from non-surgical atrial fibrillation**
MN Karacan (Hoeje Taastrup, DK, F)
- 13:45 Prognostic implication of right ventricular - pulmonary arterial coupling in patients with non-valvular atrial fibrillation**
D Kim (Seongnam, KR, M)
- 13:55 Prevalence and implications of cardiomyopathy-associated genetic variants in early-onset atrial fibrillation**
LFJ Wijdeveld (Amsterdam, NL, F)
- 14:05 Atrial Fibrillation (AF) detected by repeat handheld ECG screening and the risk of heart failure hospitalization**
W Sun (Hong Kong, HK, F)

Learning Objectives:

Categories:

Probing deeper into the pathophysiology of heart failure

Session Number: 3029

Chairpersons: C Hage (Stockholm, SE) (F) - M Lainscak (Murska Sobota, SI) (M)

- 13:15 Cardiac contractility index, a novel biomarker of incident heart failure amongst people with normal left ventricular ejection fraction in the UK Biobank**
OI Brown (Leeds, GB, M)
- 13:25 Significant correlation between the extent of myocardial fibrosis and heart failure parameters in patients undergoing transcatheter aortic valve implantation.**
K Yamaguchi (Yokohama, JP, M)
- 13:35 The effect of empagliflozin on right ventricular function in heart failure patients with reduced ejection fraction: analysis from the randomized EMPEROR-HF clinical trial**
M Callesen Hansen (Odense, DK, F)
- 13:45 Genetic and phenotypic architecture of biventricular trabeculation**
KA McGurk (London, GB, F)
- 13:55 Neurodegeneration is highly associated with comorbidity burden in HFrEF patients**
S Prausmueller (Wien, AT, F)
- 14:05 Exome sequencing in over 63,000 patients in TIMI trials uncovers pathogenic cardiomyopathy variant carriers with high risk for heart failure and cardiovascular death**
S Kany (Hamburg, DE, M)

Learning Objectives:

Categories:

Cardiovascular risk of cancer therapy

Session Number: 3106

Chairpersons: P A Henriksen (Edinburgh, GB) (M) - G Kuster (Basel, CH) (F)

- 13:15** **Artificial intelligence applied to electrocardiographic images for the risk stratification of cancer therapeutics-related cardiac dysfunction**
EK Oikonomou (New Haven, US, M)
- 13:25** **Incidence, characteristics, and prognostic impact of cancers in patients with atrial fibrillation: a report from the GLORIA-AF registry**
B Huang (Liverpool, GB, M)
- 13:35** **Immune-checkpoint myocarditis phenotype when using systematic troponin surveillance in cancer patients.**
F Cribari (Rome, IT, M)
- 13:45** **Angiotensin II as a linking factor in cardiovascular disease enhanced cancer growth**
B Van Berlo (- , NL, M)
- 13:55** **Correlative study to assess the predictive power of the ICOS HF calculator in the prediction of development of HER-2 antagonist induced cardiac dysfunction in a single center in Saudi Arabia in 2023**
M Al Qaseer (Manama, BH, F)
- 14:05** **Transcatheter mitral edge-to-edge repair in patients with prior cancer diagnosis**
R Gonzalez-Manzanares (Cordoba, ES, M)

Learning Objectives:

Categories:

What's new in imaging of valvular heart disease

Session Number: 3003

Chairpersons: A Duncan (London, GB) (F) - P Pibarot (Quebec, CA) (M)

- 13:15** **Prognostic preoperative factors for recurrence of tricuspid regurgitation following annuloplasty: examining the influence of 3d echocardiography**
D Verikas (Vilnius, LT, M)
- 13:25** **Current echocardiographic indices for right ventricular function are inadequate to predict patient outcomes in chronic tricuspid regurgitation**
CL Frost (Boston, US, F)
- 13:35** **Prognostic value of right ventricular-pulmonary arterial coupling indices in patients with moderate to severe mitral stenosis**
MW Chan (Serdang, MY, F)
- 13:45** **Diagnostic value of aortic valve displacement by tissue tracking for identification of aortic valve stenosis severity.**
A Jasinska (Warsaw, PL, F)
- 13:55** **Evolution and prognostic impact of left ventricular myocardial work indices after transcatheter aortic valve replacement in patients with severe aortic stenosis**
HW Wu (Leiden, NL, F)
- 14:05** **Echocardiographic assessment of the right heart pulmonary circulation unit in mitral regurgitation due to mitral valve prolapse**
R Maheut (Vandoeuvre Les Nancy, FR, M)

Learning Objectives:

Categories:

Pericardial disease**Session Number: 3314**Chairpersons: L Antohi (Bucharest, RO) (F) - E Conte (Milan, IT) (M)**13:15 Pericardial disease - get ready for the session**

E Conte (Milan, IT, M)

13:20 Severe pericardial effusion as manifestation of adult-onset still disease

P Urban (Ceske Budejovice, CZ, M)

13:38 " To tap or not to tap" a case of idiopathic chronic crp negative large pericardial effusion

I Kachrimanidis (Athens, GR, M)

13:56 Obstructive shock and out-of-hospital cardiac arrest as the first presentation of isolated cardiac hydatidosis

F Gonzalez-Santorum (Barcelona, ES, F)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals

Categories: Mobile App - Vote, Young Community Track

Complex interventions

Session Number: 3352

Chairpersons: AR Pereira (Almada, PT) (F) - S Sorrentino (Marigliano, IT) (M)

- 13:15 Embolization of a pulmonary stent. A rare complication following treatment of pulmonary vein stenosis post atrial fibrillation ablation**
AI Duta (Luebeck, DE, M)
- 13:27 Coronary Artery Occlusion Post-TAVR: Valve Strut Thrombosis in Patients with Low Sinus of Valsalva and Narrow Sinotubular Junction**
N Suzuki (Shimotsuke, JP, M)
- 13:39 The last resort during complex retrograde percutaneous in stent coronary chronic total occlusion intervention: externally crush a heavy calcified occluded stent in right coronary artery.**
SSB Baysal (Ankara, TR, M)
- 13:51 Intravascular lithotripsy in severely calcified left anterior descending artery**
AR Silveraju (Cheras, MY, M)
- 14:03 Successful percutaneous closure of an iatrogenic right ventricular perforation utilizing an angio-seal device.**
A Ashour (Doha Qatar, SY, M)

Learning Objectives:

Categories:

Challenges in coronary artery disease**Session Number: 3360**Chairpersons: R Sava (Bucharest, RO) (F) - E Rafflenbeul (Hamburg, DE) (M)**13:15 5 acute myocardial infarction in 5 months: the challenging case of a 38 years old woman**

M Verdoia (Biella, IT, F)

13:30 Inflammation-associated and rapidly progressive coronary de novo stenosis and restenosis

L Wang (Beijing, CN, M)

13:45 What are you going to do for aneurysm dilatations after DK crush left main diseases in end stage CRF patient?

M Rahman (Dhaka, BD, M)

14:00 A coronary triple threat - left main bifurcation stenosis, heavy calcium, and renal failure: a personalized approach to high-risk PCI

JA Borovac (Split, HR, M)

Learning Objectives:

Categories:

Daily Highlights by the Algerian Society of Cardiology

Session Number: 5126

This session is brought to you by the Algerian Society of Cardiology and is not part of the official ESC programme

Chairpersons:

Learning Objectives:

Categories: Online Live

HOT LINE 11

Session Number: 1020

Chairpersons: L Holmvang (Copenhagen O, DK) (F) - R Al-Lamee (London, GB) (F) - S Achenbach (Erlangen, DE) (M)

- 13:45 OCCUPI - Optical coherence tomography-guided coronary intervention in patients with complex lesions**
BK Byeong-Keuk (Seoul, KR, M)
- 13:57 Discussant review - OCCUPI**
U Landmesser (Berlin, DE, M)
- 14:02 Panel discussion - OCCUPI**
- 14:05 INFINITY-SWEDEHEART - Percutaneous coronary intervention with a bioadaptor compared to a contemporary drug eluting stent- one year primary outcomes**
D Erlinge (Lund, SE, M)
- 14:17 Discussant review - INFINITY - SWEDEHEART**
D Capodanno (Catania, IT, M)
- 14:22 Panel discussion - INFINITY - SWEDEHEART**
- 14:25 REC-CAGEFREE I - Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of de novo coronary artery lesions: a multicenter, non-inferiority trial**
L Tao (Xi'an, CN, F)
- 14:37 Discussant review - REC-CAGEFREE I**
V Paradies (Rotterdam, NL, F)
- 14:42 Panel discussion - REC-CAGEFREE I**

Learning Objectives:

Categories: Online Live

Practical dilemmas in atrial fibrillation therapies

Session Number: 824

Chairpersons: E Hylek (Boston, US) (F) - M Farkowski (Warsaw, PL) (M)

- 13:45 State-of-the art lecture on practical dilemmas in atrial fibrillation therapies**
AJ Camm (London, GB, M)
- 14:03 Flecainide acetate inhalation solution for cardioversion of recent-onset, symptomatic atrial fibrillation: results of the phase 3 RESTORE-1 trial**
M Rienstra (Groningen, NL, M)
- 14:22 Postoperative atrial fibrillation following noncardiac surgery is associated with long-term heart failure: insights from a nationwide cohort**
MN Karacan (Hoeje Taastrup, DK, F)
- 14:41 Strategy optimization for the combined procedure of left atrial appendage occlusion plus catheter ablation in patients with atrial fibrillation (COMBINATION): a multi-center, randomized study**
XF Du (Ningbo, CN, M)

Learning Objectives:

Categories:

Advancing the diagnosis and management of patients with cardiac arrest and cardiogenic shock

Session Number: 829

Chairpersons: A Tycinska (Bialystok, PL) (F) - J Belohlavek (Praha, CZ) (M)

- 13:45 State-of-the-art lecture on advancing diagnosis and management of patients with cardiac arrest and cardiogenic shock**
C Malta Hansen (Copenhagen, DK, F)
- 14:03 Effect of nelonemdaz for patients with out-of-hospital cardiac arrest: the AWAKE phase II randomised clinical trial**
JH Choi (Seoul, KR, M)
- 14:22 Dual guided heparin monitoring with anti-Xa and APTT during micro-axial flow pump support for cardiogenic shock**
C Van Edom (Leuven, BE, F)
- 14:41 Mixed venous to arterial pCO₂-gap is poorly correlated to cardiac index in 1526 pulmonary artery catheter monitored critically ill patients**
C Vandenbriele (Leuven, BE, M)

Learning Objectives:

Categories:

Novel drug therapies in hypertension: new kids on the block**Session Number: 224**Chairpersons: A Rodgers (Sydney, AU) (M) - B Bozkurt (Houston, US) (F)

13:45 Vaccines targeting the renin angiotensin system
U Kintscher (Berlin, DE, M)

14:00 RNA-based blood pressure lowering agents
E Schiffrin (Montreal, CA, M)

14:15 Aldosterone synthase inhibition
D Bhatt (Scarsdale, US, M)

14:30 Dual endothelin receptor antagonist
M Tadic (Ulm, DE, F)

14:45 Novel drug therapies in hypertension: new kids on the block - discussion
M Schlaich (Perth, AU, M)

Learning Objectives:

Categories: Online Live

Guidelines in Practice: 2024 ESC Guidelines for the Management of Peripheral Arterial and Aortic Diseases

Session Number: 1204

Great Debates: preventing sudden cardiac death in competitive sports and athletes competing with an ICD**Session Number: 165**Chairpersons: A Pelliccia (Rome, IT) (M) - S Gati (London, GB) (F)

- 13:45 Pre-participation screening is mandatory to prevent sudden cardiac death in competitive sports: pro**
J Basu (London, GB, F)
- 13:57 Pre-participation screening is mandatory to prevent sudden cardiac death in competitive sports: con**
A Mosterd (Amersfoort, NL, M)
- 14:09 Pre-participation screening is mandatory to prevent sudden cardiac death in competitive sports - discussion**
J Drezner (Seattle, US, M)
- 14:22 Athletes with an ICD should be allowed to compete: pro**
R Lampert (New Haven, US, F)
- 14:34 Athletes with an ICD should be allowed to compete: con**
E Solberg (Oslo, NO, M)
- 14:46 Athletes with an ICD should be allowed to compete - discussion**
A Zorzi (Padova, IT, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Online Live, Young Community Track

Registries, observational, and other studies on cardiovascular problems in pregnancy

Session Number: 1051

Chairpersons:

- 13:45 Bromocriptine treatment and outcome in patients with peripartum cardiomyopathy: the EORP PPCM registry**
P Van Der Meer (Groningen, NL, M)
- 14:00 Pregnancy in women with prosthetic heart valves: focus on anticoagulation**
JA van der Zande (Rotterdam, NL, F)
- 14:15 Prospective Pakistan registry of echocardiographic screening in asymptomatic pregnant women**
S Bhatti (Karachi, PK, F)
- 14:30 Pregnancy in women with aortic pathology or genetic predisposition for aortic disease: data from the ESC Registry of Pregnancy and Cardiac disease**
JW Roos-Hesselink (Rotterdam, NL, F)
- 14:45 Pregnancy outcomes in women with heart diseases: Results from the Tamil Nadu Pregnancy and Heart Disease Registry**
G Gnanaraj (Chennai, IN, M)
- 15:00 Artificial intelligence enabled obstetric cardiovascular screening: secondary endpoint results from the SPEC-AI Nigeria randomized clinical trial**
D Adedinsewo (Jacksonville, US, F)

Learning Objectives:

Categories:

Heart failure is the stage and amyloid a key player

Session Number: 101

Chairpersons: A Flammer (Zurich, CH) (M) - A Kontorovich (New York, US) (F)

13:45 Epidemiology of amyloidosis in heart failure and red flags

P Garcia-Pavia (Madrid, ES, M)

14:00 Pathophysiology of TTR amyloidosis

T Damy (Creteil, FR, M)

14:15 Treating heart failure in the context of amyloidosis

M Fontana (London, GB, F)

14:30 New treatment options for amyloidosis

M Maurer (New York, US, M)

14:45 Heart failure is the stage and amyloid a key player - discussion

M Grogan (Rochester, US, F)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Online Live, Young Community Track

**Primary prevention of atherosclerotic cardiovascular disease:
European vs. American perspectives****Session Number: 159**Chairpersons: M Shapiro (Portland, US) (M) - C Ingul (Trondheim, NO) (F)

- 13:45 Changing concepts in cardiovascular prevention: refocusing on primordial**
V Fuster (New York, US, M)
- 14:00 Impact of SCORE2 risk calculator in European incidence of clinical cardiovascular disease**
E Di Angelantonio (Cambridge, GB, M)
- 14:15 American scores: Framingham, PCE, and PREVENT risk calculators**
S Khan (Chicago, US, F)
- 14:30 The future of atherosclerotic cardiovascular disease risk prediction: precision medicine based on imaging**
B Ibanez (Madrid, ES, M)
- 14:45 Primary prevention of atherosclerotic cardiovascular disease: European vs. American perspectives - discussion**
E Tessitore (Geneve, CH, F)

Learning Objectives:

Categories: Spotlight of the Congress

The global obesity (globesity) epidemic and cardiovascular health**Session Number: 317**Chairpersons: V Ferreira (Oxford, GB) (F) - F Pinto (Lisbon, PT) (M)

13:45 Obesity as a cardiovascular risk factor
OJ Rider (Oxford, GB, M)

14:00 Socioeconomic and racial disparities in obesity
T Powell-Wiley (Maryland, US, F)

14:15 Ectopic fat depots: how to measure them and their impact on cardiovascular risk
HJ Lamb (Leiden, NL, F)

14:30 Current approaches to the prevention and management of obesity
D Bondermann (Vienna, AT, F)

14:45 The global obesity (globesity) epidemic and cardiovascular health - discussion

Learning Objectives:

Categories: Obesity Track, Online Live

New imaging insights into hypertrophic cardiomyopathy

Session Number: 822

Chairpersons: AMG Almeida (Lisbon, PT) (F) - T Podlesnikar (Maribor, SI) (M)

- 13:45 State-of-the-art lecture on hypertrophic cardiomyopathy**
C Manisty (London, GB, F)
- 14:03 Serial changes in left atrial strain in symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten: insights from VALOR-HCM trial**
M Desai (Cleveland, US, M)
- 14:22 Comparison of mitral valve apparatus anomalies between sarcomeric hypertrophic cardiomyopathy and Fabry disease cardiomyopathy**
P F D'Andria (Milano, IT, M)
- 14:41 How different types of cardiomyopathy with hypertrophic phenotype affect left atrial remodeling and function**
M De Raffeale (Ferrara, IT, F)

Learning Objectives:

Categories:

Real-world data: from where and for what?

Session Number: 455

Chairpersons: B Casadei (Oxford, GB) (F) - N Conrad (Leuven, GB) (F)

- 13:45 Data from snapshot surveys: value and limitations**
AP Maggioni (Milano, IT, M)
- 13:58 Data from registries: making the most of it**
G Range (Chartres, FR, M)
- 14:11 Harvesting data from EHRs (electronic health records): what are the keys to success?**
S Hansson (Uppsala, SE, F)
- 14:24 Federated data analysis: an arm's length approach to the analysis of individual patient data**
D Prieto-Alhambra (Oxford, GB, M)
- 14:37 Real-world data: from where and for what? - discussion**

Learning Objectives:

Categories:

TO_AITON: cardiovascular disease and depression comorbidity - insights into its underlying pathophysiology

Session Number: 441

Chairpersons: G Pasterkamp (Utrecht, NL) (M) - I Goncalves (Malmo, SE) (F)

- 13:45 Innate immunity in atherosclerosis**
E Latz (Berlin, DE, M)
- 14:00 Novel immune pathways in cardiometabolic comorbidities**
E Andreacos (Athens, GR, M)
- 14:15 Immuno-metabolic mechanisms of depression**
- 14:30 Therapeutic targeting of inflammation in atherosclerosis**
C Monaco (Oxford, GB, F)

Learning Objectives:
Categories:

Implementing wearables in neuro-cardiovascular care**Session Number: 296**Chairpersons: M Albert (San Francisco, US) (F) - R Bulbulia (Oxford, GB) (M)**13:45 Long-term rhythm monitoring after stroke: when? and how?**

T Glotzer (Tenafly, US, F)

14:03 Screening for atrial fibrillation: ready for prime time?

JH Svendsen (Copenhagen, DK, M)

14:22 How to start your own wearable clinic

P Badertscher (Basel, CH, M)

14:41 Mobile health applications and wearables - the patient's perspective on usability and adherence

Mr Rucinski (Blonie, PL, M)

Learning Objectives: This session will discuss the increasing number of wearables that are available and will describe their uses in detecting cardiac arrhythmias, particularly those associated with stroke.

Categories: Digital Health, Includes a patient perspective

Registries, observational, and other studies on atrial fibrillation

Session Number: 1055

Chairpersons: A Banerjee (London, GB) (M)

- 13:45 Refining the CHA2DS2VASc risk stratification scheme: Shall we drop the Sex Category?**
R Providencia (London, GB, M)
- 13:57 A comparison of vascular brain lesions on magnetic resonance imaging in patients with atrial fibrillation and patients with atherosclerosis**
T Stegmann (Leipzig, DE, F)
- 14:10 Incidence of atrial fibrillation in cryptogenic stroke with patent foramen ovale closure:the PFO-AF study**
M Badoz (Besancon, FR, M)
- 14:22 Biomarkers for improved risk prediction and biological insights in patients with atrial fibrillation**
D Conen (Ancaster, CA, M)
- 14:35 Phenotypes of pharmacological treatment in patients with atrial fibrillation: a latent class analysis from the prospective GLORIA-AF Registry Phase III**
B Corica (Modena, IT, F)
- 14:47 Longterm 13 Year Outcome of AF Ablation in Elderly Patients - German Ablation Registry**
J Brachmann (Coburg, DE, M)

Learning Objectives:

Categories:

Vascular and immune control of organ function**Session Number: 346**Chairpersons: P Alcaide (Boston, US) (F) - N Kraenkel (Berlin, DE) (F)

- 13:45 Lymphatic control of tissue repair**
PR Riley (Oxford, GB, M)
- 14:00 Vascular control of tissue repair**
M Brittan (Edinburgh, GB, F)
- 14:15 Inflammation and control of tissue repair**
JA Nicolas-Avila (Madrid, ES, M)
- 14:30 Pericyte control of tissue repair**
R Ardehali (Los Angeles, US, M)
- 14:45 Vascular and immune control of organ function - discussion**
G Luxan (Frankfurt Am Main, DE, M)

Learning Objectives:

Categories:

Heart disease in a low-resource setting

Session Number: 329 Joint session with the Sri Lanka College of Cardiology (SLCC)

Chairpersons: N Amarasena (Colombo, LK) (F) - A Vahanian (Vincennes, FR) (M)

14:30 Case: rheumatic mitral stenosis in a pregnant woman
B Ranasinghe (Colombo, LK, M)

14:45 What do the ESC Guidelines for the management of cardiovascular diseases in pregnancy say?
A Rakisheva (Almaty, KZ, F)

15:00 How to manage cardiac disease in pregnancy in a low-resource setting
S Withanawasam (Colombo, LK, M)

15:15 40-year journey of percutaneous transvenous mitral commissurotomy (PTMC)
G Elshahed (Cairo, EG, F)

Learning Objectives: This session aims to present demographic data and discuss the epidemiology of diseases more prevalent in South Asia.

Categories: Online Live

Catheter ablation for atrial fibrillation: relevance of concomitant therapies and comorbidities**Session Number: 3020**Chairpersons: M Middeldorp (Norwood, NL) (F)

- 14:30 Catheter ablation increases cerebral blood flow and cognitive function in elderly patients with atrial fibrillation**
M Manita (Naha, JP, M)
- 14:42 Effect of catheter ablation in atrial fibrillation patients irrespective of their baseline heart failure: An updated meta-analysis.**
A Helmi (Alexandria, EG, M)
- 14:54 Efficacy and safety of catheter ablation for paroxysmal atrial fibrillation as first-line therapy vs. after drug failure -analysis from Japan Nationwide Ablation (J-AB) Registry-**
J Oikawa (Sagamihara, JP, M)
- 15:06 improvement of left atrial function after ablation in patients with paroxysmal atrial fibrillation is associated with the presence of heart failure with preserved ejection fraction**
K Sun (Beijing, CN, F)
- 15:18 Efficacy of catheter ablation for atrial fibrillation in patients with heart failure: an updated meta-analysis**

Learning Objectives:

Categories:

Is artificial intelligence the valvular physician's best friend?

Session Number: 3058

Chairpersons: A Sannino (Naples, IT) (F) - PH Kolh (Liege, BE) (M)

- 14:30 Deep learning improves detection of aortic stenosis in b-mode ultrasound: results of a pivotal multicenter validation study using artificial intelligence**
N Poilvert (Seattle, US, M)
- 14:40 Machine-learning phenotyping of patients with functional mitral regurgitation undergoing transcatheter edge-to-edge repair - the MITRA-AI study**
PP Bocchino (Torino, IT, M)
- 14:50 Prediction of permanent pacemaker need after transcatheter aortic valve implantation using multimodal artificial intelligence**
M Nakase (Bern, CH, M)
- 15:00 Close clinical monitoring of patients after TAVI implantation using artificial intelligence with a virtual voice assistant**
M Herrero Brocal (Alicante, ES, F)
- 15:10 A potentially explainable artificial intelligence model for automatic classification of mitral regurgitation in echocardiographic videos**
Z Ge (Shanghai, CN, M)
- 15:20 Feature importance explanation of prosthetic valve endocarditis through machine learning via SHAP**
LE Juarez-Orozco (Utrecht, NL, M)

Learning Objectives:

Categories:

Non-invasive diagnostics and imaging in cardiovascular disease

Session Number: 3088

Chairpersons: M Acevedo (Santiago, CL) (F)

- 14:30 On-site or telephone follow-up after myocardial infarction? A nationwide observational study of data quality in 101 199 patients in contemporary clinical practice**
M Leosdottir (Malmo, SE, F)
- 14:42 AI-enabled left atrial volumetry in coronary calcium scans (AI_CAC) predicts atrial fibrillation as early as one year, improves CHARGE-AF, and outperforms NT-proBNP: MESA**
M Naghavi (Houston, US, M)
- 14:54 Investigating lifestyle determinants of carotid intima-media thickness: cross-sectional insights from the UK biobank cohort**
S Mitra (Sydney, AU, M)
- 15:06 Association of serum testosterone levels with left atrial size, function, and risk of atrial fibrillation in adult men: observational and mendelian randomization analyses**
- 15:18 Large sample size MRI measurements to assess the relation between cardiac function and structure and white matter hyperintensity volumes.**
A Saccoh (London, GB, F)

Learning Objectives:

Categories:

Novel insights into vascular remodelling

Session Number: 3128

Chairpersons: S Pullamsetti (Bad Nauheim, DE) (F) - K Peter (Melbourne, AU) (M)

- 14:30 ERBB4 activation prevents microvascular dysfunction in a large animal model of hypertensive heart disease**
- 14:40 Impact of neonatal hyperoxia on the development of the coronary vascular bed: an experimental model for the study of cardiomyopathy associated with premature birth**
P-E Girault-Sotias (Montreal, CA, M)
- 14:50 Parathyroid hormone exacerbates pulmonary hypertension via parathyroid hormone receptors on pulmonary artery smooth muscle cells**
Y Joki (Tokyo, JP, M)
- 15:00 The novel role of complement 3 in Wnt5a-mediated vascular smooth muscle cell calcification**
I Badi (Oxford, GB, F)
- 15:10 Novel balloon catheter containing therapeutic mRNA with smart RNA switch alleviate restenosis after vascular injury**
Y Fu (Shanghai, CN, F)
- 15:20 Suppression of Fibulin 5 Attenuated Pulmonary Arterial Hypertension Associated with Congenital Heart Disease via Mitigating Pulmonary Arterial Smooth Muscle Cell Dysfunction**
Y Yang (Beijing, CN, M)

Learning Objectives:

Categories:

Supraventricular tachycardia (2)

Session Number: 3326

Chairpersons: K Malaczynska-Rajpold (London, GB) (F) - N Schaerli (Basel, CH) (M)

14:30 Supraventricular tachycardia - get ready for the session

14:35 The insight of focal atrial tachycardia from right atrial appendage in a case of resistant to catheter ablation: Immunohistological assessment of the excised specimen
S Inaba (Shizuoka, JP, M)

14:48 Immediate cardiac 'resynchronization' with accessory pathway ablation: real-time visualization using intracardiac echo
C Powell (Carrigtwohill, IE, M)

15:01 Management of paroxysmal supraventricular tachycardia (PSVT) in pregnant patient with Wolff-Parkinson-White (WPW) syndrome and mitochondrial gene MT-TL1 pathogenic variant m.3243A>G
M Gray (San Francisco, US, F)

15:14 Atrial tachycardia in patient after heart transplantation: reconnection or interpolation?
V Maslova (Kiel, DE, F)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals

Categories: Mobile App - Vote, Young Community Track

Difficulties in heart transplantation

Session Number: 3342

Chairpersons: LX van Nunen (Nijmegen, NL) (M)

- 14:30** **A case of cellular and humoral rejection in hyperimmunized patient post heart transplantation: management of a complex clinical scenario**
G Colombo (Brescia, IT, F)
- 14:42** **Central nervous system involvement in chagas disease reactivation: a case report in cardiac transplant recipients**
D Guazzelli (Campinas, BR, F)
- 14:54** **Heart transplantation as the last resort for coexistence of ARVC and Ebstein anomaly**
A Jomaa (Wolfsburg, DE, M)
- 15:06** **Veno-arterial extracorporeal membrane oxygenation requirement for severe protamine reaction after heart transplant**
L Seoane (Buenos Aires, AR, M)
- 15:18** **Case report of mechanical circulatory support in patient after heart transplantation, complicated by primary biventricular graft dysfunction**
E Novikova (Kyiv, UA, F)

Learning Objectives:

Categories:

Systemic diseases affecting the heart**Session Number: 3381**Chairpersons: E C Wicks (London, GB) (F) - OI Brown (Leeds, GB) (M)

- 14:30 The silent menace: cardiac sarcoidosis manifested as ventricular arrhythmia in a patient with negative CMR**
M Kolluri (Farmington, US, F)
- 14:42 Successful treatment of a life-threatening cardiac involvement in adult-onset Still's disease**
D Kiss (Budapest, HU, M)
- 14:54 Crafting the approach to multivalvular carcinoid heart disease: emerging options, challenging decisions.**
A Hernandez Pineda (Mexico City, MX, M)
- 15:06 SPECT/CT was useful for diagnosing retroperitoneum pheochromocytoma and paraganglioma in screening secondary factors of hypertension**
Y Li (Beijing, CN, M)
- 15:18 Pneumococcal purulent pericardial effusion as a presentation of immunocompromise: the importance of asking the right questions at the right time**
K Ioakim (London, GB, F)

Learning Objectives:

Categories:

HOT LINE 12

Session Number: 1021

Chairpersons: LD Gillam (Morristown, US) (F) - NL Mills (Edinburgh, GB) (M) - H Katus (Heidelberg, DE) (M)

- 15:15 PROTEUS - A prospective randomised controlled trial evaluating the use of artificial intelligence in stress echocardiography**
R Upton (Oxford, GB, M)
- 15:27 Discussant review - PROTEUS**
V Delgado (Barcelona, ES, F)
- 15:32 Panel discussion - PROTEUS**
- 15:37 RAPIDxAI - Re-engineering the clinical approach to suspected cardiac chest pain assessment in the emergency department by expediting evidence to practice using artificial intelligence**
D Chew (Adelaide, AU, M)
- 15:49 Discussant review - RAPIDxAI**
B Backus (Dordrecht, NL, F)
- 15:54 Panel discussion - RAPIDxAI**
- 15:59 WESTCOR-POC - Point of care versus centralised high-sensitivity cardiac troponin in the emergency department**
IVL Thulin (Paradis, NO, F)
- 16:11 Discussant review - WESTCOR-POC**
C Mueller (Basel, CH, M)
- 16:16 Panel discussion - WESTCOR-POC**

Learning Objectives:

Categories: Online Live

Smaller trials, trial updates, and other studies on antiplatelet and antithrombotic therapies

Session Number: 1052

Chairpersons: S Halvorsen (Oslo, NO) (F)

- 15:15 Long-acting Factor XI Inhibition and Periprocedural Bleeding: A Secondary Analysis from AZALEA-TIMI 71**
S Patel (Boston, US, M)
- 15:27 Aspirin and hemocompatibility related adverse events after LVAD implantation in patients with diabetes mellitus, obesity and atrial fibrillation: the ARIES-HM3 randomized clinical trial**
Nir Uriel (New York, US, M)
- 15:39 Efficacy and safety of anticoagulation in patients with device-detected atrial fibrillation by indication for acetylsalicylic acid therapy**
R Schnabel (Hamburg, DE, F)
- 15:51 The Association between Age and Clinical Outcomes in Patients with Subclinical Atrial Fibrillation Treated with Apixaban: Insights from the ARTESiA Trial**
M Proietti (Milan, IT, M)
- 16:03 Changes in Cognitive Function in Patients with Subclinical Atrial Fibrillation Treated with Apixaban or Aspirin: A Sub-Study from the ARTESiA Trial**
L Rivard (Montreal, CA, F)

Learning Objectives:

Categories:

Possible shifts in paradigms for lipid-lowering therapies in acute coronary syndrome patients

Session Number: 207

Chairpersons: K Krychtiuk (Vienna, AT) (M) - S Banerjee (Reigate, GB) (F)

- 15:15 Possible shifts in paradigms for lipid-lowering therapies in acute coronary syndrome patients: combination therapy from Day 1**
M Lettino (Milano, IT, F)
- 15:30 Possible shifts in paradigms for lipid-lowering therapies in acute coronary syndrome patients: PCSK9 inhibitors from Day 1**
S Mehta (Hamilton, CA, M)
- 15:45 Possible shifts in paradigms for lipid-lowering therapies in acute coronary syndrome patients: together with anti-inflammatory therapy from Day 1**
M Sabatine (Boston, US, M)
- 16:00 Possible shifts in paradigms for lipid-lowering therapies in acute coronary syndrome patients - discussion**
J Roeters Van Lennep (Rotterdam, NL, F)

Learning Objectives:

Categories: Online Live

Personalising antithrombotic strategies in acute and chronic coronary syndromes: when and how to escalate and de-escalate**Session Number: 232**Chairpersons: C Vandenbriele (Leuven, BE) (M)**15:15 Reducing intensity of dual antiplatelet therapy in acute coronary syndromes: what is the optimal timing?**

D Gorog (London, GB, F)

15:35 Shortening dual antiplatelet therapy duration in acute coronary syndromes: should we drop aspirin or the P2Y12 inhibitor?

E Navarese (Sassari, PL, M)

15:55 When and how to escalate antithrombotic therapy beyond aspirin in chronic coronary syndromes

JL Ferreira (Tarragona, ES, M)

Learning Objectives:

Categories: Clinical Implementation Track, Spotlight of the Congress

The year in review: top trials in structural interventions impacting guidelines and patient care

Session Number: 302

Chairpersons: M Leon (New York, US) (M) - IM Lang (Vienna, AT) (F)

- 15:15 Self-expanding or balloon-expandable TAVR in patients with a small aortic annulus: the SMART trial**
A Petronio (Pisa, IT, F)
- 15:27 Transcatheter or surgical treatment of aortic-valve stenosis: the DEDICATE-DZHK6 trial**
T Rudolph (Bad Oeynhausen, DE, F)
- 15:39 A randomised trial of transcatheter tricuspid valve replacement in patients with severe tricuspid regurgitation: TRISCEND II trial**
J Granada (Orangeburg, US, M)
- 15:51 1-year outcomes from the CLASP IID randomised trial for degenerative mitral regurgitation**
M Guerrero (Rochester, US, F)
- 16:03 The year in review: top trials in structural interventions impacting guidelines and patient care - discussion**

Learning Objectives:

Categories:

Great Debate: transcatheter aortic valve implantation in non-surgical centres?**Session Number: 312**Chairpersons: H Moellmann (Dortmund, DE) (M) - M Gilard (Brest Cedex, FR) (F)

15:15 Transcatheter aortic valve implantation in non-surgical centres: pro
M Compagnone (Forli, IT, F)

15:30 Transcatheter aortic valve implantation in non-surgical centres: con
S Windecker (Bern, CH, M)

15:45 Transcatheter aortic valve implantation in non-surgical centres - discussion
J Mascherbauer (Vienna, AT, F)

Learning Objectives:

Categories: Online Live

Smaller trials, trial updates, and other studies on atrial fibrillation

Session Number: 1053

Chairpersons: A Russo (Moorestown, US) (F) - D Atar (Oslo, NO) (M)

- 15:15** **Flecainide to prevent atrial arrhythmia after patent foramen ovale closure, the AFLOAT randomized study**
G Montalescot (Paris, FR, M)
- 15:27** **Enhanced Detection and Quickened Diagnosis of Atrial Fibrillation Using Apple Watch: A Randomized Controlled Trial**
M Winter (Amsterdam, NL, M)
- 15:39** **Detection of silent atrial fibrillation in high stroke risk patients using bed sensor and smartphone app: the CARE-DETECT trial**
J Lehto (Turku, FI, M)
- 15:51** **Atrial fibrillation follow-up investigation to recover memory and learning trial**
X Du (Beijing, CN, F)
- 16:03** **Manual chest PRESSURE during direct current cardioversion for Atrial Fibrillation: a randomized control trial (PRESSURE-AF).**
D Ferreira (Wantirna, AU, M)

Learning Objectives:

Categories:

Hot off the press: heart failure-related cardiogenic shock**Session Number: 110**Chairpersons: G Tavazzi (Pavia, IT) (M) - M Jessup (Philadelphia, US) (F)**15:15 Contemporary definition of heart failure-related cardiogenic shock**

O Chioncel (Bucuresti, RO, M)

15:30 Heart failure-related cardiogenic shock: impact of extracorporeal membrane oxygenation (ECMO) on survival

J Poess (Leipzig, DE, F)

15:45 Heart failure-related cardiogenic shock: impact of percutaneous left ventricular unloading

N Udesen (Odense M, DK, F)

16:00 Hot off the press: heart failure-related cardiogenic shock - discussion

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Online Live, Young Community Track

Clinical Case Management: athletes with rhythm problems - what to consider when recommending exercise

Session Number: 146

Chairpersons: B Gray (Sydney, AU) (F) - D Corrado (Padova, IT) (M)

15:15 Case 1: an athlete with ventricular ectopy

D Niederseer (Davos, CH, M)

15:35 Case 2: an athlete with a long QT interval

E Arbelo (Barcelona, ES, F)

15:55 Clinical Case Management: athletes with rhythm problems - what to consider when recommending exercise - discussion

C Colombo (Valinhos, BR, F)

H Heidbuchel (Antwerp, BE, M)

Learning Objectives:

Categories: Clinical Implementation Track, Online Live

The role of genetics in myocarditis**Session Number: 316**Chairpersons: V Ferreira (Oxford, GB) (F) - L Cooper (Jacksonville, US) (M)

- 15:15 Genetic susceptibility to myocarditis**
A Kontorovich (New York, US, F)
- 15:30 When should genetic testing be done in acute myocarditis?**
A Lota (London, GB, M)
- 15:45 Cardiovascular magnetic resonance in myocarditis: when should a genetic cardiomyopathy be suspected?**
C Kramer (Charlottesville, US, M)
- 16:00 The role of genetics in myocarditis - discussion**
K Klingel (Tuebingen, DE, F)

Learning Objectives:

Categories:

Cutting-edge cardiovascular imaging in heart failure**Session Number: 270**Chairpersons: J Grapsa (London, GB) (F) - M Abdelhamid (Cairo, EG) (M)

15:15 Use of VExUS in acute heart failure
H Soliman Aboumarie (London, GB, M)

15:30 Differentiating ischaemic versus non-ischaemic aetiology: which imaging technique first?
A Martinez Naharro (London, GB, F)

15:45 Inflammation, infection, and infiltration causing heart failure: how to make the diagnosis?
C Wiefels (Ottawa, CA, F)

16:00 Cutting-edge cardiovascular imaging in heart failure - discussion

Learning Objectives:

Categories:

The floor is yours: bring your questions on cardiovascular treatment in the frail - how to keep calm and carry on

Session Number: 233

Chairpersons: S Sze (Leicester, GB) (F) - A Koh (Singapore, SG) (F) - S Castelletti (Milan, IT) (F)

15:15 The floor is yours: bring your questions on cardiovascular treatment in the frail - how to keep calm and carry on - get ready for the session
S Castelletti (Milan, IT, F)

15:20 The floor is yours: bring your questions on cardiovascular treatment in the frail - how to keep calm and carry on - expert panel
M Proietti (Milan, IT, M)

J Wykrzykowska (Groningen, NL, F)

G Mikhail (London, GB, F)

T Geisler (Tuebingen, DE, M)

H Atef (Newcastle Under Lyme, GB, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Mobile App - Ask a Question, Young Community Track

Lp(a) and aortic stenosis**Session Number: 458**Chairpersons: S Tsimikas (La Jolla, US) (M)

15:15 Lp(a) and aortic stenosis: biological underpinnings
S Verma (Toronto, CA, M)

15:30 Lp(a) and aortic stenosis: epidemiology

15:45 Lp(a) as a treatment target for aortic stenosis?
M Dweck (Edinburgh, GB, M)

16:00 Lp(a) and aortic stenosis - discussion
P Pibarot (Quebec, CA, M)

Learning Objectives:

Categories:

Wearables and digital tools in hypertension management: ready for prime time?

Session Number: 218

Chairpersons: AS Mihailidou (Sydney, AU) (F) - Q Zhou (Basel, CH) (F)

15:15 How to use wearables for blood pressure measurement

G Parati (Milano, IT, M)

15:30 How to integrate digital apps in hypertension management

G Stergiou (Athens, GR, M)

15:45 How to incorporate patient preference in decision-making - patient perspective

J Harris (Manchester, GB, F)

16:00 Wearables and digital tools in hypertension management: ready for prime time? - discussion

A Pathak (Monte Carlo, MC, M)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Digital Health, Includes a patient perspective, Young Community Track

UK Biobank: a unique and growing global platform for cardiovascular discovery science

Session Number: 459

Chairpersons: E Prescott (Copenhagen, DK) (F) - S Petersen (London, GB) (M)

15:15 Future direction of UK Biobank
A Lewandowski (Oxford, GB, M)

15:25 Omics and genetic data
M Miller (Cambridge, US, F)

15:35 Identifying novel pathways for cardiovascular disease
P Ellinor (Boston, US, M)

15:45 UK Biobank: a unique and growing global platform for cardiovascular discovery science - Q&A

Learning Objectives: This session will provide information about UK Biobank, highlight recent enhancements and future planned assessments, and discuss use of the cloud-based Research Analysis Platform.

Categories:

RNA as target and therapeutic tool in cardiovascular diseases**Session Number: 347**Chairpersons: L De Windt (Maastricht, NL) (M) - N Kraenkel (Berlin, DE) (F)

- 15:15 Targeting non-coding RNAs in heart failure: the clinical perspective**
T Thum (Hannover, DE, M)
- 15:30 Strategies to deliver therapeutic RNAs in cardiovascular diseases**
M Giacca (London, GB, M)
- 15:45 RNA control of inflammation in cardiovascular diseases**
K Rayner (Ottawa, CA, F)
- 16:00 RNA as target and therapeutic tool in cardiovascular diseases - discussion**
C Emanuelli (London, GB, F)

Learning Objectives: This session has been identified by the ESC Committee for Young Cardiovascular Professionals particularly relevant for young professionals.

Categories: Online Live, Young Community Track

Infections and the heart: all we need to know given new migration patterns

Session Number: 328 **Joint session with the InterAmerican Society of Cardiology (IASC)**

Chairpersons: A Baranchuk (Kingston, CA) (M)

15:45 The NET-Heart Project: neglected tropical diseases affecting the heart
CI Saldarriaga (Medellin, CO, F)

16:00 Chagas disease in non-endemic countries
C Morillo (Calgary, CA, M)

16:15 Malaria and the heart
NAB Ntusi (Cape Town, ZA, M)

16:30 Viral infections of the heart including chikungunya, dengue, and rabies
A Caforio (Padua, IT, F)

Learning Objectives: This session aims to be familiarised with neglected tropical diseases affecting the heart and the cardiovascular system; to learn new migration patterns to Europe exposing local doctors to diseases rarely seen in the past; and to learn new algorithms of management and diagnosis for these cardiovascular conditions.

Categories: Online Live

